Identification of potential core genes in hepatoblastoma via bioinformatics analysis

Basavaraj Vastrad¹, Chanabasayya Vastrad*², Iranna Kotturshetti³

1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India.

2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad, Karnataka 580001, India.

3. Department of Ayurveda, Rajiv Gandhi Education Society's Ayurvedic Medical College, Ron, Karnataka 562209, India.

* Chanabasayya Vastrad

channu.vastrad@gmail.com

Ph: +919480073398

Chanabasava Nilaya, Bharthinagar,

Dharwad 580001 , Karanataka, India

Abstract

Hepatoblastoma is the childhood liver cancer. Profound efforts have been made to illuminate the pathology, but the molecular mechanisms of hepatoblastoma are still not well understood. To identify the candidate genes in the carcinogenesis and progression of hepatoblastoma, microarray dataset GSE131329 was downloaded from Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) were identified, and pathway and Gene Ontology (GO) enrichment analysis were performed. The protein-protein interaction network (PPI), module analysis, target gene - miRNA regulatory network and target gene - TF regulatory network were constructed and analyzed. A total of 996 DEGs were identified, consisting of 499 up regulated genes and 497 down regulated genes. The pathway and Gene Ontology (GO) enrichment analysis of the DEGs include proline biosynthesis, superpathway of tryptophan utilization, chromosome organization and organic acid metabolic process. Twenty-four hub genes were identified and biological process analysis revealed that these genes were mainly enriched in cell cycle, chromosome organization, lipid metabolic process and oxidation-reduction process. Validation of hub genes showed that TP53, PLK1, AURKA, CDK1, ANLN, ESR1, FGB, ACAT1, GOT1 and ALAS1 may be involved in the carcinogenesis, invasion or recurrence of hepatoblastoma. In conclusion, DEGs and hub genes identified in the present study help us understand the molecular mechanisms underlying the carcinogenesis and progression of hepatoblastoma, and provide candidate targets for diagnosis and treatment of hepatoblastoma.

Keywords: bioinformatics; hepatoblastoma; hub genes; miRNA; survival analysis

Introduction

Hepatoblastoma is a highly complex and uncommon malignant type of liver cancer appears in infants and children [Kremer et al 2014], and accounting for just over 1% of pediatric cancers [Spector and Birch, 2012]. Despite significant advancements in treatments, including surgery [Busweiler et al 2017], chemotherapeutic [Hiyama et al 2016] and liver transplantation [Cruz Jr et al 2013], the survival rate of patients with hepatoblastoma has not sufficiently improved. The high rates of recurrence and metastasis in patients with hepatoblastoma require the critical advancement of novel diagnostic strategies and therapeutic agents to enhance patient prognosis. As the molecular mechanisms of hepatoblastoma tumorigenesis and development are not yet fully understood, there remains to be a number of unsolved issues in the diagnosis and treatment of hepatoblastoma. Therefore, it is important to identify new biomarkers and pathways linked with tumorigenesis and patient prognosis, in order to help resolve the suitable basic molecular mechanisms, and to help discover novel diagnostic and prognostic markers, and therapeutic targets.

Altered expression and mutations of genes, and signalling pathways are associated in the advancement and development of hepatoblastoma. Genes such as β -catenin [Koch et al. 1999], Axin [Miao et al. 2003], SOCS-1 [Nagai et al. 2003], lipin 1 [Ishimoto et al. 2009] and MT1G [Sakamoto et al. 2010] were linked with development of hepatoblastoma. Signalling pathways such as PI3K/Akt, ERK and p38 signaling pathways [Cui et al. 2016], MAPK signaling pathways [Yuan et al. 2013], notch signalling pathway [Aktaş et al. 2010], Wnt/ β -catenin signalling pathway [Cui et al. 2020] and EGFR-ASAP1 signaling pathway [Ranganathan et al. 2016] were responsible for progression hepatoblastoma. Hepatoblastoma remains a require disease to treat, and more investigations are required to develop the understanding of the underlying molecular mechanisms to diagnose genes and signaling for the progression of new therapies. Therefore, the pathogenesis of hepatoblastoma warrants further studies.

With the accelerated advancement of microarray technology, some high throughput platforms for analysis of gene expression are extensively used to examine the differentially expressed genes (DEGs) during cancer progression [Ma et al. 2019]. Many gene expression profiling studies on hepatoblastoma have been implemented using microarray technology and identified many up

and down regulated genes linked with progression of hepatoblastoma [Liu et al. 2018; Adesina et al. 2009].

Therefore, the purpose of the current investigations was to download and analyze expression profiling dataset of human samples from the Gene Expression Omnibus (GEO) database, and to identify DEGs between hepatoblastoma tissues samples and noncancerous liver tissue samples. Subsequently, pathway and Gene Ontology (GO) enrichment analysis were carried out. Protein-protein interaction (PPI) network analysis, module analysis, target gene - miRNA regulatory network and target gene - TF regulatory network were used to establish the molecular pathogenesis underlying carcinogenesis and progression of hepatoblastoma. Finally, the hub genes were further verified based on UALCAN, cBio Portal, The Human Protein Atlas, receiver operator characteristic (ROC) curve analysis, RT-PCR analysis and immune infiltration analysis. The results may provide new diagnostic and prognostic biomarkers, and therapeutic target molecules in hepatoblastoma metastasis.

Materials and methods

Access to public data

The GEO (<http://www.ncbi.nlm.nih.gov/geo>) is a wide platform for accumulate genomic or microarray data [Edgar et al. 2002]. Expression profiling datasets [GSE131329] were obtained from GEO. The GSE131329 dataset was tested based on the GPL6244 platform [HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version], including 53 hepatoblastoma tissues samples and 14 noncancerous liver tissue samples.

Data pre-processing

The GSE131329 gene expression profiles were preprocessed using affyPLM software

(<https://www.bioconductor.org/packages/release/bioc/html/affyPLM.html>) in the Release (3.10) package [Heber and Sick, 2006]. The original microarray data were transformed into gene symbols according to annotation information of the array platform. If certain probes coincided with the same gene, the moderate scores were determined as the gene expression value of these probes. Robust multiarray average (RMA) in R affy package [Gautier et al. 2004] was used to normalize the matrix.

DEGs analysis

The DEGs in hepatoblastoma samples compared with noncancerous liver samples were diagnosed using the Limma package (<https://www.bioconductor.org/packages/release/bioc/html/limma.html>) [Ritchie et al. 2015] in R Bioconductor. Finally, $|\log \text{foldchange (FC)}| > 1.07$ for up regulated genes; $|\log \text{foldchange (FC)}| < -1.25$ for down regulated genes and $P\text{-value} < 0.05$ were used as the threshold values for considering the DEGs.

Pathway enrichment analysis of DEGs

BIOCYC (<https://biocyc.org/>) [Caspi et al. 2016], Kyoto Encyclopedia of Genes and Genomes (KEGG) (<http://www.genome.jp/kegg/pathway.html>) [Kanehisa et al. 2018], Pathway Interaction Database (PID) (<https://wiki.nci.nih.gov/pages/viewpage.action?pageId=315491760>) [Schaefer et al. 2009], REACTOME (<https://reactome.org/>) [Fabregat et al. 2018], GenMAPP (<http://www.genmapp.org/>) [Dahlquist et al. 2002], MSigDB C2 BIOCARTA (<http://software.broadinstitute.org/gsea/msigdb/collections.jsp>) [Subramanian et al. 2005], PantherDB (<http://www.pantherdb.org/>) [Mi et al. 2017], Pathway Ontology (<http://www.obofoundry.org/ontology/pw.html>) [Petri et al. 2017] and Small Molecule Pathway Database (SMPDB) (<http://smpdb.ca/>) [Jewison et al. 2014] are a bioinformatics resource that links genomes to metabolic pathways. Pathway enrichment analysis for DEGs (up and down regulated genes) was performed by using ToppGene (ToppFun) (<https://toppgene.cchmc.org/enrichment.jsp>) [Chen et al 2009]. P-value < 0.05 was chosen as the cut-off criteria for significant pathway enrichment analysis.

GO enrichment analysis of DEGs

ToppGene (ToppFun) (<https://toppgene.cchmc.org/enrichment.jsp>) [Chen et al 2009] was used to perform Gene Ontology (GO) (<http://www.geneontology.org/>) [Lewis, 2017] enrichment analyses. P-value < 0.05 was chosen as the cut-off criteria for significant GO enrichment analysis.

Construction of the PPI network and module analysis

The PPI network was constructed based on all the DEGs (up and down regulated genes) using IID (Integrated Interactions Database) from a well-known online server (<http://iid.ophid.utoronto.ca>) [Kotlyar et al 2019], which integrates different PPI databases such as Biological General Repository for Interaction Datasets (BioGRID) (<https://thebiogrid.org/>) [Oughtred et al

2019], IntAct Molecular Interaction Database (<https://www.ebi.ac.uk/intact/>) [Orchard et al 2014], the Molecular INTERaction database (MINT) (<https://mint.bio.uniroma2.it/>) [Licata et al 2012], InnateDB (<https://www.innatedb.com/>) [Breuer et al 2013], Database of Interacting Proteins (DIP) (<http://dip.doe-mbi.ucla.edu/dip/Main.cgi>) [Salwinski et al 2004], Human Protein Reference Database (HPRD) (<http://www.hprd.org/>) [Keshava Prasad et al 2009] and Biomolecular Interaction Network Database (BIND) (<http://bond.unleashedinformatics.com/>) [Willis and Hogue, 2006]. A united score of >0.4 was determine as the threshold value for constructing the PPI network. The PPI network was visualized using Cytoscape software (version 3.7.2, <http://cytoscape.org/>) [Shannon et al 2003]. Five topological characteristics of the genes in the PPI network, including node degree [Przulj et al 2004], betweenness centrality [Nguyen et al 2011], stress centrality [Shi and Zhang, 2011], closeness centrality [Li et al 2018] and clustering coefficient [Wang et al 2012], were calculated using the Network Analyzer plugin in Cytoscape software (<http://apps.cytoscape.org/apps/NetworkAnalyzer>). In addition, PEWCC1 (<http://apps.cytoscape.org/apps/PEWCC1>) in Cytoscape software was used to analyze the most significant module, with the threshold value of 5 [Zaki et al 2013].

Construction of target genes - miRNA regulatory network

The miRNAs (microRNA) that can regulate the up and down regulated genes were predicted using the miRNet database (<https://www.mirnet.ca/>) [Fan and Xia, 2018] with default significant parameters. Only the interaction relationships can be predicted by ten common algorithms, including TarBase (<http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index>) [Vlachos et al. 2015], miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/php/download.php>) [Chou et al. 2018], miRecords (<http://miRecords.umn.edu/miRecords>) [Xiao et al. 2009], miR2Disease (<http://www.mir2disease.org/>) [Jiang et al. 2009], HMDD (<http://www.cuilab.cn/hmdd>) [Huang et al. 2019], PhenomiR (<http://mips.helmholtz-muenchen.de/phenomir/>) [Ruepp et al. 2010], SM2miR (<http://bioinfo.hrbmu.edu.cn/SM2miR/>) [Liu et al. 2013], PharmacomiR (<http://www.pharmaco-mir.org/>) [Rukov et al. 2014], EpimiR (<http://bioinfo.hrbmu.edu.cn/EpimiR/>) [Dai et al. 2014] and starBase (<http://starbase.sysu.edu.cn/>) [Li et al. 2014], were included to construct the target gene- miRNA regulatory network using the Cytoscape software.

Construction of target genes - TF regulatory network

The TFs (transcription factors) that can regulate the up and down regulated genes were predicted using the NetworkAnalyst database (<https://www.networkanalyst.ca/>) [Zhou et al 2019] with default significant parameters. Only the interaction relationships can be predicted by ENCODE (<http://cistrome.org/BETA/>) [Wang et al 2013], were included to construct the target gene- TF regulatory network using the Cytoscape software.

Validation of hub genes

UALCAN (<http://ualcan.path.uab.edu/analysis.html>) [Chandrashekar et al 2017] is a website that offers an online validation of survival biomarkers and analyzes the overall survival (OS) of patients with high and low expression of certain genes. In our investigation, up and down regulated hub genes were detected, and a survival curve was drawn. The log-rank p-value was calculated. And the UALCAN [Chandrashekar et al 2017] platform was applied to further verify the expression level of up and down regulated hub genes between hepatoblastoma and normal samples from The Cancer Genome Atlas (TCGA) portal. Next, UALCAN [Chandrashekar et al 2017] platform was applied to further verify the expression level of up and down regulated hub genes from normal to all stages of hepatoblastoma from The Cancer Genome Atlas (TCGA) portal. Mutation analysis of up and down regulated hub genes was performed by cBioPortal online platform (<http://www.cbioportal.org>) [Gao et al 2013]. We also evaluated the protein expression of up and down regulated hub genes by using the human protein atlas (HPA, www.proteinatlas.org) [Uhlen et al 2010] database considering that gene expression was not always consistent with its protein level. Receiver operating characteristic (ROC) analysis was conducted by using the generalized linear model (GLM) in machine learning algorithms [Robinet et al. 2011] to show the potential diagnostic and prognostic value of up and down regulated hub genes. $P < 0.05$ was considered to indicate a statistically significant difference. Up and down regulated hub genes were quantified using real-time PCR. Total RNA was isolated from cultured Hep G2 and normal liver cells using a TRI Reagent® (Sigma, USA). RNA was then reverse transcribed into cDNA according to the instructions of a FastQuant RT kit (with gDNase; Tiangen Biotech Co., Ltd.). RT-PCR was performed using a QuantStudio 7 Flex real-time PCR system (Thermo Fisher Scientific, Waltham, MA, USA). The reaction conditions were as follows: predenaturation at 95 °C for 10 min and 40 cycles of denaturation at 95 °C for 10 sec, annealing at 60 °C for 20 sec

and extension at 72 °C for 34 sec. β -actin was used as the internal reference for up and down regulated hub genes. The primers for up and down regulated hub genes are listed in Table 1. The $2^{-\Delta\Delta Ct}$ technique was engaged to measure the ratio of the relative expression of a target gene in the experimental group to that in the control group with the following formulas: $\Delta\Delta Ct = \Delta Ct_{\text{experimental group}} - \Delta Ct_{\text{control group}}$ and $\Delta Ct = Ct_{\text{target gene}} - Ct_{\text{internal reference}}$. Ct was the amplification cycle. Three separate experiments were conducted [Livak and Schmittgen, 2001]. The immune infiltration analysis for up and down regulated hub genes have been conducted with the scatter plot in TIMER (<https://cistrome.shinyapps.io/timer/>) [Li et al. 2017] is a RNA-Seq expression profiling database from The Cancer Genome Atlas (TCGA) portal. Immune infiltration analysis was used to check the immune infiltrates (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells) across hepatoblastoma.

Results

Data pre-processing

Gene expression profile (GSE131329) was collected from the GEO database. A total of 67 samples included 53 hepatoblastoma tissues samples and 14 noncancerous liver tissue samples. The dataset was then performed normalization and batch effect correction (Fig. 1A and 1B).

DEGs analysis

The series from each chip was analyzed separately using limma in R software, and finally, the DEGs, using adjusted P value < 0.05 and $|\log \text{foldchange (FC)}| > 1.07$ for up regulated genes; $|\log \text{foldchange (FC)}| < -1.25$ for down regulated genes as the cut-off criteria, were identified. A total of 996 DEGs, including 499 up regulated genes and 497 down regulated genes, were detected in hepatoblastoma are listed in Table 2. The heatmap of the up and down regulated hub genes are shown in Fig. 2 and Fig. 3. The volcano plot of gene expression profile data was shown in Fig. 4.

Pathway enrichment analysis of DEGs

Pathway enrichment analyses for the up regulated and down regulated genes were performed by ToppGene. The up regulated genes were mainly enriched in proline biosynthesis, epoxysqualene biosynthesis, alcoholism, cell cycle, HDACs deacetylate histones, sterol biosynthesis, urea cycle and metabolism of

amino groups, PLK1 signaling events, aurora B signaling, CDK regulation of DNA replication, Wnt/beta-catenin pathway, Wnt signaling pathway, DNA replication, G2/M DNA damage checkpoint, steroid biosynthetic, lysinuric protein intolerance and risedronate pathway are listed in Table 3. Similarly, the down regulated genes were mainly enriched in superpathway of tryptophan utilization, bile acid biosynthesis, neutral pathway, metabolic pathways, complement and coagulation cascades, ATF-2 transcription factor network, IL6-mediated signaling events, biological oxidations, complement cascade, fatty acid metabolism, tryptophan metabolism, complement pathway, intrinsic prothrombin activation pathway, blood coagulation, pyrimidine metabolism, tryptophan metabolic, statin pharmacokinetics pathway, enoxaparin pathway and glycine, serine and threonine metabolism are listed Table 4.

GO enrichment analysis of DEGs

The enriched GO terms for up and down regulated genes, which are expressed by biological process (BP), cellular component (CC) and molecular function (MF), are shown in Table 5 and Table 6. The GO functional annotation analysis of these up regulated genes revealed that (1) the BPs were mainly involved in chromosome organization and DNA conformation change, (2) the CCs of the altered genes were mainly involved in DNA packaging complex and chromosomal region, and (3) the MFs were mainly involved in DNA binding, bending and protein dimerization activity. Similarly, GO functional annotation analysis of these down regulated genes revealed that (1) the BPs were mainly involved in organic acid metabolic process and small molecule catabolic process, 2) the CCs of the altered genes were mainly involved in blood microparticle and endoplasmic reticulum membrane, and (3) the MFs were mainly involved in cofactor binding and oxidoreductase activity.

Construction of the PPI network and module analysis

To further explore the biological role of overlapping up and down regulated genes, a PPI network was created using the IID database. The PPI network for up regulated genes consisted of 4396 nodes and 7665 interactions (Fig. 5). The 12 up regulated hub genes TP53, TCTN2, PLK1, AURKA, CDK1, ANLN, TRIM28, BMP4, PLPPR1, FOXRED2, SERPINE2 and EFNA4 were screened with the highest node degree distribution, betweenness centrality, stress centrality, closeness centrality and lowest clustering coefficient using Cytoscape software (Table 6), and scatter plot along with statistical results for node degree

distribution, betweenness centrality, stress centrality, closeness centrality and clustering coefficient are presented in Fig. 6A - 6E. These up regulated hub genes were enriched in cell cycle, chromosome organization, metabolism of proteins, gene expression, nuclear division, DNA metabolic process, pathways in cancer, integral component of plasma membrane, ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins, and generation of neurons. Similarly, PPI network for down regulated genes consisted of 5582 nodes and 10377 interactions (Fig. 7). The 12 down regulated hub genes ESR1, LRRK2, AR, FOS, ICAM1, CLU, MYO1B, NPY1R, SLC22A1, FGGY, SLC10A1 and CYP4X1 were screened with the highest node degree distribution, betweenness centrality, stress centrality, closeness centrality and lowest clustering coefficient using Cytoscape software (Table 6), and scatter plot along with statistical results for node degree distribution, betweenness centrality, stress centrality, closeness centrality and clustering coefficient are presented in Fig. 8A - 8E. These down regulated hub genes were enriched in lipid metabolic process, oxidation-reduction process, response to lipid, ATF-2 transcription factor network, NF-kappa B signaling pathway, complement and coagulation cascades, ion transport, intrinsic component of plasma membrane, identical protein binding, metabolism of lipids and lipoproteins, and superpathway of tryptophan utilization.

The PEWCC1 plug-in was also used to identify significant modules. As a result, 4 significant modules (up and down regulated genes) were identified. Modules (Module 6, Module 9, Module 36 and Module 43) for up regulated genes consisted of 137 nodes and 302 edges, 128 nodes and 130 edges, 55 nodes and 103 edges, and 46 nodes and 145 edges are shown in Fig. 9. These modules included up regulated hub genes such as RRM2, PBK, CHEK1, CDC25C, SKP2, TP53, KIF11, CCNA2, CCNB2, CDK1, TOP2A, CDC6, SORT1, FOXM1, CCNB1, CDC20, RACGAP1, RCN2, CAD, HJURP, HDAC11, IGF2BP3, BUB1, NDC80, SKA1, SPC25, NUF2, SPC24, PLK1, MCM7, MCM5, ASF1B, MCM4, MCM6, MCM3, FOXQ1, MCM2 and MMS22, which exhibited the highest score. These up regulated hub genes were enriched in superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis, nuclear division, cell cycle, nuclear division, pathways in cancer, chromosome organization, cell division, DNA double-strand break repair, HTLV-I infection, M phase, metabolism of proteins, E2F transcription factor network, p75(NTR)-mediated signalling, FOXM1 transcription factor network, gene expression, RHO GTPase effectors, aurora B signalling, metabolic pathways, DNA

conformation change, alcoholism, PLK1 signaling events, regulation of cell cycle, chromosomal region, protein-containing complex binding, spindle, CDK regulation of DNA replication, DNA metabolic process, embryo development, C-MYB transcription factor network, cellular protein-containing complex assembly, microtubule cytoskeleton, nuclear chromatin, and DNA binding, bending. Modules (Module 6, Module 7, Module 9 and Module 10) for up regulated genes consisted of 147 nodes and 158 edges, 116 nodes and 134 edges, 107 nodes and 113 edges, and 105 nodes and 118 edges are shown in Fig. 10. These modules included down regulated hub genes such as C7, FOS, C8B, PON1, CLU, FGB, CTH, FGG, LPA, USP2, RNF125, HOOK1, PLA2G2A, MAP3K5, GADD45B, SOCS3, MACF1 and GLRX, which exhibited the highest score. These down regulated hub genes were enriched in complement and coagulation cascades, ATF-2 transcription factor network, defense response, metabolic pathways, lipid metabolic process, response to metal ion, organic acid metabolic process, IL6-mediated signaling events, amb2 integrin signalling, ion transport, endoplasmic reticulum membrane, identical protein binding, glypican 1 network, p38 MAPK signaling pathway, response to other organism, golgi apparatus oxidation-reduction process.

Construction of target genes - miRNA regulatory network

We constructed a target genes - miRNA regulatory network, and the network is shown in Fig. 11 and Fig. 12, which illustrates that certain miRNAs play important roles in regulating up and down regulated genes. In Fig. 11, nodes with greater degrees tend to be up regulated target genes. In this network, PLAGL2 was targeted by the 189 miRNAs (ex, hsa-mir-4710), CDK6 was targeted by the 188 miRNAs (ex, hsa-mir-4657), CCND2 was targeted by the 179 miRNAs (ex, hsa-mir-5192), SLC1A5 was targeted by the 174 miRNAs (ex, hsa-mir-4284) and PKM was targeted by the 160 miRNAs (ex, hsa-mir-4525) are listed in Table 7. These up regulated target genes were enriched in nuclear chromatin, cell cycle, nuclear division, integral component of plasma membrane and glycolysis. In Fig. 12, nodes with greater degrees tend to be down regulated target genes. In this network, SOD2 was targeted by the 257 miRNAs (ex, hsa-mir-4803), WEE1 was targeted by the 182 miRNAs (ex, hsa-mir-4647), SULT1B1 was targeted by the 131 miRNAs (ex, hsa-mir-3163), APOL6 was targeted by the 127 miRNAs (ex, hsa-mir-4455) and DHODH was targeted by the 119 miRNAs (ex, hsa-mir-1200) are listed in Table 7. These

down regulated target genes were enriched in peroxisome, biological oxidations, lipid binding and metabolic pathways.

Construction of target genes - TF regulatory network

We constructed a target gene - TF regulatory network, and the network is shown in Fig. 13 and Fig. 14, which illustrates that certain TFs play important roles in regulating up and down regulated genes. In Fig. 13, nodes with greater degrees tend to be up regulated target genes. In this network, DCDC2 was targeted by the 121 TFs (ex, KLF9), WFS1 was targeted by the 120 TFs (ex, TFDP1), ERCC2 was targeted by the 117 TFs (ex, ZNF580), DLX5 was targeted by the 107 TFs (ex, MXD3) and CCNB1 was targeted by the 105 TFs (ex, SMAD5) are listed in Table 8. These up regulated target genes were enriched in generation of neurons, metabolism of proteins, gene expression, embryo development and cell cycle. In Fig. 14, nodes with greater degrees tend to be down regulated target genes. In this network, MASP2 was targeted by the 115 TFs (ex, ATF3), OTC was targeted by the 82 TFs (ex, YY1), ACMSD was targeted by the 76 TFs (ex, MYBL2), AGXT was targeted by the 76 TFs (ex, MBD4) and SLC15A1 was targeted by the 76 TFs (ex, HNF4G) are listed in Table 8. These down regulated target genes were enriched in complement and coagulation cascades, metabolic pathways, superpathway of tryptophan utilization, glycine biosynthesis and ion transport.

Validation of hub genes

To explore the prognostic role of up and down regulated hub genes, we analyzed the relationship between mRNA expression and overall survival (OS) using the UALCAN online tool. Interestingly, we found that high expression of TP53, PLK1, AURKA, CDK1 and ANLN were resulted in shorter OS in hepatoblastoma patients (Fig. 15), whereas low expression of ESR1, FGB, ACAT1, GOT1 and ALAS1 were resulted in shorter OS in hepatoblastoma patients (Fig. 16). To further validate the results, we examined the expression of ten hub genes using the UALCAN database. The expression levels of five up regulated hub genes (TP53, PLK1, AURKA, CDK1 and ANLN) and five down regulated hub genes (ESR1, FGB, ACAT1, GOT1 and ALAS1) were significantly different between hepatoblastoma samples and noncancerous liver samples (Fig. 17). The expression trends of the ten hub genes were consistent with the results we obtained. The stage analyses of TP53, PLK1, AURKA, CDK1, ANLN, ESR1, FGB, ACAT1, GOT1 and ALAS1 in human tissues were

visualized using UALCAN online tool. The present study revealed that TP53, PLK1, AURKA, CDK1 and ANLN exhibited higher expression levels in all stage of hepatoblastoma compared with the noncancerous liver samples (Fig. 18 A-E), whereas ESR1, FGB, ACAT1, GOT1 and ALAS1 exhibited lower expression levels in all stage of hepatoblastoma compared with the noncancerous liver samples (Fig. 18 F-J). We explored the genetic mutations of up and down regulated hub genes using the cBioPortal tool in TCGA data and found that TP53 (32%), PLK1 (0.3%), AURKA (2%), CDK1 (0.6%), ANLN (1.7%), ESR1 (2.8%), FGB (2%), ACAT1 (1.1%), GOT1 (0.8%) and ALAS1 (1.1%) were the most frequently muted genes in the ten query genes, including inframe mutation (putative driver), missense mutation (putative driver), truncating mutation (putative driver), deep deletion, missense mutation (unknown significance), amplification, truncating mutation (unknown significance) and fusion (Fig. 19). Based on the immunohistochemical staining results from HPA database, the protein expression level of TP53, PLK1, AURKA, CDK1 and ANLN was consistent with their gene expression, that is, the protein levels of hub genes were also in a higher expression state in hepatoblastoma tissues compared to noncancerous liver (Fig. 20 A-E), whereas the protein expression level of ESR1, FGB, ACAT1, GOT1 and ALAS1 was consistent with their gene expression, that is, the protein levels of hub genes were also in a lower expression state in hepatoblastoma tissues compared to noncancerous liver (Fig. 20 F-J). ROC curve analysis revealed that five up regulated hub genes (TP53, PLK1, AURKA, CDK1 and ANLN) and five down regulated hub genes (ESR1, FGB, ACAT1, GOT1 and ALAS1) serve valuable biomarkers for distinguishing hepatoblastoma from those with noncancerous liver, with the AUC exceeded 0.90 (Fig. 21). For up regulated genes, the AUC was 0.934 for TP53, 0.973 for PLK1, 0.956 for AURKA, 0.976 for CDK1 and 0.942 for ANLN. For down regulated genes, the AUC was 0.950 for ESR1, 0.950 for FGB, 0.957 for ACAT1, 0.972 for GOT1 and 0.933 for ALAS1. Consistent with the bioinformatics analysis results, the RT-PCR results revealed. As shown in Fig. 22, the expression levels of TP53, PLK1, AURKA, CDK1 and ANLN were significantly higher in the hepatoblastoma than in the noncancerous liver, whereas expression levels of ESR1, FGB, ACAT1, GOT1 and ALAS1 were significantly lower in the hepatoblastoma than in the noncancerous liver. Immune infiltration analysis was found that the high expression level of TP53, PLK1, AURKA, CDK1 and ANLN were all negatively associated with tumor purity (Fig. 23 A-E), whereas low expression

level of ESR1, FGB, ACAT1, GOT1 and ALAS1 were all positively associated with tumor purity (Fig. 23 F-J). This finding further confirmed the key role of these up and down regulated hub genes probably expressed not in the microenvironment, but expressed in the tumor cells. These findings further confirmed the key role of these up and down regulated hub genes in the onset of hepatoblastoma.

Discussion

Presently, the speedy forward in microarray and high-throughput technologies has spread the function biomedicine in clinical practice, such as cancer initial diagnosis, new targeted drug exploration and prognosis prediction. GEO database, as a public repository for archiving high-throughput microarray experimental gene expression data, has contributed the dynamic tools to resolve important genes and pathways linked with the molecular pathogenesis of tumors [Wu et al. 2019]. In the current investigation, based on the GEO database, single gene expression profile including 53 hepatoblastoma tissues samples and 14 noncancerous liver tissue samples were integrated for a comprehensive bioinformatics analysis. The aim of our investigation was to identify the possible small molecule drugs for the treatment of hepatoblastoma and to determine the new biomarkers correspond with the molecular pathogenesis and prognosis of hepatoblastoma. A total of 996 DEGs between hepatoblastoma tissues and corresponding noncancerous liver tissues were diagnosed, which consisted of 499 up regulated genes and 497 down regulated genes. Genes such as DLK1 [Falix et al. 2012] and EPCAM (epithelial cell adhesion molecule) [Lopez-Nunez et al. 2019] were linked with development of hepatoblastoma. Genes such as NKD1 [Wang et al. 2017] and TNFRSF19 [Guo et al. 2020] were liable for proliferation of hepatocellular carcinoma cells, but these genes may be linked with development of proliferation of hepatoblastoma cells. NPNT (nephronectin) was associated with invasion of breast cancer cells [Wang et al. 2018], but this gene may be responsible for invasion of hepatoblastoma cells. Decrease expression of tumour suppressor genes such as C3P1 [Zhong et al. 2018], SLC22A1 [Grimm et al. 2016], RDH16 [Zhu et al. 2020], HAO2 [Mattu et al. 2016] and GLS2 [Kuo et al. 2016] were linked with progression of hepatocellular carcinoma, but low expression of these genes may associated with invasion of hepatoblastoma cells.

Pathway enrichment analyses were performed using the 499 up regulated genes to elucidate the action of hepatoblastoma. PYCR1 was associated with

metabolism in hepatocellular carcinoma [Zhuang et al. 2019], but this gene may be liable for linked with metabolism in hepatoblastoma. Enriched genes such as ALDH18A1 [Guo et al. 2020] and HDAC11 [Thole et al. 2017] were linked with development of neuroblastoma, but these genes may be involved in progression of hepatoblastoma. Enriched methylated enriched genes such as GNG4 [Pal et al. 2016], CCND2 [Tsutsui et al. 2010], CDH13 [Moelans et al. 2011] and HELLS (helicase, lymphoid specific) [Law et al. 2019] were liable for progression of various cancer types, but these methylated genes may be important for advancement of hepatoblastoma. Enriched genes such as KIF18A [Luo et al. 2018], MCM6 [Liu et al. 2018], SKA1 [Xiao et al. 2019] and ACTG2 [Wu et al. 2017] were involved in invasion of hepatocellular carcinoma cells, but these genes may be associated with invasion of hepatoblastoma cells. Enriched genes such as PTTG1 [Lin et al. 2019], CENPF (centromere protein F) [Li et al. 2018], HJURP (Holliday junction recognition protein) [Chen et al. 2018], MCM2 [Yang et al. 2018], MCM7 [Qu et al. 2017], RRM2 [Wang et al. 2016], SGO1 [Wang et al. 2015], NDC80 [Ju et al. 2017], FOXM1 [Yu et al. 2016], SKP2 [Wei et al. 2018], TPX2 [Chen et al. 2018], PLK4 [Bao et al. 2018], NUF2 [Wang et al. 2019], CENPK (centromere protein K) [Wang et al. 2019], NCAPG (non-SMC condensin I complex subunit G) [Zhang et al. 2018], BUB1 [Xu et al. 2017], E2F5 [Sun et al. 2016], RFC3 [Yao et al. 2015], NCAPH (non-SMC condensin I complex subunit H) [Sun et al. 2019], CCNB1 [Gu et al. 2019], CDK1 [Gao et al. 2018], CDC25C [Sun et al. 2015], MAD2L1 [Li et al. 2017], CDK6 [Zhu et al. 2016], DKK1 [Zhang et al. 2016], DKK4 [Chouhan et al. 2016], DKK2 [Lin et al. 2016] and LEF1 [Hu et al. 2018] were important for proliferation of hepatocellular carcinoma cells, but these genes may be involved in proliferation of hepatoblastoma cells. High expression of enriched genes such as SPC25 [Chen et al. 2018], MCM4 [Xie et al. 2017], TYMS (thymidylatesynthetase) [Lee et al. 2013], KNTC1 [Liu et al. 2019] and CDH11 [Chen et al. 2018] were responsible for advancement of various cancer types, but over expression these gene may be liable for progression of hepatoblastoma. Elevated expression of enriched genes such as MCM3 [Meng et al. 2019], CHEK1 [Gong et al. 2020], SPC24 [Zhu et al. 2015], MYBL2 [Guan et al. 2018], KIF20A [Lu et al. 2018], CCNB2 [Li et al. 2019], CDC20 [Zhuang et al. 2018], SQLE (squaleneepoxidase) [Liu et al. 2018], ECT2 [Yu et al. 2019], SFRP4 [Xu et al. 2015], FRZB (frizzled related protein) [Shen et al. 2015] and BCL9 [Xu et al. 2017] were associated with advancement of hepatocellular carcinoma, but over expression of these genes may be linked

with development of hepatoblastoma. Enriched genes such as MCM5 [Mio et al. 2016], PRIM1 [Lee et al. 2019], GINS2 [Chi et al. 2020], GINS1 [Tang et al. 2019] and CCNA2 [Li et al. 2019] were responsible for proliferation of various cancer types, but these genes may be linked with proliferation of hepatoblastoma cells. Mutation in TUBG1 was liable for advancement of breast cancer [Blanco et al. 2015], but alteration in this gene may be liable for progression of hepatoblastoma. Enriched genes such as PLK1 [Yamada et al. 2004], AURKA (aurora kinase A) [Zhang et al. 2018], TP53 [Yang et al. 2019], CDK4 [Kim et al. 1998] and AXIN2 [Koch et al. 2004] were involved in development of hepatoblastoma. Enriched genes such as POLE2 [Li et al. 2018], CENPI (centromere protein I) [Ding et al. 2018] and SPDL1 [Kodama et al. 2019] were responsible for invasion of various cancer cell types, but these genes may be involved in invasion of hepatoblastoma cells. Single nucleotide polymorphism (SNP) in CDC6 was liable for advancement of hepatocellular carcinoma [Xiong et al. 2009], but this polymorphic gene may be involved in development of hepatoblastoma. Our study found that H4C9, H2AC15, H2AC14, H2AC16, H2AC6, H2AC4, H2AC17, H2AC20, H2BC8, H2BC13, H2BC14, H2BC7, H2BC6, H2BC9, H2BC10, H3C1, H3C3, H3C6, H3C11, H3C8, H3C12, H3C10, H3C2, H4C4, H4C2, H4C5, H4C13, H4C14, MACROH2A2, H2AC12, H2AC21, H3C7, H2AC11, H2AC8, H2AZ1, H2BC5, H2BC3, MND1, RPS27, NCAPD2, RHNO1, FDFT1, MYH7B, MYCN (MYCN proto-oncogene, bHLH transcription factor) and SLC7A6 are up regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target. Similarly, pathway enrichment analyses were performed using the 497 down regulated genes to elucidate the action of hepatoblastoma. SNP in enriched genes such as ADH1B [Shih et al. 2018], NAT2 [Farker et al. 2003], CYP1A1 [Abo-Hashem et al. 2016], CYP2D6 [Agundez et al. 1996], GSTA1 [Akhdar et al. 2016], MBL2 [Wang et al. 2016] C6 [Wang et al. 2016] and SERPINE1 [Divella et al. 2015] were linked with advancement of hepatocellular carcinoma, but these polymorphic genes may be responsible for progression of hepatoblastoma. Enriched genes such as KMO (kynurenine 3-monooxygenase) [Jin et al. 2015], HMGCS2 [Wang et al. 2019], LIPG (lipase G, endothelial type) [Cadenas et al. 2019], PON3 [Cai et al. 2016], AASS (aminoadipate-semialdehyde synthase) [Xue et al. 2019], PCK2 [Liu et al. 2012], PPARGC1A [Wang et al. 2018] and JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [Kim et al. 2001] were associated with proliferation of hepatocellular carcinoma cells, but these

genes may be associated with proliferation of hepatoblastoma cells. Enriched genes such as CYP1A2 [Biazi et al. 2017], ADH4 [Wei et al. 2012], ACSL1 [Cui et al. 2014], UGT2B4 [Wijayakumara et al. 2017], ALDH1A1 [Yan et al. 2016], PON1 [Shu et al. 2017], ASS1 [Frulio et al. 2019], AKR1D1 [Nikolaou et al. 2019], PTGS2 [Chen et al. 2019], NNMT (nicotinamide N-methyltransferase) [Kim et al. 2009], GPT (glutamic--pyruvic transaminase) [Shimokawa et al. 1977], NNT (nicotinamide nucleotide transhydrogenase) [Lu et al. 2017] and PCK1 [Xiang et al. 2020] were linked with metabolic activity in hepatocellular carcinoma, but these genes may be involved in metabolic activity in hepatoblastoma. Low expression of enriched genes such as CYP2C19 [Ashida et al. 2018], ABAT (4-aminobutyrate aminotransferase) [Jansen et al. 2015], ACOX1 [Chen et al. 2018], ACSM3 [Ruan et al. 2017], FBP1 [Liu et al. 2018], ST3GAL6 [Souady et al. 2011], AGXT (alanine--glyoxylate and serine--pyruvate aminotransferase) [Sun et al. 2019], ALDOB (aldolase, fructose-bisphosphate B) [Tao et al. 2015], ALDH6A1 [Shin et al. 2020], XDH (xanthine dehydrogenase) [Chen et al. 2017], OGDHL (oxoglutarate dehydrogenase like) [Jiao et al. 2019], CYP2C8 [Li et al. 2019], CYP2C9 [Yu et al. 2015], CYP3A5 [Jiang et al. 2015], BHMT (betaine--homocysteine S-methyltransferase) [Jin et al. 2016], TAT (tyrosine aminotransferase) [Fu et al. 2010], SLC27A5 [Gao et al. 2020], GYS2 [Chen et al. 2019], GLYAT (glycine-N-acyltransferase) [Matsuo et al. 2012], CES3 [Quiroga et al. 2016], MASP2 [Ding et al. 2014], C7 [Seol et al. 2016] and F11 [Du et al. 2019] were involved in progression of hepatocellular carcinoma, but decrease expression these genes may be identified with growth of hepatoblastoma. Enriched genes such as SULT1A2 [Fernandez-Santander et al. 2013], PIK3C2G [Li et al. 2015], AGL (amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase) [Richmond et al. 2018], UGT2B10 [Lu et al. 2018], CTH (cystathionine gamma-lyase) [Xu et al. 2020] and CYP26A1 [Osanai and Lee, 2015] were involved in metabolic activity of various cancer types, but these genes may liable for metabolic activity of in hepatoblastoma. Enriched genes such as TDO2 [Pham et al. 2018], EPHX2 [Vainio et al. 2011], PLA2G2A [Ganesan et al. 2008], INPP1 [Li et al. 2019], GCH1 [Gao et al. 2016], GNE (glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase) [Kemmerer et al. 2012], PAPSS2 [Zhang et al. 2019], GLYATL1 [Eich et al. 2019], CFB (complement factor B) [Kim et al. 2019], C1R [Riihilä et al. 2020], C1S [Riihilä et al. 2020], C9 [Chong et al. 2010], FGB (fibrinogen beta chain) [Repetto et al. 2018] and KNG1 [Quesada-Calvo et al. 2017] were linked with development of various

cancer types, but these genes may be culpable for advancement of hepatoblastoma. Methylation inactivation of tumor suppressor enriched genes such as HAAO (3-hydroxyanthranilate 3,4-dioxygenase) [Huang et al. 2010] and AOX1 [Vantaku et al. 2019] were identified with growth of various cancer types, but loss of these genes may be liable for progression of hepatoblastoma. Epigenetic inactivation of enriched tumor suppressor genes such as CDO1 [Choi et al. 2017], DUSP5 [Liu et al. 2017] and SOCS3 [Zhang et al. 2015] were liable for progression of hepatocellular carcinoma, but loss of these genes may be linked with development of hepatoblastoma. Enriched genes such as SGMS2 [Zheng et al. 2019], ACAT1 [Ye et al. 2016], UGP2 [Zeng et al. 2019], GOT1 [Wang et al. 2019], CDA (cytidinedeaminase) [Ye et al. 2015] and FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [Liu et al. 2018] were important for proliferation of various cancer cells types, but these genes may be involved in proliferation of hepatoblastoma cells. SNP in enriched genes such as MAT1A [Mumbreakar et al. 2017], ADH1C [Hidaka et al. 2015], UGT2B7 [Sutiman et al. 2016], HSD11B1 [Wang et al. 2013], CYP2B6 [Kuo et al. 2017], CHST9 [Yuan et al. 2017], CYP39A1 [Melchardt et al. 2015], FMO3 [Bae et al. 2006], CYP3A43 [Han et al. 2015], CYP4F3 [Yin et al. 2017], CYP4F11 [Cardenas-Rodriguez et al. 2012], SULT2A1 [Wilborn et al. 2006], GSTA2 [Maekawa et al. 2011] and GSTA3 [Duan et al. 2018] were involved in progression of various cancer types, but these polymorphic genes may be linked with development of hepatoblastoma. Enriched genes such as MGLL (monoglyceride lipase) [Yang et al. 2018], DMGDH (dimethylglycine dehydrogenase) [Liu et al. 2016], SHMT1 [Dou et al. 2019], ARG1 [You et al. 2018], CXCL8 [Li et al. 2015] and FGG (fibrinogen gamma chain) [Zhang et al. 2019] were involved in invasion of hepatocellular carcinoma cells, but these genes may be responsible for invasion of hepatoblastoma cells. Enriched genes such as CYP3A4 [Holownia and Braszko, 2004], OTC (ornithine carbamoyltransferase) [Mavri-Damelin et al. 2007] and DUSP1 [Casteel et al. 2010] were associated with development of hepatoblastoma. GCLM (glutamate-cysteine ligase modifier subunit) was linked with drug resistance in lung cancer [Nishi et al. 2005], but this gene may be linked with chemoresistance in hepatoblastoma. Our study found that CYP4X1, KYNU (kynureninase), ACMSD (aminocarboxymuconatesemialdehyde decarboxylase), HGD (homogentisate 1,2-dioxygenase), ACACB (acetyl-CoA carboxylase beta), ACADL (acyl-CoA dehydrogenase long chain), ACADSB (acyl-CoA dehydrogenase short/branched chain), CES1, PIPOX (pipecolic acid and

sarcosine oxidase), AKR1C4, HAO1, NDST3, HPD (4-hydroxyphenylpyruvate dioxygenase), SCP2, ALAS1, ALPL (alkaline phosphatase, biomineralization associated), AGPAT2, CYP4F2, ETNPPL (ethanolamine-phosphate phospholyase), GBA3, AGXT2, GDA (guanine deaminase), HSD17B6, LPIN2, MMUT (methylmalonyl-CoA mutase), UPB1, CYP2C18, MBOAT1, CYP4A11, CYP8B1, BAAT (bile acid-CoA:amino acid N-acyltransferase), GATM (glycine amidinotransferase), DAO (D-amino acid oxidase), UROC1, SUCLG2, PTS (6-pyruvoyltetrahydropterin synthase), DHODH (dihydroorotate dehydrogenase (quinone)), ACSM5, SDS (serine dehydratase), CNBP1, DPYS (dihydropyrimidinase), GPAT3, AMDHD1, NAMPT (nicotinamidephosphoribosyltransferase), EHHADH (enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase), HAL (histidine ammonia-lyase), AADAT (amino adipate aminotransferase), AADAC (arylacetamidedeacetylase), AKR7L, CYP4F22, SULT1B1, CYP4V2, CYP4A22, ACADM (acyl-CoA dehydrogenase medium chain), C5, C8A, F8, F9, F13B, SERPINC1 and KLKB1 are down regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target.

GO enrichment analyses were performed using the 499 up regulated genes to elucidate the action of hepatoblastoma. Enriched genes such as NUSAP1 [Garrido-Rodríguez et al. 2019], ASF1B [Han et al. 2018] and PRKAA2 [Zhang et al. 2020] were associated with proliferation of various cancer types cells, but these genes may be linked with proliferation of hepatoblastoma cells. SNP in enriched genes such as ERCC2 [Zhao et al. 2019] and MSH2 [Zhu et al. 2018] were involved in progression of hepatocellular carcinoma, but these polymorphic genes may be linked with development of hepatoblastoma. Enriched genes such as TTK (TTK protein kinase) [Miao et al. 2016], MKI67 [Yang et al. 2017], TET1 [Lin et al. 2015], DLGAP5 [Liao et al. 2013] and SMYD2 [Zuo et al. 2018] were involved in proliferation of hepatocellular carcinoma cells, but these genes may be responsible for proliferation of hepatoblastoma cells. Over expression of USP21 was liable for progression of pancreatic cancer [Hou et al. 2019], but high expression of this gene may be linked with advancement of hepatoblastoma. Increased expression of enriched genes such as RACGAP1 [Wang et al. 2011], PRKD1 [Döppler et al. 2016], EHMT2 [Song et al. 2019], KIFC1 [Han et al. 2019], TERC (telomerase RNA component) [Baena-Del et al. 2018], TRIM28 [Jin et al. 2017] and TOP2A [Panvichian et al. 2015] were involved in progression of hepatocellular carcinoma, but over expression these genes may be associated

with advancement of hepatoblastoma. Enriched genes such as UHRF1 [Beck et al. 2018] and HMGA2 [Li et al. 2020] were responsible for advancement of hepatoblastoma. NAP1L1 was linked with chemoresistance in hepatocellular carcinoma [Le et al. 2019], but this gene may be liable for drug resistance in hepatoblastoma. PRC1 was associated with invasion of hepatocellular carcinoma cell [Tang et al. 2019], but this gene may be liable for invasion of hepatoblastoma cells. Our study found that NPM3, SUPT3H, PCGF2, H1-2 (H1.2 linker histone, cluster member) and H1-5 (H1.5 linker histone, cluster member) are up regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target. Similarly, GO enrichment analyses were performed using the 497 down regulated genes to elucidate the action of hepatoblastoma. Enriched genes such as HGF (hepatocyte growth factor) [Purcell et al. 2011], ABCB11 [Vilarinho et al. 2014] and TLR4 [Hsiao et al. 2015] were linked with advancement of hepatoblastoma. Enriched genes such as VNN3 [Ha et al. 2019], HPGD (15-hydroxyprostaglandin dehydrogenase) [He et al. 2016], VNN2 [Chen et al. 2018], VNN1 [Zhang et al. 2017], GPD1 [Zhou et al. 2017], CFH (complement factor H) [Campa et al. 2015], SERPINA3 [Cao et al. 2018], AFM (afamin) [Shen et al. 2016], HPR (haptoglobin-related protein) [Epelbaum et al. 1998], C4BPA [Sogawa et al. 2016], CYP4Z1 [Zheng et al. 2019], SRD5A1 [Sinreih et al. 2015] and STEAP4 [Xue et al. 2017] were linked with progression of various cancer types, but these genes may be involved in development of hepatoblastoma. Low expression of enriched genes such as ETFDH (electron transfer flavoprotein dehydrogenase) [Wu et al. 2019], GNMT (glycine N-methyltransferase) [Chen et al. 1998], DCN (decorin) [Ju et al. 2015], ITIH4 [Li et al. 2018], GHR (growth hormone receptor) [Qi et al. 2016], LYVE1 [Kitagawa et al. 2013] and HP (haptoglobin) [Mondal et al. 2016] were identified with development of hepatocellular carcinoma, but decrease expression of these genes may be associated with development of hepatoblastoma. SNP in PRKAG2 was responsible for advancement of colon and rectal cancer [Slattery et al. 2010], but this polymorphic gene may be liable for progression of hepatoblastoma. Enriched genes such as STAB2 [Wu et al. 2018], IGF1 [Shi and Teng, 2015], HRG (histidine rich glycoprotein) [Zhang et al. 2015], CFHR3 [Liu et al. 2020] and CD5L [Aran et al. 2018] were linked with proliferation of hepatocellular carcinoma cells, but these genes may be involved in proliferation of hepatoblastoma cells. Methylation inactivation of ADHFE1 was identified with growth of colorectal cancer [Hu et al. 2019], but

loss this gene may be responsible for progression of hepatoblastoma. Enriched genes such as ANGPTL3 [El-Shal et al. 2017], CLU (clusterin) [Zheng et al. 2016], FCN2 [Yang et al. 2016], HPX (hemopexin) [Kobayashi et al. 2012], CP (ceruloplasmin) [Pousset et al. 2001] and BCHE (butyrylcholinesterase) [Yokoyama et al. 1982] were involved in invasion of hepatocellular carcinoma cells, but these genes may be associated invasion of hepatoblastoma cells. Enriched genes such as SLC27A2 [Chen et al. 2018] and ABHD2 [Yamanoi et al. 2016] were important for drug resistance in various cancer types, but these genes may be involved in chemo resistance in hepatoblastoma. Our study found that RIDA (reactive intermediate imine deaminase A homolog), ALDH8A1, PFKFB1, PHYH (phytanoyl-CoA 2-hydroxylase), DHTKD1, IYD (iodotyrosinedeiodinase), APOC3, SLC7A2, ART4, CYP2D7, SLC17A3, AVPR1A, INSIG1, GCKR (glucokinase regulator), APOA5, ASPG (asparaginase), BCO2, CFHR1, APCS (amyloid P component, serum), APOL1, FCN3, C8G, PZP (PZP alpha-2-macroglobulin like), ORM1, ASPDH (aspartate dehydrogenase domain containing) and FMO4 are down regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target.

In PPI network and module analysis, we found out the top up regulated hub genes. Over expression of hub genes such as ANLN (anillin actin binding protein) [Zhang et al. 2018], CHEK1 [Yang et al. 2017], IGF2BP3 [Li et al. 2015] and FOXQ1 [Huang et al. 2015] were linked with progression of hepatocellular carcinoma, but these genes may be involved in the advancement of hepatoblastoma. Hub genes such as BMP4 [Deng et al. 2018] and RCN2 [Ding et al. 2017] were responsible for proliferation of hepatocellular carcinoma cells, but this gene may be associated with proliferation of hepatoblastoma cells. Elevated expression of hub genes such as SERPINE2 [Stępień et al. 2017] and KIF11 [Schneider et al. 2017] were liable for progression of thyroid cancer, but this gene may be identified with growth of hepatoblastom. Our study found that TCTN2, PLPPR1, FOXRED2, EFNA4, SORT1, CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase) and MMS22 are up regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target. Similarly, PPI network and module analysis, we found out the top down regulated hub genes. Methylation inactivation tumor suppressor ESR1 was linked with development of hepatocellular carcinoma [Dou et al. 2016], but loss of this gene may be responsible for progression of hepatoblastom. Low expression of hub genes

such as AR (androgen receptor) [Shi et al. 2017] and NPY1R [Lv et al. 2016] were liable for progression of hepatocellular carcinoma, but decrease expression of this gene may be identified with growth of hepatoblastom. Hub genes such as ICAM1 [Guo et al. 2016], LPA (lipoprotein(a)) [Malaguarnera et al. 2017], HOOK1 [Sun et al. 2017] and GADD45B [Xia et al. 2017] were responsible for invasion of hepatocellular carcinoma cells, but this gene may be involved in invasion of hepatoblastom cells. Hub genes such as FGGY (FGGY carbohydrate kinase domain containing) [Zhang et al. 2019], USP2 [Davis et al. 2016] and MAP3K5 [Stark et al. 2011] were involved in progression of various cancer types, but these gene may be involved in development of hepatoblastom. SNP in SLC10A1 was responsible for advancement of hepatocellular carcinoma [Hu et al. 2016], but this polymorphic gene may associated with development of hepatoblastom. Our study found that LRRK2, MYO1B, C8B, RNF125, MACF1 and GLRX (glutaredoxin) are down regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target.

In target genes - miRNA regulatory network analysis, we found out the top up regulated target genes. High expression of target genes such as PLAGL2 [Xu et al. 2018] and SLC1A5 [Toda et al. 2017] were involved in progression of various cancer types, but elevated expression of these genes may be associated with development of hepatoblastom. Our study found that PKM (pyruvate kinase M1/2) is up regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target. Similarly, target genes - miRNA regulatory network analysis, we found out the top down regulated target genes. Decreased expression of target genes such as SOD2 [Wang et al. 2016] and WEE1 [Cuneo et al. 2016] were liable for advancement of hepatocellular carcinoma, but reduced expression these genes may be involved in development of hepatoblastoma. Our study found that APOL6 is down regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target.

In target genes - TF regulatory network analysis, we found out the top up regulated target genes. Methylation inactivation of DCDC2 was responsible for progression of hepatocellular carcinoma [Inokawa et al. 2013], but loss of this gene may be liable for development of hepatoblastoma. Increase expression of DLX5 was important for proliferation of ovarian cancer cells [Tan et al. 2010], but this gene may be associated with proliferation of hepatoblastoma

cells. Our study found that WFS1 is up regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target. Similarly, target genes - TF regulatory network analysis, we found out the top down regulated target genes. Our study found that SLC15A1 is down regulated in hepatoblastoma and has potential as a novel diagnostic and prognostic biomarker, and therapeutic target.

Ten candidate genes (TP53, PLK1, AURKA, CDK1, ANLN, ESR1, FGB, ACAT1, GOT1 and ALAS1) that were closely related to the survival rate of patients with hepatoblastoma were diagnosed by analyzing the corresponding total survival information from patients with hepatoblastoma from TCGA program. Survival analysis, expression verification, stage analysis, mutation analysis, immuno infiltration analysis and immuno histochemical analysis of these candidate genes were analyzed according to the TCGA database and the human protein atlas database. ROC analysis of these candidate genes were analyzed according to the GSE131329 dataset for prognostic and diagnostic value of candidate genes. Simultaneously, these ten candidate genes were further verified by RT-PCR using hepatoblastoma patient samples. Overall, the survival characteristics of the ten candidate genes may suggest the prognosis and diagnosis of hepatoblastoma, and thus may be a promising biomarker and therapeutic target for hepatoblastoma.

In summary, the current study used the GEO database, TCGA database and the human protein atlas database to diagnose ten candidate genes as possible biomarkers for patients with hepatoblastoma and documented the existence of the ten candidate genes by RT-PCR. The results of the current study provide a potential biomarker for hepatoblastoma screening and diagnosis, therapeutic targets, and prognosis. However, further investigations and follow-up of clinical cases are required to expose the molecular pathogenesis and prognosis of hepatoblastoma.

Acknowledgement

I thank Eiso Hiyama, Hiroshima University, Natural Science Center for Basic Research and Development, Life Science, Hiroshima, Japan, very much, the author who deposited their microarray dataset, GSE131329, into the public GEO database.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

No informed consent because this study does not contain human or animals participants.

Availability of data and materials

The datasets supporting the conclusions of this article are available in the GEO (Gene Expression Omnibus) (<https://www.ncbi.nlm.nih.gov/geo/>) repository. [(GSE131329) (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE131329>)]

Consent for publication

Not applicable.

Funding

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author Contributions

B. V. - Writing original draft, and review and editing

C. V. - Software and investigation

I. K. - Supervision and resources

Authors

Basavaraj Vastrad ORCID ID: [0000-0003-2202-7637](https://orcid.org/0000-0003-2202-7637)

Chanabasayya Vastrad ORCID ID: [0000-0003-3615-4450](https://orcid.org/0000-0003-3615-4450)

Iranna Kotturshetti ORCID ID: [0000-0003-1988-7345](https://orcid.org/0000-0003-1988-7345)

References

- Abo-Hashem EM, El-Emshaty WM, Farag Rel S, Zakaria S, Abd El-Aziz M, Ghonaim A (2016) Genetic Polymorphisms of Cytochrome P4501A1 (CYP1A1) and Glutathione S-Transferase P1 (GSTP1) and Risk of Hepatocellular Carcinoma Among Chronic Hepatitis C Patients in Egypt. *Biochem Genet* 54:696–713. doi:[10.1007/s10528-016-9749-6](https://doi.org/10.1007/s10528-016-9749-6)
- Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, Pulliam J, Margolin J, Finegold MJ (2009) Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. *Hum Pathol* 40:843–853. doi:[10.1016/j.humpath.2008.10.022](https://doi.org/10.1016/j.humpath.2008.10.022)
- Agundez JA, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, Benitez J (1996) Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. *Pharmacogenetics* 6:501–512. doi:[10.1097/00008571-199612000-00003](https://doi.org/10.1097/00008571-199612000-00003)
- Akhdar H, El Shamieh S, Musso O, Désert R, Joumaa W, Guyader D, Aninat C, Corlu A, Morel F (2016) The rs3957357C>T SNP in GSTA1 Is Associated with a Higher Risk of Occurrence of Hepatocellular Carcinoma in European Individuals. *PLoS One* 11:e0167543. doi:[10.1371/journal.pone.0167543](https://doi.org/10.1371/journal.pone.0167543)
- Aktaş S, Zadeoğlulari Z, Erçetin P, Olgun N (2010) The effect of differentiating and apoptotic agents on notch signalling pathway in hepatoblastoma. *Hepatogastroenterology* 57:891–898.
- Aran G, Sanjurjo L, Bárcena C, Simon-Coma M, Téllez É, Vázquez-Vitali M, Garrido M, Guerra L, Díaz E, Ojanguren I et al (2018) CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78). *FASEB J* 32:3878–3891. doi:[10.1096/fj.201700941RR](https://doi.org/10.1096/fj.201700941RR)
- Ashida R, Okamura Y, Ohshima K, Kakuda Y, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Sugino T, Urakami K et al (2018) The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma. *Oncotarget* 9:22058–22068. doi:[10.18632/oncotarget.25178](https://doi.org/10.18632/oncotarget.25178)

Bae SY, Choi SK, Kim KR, Park CS, Lee SK, Roh HK, Shin DW, Pie JE, Woo ZH, Kang JH (2006) Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. *Cancer Sci* 97:774–779. doi:[10.1111/j.1349-7006.2006.00241.x](https://doi.org/10.1111/j.1349-7006.2006.00241.x)

Baena Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ et al (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. *J Pathol* 244:11–24. doi:[10.1002/path.4980](https://doi.org/10.1002/path.4980)

Bao J, Yu Y, Chen J, He Y, Chen X, Ren Z, Xue C, Liu L, Hu Q, Li J et al (2018) MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. *Cell Death Dis* 9:1045. doi:[10.1038/s41419-018-1020-0](https://doi.org/10.1038/s41419-018-1020-0)

Beck A, Trippel F, Wagner A, Joppien S, Felle M, Vokuhl C, Schwarzmayer T, Strom TM, von Schweinitz D, Längst G et al (2018) Overexpression of UHRF1 promotes silencing of tumor suppressor genes and predicts outcome in hepatoblastoma. *Clin Epigenetics* 10:27. doi:[10.1186/s13148-018-0462-7](https://doi.org/10.1186/s13148-018-0462-7)

Biazi BI, Zanetti TA, Baranoski A, Corveloni AC, Mantovani MS (2017) Cis-Nerolidol Induces Endoplasmic Reticulum Stress and Cell Death in Human Hepatocellular Carcinoma Cells through Extensive CYP2C19 and CYP1A2 Oxidation. *Basic Clin Pharmacol Toxicol* 121:334–341. doi:[10.1111/bcpt.12772](https://doi.org/10.1111/bcpt.12772)

Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, De Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N et al (2015) Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS One* 10:e0120020. doi:[10.1371/journal.pone.0120020](https://doi.org/10.1371/journal.pone.0120020)

Breuer K, Foroushani AK, Laird MR, Chen C, Sribnaia A, Lo R, Winsor GL, Hancock RE, Brinkman FS, Lynn DJ (2013) InnateDB: systems biology of innate immunity and beyond--recent updates and continuing curation. *Nucleic Acids Res* 41:D1228–D1233. doi:[10.1093/nar/gks1147](https://doi.org/10.1093/nar/gks1147)

Busweiler LA, Wijnen MH, Wilde JC, Sieders E, van Scheltinga SE, van Heurn LE, Ziros J, Bakx R, Heij HA (2017) Surgical treatment of childhood hepatoblastoma in the Netherlands (1990-2013). *Pediatr Surg Int* 33:23–31. doi:[10.1007/s00383-016-3989-8](https://doi.org/10.1007/s00383-016-3989-8)

Cadenas C, Vosbeck S, Edlund K, Grgas K, Madjar K, Hellwig B, Adawy A, Glotzbach A, Stewart JD, Lesjak MS et al (2019) LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer. *Int J Cancer* 145:901–915. doi:[10.1002/ijc.32138](https://doi.org/10.1002/ijc.32138)

Cai J, Yuan SX, Yang F, Tao QF, Yang Y, Xu QG, Wang ZG, Yu J, Lin KY, Wang ZY et al (2016) Paraoxonase 3 inhibits cell proliferation and serves as a prognostic predictor in hepatocellular carcinoma. *Oncotarget* 7:70045–70057. doi:[10.18632/oncotarget.12145](https://doi.org/10.18632/oncotarget.12145)

Campa MJ, Gottlin EB, Bushey RT, Patz EF Jr (2015) Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. *Cancer Immunol Res* 3:1325–1332. doi:[10.1158/2326-6066.CIR-15-0122](https://doi.org/10.1158/2326-6066.CIR-15-0122)

Cao LL, Pei XF, Qiao X, Yu J, Ye H, Xi CL, Wang PY, Gong ZL (2018) SERPINA3 Silencing Inhibits the Migration, Invasion, and Liver Metastasis of Colon Cancer Cells. *Dig Dis Sci* 63:2309–2319. doi:[10.1007/s10620-018-5137-x](https://doi.org/10.1007/s10620-018-5137-x)

Cardenas-Rodriguez N, Lara-Padilla E, Bandala C, López-Cruz J, Uscanga-Carmona C, Lucio-Monter PF, Floriano-Sánchez E (2012) CYP2W1, CYP4F11 and CYP8A1 polymorphisms and interaction of CYP2W1 genotypes with risk factors in Mexican women with breast cancer. *Asian Pac J Cancer Prev* 13:837–846. doi:[10.7314/apjcp.2012.13.3.837](https://doi.org/10.7314/apjcp.2012.13.3.837)

Caspi R, Billington R, Ferrer L, Foerster H, Fulcher CA, Keseler IM, Kothari A, Krummenacker M, Latendresse M, Mueller LA et al (2016) The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. *Nucleic Acids Res* 44:D471–D480. doi:[10.1093/nar/gkv1164](https://doi.org/10.1093/nar/gkv1164)

Casteel M, Nielsen C, Kothlow S, Dietrich R, Märklbauer E (2010) Impact of DUSP1 on the apoptotic potential of deoxynivalenol in the epithelial cell line HepG2. *Toxicol Lett* 199:43–50. doi:[10.1016/j.toxlet.2010.08.004](https://doi.org/10.1016/j.toxlet.2010.08.004)

Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S (2017) UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. *Neoplasia* 19:649–658. doi:[10.1016/j.neo.2017.05.002](https://doi.org/10.1016/j.neo.2017.05.002)

Chen FD, Chen HH, Ke SC, Zheng LR, Zheng XY (2018) SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer. *Neoplasma* 65:915–924. doi:[10.4149/neo_2018_180122N48](https://doi.org/10.4149/neo_2018_180122N48)

Chen HN, Chen Y, Zhou ZG, Wei Y, Huang C (2019) A novel role for ketoconazole in hepatocellular carcinoma treatment: linking PTGS2 to mitophagy machinery. *Autophagy* 15:733–734. doi:[10.1080/15548627.2019.1569934](https://doi.org/10.1080/15548627.2019.1569934)

Chen GL, Ye T, Chen HL, Zhao ZY, Tang WQ, Wang LS, Xia JL (2017) Xanthine dehydrogenase downregulation promotes TGF β signaling and cancer stem cell-related gene expression in hepatocellular carcinoma. *Oncogenesis* 6:e382. . doi:[10.1038/oncsis.2017.81](https://doi.org/10.1038/oncsis.2017.81)

Chen J, Bardes EE, Aronow BJ, Jegga AG (2009) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. *Nucleic Acids Res* 37:W305-W311. doi:[10.1093/nar/gkp427](https://doi.org/10.1093/nar/gkp427)

Chen J, Chen H, Yang H, Dai H (2018) SPC25 upregulation increases cancer stem cell properties in non-small cell lung adenocarcinoma cells and independently predicts poor survival. *Biomed Pharmacother* 100:233–239. doi:[10.1016/j.biopha.2018.02.015](https://doi.org/10.1016/j.biopha.2018.02.015)

Chen PF, Wang F, Nie JY, Feng JR, Liu J, Zhou R, Wang HL, Zhao Q (2018) Co-expression network analysis identified CDH11 in association with progression and prognosis in gastric cancer. *Onco Targets Ther* 11:6425–6436. doi:[10.2147/OTT.S176511](https://doi.org/10.2147/OTT.S176511)

Chen SL, Zhang CZ, Liu LL, Lu SX, Pan YH, Wang CH, He YF, Lin CS, Yang X, Xie D et al (2019) A GYS2/p53 Negative Feedback Loop Restricts Tumor Growth in HBV-Related Hepatocellular Carcinoma. *Cancer Res* 79:534–545. doi:[10.1158/0008-5472.CAN-18-2357](https://doi.org/10.1158/0008-5472.CAN-18-2357)

Chen T, Huang H, Zhou Y, Geng L, Shen T, Yin S, Zhou L, Zheng S (2018) HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3 β signaling pathways. *J Exp Clin Cancer Res* 37:193. doi:[10.1186/s13046-018-0866-4](https://doi.org/10.1186/s13046-018-0866-4)

Chen XF, Tian MX, Sun RQ, Zhang ML, Zhou LS, Jin L, Chen LL, Zhou WJ, Duan KL, Chen YJ et al (2018) SIRT5 inhibits peroxisomal ACOX1 to prevent

oxidative damage and is downregulated in liver cancer. *EMBO Rep* 19:e45124. doi:[10.15252/embr.201745124](https://doi.org/10.15252/embr.201745124)

Chen Y, Huang T, Yang X, Liu C, Li P, Wang Z, Zhi S (2018) MicroRNA-106a regulates the proliferation and invasion of human osteosarcoma cells by targeting VNN2. *Oncol Rep* 40:2251–2259. doi:[10.3892/or.2018.6601](https://doi.org/10.3892/or.2018.6601)

Chen YC, Chen IS, Huang GJ, Kang CH, Wang KC, Tsao MJ, Pan HW (2018) Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells. *Onco Targets Ther* 11:1601–1616. doi:[10.2147/OTT.S147453](https://doi.org/10.2147/OTT.S147453)

Chen YM, Shiu JY, Tzeng SJ, Shih LS, Chen YJ, Lui WY, Chen PH (1998) Characterization of glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma. *Int J Cancer* 75:787–793. doi:[10.1002/\(sici\)1097-0215\(19980302\)75:5<787::aid-ijc20>3.0.co;2-2](https://doi.org/10.1002/(sici)1097-0215(19980302)75:5<787::aid-ijc20>3.0.co;2-2)

Chi F, Wang Z, Li Y, Chang N (2020) Knockdown of GINS2 inhibits proliferation and promotes apoptosis through the p53/GADD45A pathway in non-small cell lung cancer. *Biosci Rep* BSR20193949. doi:[10.1042/BSR20193949](https://doi.org/10.1042/BSR20193949)

Choi JI, Cho EH, Kim SB, Kim R, Kwon J, Park M, Shin HJ, Ryu HS, Park SH, Lee KH (2017) Promoter methylation of cysteine dioxygenase type 1: gene silencing and tumorigenesis in hepatocellular carcinoma. *Ann Hepatobiliary Pancreat Surg* 21:181–187. doi:[10.14701/ahbps.2017.21.4.181](https://doi.org/10.14701/ahbps.2017.21.4.181)

Chong PK, Lee H, Loh MC, Choong LY, Lin Q, So JB, Lim KH, Soo RA, Yong WP, Chan SP et al (2010) Upregulation of plasma C9 protein in gastric cancer patients. *Proteomics* 10:3210–3221. doi:[10.1002/pmic.201000127](https://doi.org/10.1002/pmic.201000127)

Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH et al (2018) miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. *Nucleic Acids Res* 46:D296–D302. doi:[10.1093/nar/gkx1067](https://doi.org/10.1093/nar/gkx1067)

Chouhan S, Singh S, Athavale D, Ramteke P, Pandey V, Joseph J, Mohan R, Shetty PK, Bhat MK (2016) Glucose induced activation of canonical Wnt signaling pathway in hepatocellular carcinoma is regulated by DKK4. *Sci Rep* 6:27558. doi:[10.1038/srep27558](https://doi.org/10.1038/srep27558)

Cruz Jr RJ, Ranganathan S, Mazariegos G, Soltys K, Nayyar N, Sun Q, Bond G, Shaw PH, Haberman K, Krishnamurti L et al (2013) Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities. *Surgery* 153:150–159. doi:[10.1016/j.surg.2012.11.006](https://doi.org/10.1016/j.surg.2012.11.006)

Cui M, Wang Y, Sun B, Xiao Z, Ye L, Zhang X (2014) MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. *Biochem Biophys Res Commun* 444:270–275. doi:[10.1016/j.bbrc.2014.01.051](https://doi.org/10.1016/j.bbrc.2014.01.051)

Cui X, Wang Z, Li J, Zhu J, Ren Z, Zhang D, Zhao W, Fan Y, Zhang D, Sun R (2020) Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/ β -catenin signalling pathway. *Cell Prolif* e12768. doi:[10.1111/cpr.12768](https://doi.org/10.1111/cpr.12768)

Cui Y, Lu P, Song G, Liu Q, Zhu D, Liu X (2016) Involvement of PI3K/Akt, ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis. *Food Chem Toxicol* 92:26–37. doi:[10.1016/j.fct.2016.03.013](https://doi.org/10.1016/j.fct.2016.03.013)

Cuneo KC, Morgan MA, Davis MA, Parcels LA, Parcels J, Karnak D, Ryan C, Liu N, Maybaum J, Lawrence TS (2016) Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress. *Int J Radiat Oncol Biol Phys* 95:782–790. doi:[10.1016/j.ijrobp.2016.01.028](https://doi.org/10.1016/j.ijrobp.2016.01.028)

Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR (2002) GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. *Nat Genet* 31:19–20. doi:[10.1038/ng0502-19](https://doi.org/10.1038/ng0502-19)

Dai E, Yu X, Zhang Y, Meng F, Wang S, Liu X, Liu D, Wang J, Li X, Jiang W (2014) EpimiR: a database of curated mutual regulation between miRNAs and epigenetic modifications. *Database* (Oxford) 2014:bau023. doi:[10.1093/database/bau023](https://doi.org/10.1093/database/bau023)

Davis MI, Prangani R, Fox JT, Shen M, Parmar K, Gaudiano EF, Liu L, Tanega C, McGee L, Hall MD et al (2016) Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models. *J Biol Chem* 291:24628–24640. doi:[10.1074/jbc.M116.738567](https://doi.org/10.1074/jbc.M116.738567)

Deng G, Zeng S, Qu Y, Luo Q, Guo C, Yin L, Han Y, Li Y, Cai C, Fu Y et al (2018) BMP4 promotes hepatocellular carcinoma proliferation by autophagy activation through JNK1-mediated Bcl-2 phosphorylation. *J Exp Clin Cancer Res* 37:156. doi:[10.1186/s13046-018-0828-x](https://doi.org/10.1186/s13046-018-0828-x)

Ding D, Huang H, Jiang W, Yu W, Zhu H, Liu J, Saiyin H, Wu J, Jiang S, Yu L (2017) Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway. *Oncogene* 36:6691–6700. doi:[10.1038/onc.2017.230](https://doi.org/10.1038/onc.2017.230)

Ding N, Li R, Shi W, He C (2018) CENPI is overexpressed in colorectal cancer and regulates cell migration and invasion. *Gene* 674:80–86. doi:[10.1016/j.gene.2018.06.067](https://doi.org/10.1016/j.gene.2018.06.067)

Ding W, Qiu Q, Liu G, Liu J, Mao R, Lin B (2014) Metadata checklist: identification of CHI3L1 and MASP2 as a biomarker pair for liver cancer through integrative secretome and transcriptome analysis. *OMICS* 18:658–661. doi:[10.1089/omi.2014.0090](https://doi.org/10.1089/omi.2014.0090)

Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD et al (2015) Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE. *Transl Oncol* 8:273–278. doi:[10.1016/j.tranon.2015.05.002](https://doi.org/10.1016/j.tranon.2015.05.002)

Döppler H, Panayiotou R, Reid EM, Maimo W, Bastea L, Storz P (2016) The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer. *Sci Rep* 6:33758. doi:[10.1038/srep33758](https://doi.org/10.1038/srep33758)

Dou C, Xu Q, Liu J, Wang Y, Zhou Z, Yao W, Jiang K, Cheng J, Zhang C, Tu K (2019) SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production. *J Exp Clin Cancer Res* 38:70. doi:[10.1186/s13046-019-1067-5](https://doi.org/10.1186/s13046-019-1067-5)

Dou CY, Fan YC, Cao CJ, Yang Y, Wang K (2016) Sera DNA Methylation of CDH1, DNMT3b and ESR1 Promoters as Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma. *Dig Dis Sci* 61:1130–1138. doi:[10.1007/s10620-015-3975-3](https://doi.org/10.1007/s10620-015-3975-3)

Du J, Chen M, Liu J, Hu P, Guan H, Jiao X (2019) LncRNA F11-AS1 suppresses liver hepatocellular carcinoma progression by competitively binding

with miR-3146 to regulate PTEN expression. *J Cell Biochem* 120:18457–18464. doi:[10.1002/jcb.29163](https://doi.org/10.1002/jcb.29163)

Duan S, Gong B, Wang P, Huang H, Luo L, Liu F (2018) Novel prognostic biomarkers of gastric cancer based on gene expression microarray: COL12A1, GSTA3, FGA and FGG. *Mol Med Rep* 18:3727–3736. doi:[10.3892/mmr.2018.9368](https://doi.org/10.3892/mmr.2018.9368)

Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res* 30:207–210. doi:[10.1093/nar/30.1.207](https://doi.org/10.1093/nar/30.1.207)

Eich ML, Chandrashekar DS, Rodriguez Penˆa MD, Robinson AD, Siddiqui J, DaignaultˆNewton S, Chakravarthi BV, Kunju LP, Netto GJ, Varambally S (2019) Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer. *Prostate* 79:1629–1639. doi:[10.1002/pros.23887](https://doi.org/10.1002/pros.23887)

El-Shal AS, Zidan HE, Rashad NM, Wadea FM (2017) Angiopoietin-like protein 3 and 4 expression 4 and their serum levels in hepatocellular carcinoma. *Cytokine* 96:75–86. doi:[10.1016/j.cyto.2017.03.006](https://doi.org/10.1016/j.cyto.2017.03.006)

Epelbaum R, Shalitin C, Segal R, Valansi C, Arselan I, Faraggi D, Leviov M, Ben-Shahar M, Haim N (1998) Haptoglobin-related protein as a serum marker in malignant lymphoma. *Pathol Oncol Res* 4:271–276. doi:[10.1007/bf02905217](https://doi.org/10.1007/bf02905217)

Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B et al (2018) The Reactome Pathway Knowledgebase. *Nucleic Acids Res* 46:D649–D655. doi:[10.1093/nar/gkx1132](https://doi.org/10.1093/nar/gkx1132)

Falix FA, Aronson DC, Lamers WH, Hiralall JK, Seppen J (2012) DLK1, a serum marker for hepatoblastoma in young infants. *Pediatr Blood Cancer* 59:743–745. doi:[10.1002/pbc.24024](https://doi.org/10.1002/pbc.24024)

Fan Y, Xia J (2018) miRNet-Functional Analysis and Visual Exploration of miRNA-Target Interactions in a Network Context. *Methods Mol Biol* 1819:215–233. doi:[10.1007/978-1-4939-8618-7_10](https://doi.org/10.1007/978-1-4939-8618-7_10)

Fernandez-Santander A, Gaibar M, Novillo A, Romero-Lorca A, Rubio M, Chicharro LM, Tejerina A, Bandres F (2013) Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients. *PLoS One* 8:e70183. doi:[10.1371/journal.pone.0070183](https://doi.org/10.1371/journal.pone.0070183)

Frulio N, Balabaud C, Laurent C, Trillaud H, Bioulac-Sage P (2019) Unclassified hepatocellular adenoma expressing ASS1 associated with inflammatory hepatocellular adenomas. *Clin Res Hepatol Gastroenterol* 43:e63–e67. doi:[10.1016/j.clinre.2019.03.012](https://doi.org/10.1016/j.clinre.2019.03.012)

Fu L, Dong SS, Xie YW, Tai LS, Chen L, Kong KL, Man K, Xie D, Li Y, Cheng Y et al (2010) Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma. *Hepatology* 51:1624–1634. doi:[10.1002/hep.23540](https://doi.org/10.1002/hep.23540)

Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B et al (2008) Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. *Cancer Res* 68:4277–4286. doi:[10.1158/0008-5472.CAN-07-6517](https://doi.org/10.1158/0008-5472.CAN-07-6517)

Gao CL, Wang GW, Yang GQ, Yang H, Zhuang L (2018) Karyopherin subunit- α 2 expression accelerates cell cycle progression by upregulating CCNB2 and CDK1 in hepatocellular carcinoma. *Oncol Lett* 15:2815–2820. doi:[10.3892/ol.2017.7691](https://doi.org/10.3892/ol.2017.7691)

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 6(269):pl1. doi:[10.1126/scisignal.2004088](https://doi.org/10.1126/scisignal.2004088)

Gao Q, Zhang G, Zheng Y, Yang Y, Chen C, Xia J, Liang L, Lei C, Hu Y, Cai X et al (2020) SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC. *Cell Death Differ* 27:1086–1104. doi:[10.1038/s41418-019-0399-1](https://doi.org/10.1038/s41418-019-0399-1)

Gao Y, Wang W, Cao J, Wang F, Geng Y, Cao J, Xu X, Zhou J, Liu P, Zhang S (2016) Upregulation of AUF1 is involved in the proliferation of esophageal squamous cell carcinoma through GCH1. *Int J Oncol* 49:2001–2010. doi:[10.3892/ijo.2016.3713](https://doi.org/10.3892/ijo.2016.3713)

Garrido-Rodríguez M, Ortea I, Calzado MA, Muñoz E, García V (2019) SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. *J Proteomics* 193:217–229. doi:[10.1016/j.jprot.2018.10.012](https://doi.org/10.1016/j.jprot.2018.10.012)

Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy--analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics* 20:307–315. doi:[10.1093/bioinformatics/btg405](https://doi.org/10.1093/bioinformatics/btg405)

Gong D, Feng PC, Ke XF, Kuang HL, Pan LL, Ye Q, Wu JB (2020) Silencing Long Non-coding RNA LINC01224 Inhibits Hepatocellular Carcinoma Progression via MicroRNA-330-5p-Induced Inhibition of CHEK1. *Mol Ther Nucleic Acids* 19:482–497. doi:[10.1016/j.omtn.2019.10.007](https://doi.org/10.1016/j.omtn.2019.10.007)

Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM et al (2016) Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. *BMC Cancer* 16:94. doi:[10.1186/s12885-016-2150-3](https://doi.org/10.1186/s12885-016-2150-3)

Gu J, Liu X, Li J, He Y (2019) MicroRNA-144 inhibits cell proliferation, migration and invasion in human hepatocellular carcinoma by targeting CCNB1. *Cancer Cell Int* 19:15. doi:[10.1186/s12935-019-0729-x](https://doi.org/10.1186/s12935-019-0729-x)

Guan Z, Cheng W, Huang D, Wei A (2018) High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma. *Curr Res Transl Med* 66:27–32. doi:[10.1016/j.retram.2017.11.002](https://doi.org/10.1016/j.retram.2017.11.002)

Guo L, Gao R, Gan J, Zhu Y, Ma J, Lv P, Zhang Y, Li S, Tang H (2020) Downregulation of TNFRSF19 and RAB43 by a novel miRNA, miR-HCC3, promotes proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma cells. *Biochem Biophys Res Commun* S0006-291X(20)30379-X. doi:[10.1016/j.bbrc.2020.02.105](https://doi.org/10.1016/j.bbrc.2020.02.105)

Guo W, Liu S, Cheng Y, Lu L, Shi J, Xu G, Li N, Cheng K, Wu M, Cheng S et al (2016) ICAM-1-Related Noncoding RNA in Cancer Stem Cells Maintains ICAM-1 Expression in Hepatocellular Carcinoma. *Clin Cancer Res* 22:2041–2050. doi:[10.1158/1078-0432.CCR-14-3106](https://doi.org/10.1158/1078-0432.CCR-14-3106)

Guo YF, Duan JJ, Wang J, Li L, Wang D, Liu XZ, Yang J, Zhang HR, Lv J, Yang YJ et al (2020) Inhibition of the ALDH18A1-MYCN positive feedback loop attenuates MYCN-amplified neuroblastoma growth. *Sci Transl Med* 12:eaax8694. doi:[10.1126/scitranslmed.aax8694](https://doi.org/10.1126/scitranslmed.aax8694)

Ha M, Jeong H, Roh JS, Lee B, Lee D, Han ME, Oh SO, Sohn DH, Kim YH (2019) VNN3 is a potential novel biomarker for predicting prognosis in clear

cell renal cell carcinoma. *Anim Cells Syst* (Seoul) 23:112–117. doi:[10.1080/19768354.2019.1583126](https://doi.org/10.1080/19768354.2019.1583126)

Han G, Zhang X, Liu P, Yu Q, Li Z, Yu Q, Wei X (2018) Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer. *Int J Oncol* 53:2056–2066. doi:[10.3892/ijo.2018.4526](https://doi.org/10.3892/ijo.2018.4526)

Han J, Wang F, Lan Y, Wang J, Nie C, Liang Y, Song R, Zheng T, Pan S, Pei T et al (2019) KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling. *Oncogene* 38:406–420. doi:[10.1038/s41388-018-0440-8](https://doi.org/10.1038/s41388-018-0440-8)

Han JH, Lee YS, Kim HJ, Lee SY, Myung SC (2015) Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population. *Asian J Androl* 17:285–291. doi:[10.4103/1008-682X.133320](https://doi.org/10.4103/1008-682X.133320)

He Q, Chen Z, Dong Q, Zhang L, Chen D, Patel A, Koya A, Luan X, Cabay RJ, Dai Y et al (2016) MicroRNA-21 regulates prostaglandin E2 signaling pathway by targeting 15-hydroxyprostaglandin dehydrogenase in tongue squamous cell carcinoma. *BMC Cancer* 16:685. doi:[10.1186/s12885-016-2716-0](https://doi.org/10.1186/s12885-016-2716-0)

Heber S, Sick B (2006) Quality assessment of Affymetrix GeneChip data. *OMICS* 10:358–368. doi:[10.1089/omi.2006.10.358](https://doi.org/10.1089/omi.2006.10.358)

Hidaka A, Sasazuki S, Matsuo K, Ito H, Sawada N, Shimazu T, Yamaji T, Iwasaki M, Inoue M, Tsugane S (2015) Genetic polymorphisms of ADH1B, ADH1C and ALDH2, alcohol consumption, and the risk of gastric cancer: the Japan Public Health Center-based prospective study. *Carcinogenesis* 36:223–231. doi:[10.1093/carcin/bgu244](https://doi.org/10.1093/carcin/bgu244)

Hiyama E, Hishiki T, Watanabe K, Ida K, Yano M, Oue T, Iehara T, Hoshino K, Koh K, Tanaka Y et al (2016) Resectability and tumor response after preoperative chemotherapy in hepatoblastoma treated by the Japanese Study Group for Pediatric Liver Tumor (JPLT)-2 protocol. *J Pediatr Surg* 51:2053–2057. doi:[10.1016/j.jpedsurg.2016.09.038](https://doi.org/10.1016/j.jpedsurg.2016.09.038)

Holownia A, Braszko JJ (2004) Tamoxifen cytotoxicity in hepatoblastoma cells stably transfected with human CYP3A4. *Biochem Pharmacol* 67:1057–1064. doi:[10.1016/j.bcp.2003.10.027](https://doi.org/10.1016/j.bcp.2003.10.027)

Hou P, Ma X, Zhang Q, Wu CJ, Liao W, Li J, Wang H, Zhao J, Zhou X, Guan C et al (2019) USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation. *Genes Dev* 33:1361–1366. doi:[10.1101/gad.326314.119](https://doi.org/10.1101/gad.326314.119)

Hsiao CC, Chen PH, Cheng CI, Tsai MS, Chang CY, Lu SC, Hsieh MC, Lin YC, Lee PH, Kao YH (2015) Toll-like receptor-4 is a target for suppression of proliferation and chemoresistance in HepG2 hepatoblastoma cells. *Cancer Lett* 368:144–152. doi:[10.1016/j.canlet.2015.08.004](https://doi.org/10.1016/j.canlet.2015.08.004)

Hu HH, Liu J, Lin YL, Luo WS, Chu YJ, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY et al (2016) The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B. *Gut* 65:1514–1521. doi:[10.1136/gutjnl-2015-310686](https://doi.org/10.1136/gutjnl-2015-310686)

Hu Y, Guo X, Wang J, Liu Y, Gao H, Fan H, Nong X, Yang X, Liu M, Li S et al (2018) A novel microRNA identified in hepatocellular carcinomas is responsive to LEF1 and facilitates proliferation and epithelial-mesenchymal transition via targeting of NFIX. *Oncogenesis* 7:22. doi:[10.1038/s41389-017-0010-x](https://doi.org/10.1038/s41389-017-0010-x)

Hu YH, Ma S, Zhang XN, Zhang ZY, Zhu HF, Ji YH, Li J, Qian XL, Wang YX (2019) Hypermethylation Of ADHFE1 Promotes The Proliferation Of Colorectal Cancer Cell Via Modulating Cell Cycle Progression. *Onco Targets Ther* 12:8105–8115. doi:[10.2147/OTT.S223423](https://doi.org/10.2147/OTT.S223423)

Huang W, Chen Z, Shang X, Tian D, Wang D, Wu K, Fan D, Xia L (2015) Sox12, a direct target of FoxQ1, promotes hepatocellular carcinoma metastasis through up-regulating Twist1 and FGFBP1. *Hepatology* 61:1920–1933. doi:[10.1002/hep.2775](https://doi.org/10.1002/hep.2775)

Huang YW, Luo J, Weng YI, Mutch DG, Goodfellow PJ, Miller DS, Huang TH (2010) Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. *Gynecol Oncol* 117:239–247. doi:[10.1016/j.ygyno.2010.02.006](https://doi.org/10.1016/j.ygyno.2010.02.006)

Huang Z, Shi J, Gao Y, Cui C, Zhang S, Li J, Zhou Y, Cui Q (2019) HMDD v3.0: a database for experimentally supported human microRNA-disease associations. *Nucleic Acids Res* 47:D1013-D1017. doi:[10.1093/nar/gky1010Z](https://doi.org/10.1093/nar/gky1010Z)

Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S et al (2013) Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. *J Exp Clin Cancer Res* 32:65. doi:[10.1186/1756-9966-32-65](https://doi.org/10.1186/1756-9966-32-65)

Ishimoto K, Nakamura H, Tachibana K, Yamasaki D, Ota A, Hirano KI, Tanaka T, Hamakubo T, Sakai J, Kodama T et al (2009) Sterol-mediated regulation of human lipin 1 gene expression in hepatoblastoma cells. *J Biol Chem* 284:22195–22205. doi:[10.1074/jbc.M109.028753](https://doi.org/10.1074/jbc.M109.028753)

Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM et al (2015) Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. *Mol Oncol* 9:1218–1233. doi:[10.1016/j.molonc.2015.02.006](https://doi.org/10.1016/j.molonc.2015.02.006)

Jewison T, Su Y, Disfany FM, Liang Y, Knox C, Maciejewski A, Poelzer J, Huynh J, Zhou Y, Arndt D et al (2014) SMPDB 2.0: big improvements to the Small Molecule Pathway Database. *Nucleic Acids Res* 42:D478–D484. doi:[10.1093/nar/gkt1067](https://doi.org/10.1093/nar/gkt1067)

Jiang F, Chen L, Yang YC, Wang XM, Wang RY, Li L, Wen W, Chang YX, Chen CY, Tang J et al (2015) CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling. *Cancer Res* 75:1470–1481. doi:[10.1158/0008-5472.CAN-14-1589](https://doi.org/10.1158/0008-5472.CAN-14-1589)

Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu Y (2009) miR2Disease: a manually curated database for microRNA deregulation in human disease. *Nucleic Acids Res* 37:D98-104. doi:[10.1093/nar/gkn714](https://doi.org/10.1093/nar/gkn714)

Jiao Y, Li Y, Fu Z, Hou L, Chen Q, Cai Y, Jiang P, He M, Yang Z (2019) OGDHL Expression as a Prognostic Biomarker for Liver Cancer Patients. *Dis Markers* 2019:9037131. doi:[10.1155/2019/9037131](https://doi.org/10.1155/2019/9037131)

Jin B, Gong Z, Yang N, Huang Z, Zeng S, Chen H, Hu S, Pan G (2016) Downregulation of betaine homocysteine methyltransferase (BHMT) in

hepatocellular carcinoma associates with poor prognosis. *Tumour Biol* 37:5911–5917. doi:[10.1007/s13277-015-4443-6](https://doi.org/10.1007/s13277-015-4443-6)

Jin H, Zhang Y, You H, Tao X, Wang C, Jin G, Wang N, Ruan H, Gu D, Huo X et al (2015) Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. *Sci Rep* 5:10466. doi:[10.1038/srep10466](https://doi.org/10.1038/srep10466)

Jin X, Pan Y, Wang L, Zhang L, Ravichandran R, Potts PR, Jiang J, Wu H, Huang H (2017) MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation. *Oncogenesis* 6:e312. doi:[10.1038/oncsis.2017.21](https://doi.org/10.1038/oncsis.2017.21)

Ju LL, Chen L, Li JH, Wang YF, Lu RJ, Bian ZL, Shao JG (2017) Effect of NDC80 in human hepatocellular carcinoma. *World J Gastroenterol* 23:3675–3683. doi:[10.3748/wjg.v23.i20.3675](https://doi.org/10.3748/wjg.v23.i20.3675)

Ju W, Li S, Wang Z, Liu Y, Wang D (2015) Decorin protects human hepatoma HepG2 cells against oxygen-glucose deprivation via modulating autophagy. *Int J Clin Exp Med* 8:13347–13352.

Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M (2019) New approach for understanding genome variations in KEGG. *Nucleic Acids Res* 47:D590–D595. doi:[10.1093/nar/gky962](https://doi.org/10.1093/nar/gky962)

Kemmner W, Kessel P, Sanchez-Ruderisch H, Möller H, Hinderlich S, Schlag PM, Detjen K (2012) Loss of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) induces apoptotic processes in pancreatic carcinoma cells. *FASEB J* 26:938–946. doi:[10.1096/fj.11-186700](https://doi.org/10.1096/fj.11-186700)

Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A et al (2009) Human Protein Reference Database--2009 update. *Nucleic Acids Res* 37:D767–D772. doi:[10.1093/nar/gkn892](https://doi.org/10.1093/nar/gkn892)

Kim H, Ham EK, Kim YI, Chi JG, Lee HS, Park SH, Jung YM, Myung NK, Lee MJ, Jang JJ (1998) Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas. *Cancer Lett* 131:177–183. doi:[10.1016/s0304-3835\(98\)00151-7](https://doi.org/10.1016/s0304-3835(98)00151-7)

Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS (2009) Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. *J Exp Clin Cancer Res* 28:20. doi:[10.1186/1756-9966-28-20](https://doi.org/10.1186/1756-9966-28-20)

Kim SA, Um SJ, Kang JH, Hong KJ (2001) Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun/AP-1. *Mol Cell Biochem* 216:21–29. doi:[10.1023/a:1011022822077](https://doi.org/10.1023/a:1011022822077)

Kim SH, Lee MJ, Hwang HK, Lee SH, Kim H, Paik YK, Kang CM (2019) Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study. *Cancer Biomark* 24:335–342. doi:[10.3233/CBM-181847](https://doi.org/10.3233/CBM-181847)

Kitagawa K, Nakajima G, Kuramochi H, Ariizumi SI, Yamamoto M (2013) Lymphatic vessel endothelial hyaluronan receptor-1 is a novel prognostic indicator for human hepatocellular carcinoma. *Mol Clin Oncol* 1:1039–1048. doi:[10.3892/mco.2013.167](https://doi.org/10.3892/mco.2013.167)

Kobayashi S, Nouse K, Kinugasa H, Takeuchi Y, Tomoda T, Miyahara K, Hagihara H, Kuwaki K, Onishi H, Nakamura S et al (2012) Clinical utility of serum fucosylated hemopexin in Japanese patients with hepatocellular carcinoma. *Hepatol Res* 42:1187–1195. doi:[10.1111/j.1872-034X.2012.01044.x](https://doi.org/10.1111/j.1872-034X.2012.01044.x)

Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T (1999) Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. *Cancer Res* 59:269–273.

Koch A, Weber N, Waha A, Hartmann W, Denkhaus D, Behrens J, Birchmeier W, Schweinitz DV, Pietsch T (2004) Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. *J Pathol* 204:546–554. doi:[10.1002/path.1662](https://doi.org/10.1002/path.1662)

Kodama T, Marian TA, Lee H, Kodama M, Li J, Parmacek MS, Jenkins NA, Copeland NG, Wei Z (2019) MRTFB suppresses colorectal cancer development through regulating SPDL1 and MCAM. *Proc Natl Acad Sci U S A* 116:23625–23635. doi:[10.1073/pnas.1910413116](https://doi.org/10.1073/pnas.1910413116)

Kotlyar M, Pastrello C, Malik Z, Jurisica I (2019) IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and

domesticated species. Nucleic Acids Res 47:D581–D589. doi:[10.1093/nar/gky1037](https://doi.org/10.1093/nar/gky1037)

Kremer N, Walther AE, Tiao GM (2014) Management of hepatoblastoma: an update. *Curr Opin Pediatr* 26:362–369. doi:[10.1097/MOP.0000000000000081](https://doi.org/10.1097/MOP.0000000000000081)

Kuo SH, Yang SY, You SL, Lien HC, Lin CH, Lin PH, Huang CS (2017) Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. *Oncotarget* 8:20925–20938. doi:[10.18632/oncotarget.14995](https://doi.org/10.18632/oncotarget.14995)

Kuo TC, Chen CK, Hua KT, Yu P, Lee WJ, Chen MW, Jeng YM, Chien MH, Kuo KT, Hsiao M et al (2016) Glutaminase 2 stabilizes Dicer to repress Snail and metastasis in hepatocellular carcinoma cells. *Cancer Lett* 383:282–294. doi:[10.1016/j.canlet.2016.10.012](https://doi.org/10.1016/j.canlet.2016.10.012)

Law CT, Wei L, Tsang FH, Chan CY, Xu IM, Lai RK, Ho DW, Lee JM, Wong CC, Ng IO et al (2019) HELLS Regulates Chromatin Remodeling and Epigenetic Silencing of Multiple Tumor Suppressor Genes in Human Hepatocellular Carcinoma. *Hepatology* 69:2013–2030. doi:[10.1002/hep.30414](https://doi.org/10.1002/hep.30414)

Le Y, Kan A, Li QJ, He MK, Chen HL, Shi M (2019) NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma. *Cancer Cell Int* 19:228. doi:[10.1186/s12935-019-0949-0](https://doi.org/10.1186/s12935-019-0949-0)

Lee SW, Chen TJ, Lin LC, Li CF, Chen LT, Hsing CH, Hsu HP, Tsai CJ, Huang HY, Shiue YL (2013) Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma. *Exp Mol Pathol* 95:83–90. doi:[10.1016/j.yexmp.2013.05.006](https://doi.org/10.1016/j.yexmp.2013.05.006)

Lee WH, Chen LC, Lee CJ, Huang CC, Ho YS, Yang PS, Ho CT, Chang HL, Lin IH, Chang HW et al (2019) DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint. *Int J Cancer* 144:615–630. doi:[10.1002/ijc.31788](https://doi.org/10.1002/ijc.31788)

Lewis SE (2017) The Vision and Challenges of the Gene Ontology. *Methods Mol Biol* 1446:291–302. doi:[10.1007/978-1-4939-3743-1_21](https://doi.org/10.1007/978-1-4939-3743-1_21)

Li A, Chen H, Lin M, Zhang C, Tang E, Peng J, Wei Q, Li H, Yin L (2015) PIK3C2G copy number is associated with clinical outcomes of colorectal cancer patients treated with oxaliplatin. *Int J Clin Exp Med* 8:1137–1143.

Li C, Zhou D, Jiang X, Liu M, Tang H, Mei Z (2019) Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker. *Gene* 698:9–18. doi:[10.1016/j.gene.2019.02.062](https://doi.org/10.1016/j.gene.2019.02.062)

Li G, Li M, Wang J, Li Y, Pan Y (2018) United neighborhood closeness centrality and orthology for predicting essential proteins. *IEEE/ACM Trans Comput Biol Bioinform* 10.1109/TCBB.2018.2889978. doi:[10.1109/TCBB.2018.2889978](https://doi.org/10.1109/TCBB.2018.2889978)

Li J, Wang J, Yu J, Zhao Y, Dong Y, Fan Y, Li N, Zhang Y, Wang Y (2018) Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro. *Oncol Rep* 40:2477–2486. doi:[10.3892/or.2018.6659](https://doi.org/10.3892/or.2018.6659)

Li J, Ying Y, Xie H, Jin K, Yan H, Wang S, Xu M, Xu X, Wang X, Yang K et al (2019) Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer. *FASEB J* 33:1374–1388. doi:[10.1096/fj.201800667R](https://doi.org/10.1096/fj.201800667R)

Li JH, Liu S, Zhou H, Qu LH, Yang JH (2014) starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. *Nucleic Acids Res* 42:D92-D97. doi:[10.1093/nar/gkt1248](https://doi.org/10.1093/nar/gkt1248)

Li L, Zhuo Z, Yang Z, Zhu J, He X, Yang Z, Zhang J, Xin Y, He J, Zhang T (2020) HMGA2 Polymorphisms and Hepatoblastoma Susceptibility: A Five-Center Case-Control Study. *Pharmgenomics Pers Med* 13:51–57. doi:[10.2147/PGPM.S241100](https://doi.org/10.2147/PGPM.S241100)

Li M, Zhang L, Ge C, Chen L, Fang T, Li H, Tian H, Liu J, Chen T, Jiang G et al (2015) An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. *Oncotarget* 6:25149–25160. doi:[10.18632/oncotarget.4438](https://doi.org/10.18632/oncotarget.4438)

Li P, Zhang Q, Tang H 2019 () INPP1 up-regulation by miR-27a contributes to the growth, migration and invasion of human cervical cancer. *J Cell Mol Med* 23:7709–7716. doi:[10.1111/jcmm.14644](https://doi.org/10.1111/jcmm.14644)

Li R, Jiang X, Zhang Y, Wang S, Chen X, Yu X, Ma J, Huang X (2019) Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis. *Arch Med Res* 50:10–17. doi:[10.1016/j.arcmed.2019.03.003](https://doi.org/10.1016/j.arcmed.2019.03.003)

Li S, Li X, Xu A, Zhang B, He X, Chen H, Huang J (2018) Screening and clinical evaluation of dominant peptides of centromere protein F antigen for early diagnosis of hepatocellular carcinoma. *Mol Med Rep* 17:4720–4728. doi:[10.3892/mmr.2018.8372](https://doi.org/10.3892/mmr.2018.8372)

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS (2017) TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. *Cancer Res* 77:e108–e110. doi:[10.1158/0008-5472.CAN-17-0307](https://doi.org/10.1158/0008-5472.CAN-17-0307)

Li X, Li B, Li B, Guo T, Sun Z, Li X, Chen L, Chen W, Chen P, Mao Y et al (2018) Effective Serum Marker, Early Warning and Diagnosis, Hepatocellular Carcinoma. *Pathol Oncol Res* 24:663–670. doi:[10.1007/s12253-017-0285-4](https://doi.org/10.1007/s12253-017-0285-4)

Li XP, Yang XY, Biskup E, Zhou J, Li HL, Wu YF, Chen ML, Xu F (2015) Co-expression of CXCL8 and HIF-1 α is associated with metastasis and poor prognosis in hepatocellular carcinoma. *Oncotarget* 6:22880–22889. doi:[10.18632/oncotarget.4412](https://doi.org/10.18632/oncotarget.4412)

Li Y, Bai W, Zhang J (2017) MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1. *Biomed Pharmacother* 92:1038–1044. doi:[10.1016/j.biopha.2017.05.092](https://doi.org/10.1016/j.biopha.2017.05.092)

Liao W, Liu W, Yuan Q, Liu X, Ou Y, He S, Yuan S, Qin L, Chen Q, Nong K et al (2013) ilencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. *PLoS One* 8:e80789. doi:[10.1371/journal.pone.0080789](https://doi.org/10.1371/journal.pone.0080789)

Licata L, Briganti L, Peluso D, Perfetto L, Iannuccelli M, Galeota E, Sacco F, Palma A, Nardozza AP, Santonico E et al (2012) MINT, the molecular interaction database: 2012 update. *Nucleic Acids Res* 40:D857–D861. doi:[10.1093/nar/gkr930](https://doi.org/10.1093/nar/gkr930)

Lin LL, Wang W, Hu Z, Wang LW, Chang J, Qian H (2015) Erratum to: Negative feedback of miR-29 family TET1 involves in hepatocellular cancer. *Med Oncol* 32:39. doi:[10.1007/s12032-014-0437-2](https://doi.org/10.1007/s12032-014-0437-2)

Lin X, Yang Y, Guo Y, Liu H, Jiang J, Zheng F, Wu B (2019) PTTG1 is involved in TNF- α -related hepatocellular carcinoma via the induction of c-myc. *Cancer Med* 8:5702–5715. doi:[10.1002/cam4.2473](https://doi.org/10.1002/cam4.2473)

Lin YF, Li LH, Lin CH, Tsou MH, Chuang MT, Wu KM, Liao TL, Li JC, Wang WJ, Tomita A et al (2016) Selective Retention of an Inactive Allele of the DKK2 Tumor Suppressor Gene in Hepatocellular Carcinoma. *PLoS Genet* 1:e1006051. doi:[10.1371/journal.pgen.1006051](https://doi.org/10.1371/journal.pgen.1006051)

Liu B, Li J, Liu X, Zheng M, Yang Y, Lyu Q, Jin L (2017) Long non-coding RNA HOXA11-AS promotes the proliferation HCC cells by epigenetically silencing DUSP5. *Oncotarget* 8:109509–109521. doi:[10.18632/oncotarget.22723](https://doi.org/10.18632/oncotarget.22723)

Liu BH, Zhang BB, Liu XQ, Zheng S, Dong KR, Dong R (2018) Expression Profiling Identifies Circular RNA Signature in Hepatoblastoma. *Cell Physiol Biochem* 45:706–719. doi:[10.1159/000487163](https://doi.org/10.1159/000487163)

Liu CT, Min L, Wang YJ, Li P, Wu YD, Zhang ST (2019) shRNA-mediated knockdown of KNTC1 suppresses cell viability and induces apoptosis in esophageal squamous cell carcinoma. *Int J Oncol* 54:1053–1060. doi:[10.3892/ijo.2019.4672](https://doi.org/10.3892/ijo.2019.4672)

Liu D, Wong CC, Fu L, Chen H, Zhao L, Li C, Zhou Y, Zhang Y, Xu W, Yang Y et al (2018) Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target. *Sci Transl Med* 10:eaap9840. doi:[10.1126/scitranslmed.aap9840](https://doi.org/10.1126/scitranslmed.aap9840)

Liu G, Hou G, Li L, Li Y, Zhou W, Liu L (2016) Potential diagnostic and prognostic marker dimethylglycine dehydrogenase (DMGDH) suppresses hepatocellular carcinoma metastasis in vitro and in vivo. *Oncotarget* 7:32607–32616. doi:[10.18632/oncotarget.8927](https://doi.org/10.18632/oncotarget.8927)

Liu GM, Li Q, Zhang PF, Shen SL, Xie WX, Chen B, Wu J, Hu WJ, Huang XY, Peng BG (2018) Restoration of FBP1 suppressed Snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma. *Cell Death Dis* 9:1132. doi:[10.1038/s41419-018-1165-x](https://doi.org/10.1038/s41419-018-1165-x)

Liu J, Li W, Zhao H (2020) CFHR3 is a potential novel biomarker for hepatocellular carcinoma. *J Cell Biochem* 121:2970–2980. doi:[10.1002/jcb.29551](https://doi.org/10.1002/jcb.29551)

Liu M, Hu Q, Tu M, Wang X, Yang Z, Yang G, Luo R (2018) MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence. *J Exp Clin Cancer Res* 37:10. doi:[10.1186/s13046-017-0669-z](https://doi.org/10.1186/s13046-017-0669-z)

Liu S, Luan J, Ding Y (2018) miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1 Pancreatic Cancer Cells. *Oncol Res* 26:683–690. doi:[10.3727/096504017X14982585511252](https://doi.org/10.3727/096504017X14982585511252)

Liu X, Wang S, Meng F, Wang J, Zhang Y, Dai E, Yu X, Li X, Jiang W (2013) SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression. *Bioinformatics* 29:409–411. doi:[10.1093/bioinformatics/bts698](https://doi.org/10.1093/bioinformatics/bts698)

Liu YX, Zhang SF, Ji YH, Guo SJ, Wang GF, Zhang GW (2012) Whole-exome sequencing identifies mutated PCK2 and HUWE1 associated with carcinoma cell proliferation in a hepatocellular carcinoma patient. *Oncol Lett* 4:847–851. doi:[10.3892/ol.2012.825](https://doi.org/10.3892/ol.2012.825)

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2⁻(-Delta Delta C(T)) Method. *Methods* 25:402–408. doi:[10.1006/meth.2001.1262](https://doi.org/10.1006/meth.2001.1262)

Lopez-Nunez O, Ranganathan S (2019) Immunohistochemical Expression Analysis of EpCAM in Hepatoblastomas. *Appl Immunohistochem Mol Morphol* 10.1097/PAI.0000000000000826. doi:[10.1097/PAI.0000000000000826](https://doi.org/10.1097/PAI.0000000000000826)

Lu D, Dong D, Xie Q, Li Z, Wu B (2018) Disposition of Mianserin and Cyclizine in UGT2B10-Overexpressing Human Embryonic Kidney 293 Cells: Identification of UGT2B10 as a Novel N-Glucosidation Enzyme and Breast Cancer Resistance Protein as an N-Glucoside Transporter. *Drug Metab Dispos* 46:970–979. doi:[10.1124/dmd.118.080804](https://doi.org/10.1124/dmd.118.080804)

Lu M, Huang X, Chen Y, Fu Y, Xu C, Xiang W, Li C, Zhang S, Yu C (2018) Aberrant KIF20A expression might independently predict poor overall survival and recurrence-free survival of hepatocellular carcinoma. *IUBMB Life* 70:328–335. doi:[10.1002/iub.1726](https://doi.org/10.1002/iub.1726)

Lu YB, Jiang Q, Yang MY, Zhou JX, Zhang Q (2017) Long noncoding RNA NNT-AS1 promotes hepatocellular carcinoma progression and metastasis through miR-363/CDK6 axis. *Oncotarget* 8:88804–88814. doi:[10.18632/oncotarget.21321](https://doi.org/10.18632/oncotarget.21321)

Luo W, Liao M, Liao Y, Chen X, Huang C, Fan J, Liao W (2018) The role of kinesin KIF18A in the invasion and metastasis of hepatocellular carcinoma. *World J Surg Oncol* 16:36. doi:[10.1186/s12957-018-1342-5](https://doi.org/10.1186/s12957-018-1342-5)

Lv X, Zhao F, Huo X, Tang W, Hu B, Gong X, Yang J, Shen Q, Qin W (2016) Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma. *Med Oncol* 33:70. doi:[10.1007/s12032-016-0785-1](https://doi.org/10.1007/s12032-016-0785-1)

Ma Q, Xu Y, Liao H, Cai Y, Xu L, Xiao D, Liu C, Pu W, Zhong X, Guo X (2019) Identification and validation of key genes associated with non-small-cell lung cancer. *J Cell Physiol* 234:22742–22752. doi:[10.1002/jcp.28839](https://doi.org/10.1002/jcp.28839)

Maekawa K, Hamaguchi T, Saito Y, Tatewaki N, Kurose K, Kaniwa N, Nakajima TE, Kato K, Yamada Y, Shimada Y et al (2011) Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients. *Drug Metab Pharmacokinet* 26:646–658. doi:[10.2133/dmpk.DMPK-11-SC-050](https://doi.org/10.2133/dmpk.DMPK-11-SC-050)

Malaguarnera G, Catania VE, Francaviglia A, Malaguarnera M, Drago F, Motta M, Latteri S (2017) Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis. *Aging Clin Exp Res* 29:185–190. doi:[10.1007/s40520-016-0653-z](https://doi.org/10.1007/s40520-016-0653-z)

Miao R, Wu Y, Zhang H, Zhou H, Sun X, Csizmadia E, He L, Zhao Y, Jiang C, Miksad RA et al (2016) Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer. *Sci Rep* 6:33121. doi:[10.1038/srep33121](https://doi.org/10.1038/srep33121)

Matsuo M, Terai K, Kameda N, Matsumoto A, Kurokawa Y, Funase Y, Nishikawa K, Sugaya N, Hiruta N, Kishimoto T (2012) Designation of enzyme activity of glycine-N-acyltransferase family genes and depression of glycine-N-acyltransferase in human hepatocellular carcinoma. *Biochem Biophys Res Commun* 420:901–906. doi:[10.1016/j.bbrc.2012.03.099](https://doi.org/10.1016/j.bbrc.2012.03.099)

Mattu S, Fornari F, Quagliata L, Perra A, Angioni MM, Petrelli A, Menegon S, Morandi A, Chiarugi P, Ledda-Columbano GM et al (2016) The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. *J Hepatol* 64:891–898. doi:[10.1016/j.jhep.2015.11.029](https://doi.org/10.1016/j.jhep.2015.11.029)

Mavri-Damelin D, Eaton S, Damelin LH, Rees M, Hodgson HJ, Selden C (2007) Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2. *Int J Biochem Cell Biol* 39:555–564. doi:[10.1016/j.biocel.2006.10.007](https://doi.org/10.1016/j.biocel.2006.10.007)

Melchardt T, Hufnagl C, Magnes T, Weiss L, Hutarew G, Neureiter D, Schlattau A, Moser G, Gaggl A, Tränkensschuh W et al (2015) CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. *BMC Cancer* 15:725. doi:[10.1186/s12885-015-1776-x](https://doi.org/10.1186/s12885-015-1776-x)

Meng W, Xie B, Yang Q, Jia C, Tang H, Zhang X, Zhang Y, Zhang J, Li H, Fu B (2019) Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF- κ B pathway. *J Exp Clin Cancer Res* 38:263. doi:[10.1186/s13046-019-1241-9](https://doi.org/10.1186/s13046-019-1241-9)

Mi H, Huang X, Muruganujan A, Tang H, Mills C, Kang D, Thomas PD (2017) PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. *Nucleic Acids Res* 45:D183–D189. doi:[10.1093/nar/gkw1138](https://doi.org/10.1093/nar/gkw1138)

Miao J, Kusafuka T, Udatsu Y, Okada A (2003) Sequence variants of the Axin gene in hepatoblastoma. *Hepatol Res* 25:174–179. doi:[10.1016/s1386-6346\(02\)00264-4](https://doi.org/10.1016/s1386-6346(02)00264-4)

Mio C, Lavarone E, Conzatti K, Baldan F, Toffoletto B, Puppini C, Filetti S, Durante C, Russo D, Orlicchio A et al (2016) MCM5 as a target of BET inhibitors in thyroid cancer cells. *Endocr Relat Cancer* 23:335–347. doi:[10.1530/ERC-15-0322](https://doi.org/10.1530/ERC-15-0322)

Moelans CB, Verschuur-Maes AH, van Diest PJ (2011) Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. *J Pathol* 225:222–231. doi:[10.1002/path.2930](https://doi.org/10.1002/path.2930)

Mondal G, Saroha A, Bose PP, Chatterjee BP (2016) Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. *Glycoconj J* 33:209–218. doi:[10.1007/s10719-016-9658-2](https://doi.org/10.1007/s10719-016-9658-2)

Mumbreakar KD, Sadashiva SR, Kabekkodu SP, Fernandes DJ, Vadhiraja BM, Suga T, Shoji Y, Nakayama F, Imai T, Satyamoorthy K (2017) Genetic Variants in CD44 and MAT1A Confer Susceptibility to Acute Skin Reaction in Breast Cancer Patients Undergoing Radiation Therapy. *Int J Radiat Oncol Biol Phys* 97:118–127. doi:[10.1016/j.ijrobp.2016.09.017](https://doi.org/10.1016/j.ijrobp.2016.09.017)

Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, Jin E, Kawanami O, Kishimoto T, Konishi N, Nakamura M. et al (2003) Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. *J Hum Genet* 48:65–69. doi:[10.1007/s100380300008](https://doi.org/10.1007/s100380300008)

Nguyen TP, Liu WC, Jordán F (2011) Inferring pleiotropy by network analysis: linked diseases in the human PPI network. *BMC Syst Biol* 5:179. doi:[10.1186/1752-0509-5-179](https://doi.org/10.1186/1752-0509-5-179)

Nikolaou N, Gathercole LL, Kirkwood L, Dunford JE, Hughes BA, Gilligan LC, Oppermann U, Penning TM, Arlt W, Hodson L et al (2019) AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells. *J Steroid Biochem Mol Biol* 189:218–227. doi:[10.1016/j.jsbmb.2019.02.002](https://doi.org/10.1016/j.jsbmb.2019.02.002)

Nishi M, Abe Y, Fujimori S, Hamamoto A, Inoue Y, Miyazaki N, Oida Y, Ikoma N, Ohnishi Y, Yamazaki H et al (2005) The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo. *Oncol Rep* 14:421–424.

Orchard S, Ammari M, Aranda B, Breuza L, Briganti L, Broackes-Carter F, Campbell NH, Chavali G, Chen C, del-Toro N, Duesbury M et al (2014) The MIntAct project--IntAct as a common curation platform for 11 molecular interaction databases. *Nucleic Acids Res* 42:D358–D363. doi:[10.1093/nar/gkt1115](https://doi.org/10.1093/nar/gkt1115)

Osanai M, Lee GH (2015) The retinoic acid-metabolizing enzyme CYP26A1 upregulates fascin and promotes the malignant behavior of breast carcinoma cells. *Oncol Rep* 34:850–858. doi:[10.3892/or.2015.4042](https://doi.org/10.3892/or.2015.4042)

Oughtred R, Stark C, Breitkreutz BJ, Rust J, Boucher L, Chang C, Kolas N, O'Donnell L, Leung G, McAdam R et al (2019) The BioGRID interaction database: 2019 update. *Nucleic Acids Res* 47:D529–D541. doi:[10.1093/nar/gky1079](https://doi.org/10.1093/nar/gky1079)

Pal J, Patil V, Mondal B, Shukla S, Hegde AS, Arivazhagan A, Santosh V, Somasundaram K (2016) Epigenetically silenced GNG4 inhibits SDF1 α /CXCR4 signaling in mesenchymal glioblastoma. *Genes Cancer* 7:136–147. doi:[10.18632/genesandcancer.105](https://doi.org/10.18632/genesandcancer.105)

Panvichian R, Tantiwetrueangdet A, Angkathunyakul N, Leelaudomlipi S (2015) TOP2A amplification and overexpression in hepatocellular carcinoma tissues. *Biomed Res Int* 2015:381602. doi:[10.1155/2015/381602](https://doi.org/10.1155/2015/381602)

Petri V, Jayaraman P, Tutaj M, Hayman GT, Smith JR, De Pons J, Laulederkind SJ, Lowry TF, Nigam R, Wang SJ et al (2014) The pathway ontology - updates and applications. *J Biomed Semantics* 5:7. doi:[10.1186/2041-1480-5-7](https://doi.org/10.1186/2041-1480-5-7)

Pham QT, Oue N, Sekino Y, Yamamoto Y, Shigematsu Y, Sakamoto N, Sentani K, Uraoka N, Yasui W (2018) TDO2 Overexpression Is Associated with Cancer Stem Cells and Poor Prognosis in Esophageal Squamous Cell Carcinoma. *Oncology* 95:297–308. doi:[10.1159/000490725](https://doi.org/10.1159/000490725)

Pousset D, Piller V, Bureaud N, Piller F (2001) High levels of ceruloplasmin in the serum of transgenic mice developing hepatocellular carcinoma. *Eur J Biochem* 268:1491–1499. doi:[10.1046/j.1432-1327.2001.02015.x](https://doi.org/10.1046/j.1432-1327.2001.02015.x)

Przulj N, Wagle DA, Jurisica I (2004) Functional topology in a network of protein interactions. *Bioinformatics* 20:340–348. doi:[10.1093/bioinformatics/btg415](https://doi.org/10.1093/bioinformatics/btg415)

Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, Sullivan M (2011) HGF/c-Met related activation of β -catenin in hepatoblastoma. *J Exp Clin Cancer Res* 30:96. doi:[10.1186/1756-9966-30-96](https://doi.org/10.1186/1756-9966-30-96)

Qi HL, Li CS, Qian CW, Xiao YS, Yuan YF, Liu QY, Liu ZS (2016) The long noncoding RNA, EGFR-AS1, a target of GHR, increases the expression of EGFR in hepatocellular carcinoma. *Tumour Biol* 37:1079–1089. doi:[10.1007/s13277-015-3887-z](https://doi.org/10.1007/s13277-015-3887-z)

Quesada-Calvo F, Massot C, Bertrand V, Longuespée R, Blétard N, Somja J, Mazzucchelli G, Smargiasso N, Baiwir D, De Pauw-Gillet M et al (2017) OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages. Clin Proteomics 14:9. doi:[10.1186/s12014-017-9143-3](https://doi.org/10.1186/s12014-017-9143-3)

Quiroga AD, Ceballos MP, Parody JP, Comanzo CG, Lorenzetti F, Pisani GB, Ronco MT, Alvarez MD, Carrillo MC (2016) Hepatic carboxylesterase 3 (Ces3/Tgh) is downregulated in the early stages of liver cancer development in the rat. Biochim Biophys Acta 1862:2043–2053. doi:[10.1016/j.bbadis.2016.08.006](https://doi.org/10.1016/j.bbadis.2016.08.006)

Ranganathan S, Ningappa M, Ashokkumar C, Higgs BW, Min J, Sun Q, Schmitt L, Subramaniam S, Hakonarson H, Sindhi R (2016) Loss of EGFR-ASAP1 signaling in metastatic and unresectable hepatoblastoma. Sci Rep 6:38347. doi:[10.1038/srep38347](https://doi.org/10.1038/srep38347)

Repetto O, Maiero S, Magris R, Miolo G, Cozzi MR, Steffan A, Canzonieri V, Cannizzaro R, De Re V (2018) Quantitative Proteomic Approach Targeted to Fibrinogen β Chain in Tissue Gastric Carcinoma. Int J Mol Sci 19:759. doi:[10.3390/ijms19030759](https://doi.org/10.3390/ijms19030759)

Richmond CS, Oldenburg D, Dancik G, Meier DR, Weinhaus B, Theodorescu D, Guin S (2018) Glycogen Debranching Enzyme (AGL) Is a Novel Regulator of Non-Small Cell Lung Cancer Growth. Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth. Oncotarget 9:16718–16730. doi:[10.18632/oncotarget.24676](https://doi.org/10.18632/oncotarget.24676)

Riihilä P, Viikklepp K, Nissinen L, Farshchian M, Kallajoki M, Kivisaari A, Meri S, Peltonen J, Peltonen S, Kähäri VM (2020) tumour-cell-derived complement components C1r and C1s promote growth of cutaneous squamous cell carcinoma. Br J Dermatol 182:658–670. doi:[10.1111/bjd.18095](https://doi.org/10.1111/bjd.18095)

Ritchie ME, Phipson B, Wu DI, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47. doi:[10.1093/nar/gkv007](https://doi.org/10.1093/nar/gkv007)

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77. doi:[10.1186/1471-2105-12-77](https://doi.org/10.1186/1471-2105-12-77)

Ruan HY, Yang C, Tao XM, He J, Wang T, Wang H, Wang C, Jin GZ, Jin HJ, Qin WX (2017) Downregulation of ACSM3 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. *Am J Cancer Res* 7:543–553.

Ruepp A, Kowarsch A, Schmidl D, Buggenthin F, Brauner B, Dunger I, Fobo G, Frishman G, Montrone C, Theis FJ (2010) PhenomiR: a knowledgebase for microRNA expression in diseases and biological processes. *Genome Biol* 11:R6. doi:[10.1186/gb-2010-11-1-r6](https://doi.org/10.1186/gb-2010-11-1-r6)

Rukov JL, Wilentzik R, Jaffe I, Vinther J, Shomron N (2014) Pharmaco-miR: linking microRNAs and drug effects. *Brief Bioinform* 15:648–659. doi:[10.1093/bib/bbs082](https://doi.org/10.1093/bib/bbs082)

Sakamoto LH, DE Camargo B, Cajaiba M, Soares FA, Vettore AL (2010) MT1G hypermethylation: a potential prognostic marker for hepatoblastoma. *Pediatr Res* 67:387–393. doi:[10.1203/PDR.0b013e3181d01863](https://doi.org/10.1203/PDR.0b013e3181d01863)

Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, Eisenberg D (2004) The Database of Interacting Proteins: 2004 update. *Nucleic Acids Res* 32:D449–D451. doi:[10.1093/nar/gkh086](https://doi.org/10.1093/nar/gkh086)

Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH (2009) PID: the Pathway Interaction Database. *Nucleic Acids Res* 37:D674–D679. doi:[10.1093/nar/gkn653](https://doi.org/10.1093/nar/gkn653)

Schneider MA, Christopoulos P, Muley T, Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller NS, Theis F et al (2017) AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. *Int J Oncol* 50:365–372. doi:[10.3892/ijo.2017.3834](https://doi.org/10.3892/ijo.2017.3834)

Seol HS, Lee SE, Song JS, Rhee JK, Singh SR, Chang S, Jang SJ (2016) Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1. *Cancer Lett* 372:24–35. doi:[10.1016/j.canlet.2015.12.005](https://doi.org/10.1016/j.canlet.2015.12.005)

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 13:2498–2504. doi:[10.1101/gr.1239303](https://doi.org/10.1101/gr.1239303)

Shen CT, Wei WJ, Qiu ZL, Song HJ, Luo QY (2016) Afamin promotes glucose metabolism in papillary thyroid carcinoma. *Mol Cell Endocrinol* 434:108–115. doi:[10.1016/j.mce.2016.06.013](https://doi.org/10.1016/j.mce.2016.06.013)

Shen Y, Zhang F, Lan H, Chen K, Zhang Q, Xie G, Teng L, Jin K (2015) FRZB up-regulation is correlated with hepatic metastasis and poor prognosis in colon carcinoma patients with hepatic metastasis. *Int J Clin Exp Pathol* 8:4083–4090.

Shi L, Yan P, Liang Y, Sun Y, Shen J, Zhou S, Lin H, Liang X, Cai X (2017) Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma. *Cell Death Dis* 8:e3171. doi:[10.1038/cddis.2017.556](https://doi.org/10.1038/cddis.2017.556)

Shi X, Teng F (2015) Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor proliferation and migration by targeting insulin-like growth factor-1 (IGF-1). *Mol Cell Biochem* 408:283–293. doi:[10.1007/s11010-015-2506-z](https://doi.org/10.1007/s11010-015-2506-z)

Shi Z, Zhang B (2011) Fast network centrality analysis using GPUs. *BMC Bioinformatics* 12:149. doi:[10.1186/1471-2105-12-149](https://doi.org/10.1186/1471-2105-12-149)

Shih S, Huang YT, Yang HI (2018) A multiple mediator analysis approach to quantify the effects of the ADH1B and ALDH2 genes on hepatocellular carcinoma risk. *Genet Epidemiol* 42:394–404. doi:[10.1002/gepi.22120](https://doi.org/10.1002/gepi.22120)

Shimokawa Y, Okuda K, Kubo Y, Kaneko A, Arishima T, Nagata E, Hashimoto M, Sawa Y, Nagasaki Y, Kojiro M et al (1977) Serum glutamic oxalacetic transaminase/glutamic pyruvic transaminase ratios in hepatocellular carcinoma. *Cancer* 40:319–324. doi:[10.1002/1097-0142\(197707\)40:1<319::aid-cncr2820400145>3.0.co;2-q](https://doi.org/10.1002/1097-0142(197707)40:1<319::aid-cncr2820400145>3.0.co;2-q)

Shin H, Cha HJ, Lee MJ, Na K, Park D, Kim CY, Han DH, Kim H, Paik YK (2020) Identification of ALDH6A1 as a Potential Molecular Signature in Hepatocellular Carcinoma via Quantitative Profiling of the Mitochondrial Proteome. *J Proteome Res* 10.1021/acs.jproteome.9b00846. doi:[10.1021/acs.jproteome.9b00846](https://doi.org/10.1021/acs.jproteome.9b00846)

Shu H, Li W, Shang S, Qin X, Zhang S, Liu Y (2017) Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1. *Discov Med* 23:163–168.

Sinreih M, Anko M, Zukunft S, Adamski J, Rižner TL (2015) Important roles of the AKR1C2 and SRD5A1 enzymes in progesterone metabolism in endometrial cancer model cell lines. *Chem Biol Interact* 234:297–308. doi:[10.1016/j.cbi.2014.11.012](https://doi.org/10.1016/j.cbi.2014.11.012)

Slattery ML, Herrick JS, Lundgreen A, Fitzpatrick FA, Curtin K, Wolff RK (2010) Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. *Carcinogenesis* 31:1604–1611. doi:[10.1093/carcin/bgq142](https://doi.org/10.1093/carcin/bgq142)

Sogawa K, Takano S, Iida F, Satoh M, Tsuchida S, Kawashima Y, Yoshitomi H, Sanda A, Kodera Y, Takizawa H et al (2016) Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α -chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. *Br J Cancer* 115:949–956. doi:[10.1038/bjc.2016.295](https://doi.org/10.1038/bjc.2016.295)

Song W, Gu Y, Lu S, Wu H, Cheng Z, Hu J, Qian Y, Zheng Y, Fan H (2019) LncRNA TRERNA1 facilitates hepatocellular carcinoma metastasis by dimethylating H3K9 in the CDH1 promoter region via the recruitment of the EHMT2/SNAI1 complex. *Cell Prolif* 52:e12621. doi:[10.1111/cpr.12621](https://doi.org/10.1111/cpr.12621)

Souady J, Hülsewig M, Distler U, Haier J, Denz A, Pilarsky C, Senninger N, Dreisewerd K, Peter-Katalinić J, Müthing J (2011) Differences in CD75s- and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues. *Glycobiology* 21:584–594. doi:[10.1093/glycob/cwq200](https://doi.org/10.1093/glycob/cwq200)

Spector LG, Birch J (2012) The epidemiology of hepatoblastoma. *Pediatr Blood Cancer* 59:776–779. doi:[10.1002/pbc.24215](https://doi.org/10.1002/pbc.24215)

Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, Chow D, Sereduk C, Niemi NM, Tang N et al (2011) Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. *Nat Genet* 44:165–169. doi:[10.1038/ng.1041](https://doi.org/10.1038/ng.1041)

Stępień T, Brożyna M, Kuzdak K, Motylewska E, Komorowski J, Stępień H, Ławnicka H (2017) Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. *Dis Markers* 2017:4962137. doi:[10.1155/2017/4962137](https://doi.org/10.1155/2017/4962137)

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 102:15545–15550. doi:[10.1073/pnas.0506580102](https://doi.org/10.1073/pnas.0506580102)

Sun C, Huang S, Wang H, Xie R, Zhang L, Zhou Q, He X, Ju W (2019) Non-SMC condensin I complex subunit H enhances proliferation, migration, and invasion of hepatocellular carcinoma. *Mol Carcinog* 58:2266–2275. doi:[10.1002/mc.23114](https://doi.org/10.1002/mc.23114)

Sun J, Li H, Huo Q, Cui M, Ge C, Zhao F, Tian H, Chen T, Yao M, Li J (2016) The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells. *Oncotarget* 7:43534–43545. doi:[10.18632/oncotarget.9780](https://doi.org/10.18632/oncotarget.9780)

Sun WJ, Huang H, He B, Hu DH, Li PH, Yu YJ, Zhou XH, Lv Z, Zhou L, Hu TY et al (2017) Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. *Biochem Pharmacol* 127:90–100. doi:[10.1016/j.bcp.2016.12.008](https://doi.org/10.1016/j.bcp.2016.12.008)

Sun X, Zhang Q, Chen W, Hu Q, Lou Y, Fu QH, Zhang JY, Chen YW, Ye LY, Wang Y et al (2017) Hook1 inhibits malignancy and epithelial-mesenchymal transition in hepatocellular carcinoma. *Tumour Biol* 39:1010428317711098. doi:[10.1177/1010428317711098](https://doi.org/10.1177/1010428317711098)

Sun Y, Li W, Shen S, Yang X, Lu B, Zhang X, Lu P, Shen Y, Ji J (2019) Loss of alanine-glyoxylate and serine-pyruvate aminotransferase expression accelerated the progression of hepatocellular carcinoma and predicted poor prognosis. *J Transl Med* 17:390. doi:[10.1186/s12967-019-02138-5](https://doi.org/10.1186/s12967-019-02138-5)

Sutiman N, Lim JS, Muerdter TE, Singh O, Cheung YB, Ng RC, Yap YS, Wong NS, Ang PC, Dent R et al (2016) Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients. *Clin Pharmacokinet* 55:1239–1250. doi:[10.1007/s40262-016-0402-7](https://doi.org/10.1007/s40262-016-0402-7)

Tan Y, Cheung M, Pei J, Menges CW, Godwin AK, Testa JR (2010) Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing

IRS-2-AKT signaling. *Cancer Res* 70:9197–9206. doi:[10.1158/0008-5472.CAN-10-1568](https://doi.org/10.1158/0008-5472.CAN-10-1568)

Tang H, Zhao H, Yu ZY, Feng X, Fu BS, Qiu CH, Zhang JW (2019) MicroRNA-194 inhibits cell invasion and migration in hepatocellular carcinoma through PRC1-mediated inhibition of Wnt/ β -catenin signaling pathway. *Dig Liver Dis* 51:1314–1322. doi:[10.1016/j.dld.2019.02.012](https://doi.org/10.1016/j.dld.2019.02.012)

Tang L, Yu W, Wang Y, Li H, Shen Z (2019) Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. *Clin Transl Oncol* 21:1624–1633. doi:[10.1007/s12094-019-02090-2](https://doi.org/10.1007/s12094-019-02090-2)

Tao QF, Yuan SX, Yang F, Yang S, Yang Y, Yuan JH, Wang ZG, Xu QG, Lin KY, Cai J et al (2015) Aldolase B inhibits metastasis through Ten-Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma. *Mol Cancer* 14:170. doi:[10.1186/s12943-015-0437-7](https://doi.org/10.1186/s12943-015-0437-7)

Thole TM, Lodrini M, Fabian J, Wuenschel J, Pfeil S, Hielscher T, Kopp-Schneider A, Heinicke U, Fulda S, Witt O et al (2017) Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. *Cell Death Dis* 8:e2635. doi:[10.1038/cddis.2017.49](https://doi.org/10.1038/cddis.2017.49)

Toda K, Nishikawa G, Iwamoto M, Itatani Y, Takahashi R, Sakai Y, Kawada K (2017) Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer. *Int J Mol Sci* 18:1632. doi:[10.3390/ijms18081632](https://doi.org/10.3390/ijms18081632)

Tsutsui M, Iizuka N, Moribe T, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Fujita Y, Hamamoto Y, Tsunedomi R et al (2010) Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma. *Clin Chim Acta* 411:516–520. doi:[10.1016/j.cca.2010.01.004](https://doi.org/10.1016/j.cca.2010.01.004)

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S et al (2010) Towards a knowledge-based Human Protein Atlas. *Nat Biotechnol* 28:1248-1250. doi:[10.1038/nbt1210-1248](https://doi.org/10.1038/nbt1210-1248)

Vainio P, Gupta S, Ketola K, Mirtti T, Mpindi JP, Kohonen P, Fey V, Perälä M, Smit F, Verhaegh G et al (2011) Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. *Am J Pathol* 178:525–536. doi:[10.1016/j.ajpath.2010.10.002](https://doi.org/10.1016/j.ajpath.2010.10.002)

Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Rajapakshe K, Donepudi SR, von Rundstedt FC, Devarakonda V et al (2019) Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. *Oncogene* 10.1038/s41388-019-0902-7. doi:[10.1038/s41388-019-0902-7](https://doi.org/10.1038/s41388-019-0902-7)

Vilarinho S, Erson-Omay EZ, Harmanci AS, Morotti R, Carrion-Grant G, Baranoski J, Knisely AS, Ekong U, Emre S, Yasuno K et al (2014) Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations. *J Hepatol* 61:1178–1183. doi:[10.1016/j.jhep.2014.07.003](https://doi.org/10.1016/j.jhep.2014.07.003)

Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K, Kalfakakou D et al (2015) DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. *Nucleic Acids Res* 43:D153-D159. doi:[10.1093/nar/gku1215](https://doi.org/10.1093/nar/gku1215)

Wang C, Mou L, Chai HX, Wang F, Yin YZ, Zhang XY (2017) Long non-coding RNA HNF1A-AS1 promotes hepatocellular carcinoma cell proliferation by repressing NKD1 and P21 expression. *Biomed Pharmacother* 89:926–932. doi:[10.1016/j.biopha.2017.01.031](https://doi.org/10.1016/j.biopha.2017.01.031)

Wang D, Zhao C, Gao L, Wang Y, Gao X, Tang L, Zhang K, Li Z, Han J, Xiao J (2018) NPNT promotes early-stage bone metastases in breast cancer by regulation of the osteogenic niche. *J Bone Oncol* 13:91–96. doi:[10.1016/j.jbo.2018.09.006](https://doi.org/10.1016/j.jbo.2018.09.006)

Wang J, Gao Y, Wang L, Liu X, Li J, Wang Z, Zhou J, Wang K (2013) A variant (rs932335) in the HSD11B1 gene is associated with colorectal cancer in a Chinese population. *Eur J Cancer Prev* 22:523–528. doi:[10.1097/CEJ.0b013e328365634](https://doi.org/10.1097/CEJ.0b013e328365634)

Wang J, Li H, Xia C, Yang X, Dai B, Tao K, Dou K (2019) Downregulation of CENPK suppresses hepatocellular carcinoma malignant progression through regulating YAP1. *Onco Targets Ther* 12:869–882. doi:[10.2147/OTT.S190061](https://doi.org/10.2147/OTT.S190061)

Wang J, Li M, Wang H, Pan Y (2012) Identification of essential proteins based on edge clustering coefficient. *IEEE/ACM Trans Comput Biol Bioinform* 9:1070–1080. doi:[10.1109/TCBB.2011.147](https://doi.org/10.1109/TCBB.2011.147)

Wang J, Wang B, Ren H, Chen W (2019) miR-9-5p inhibits pancreatic cancer cell proliferation, invasion and glutamine metabolism by targeting GOT1. *Biochem Biophys Res Commun* 509:241–248. doi:[10.1016/j.bbrc.2018.12.114](https://doi.org/10.1016/j.bbrc.2018.12.114)

Wang LH, Yen CJ, Li TN, Elowe S, Wang WC, Wang LH (2015) Sgo1 is a potential therapeutic target for hepatocellular carcinoma. *Oncotarget* 6:2023–2033. doi:[10.18632/oncotarget.2764](https://doi.org/10.18632/oncotarget.2764)

Wang PS, Kuai J, Li H, Wang CG, Shi BJ, Zhong L (2016) Mannose-binding lectin 2 rs11003123 polymorphism is associated with the development of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis in the Chinese population. *Hepatobiliary Pancreat Dis Int* 15:282–288. doi:[10.1016/s1499-3872\(16\)60050-4](https://doi.org/10.1016/s1499-3872(16)60050-4)

Wang R, Yin C, Li XX, Yang XZ, Yang Y, Zhang MY, Wang HY, Zheng XS (2016) Reduced SOD2 expression is associated with mortality of hepatocellular carcinoma patients in a mutant p53-dependent manner. *Aging (Albany NY)* 8:1184–1200. doi:[10.18632/aging.100967](https://doi.org/10.18632/aging.100967)

Wang S, Sun H, Ma J, Zang C, Wang C, Wang J, Tang Q, Meyer CA, Zhang Y, Liu XS (2013) Target analysis by integration of transcriptome and ChIP-seq data with BETA. *Nat Protoc* 8:2502–2515. doi:[10.1038/nprot.2013.150](https://doi.org/10.1038/nprot.2013.150)

Wang SM, Ooi LL, Hui KM (2011) Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. *Clin Cancer Res* 17:6040–6051. doi:[10.1158/1078-0432.CCR-11-0557](https://doi.org/10.1158/1078-0432.CCR-11-0557)

Wang X, Liao Z, Bai Z, He Y, Duan J, Wei L (2018) MiR-93-5p Promotes Cell Proliferation through Down-Regulating PPARGC1A in Hepatocellular Carcinoma Cells by Bioinformatics Analysis and Experimental Verification. *Genes (Basel)* 9:51. doi:[10.3390/genes9010051](https://doi.org/10.3390/genes9010051)

Wang Y, Tan PY, Handoko YA, Sekar K, Shi M, Xie C, Jiang XD, Dong QZ, Goh BK, Ooi LL et al (2019) NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection. *Int J Cancer* 145:662–670. doi:[10.1002/ijc.32134](https://doi.org/10.1002/ijc.32134)

Wang Y, Zhi Q, Ye Q, Zhou C, Zhang L, Yan W, Wu Q, Zhang D, Li P, Huo K (2016) SCYL1-BP1 affects cell cycle arrest in human hepatocellular carcinoma

cells via Cyclin F and RRM2. *Anticancer Agents Med Chem* 16:440–446. doi:[10.2174/1871520615666150518093814](https://doi.org/10.2174/1871520615666150518093814)

Wang YH, Liu CL, Chiu WC, Twu YC, Liao YJ (2019) HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. *Cancers (Basel)* 11:1876. doi:[10.3390/cancers11121876](https://doi.org/10.3390/cancers11121876)

Wang Z, Liao J, Wu S, Li C, Fan J, Peng Z (2016) Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population. *Cancer Gene Ther* 23:157–161. doi:[10.1038/cgt.2016.7](https://doi.org/10.1038/cgt.2016.7)

Wei RR, Zhang MY, Rao HL, Pu HY, Zhang HZ, Wang HY (2012) Identification of ADH4 as a novel and potential prognostic marker in hepatocellular carcinoma. *Med Oncol* 29:2737–2743. doi:[10.1007/s12032-011-0126-3](https://doi.org/10.1007/s12032-011-0126-3)

Wei X, Li X, Yan W, Zhang X, Sun Y, Zhang F (2018) SKP2 Promotes Hepatocellular Carcinoma Progression Through Nuclear AMPK-SKP2-CARM1 Signaling Transcriptionally Regulating Nutrient-Deprived Autophagy Induction. *Cell Physiol Biochem* 47:2484–2497. doi:[10.1159/000491622](https://doi.org/10.1159/000491622)

Wijayakumara DD, Mackenzie PI, McKinnon RA, Hu DG, Meech R (2017) Regulation of UDP-Glucuronosyltransferases UGT2B4 and UGT2B7 by MicroRNAs in Liver Cancer Cells. *J Pharmacol Exp Ther* 361:386–397. doi:[10.1124/jpet.116.239707](https://doi.org/10.1124/jpet.116.239707)

Wilborn TW, Lang NP, Smith M, Meleth S, Falany CN (2006) Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men. *J Steroid Biochem Mol Biol* 99:209–214. doi:[10.1016/j.jsbmb.2006.01.006](https://doi.org/10.1016/j.jsbmb.2006.01.006)

Willis RC, Hogue CW (2006) Searching, viewing, and visualizing data in the Biomolecular Interaction Network Database (BIND). *Curr Protoc Bioinformatics* Chapter 8. doi:[10.1002/0471250953.bi0809s12](https://doi.org/10.1002/0471250953.bi0809s12)

Wu G, Li Z, Wang Y, Ju X, Huang R (2018) miR-34a Inhibits Cell Proliferation by Targeting SATB2 in Hepatocellular Carcinoma. *Biomed Res Int* 2018:2863902. doi:[10.1155/2018/2863902](https://doi.org/10.1155/2018/2863902)

Wu Q, Zhang B, Sun Y, Xu R, Hu X, Ren S, Ma Q, Chen C, Shu J, Qi F et al (2019) Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis. *Onco Targets Ther* 12:3545–3563. doi:[10.2147/OTT.S198621](https://doi.org/10.2147/OTT.S198621)

Wu Y, Liu ZG, Shi MQ, Yu HZ, Jiang XY, Yang AH, Fu XS, Xu Y, Yang S, Ni H et al (2017) Identification of ACTG2 functions as a promoter gene in hepatocellular carcinoma cells migration and tumor metastasis. *Biochem Biophys Res Commun* 491(2):537–544. doi:[10.1016/j.bbrc.2017.04.007](https://doi.org/10.1016/j.bbrc.2017.04.007)

Wu Y, Zhang X, Shen R, Huang J, Lu X, Zheng G, Chen X (2019) Expression and significance of ETV6 in hepatocellular carcinoma. *Pathol Res Pract* 215:152702. doi:[10.1016/j.prp.2019.152702](https://doi.org/10.1016/j.prp.2019.152702)

Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, Seshachalam VP, Goh BK, Ooi LL, Hui KM (2017) Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. *Cell Death Discov* 3:17058. doi:[10.1038/cddiscovery.2017.58](https://doi.org/10.1038/cddiscovery.2017.58)

Xiang J, Zhang Y, Tuo L, Liu R, Gou D, Liang L, Chen C, Xia J, Tang N, Wang K (2019) Transcriptomic changes associated with PCK1 overexpression in hepatocellular carcinoma cells detected by RNA-seq. *Genes Dis* 7:150–159. doi:[10.1016/j.gendis.2019.04.004](https://doi.org/10.1016/j.gendis.2019.04.004)

Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T (2009) miRecords: an integrated resource for microRNA-target interactions. *Nucleic Acids Res* 37:D105-D110. doi:[10.1093/nar/gkn851](https://doi.org/10.1093/nar/gkn851)

Xiao J, Yu H, Ma Z (2019) LINC00339 promotes growth and invasiveness of hepatocellular carcinoma by the miR-1182/SKA1 pathway. *Onco Targets Ther* 12:4481–4488. doi:[10.2147/OTT.S207397](https://doi.org/10.2147/OTT.S207397)

Xie L, Li T, Yang LH (2017) E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival. *Eur Rev Med Pharmacol Sci* 21:2150–2156.

Xiong XD, Qiu FE, Fang JH, Shen Y, Liang C, Jiang W, Zhuang SM (2009) Association analysis between the Cdc6 G1321A polymorphism and the risk for non-Hodgkin lymphoma and hepatocellular carcinoma. *Mutat Res* 662:10–15. doi:[10.1016/j.mrfmmm.2008.11.014](https://doi.org/10.1016/j.mrfmmm.2008.11.014)

Xu B, Xu T, Liu H, Min Q, Wang S, Song Q (2017) MiR-490-5p Suppresses Cell Proliferation and Invasion by Targeting BUB1 in Hepatocellular Carcinoma Cells. *Pharmacology* 100:269–282. doi:[10.1159/000477667](https://doi.org/10.1159/000477667)

Xu B, Zhang X, Wang S, Shi B (2018) MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer. *Pathol Res Pract* 214:790–795. doi:[10.1016/j.prp.2017.12.012](https://doi.org/10.1016/j.prp.2017.12.012)

Xu C, Zeng XH, Wang L, Tao SQ, Wu QX, Zhu P, Deng GH, Wang YM (2015) sFRP-4, a potential novel serum marker for chronic hepatitis B-related hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int* 14:164–170. doi:[10.1016/s1499-3872\(15\)60352-6](https://doi.org/10.1016/s1499-3872(15)60352-6)

Xu S, Pan J, Cheng X, Zheng J, Wang X, Guan H, Yu H, Bao J, Zhang L (2020) Diallyl trisulfide, a H₂S donor, inhibits cell growth of human papillary thyroid carcinoma KTC-1 cells through a positive feedback loop between H₂S and cystathionine-gamma-lyase. *Phytother Res* 10.1002/ptr.6586. doi:[10.1002/ptr.6586](https://doi.org/10.1002/ptr.6586)

Xu W, Zhou W, Cheng M, Wang J, Liu Z, He S, Luo X, Huang W, Chen T, Yan W et al (2017) Hypoxia activates Wnt/ β -catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. *Sci Rep* 7:40446. doi:[10.1038/srep40446](https://doi.org/10.1038/srep40446)

Xue F, Shi C, Yang L, Li C, Liu Y, Sun Y, Ge R (2019) Prognostic biomarker AASS suppresses proliferation, migration and predicts a good survival of hepatocellular carcinoma in vivo and in vitro. *Life Sci* S0024-3205(19)30436-9. doi:[10.1016/j.lfs.2019.05.080](https://doi.org/10.1016/j.lfs.2019.05.080)

Xue X, Bredell BX, Anderson ER, Martin A, Mays C, Nagao-Kitamoto H, Huang S, Györffy B, Greenson JK, Hardiman K et al (2017) Quantitative proteomics identifies STEAP4 as a critical regulator of mitochondrial dysfunction linking inflammation and colon cancer. *Proc Natl Acad Sci U S A* 114:E9608–E9617. doi:[10.1073/pnas.1712946114](https://doi.org/10.1073/pnas.1712946114)

Yokoyama S, Kaneko A, Dempo K, Chisaka N, Mori M, Onoe T (1982) Histochemical and cytochemical study of butyrylcholinesterase activity in rat hepatocellular carcinomas induced by 3'-methyl-4-dimethylaminoazobenzene. *Cancer Res* 42:4158–4163.

Yamada SI, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, Sugano S, Hirata T, Goto T, Matsunaga T et al (2004) Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. *Oncogene* 23:5901–5911. doi:[10.1038/sj.onc.1207782](https://doi.org/10.1038/sj.onc.1207782)

Yamanoi K, Matsumura N, Murphy SK, Baba T, Abiko K, Hamanishi J, Yamaguchi K, Koshiyama M, Konishi I, Mandai M (2016) Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. *Oncotarget* 7:47620–47636. doi:[10.18632/oncotarget.9951](https://doi.org/10.18632/oncotarget.9951)

Yan Z, Xu L, Zhang J, Lu Q, Luo S, Xu L (2016) Aldehyde dehydrogenase 1A1 stabilizes transcription factor Gli2 and enhances the activity of Hedgehog signaling in hepatocellular cancer. *Biochem Biophys Res Commun* 471:466–473. doi:[10.1016/j.bbrc.2016.02.052](https://doi.org/10.1016/j.bbrc.2016.02.052)

Yang CK, Yu TD, Han CY, Qin W, Liao XW, Yu L, Liu XG, Zhu GZ, Su H, Lu SC (2017) Genome-Wide Association Study of MKI67 Expression and its Clinical Implications in HBV-Related Hepatocellular Carcinoma in Southern China. *Cell Physiol Biochem* 42:1342–1357. doi:[10.1159/000478963](https://doi.org/10.1159/000478963)

Yang G, Liang Y, Zheng T, Song R, Wang J, Shi H, Sun B, Xie C, Li Y, Han J et al (2016) FCN2 inhibits epithelial-mesenchymal transition-induced metastasis of hepatocellular carcinoma via TGF- β /Smad signaling. *Cancer Lett* 378:80–86. doi:[10.1016/j.canlet.2016.05.007](https://doi.org/10.1016/j.canlet.2016.05.007)

Yang J, Xie Q, Zhou H, Chang L, Wei W, Wang Y, Li H, Deng Z, Xiao Y, Wu J et al (2018) Proteomic Analysis and NIR-II Imaging of MCM2 Protein in Hepatocellular Carcinoma. *J Proteome Res* 17:2428–2439. doi:[10.1021/acs.jproteome.8b00181](https://doi.org/10.1021/acs.jproteome.8b00181)

Yang T, Wen Y, Li J, Yang J, Tan T, Pan J, Hu C, Zhang J, Xin Y, Li S et al (2019) Association of the TP53 rs1042522 C>G polymorphism and hepatoblastoma risk in Chinese children. *J Cancer* 10:3444–3449. doi:[10.7150/jca.33063](https://doi.org/10.7150/jca.33063)

Yang X, Zhang D, Liu S, Li X, Hu W, Han C (2018) KLF4 suppresses the migration of hepatocellular carcinoma by transcriptionally upregulating monoglyceride lipase. *Am J Cancer Res* 8:1019–1029.

Yang YF, Pan YH, Cao Y, Fu J, Yang X, Zhang MF, Tian QH (2017) PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β -Catenin signaling in hepatocellular carcinoma. *Oncotarget* 8:47195–47205. doi:[10.18632/oncotarget.17587](https://doi.org/10.18632/oncotarget.17587)

Yao Z, Hu K, Huang H, Xu S, Wang Q, Zhang P, Yang P, Liu B (2015) shRNA-mediated silencing of the RFC3 gene suppresses hepatocellular carcinoma cell proliferation. *Int J Mol Med* 36:1393–1399. doi:[10.3892/ijmm.2015.2350](https://doi.org/10.3892/ijmm.2015.2350)

Ye FG, Song CG, Cao ZG, Xia C, Chen DN, Chen L, Li S, Qiao F, Ling H, Yao L et al (2015) Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. *Cancer Res* 75:1504–1515. doi:[10.1158/0008-5472.CAN-14-2341](https://doi.org/10.1158/0008-5472.CAN-14-2341)

Ye K, Wu Y, Sun Y, Lin J, Xu J (2016) TLR4 siRNA inhibits proliferation and invasion in colorectal cancer cells by downregulating ACAT1 expression. *Life Sci* 155:133–139. doi:[10.1016/j.lfs.2016.05.012](https://doi.org/10.1016/j.lfs.2016.05.012)

Yin J, Liu H, Liu Z, Owzar K, Han Y, Su L, Wei Y, Hung RJ, Brhane Y, McLaughlin J et al (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. *Mol Carcinog* 56:1663–1672. doi:[10.1002/mc.22622](https://doi.org/10.1002/mc.22622)

You J, Chen W, Chen J, Zheng Q, Dong J, Zhu Y (2018) The Oncogenic Role of ARG1 in Progression and Metastasis of Hepatocellular Carcinoma. *Biomed Res Int* 2018:2109865. doi:[10.1155/2018/2109865](https://doi.org/10.1155/2018/2109865)

Yu D, Green B, Marrone A, Guo Y, Kadlubar S, Lin D, Fuscoe J, Pogribny I, Ning B (2015) Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. *Sci Rep* 5:8534. . doi:[10.1038/srep08534](https://doi.org/10.1038/srep08534)

Yu M, Tang Z, Meng F, Tai M, Zhang J, Wang R, Liu C, Wu Q (2016) Elevated expression of FoxM1 promotes the tumor cell proliferation in hepatocellular carcinoma. *Tumour Biol* 37:1289–1297. doi:[10.1007/s13277-015-3436-9](https://doi.org/10.1007/s13277-015-3436-9)

Yu Y, Cai O, Wu P, Tan S (2019) MiR-490-5p inhibits the stemness of hepatocellular carcinoma cells by targeting ECT2. *J Cell Biochem* 120:967–976. doi:[10.1002/jcb.27459](https://doi.org/10.1002/jcb.27459)

Yuan J, Zhang N, Zhu H, Liu J, Xing H, Ma F, Yang M (2017) CHST9 rs1436904 genetic variant contributes to prognosis of triple-negative breast cancer. *Sci Rep* 7:11802. doi:[10.1038/s41598-017-12306-6](https://doi.org/10.1038/s41598-017-12306-6)

Yuan L, Wang J, Xiao H, Wu W, Wang Y, Liu X (2013) MAPK signaling pathways regulate mitochondrial-mediated apoptosis induced by isoorientin in human hepatoblastoma cancer cells. *Food Chem Toxicol* 53:62–68. doi:[10.1016/j.fct.2012.11.048](https://doi.org/10.1016/j.fct.2012.11.048)

Zaki N, Efimov D, Berenguères J (2013) Protein complex detection using interaction reliability assessment and weighted clustering coefficient. *BMC Bioinformatics* 14:163. doi:[10.1186/1471-2105-14-163](https://doi.org/10.1186/1471-2105-14-163)

Zeng C, Xing W, Liu Y (2019) Identification of UGP2 as a progression marker that promotes cell growth and motility in human glioma. *J Cell Biochem* 120:12489–12499. doi:[10.1002/jcb.28515](https://doi.org/10.1002/jcb.28515)

Zhang H, Yu C, Chen M, Li Z, Tian S, Jiang J, Sun C (2016) miR-522 contributes to cell proliferation of hepatocellular carcinoma by targeting DKK1 and SFRP2. *Tumour Biol* 37:11321–11329. doi:[10.1007/s13277-016-4995-0](https://doi.org/10.1007/s13277-016-4995-0)

Zhang L, Li L, Gao G, Wei G, Zheng Y, Wang C, Gao N, Zhao Y, Deng J, Chen H et al (2017) Elevation of GPRC5A expression in colorectal cancer promotes tumor progression through VNN-1 induced oxidative stress. *Int J Cancer* 140:2734–2747. doi:[10.1002/ijc.30698](https://doi.org/10.1002/ijc.30698)

Zhang Q, Hong Z, Zhu J, Zeng C, Tang Z, Wang W, Huang H (2020) miR-4999-5p Predicts Colorectal Cancer Survival Outcome and Reprograms Glucose Metabolism by Targeting PRKAA2. *Onco Targets Ther* 13:1199–1210. doi:[10.2147/OTT.S234666](https://doi.org/10.2147/OTT.S234666)

Zhang Q, Jiang K, Li Y, Gao D, Sun L, Zhang S, Liu T, Guo K, Liu Y (2015) Histidine-rich glycoprotein function in hepatocellular carcinoma depends on its N-glycosylation status, and it regulates cell proliferation by inhibiting Erk1/2 phosphorylation. *Oncotarget* 6:30222–30231. doi:[10.18632/oncotarget.4997](https://doi.org/10.18632/oncotarget.4997)

Zhang Q, Su R, Shan C, Gao C, Wu P (2018) Non-SMC Condensin I Complex, Subunit G (NCAPG) is a Novel Mitotic Gene Required for Hepatocellular Cancer Cell Proliferation and Migration. *Oncol Res* 26:269–276. doi:[10.3727/096504017X15075967560980](https://doi.org/10.3727/096504017X15075967560980)

Zhang R, Zhang F, Sun Z, Liu P, Zhang X, Ye Y, Cai B, Walsh MJ, Ren X, Hao X et al (2019) LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY. *Cancer Res* 79:4453–4465. doi:[10.1158/0008-5472.CAN-19-0076](https://doi.org/10.1158/0008-5472.CAN-19-0076)

Zhang S, Nguyen LH, Zhou K, Tu HC, Sehgal A, Nassour I, Li L, Gopal P, Goodman J, Singal AG et al (2018) Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration. *Gastroenterology* 154:1421–1434. doi:[10.1053/j.gastro.2017.12.013](https://doi.org/10.1053/j.gastro.2017.12.013)

Zhang X, Wang F, Huang Y, Ke K, Zhao B, Chen L, Liao N, Wang L, Li Q, Liu X et al (2019) FGG promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition. *Cancer Manag Res* 11:1653–1665. doi:[10.2147/CMAR.S188248](https://doi.org/10.2147/CMAR.S188248)

Zhang X, You Q, Zhang X, Chen X (2015) SOCS3 Methylation Predicts a Poor Prognosis in HBV Infection-Related Hepatocellular Carcinoma. *Int J Mol Sci* 16:22662–22675. doi:[10.3390/ijms160922662](https://doi.org/10.3390/ijms160922662)

Zhang Y, Zou X, Qian W, Weng X, Zhang L, Zhang L, Wang S, Cao X, Ma L, Wei G et al (2019) Enhanced PAPSS2/VCAN sulfation axis is essential for Snail-mediated breast cancer cell migration and metastasis. *Cell Death Differ* 26:565–579. doi:[10.1038/s41418-018-0147-y](https://doi.org/10.1038/s41418-018-0147-y)

Zhang Y, Zhao Y, Wu J, Liangpunsakul S, Niu J, Wang L (2018) MicroRNA-26-5p functions as a new inhibitor of hepatoblastoma by repressing lin-28 homolog B and aurora kinase a expression. *Hepatol Commun* 2:861–871. doi:[10.1002/hep4.1185](https://doi.org/10.1002/hep4.1185)

Zhao Y, Zhao E, Zhang J, Chen Y, Ma J, Li H (2019) A Comprehensive Evaluation of the Association between Polymorphisms in XRCC1, ERCC2, and XRCC3 and Prognosis in Hepatocellular Carcinoma: A Meta-Analysis. *J Oncol* 2019:2408946. doi:[10.1155/2019/2408946](https://doi.org/10.1155/2019/2408946)

Zheng K, Chen Z, Feng H, Chen Y, Zhang C, Yu J, Luo Y, Zhao L, Jiang X, Shi F (2019) Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homeostasis of ceramide and sphingomyelin. *Cell Death Dis* 10:157. doi:[10.1038/s41419-019-1303-0](https://doi.org/10.1038/s41419-019-1303-0)

Zheng L, Guo Q, Xiang C, Liu S, Jiang Y, Gao L, Ni H, Wang T, Zhao Q, Liu H et al (2019) Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells. *J Hematol Oncol* 12:23. doi:[10.1186/s13045-019-0697-6](https://doi.org/10.1186/s13045-019-0697-6)

Zheng W, Yao M, Sai W, Qian Q, Pan L, Qiu L, Huang J, Wu W, Yao D (2016) Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma. *Tumour Biol* 37:999–1008. doi:[10.1007/s13277-015-3875-3](https://doi.org/10.1007/s13277-015-3875-3)

Zhong L, Wang Y, Cheng Y, Wang W, Lu B, Zhu L, Ma Y (2018) Circular RNA circC3P1 suppresses hepatocellular carcinoma growth and metastasis through miR-4641/PCK1 pathway. *Biochem Biophys Res Commun* 499:1044–1049. doi:[10.1016/j.bbrc.2018.03.221](https://doi.org/10.1016/j.bbrc.2018.03.221)

Zhou C, Yu J, Wang M, Yang J, Xiong H, Huang H, Wu D, Hu S, Wang Y, Chen XZ et al (2017) Identification of glycerol-3-phosphate Dehydrogenase 1 as a Tumour Suppressor in Human Breast Cancer. Identification of glycerol-3-phosphate dehydrogenase 1 as a tumour suppressor in human breast cancer. *Oncotarget* 8:101309–101324. doi:[10.18632/oncotarget.21087](https://doi.org/10.18632/oncotarget.21087)

Zhou G, Soufan O, Ewald J, Hancock REW, Basu N, Xia J (2019) NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. *Nucleic Acids Res* 47:W234-W241. doi:[10.1093/nar/gkz240](https://doi.org/10.1093/nar/gkz240)

Zhu H, Wang G, Zhou X, Song X, Gao H, Ma C, Chang H, Li H, Liu FF, Lu J et al (2016) miR-1299 suppresses cell proliferation of hepatocellular carcinoma (HCC) by targeting CDK6. *Biomed Pharmacother* 83:792–797. doi:[10.1016/j.biopha.2016.07.037](https://doi.org/10.1016/j.biopha.2016.07.037)

Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S (2015) A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. *Oncotarget* 6:41383–41397. doi:[10.18632/oncotarget.5510](https://doi.org/10.18632/oncotarget.5510)

Zhu X, Wang Z, Qiu X, Wang W, Bei C, Tan C, Qin L, Ren Y, Tan S (2018) Rs2303428 of MSH2 Is Associated with Hepatocellular Carcinoma Prognosis in a Chinese Population. *DNA Cell Biol* 37:634–641. doi:[10.1089/dna.2018.4224](https://doi.org/10.1089/dna.2018.4224)

Zhu YH, Li JB, Wu RY, Yu Y, Li X, Li ZL, Zhang HL, Feng GK, Deng R, Zhu XF (2020) Clinical significance and function of RDH16 as a tumor-suppressing gene in hepatocellular carcinoma. *Hepatol Res* 50:110–120. doi:[10.1111/hepr.1343](https://doi.org/10.1111/hepr.1343)

Zhuang J, Song Y, Ye Y, He S, Ma X, Zhang M, Ni J, Wang J, Xia W (2019) PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer. *J Transl Med* 17:343. doi:[10.1186/s12967-019-2091-0](https://doi.org/10.1186/s12967-019-2091-0)

Zhuang L, Yang Z, Meng Z (2018) Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients. *Biomed Res Int* 2018:7897346. doi:[10.1155/2018/7897346](https://doi.org/10.1155/2018/7897346)

Zuo SR, Zuo XC, He Y, Fang WJ, Wang CJ, Zou H, Chen P, Huang LF, Huang LH, Xiang H et al (2018) Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma. *J Cancer* 9:321–330. doi:[10.7150/jca.22218](https://doi.org/10.7150/jca.22218)

Tables

Table 1. Primers used for quantitative PCR

Gene	Primer sequence (5'→3')	
	Forward	Reverse
TP53	CAGCACATGACGGAGGTTGT	TCATCCAAATACTCCACACGC
PLK1	AAAGAGATCCCGGAGGTCCTA	GGCTGCGGTGAATGGATATTTT
AURKA	GAGGTCCAAAACGTGTTCTCG	ACAGGATGAGGTACACTGGTTG
CDK1	AAACTACAGGTCAAGTGGTAGCC	TCCTGCATAAGCACATCCTGA
ANLN	TGCCAGGCGAGAGAATCTTC	CGCTTAGCATGAGTCATAGACCT
ESR1	CCCACTCAACAGCGTGTCTC	CGTCGATTATCTGAATTTGGCCT
FGB	AGTGATTGAGAACCCTCAAGAC	CATCCTGGTAAGCTGGCTAATTT
ACAT1	AAGGCAGGCAGTATTGGGTG	ACATCAGTTAGCCCGTCTTTTAC
GOT1	ATGGCACCTCCGTCACTCT	AGTCATCCGTGCGATATGCTC
ALAS1	CGCCGCTGCCATTCTTAT	TCTGTTGGACCTTGGCCTTAG

Probe Id	Gene Symbol	logFC	pValue	adj.P.Val	t value	Regulation	Gene Name
-------------	----------------	-------	--------	-----------	---------	------------	-----------

Table 2 The statistical metrics for key differentially expressed genes (DEGs)

7976783	DLK1	4.113511	1.52E-24	4.9E-20	15.80084	Up	delta like non-canonical Notch ligand 1
8080964	GXYLT2	3.259808	2.21E-23	3.58E-19	15.02703	Up	glucosidexylosyltransferase 2
7995525	NKD1	3.137271	5.93E-21	3.2E-17	13.47981	Up	NKD inhibitor of WNT signaling pathway 1
7968015	TNFRSF19	2.516001	3.79E-20	1.2E-16	12.98412	Up	TNF receptor superfamily member 19
8041853	EPCAM	3.294629	3.87E-20	1.2E-16	12.97881	Up	epithelial cell adhesion molecule
8096704	NPNT	3.225945	4.08E-20	1.2E-16	12.9651	Up	nephronectin
8098439	EPCAM	3.830281	1.29E-19	2.61E-16	12.66176	Up	epithelial cell adhesion molecule
8088919	ROBO1	2.160142	1.81E-19	3.44E-16	12.5732	Up	roundabout guidance receptor 1
8006415	TMEM98	1.846189	2.91E-19	4.95E-16	12.44935	Up	transmembrane protein 98
8175234	GPC3	4.165105	4.44E-19	7.18E-16	12.33928	Up	glypican 3
7979241	BMP4	2.738247	8.02E-19	1.23E-15	12.18639	Up	bone morphogenetic protein 4
7957140	LGR5	3.866313	1.42E-18	1.91E-15	12.03904	Up	leucine rich repeat containing G protein-coupled receptor 5
8019334	NOTUM	3.394432	3.47E-18	3.87E-15	11.81037	Up	notum, palmitoleoyl-protein carboxylesterase
8105267	ITGA2	2.928809	3.47E-18	3.87E-15	11.81017	Up	integrin subunit alpha 2
8040365	TRIB2	1.628254	7.83E-18	7.91E-15	11.60346	Up	tribblespseudokinase 2
8008151	IGF2BP1	3.212271	8.72E-18	8.54E-15	11.57612	Up	insulin like growth factor 2 mRNA binding protein 1
8167656	MAGED1	1.540701	1.58E-17	1.46E-14	11.42582	Up	MAGE family member D1
8059376	SERPINE2	2.631715	2.04E-17	1.66E-14	11.3616	Up	serpin family E member 2
8019842	TYMS	2.572342	2.16E-17	1.71E-14	11.34664	Up	thymidylatesynthetase
7926875	BAMBI	2.043253	3.37E-17	2.42E-14	11.23561	Up	BMP and activin membrane bound inhibitor
8134339	PEG10	3.579138	4.02E-17	2.71E-14	11.19104	Up	paternally expressed 10
8003116	HSDL1	1.388826	1.11E-16	6.77E-14	10.9372	Up	hydroxysteroid dehydrogenase like 1
8020141	APCDD1	3.490123	1.5E-16	8.67E-14	10.86241	Up	APC down-regulated 1
8111892	OXCT1	1.708043	1.5E-16	8.67E-14	10.86209	Up	3-oxoacid CoA-transferase 1
7927631	DKK1	4.545866	2.62E-16	1.34E-13	10.72426	Up	dickkopf WNT signaling pathway inhibitor 1
8092552	IGF2BP2	1.933414	2.78E-16	1.4E-13	10.7092	Up	insulin like growth factor 2 mRNA binding protein 2
8137865	GNA12	1.382382	4.1E-16	2.04E-13	10.61329	Up	G protein subunit alpha 12
7928107	MACROH2A2	1.792853	8.06E-16	3.62E-13	10.44687	Up	macroH2A.2 histone
8102232	LEF1	2.946948	1.09E-15	4.63E-13	10.37302	Up	lymphoid enhancer binding factor 1
8040292	GREB1	2.435845	2.1E-15	8.28E-13	10.21171	Up	growth regulating estrogen receptor binding 1
8117372	H2AC6	1.324135	2.22E-15	8.54E-13	10.1984	Up	H2A clustered histone 6
7963157	RACGAP1	1.702383	2.31E-15	8.78E-13	10.18853	Up	RacGTPase activating protein 1
7953130	RHNO1	1.329226	2.38E-15	8.87E-13	10.18121	Up	RAD9-HUS1-RAD1 interacting nuclear orphan 1
8068684	FAM3B	3.172667	2.44E-15	8.87E-13	10.1748	Up	family with sequence similarity 3 member B
7996772	SLC7A6	1.626316	2.56E-15	9.21E-13	10.16299	Up	solute carrier family 7 member 6
8016994	RNF43	2.212143	2.9E-15	9.96E-13	10.13313	Up	ring finger protein 43
8062623	PLCG1	1.389693	3.73E-15	1.24E-12	10.0716	Up	phospholipase C gamma 1
8167815	MAGED2	1.335218	4.85E-15	1.51E-12	10.00733	Up	MAGE family member D2
8095907	FRAS1	2.762056	5.67E-15	1.73E-12	9.969361	Up	Fraser extracellular matrix complex subunit 1
8163109	FRRS1L	2.992961	5.86E-15	1.75E-12	9.961646	Up	ferric chelate reductase 1 like
7925250	GNG4	2.985545	6.69E-15	1.98E-12	9.929134	Up	G protein subunit gamma 4
8046380	ITGA6	2.327218	8.65E-15	2.45E-12	9.866792	Up	integrin subunit alpha 6
7976012	NRXN3	2.338707	1.03E-14	2.89E-12	9.824912	Up	neurexin 3
8054395	UXS1	1.161334	1.18E-14	3.26E-12	9.79133	Up	UDP-glucuronate decarboxylase 1

8017718	AXIN2	1.63549	1.66E-14	4.46E-12	9.709379	Up	axin 2
8083166	TRPC1	1.497938	1.91E-14	4.99E-12	9.67533	Up	transient receptor potential cation channel subfamily C member 1
7923978	CD34	1.62607	1.92E-14	4.99E-12	9.674077	Up	CD34 molecule
7976812	SNORD113-4	3.888398	2.07E-14	5.3E-12	9.655838	Up	small nucleolar RNA, C/D box 113-4
7924207	PTPN14	1.660471	2.81E-14	6.89E-12	9.581146	Up	protein tyrosine phosphatase non-receptor type 14
7976816	SNORD114-3	2.764436	2.94E-14	7.03E-12	9.570781	Up	small nucleolar RNA, C/D box 114-3
8087935	NT5DC2	2.672105	3.86E-14	8.97E-12	9.504965	Up	5'-nucleotidase domain containing 2
7976826	SNORD114-26	3.500075	5.14E-14	1.18E-11	9.43543	Up	small nucleolar RNA, C/D box 114-26
8177222	CD24	2.046121	5.46E-14	1.23E-11	9.421122	Up	CD24 molecule
7918323	SORT1	1.555872	5.79E-14	1.28E-11	9.406769	Up	sortilin 1
7974288	ABHD12B	2.969266	6.54E-14	1.42E-11	9.377584	Up	abhydrolase domain containing 12B
8047709	PARD3B	1.332102	6.97E-14	1.5E-11	9.362183	Up	par-3 family cell polarity regulator beta
8072160	ZNRF3	1.696436	8.49E-14	1.77E-11	9.314723	Up	zinc and ring finger 3
8101828	TSPAN5	3.136839	8.53E-14	1.77E-11	9.313594	Up	tetraspanin 5
7972682	POGLUT2	1.21036	1.1E-13	2.24E-11	9.252202	Up	protein O-glucosyltransferase 2
8138602	GSDME	1.255804	1.45E-13	2.87E-11	9.18698	Up	gasdermin E
7929831	HIF1AN	1.118102	1.62E-13	3.15E-11	9.160219	Up	hypoxia inducible factor 1 subunit alpha inhibitor
8013753	RAB34	1.892059	1.78E-13	3.43E-11	9.136603	Up	RAB34, member RAS oncogene family
7977761	SALL2	1.452583	1.84E-13	3.51E-11	9.129421	Up	spalt like transcription factor 2
8087254	IMPDH2	1.482529	2.04E-13	3.84E-11	9.103799	Up	inosine monophosphate dehydrogenase 2
7901460	GPX7	1.914138	2.62E-13	4.87E-11	9.04402	Up	glutathione peroxidase 7
8120279	LRRC1	1.212828	2.72E-13	5E-11	9.035183	Up	leucine rich repeat containing 1
7909628	FLVCR1	2.018228	3.69E-13	6.48E-11	8.96213	Up	feline leukemia virus subgroup C cellular receptor 1
8115600	ZBED8	1.579939	4.73E-13	8E-11	8.902773	Up	zinc finger BED-type containing 8
7953351	NCAPD2	1.506645	4.96E-13	8.31E-11	8.891287	Up	non-SMC condensin I complex subunit D2
8102800	SLC7A11	3.383052	4.99E-13	8.32E-11	8.889747	Up	solute carrier family 7 member 11
8148280	SQLE	2.534481	5.41E-13	8.83E-11	8.870684	Up	squaleneepoxidase
8102214	PAPSS1	1.214629	5.48E-13	8.89E-11	8.867655	Up	3'-phosphoadenosine 5'-phosphosulfate synthase 1
8157582	GSN	1.53687	8.98E-13	1.36E-10	8.749383	Up	gelsolin
8124423	H2BC8	1.608558	1.12E-12	1.62E-10	8.696875	Up	H2B clustered histone 8
7908041	LAMC1	1.4501	1.25E-12	1.77E-10	8.670225	Up	laminin subunit gamma 1
8045768	ARL6IP6	1.246577	1.26E-12	1.77E-10	8.669011	Up	ADP ribosylation factor like GTPase 6 interacting protein 6
8042310	SLC1A4	1.637666	1.31E-12	1.83E-10	8.659492	Up	solute carrier family 1 member 4
7915682	ZSWIM5	1.82227	1.43E-12	1.94E-10	8.639109	Up	zinc finger SWIM-type containing 5
8030914	ZNF610	1.138321	2.05E-12	2.63E-10	8.552415	Up	zinc finger protein 610
8148501	PTP4A3	1.514481	2.2E-12	2.76E-10	8.535144	Up	protein tyrosine phosphatase 4A3
7898809	EPHB2	1.524627	3.14E-12	3.67E-10	8.450802	Up	EPH receptor B2
7913566	HTR1D	2.940729	3.68E-12	4.17E-10	8.413036	Up	5-hydroxytryptamine receptor 1D
7956867	HMGA2	1.890133	4.2E-12	4.7E-10	8.381162	Up	high mobility group AT-hook 2
8108301	KIF20A	2.228882	4.48E-12	4.99E-10	8.365923	Up	kinesin family member 20A
7933821	RHOBTB1	1.619158	4.59E-12	5.09E-10	8.360403	Up	Rho related BTB domain containing 1
8018652	RNF157	1.524361	5.05E-12	5.46E-10	8.337418	Up	ring finger protein 157
8167125	USP11	1.22401	5.81E-12	6.15E-10	8.303935	Up	ubiquitin specific peptidase 11
8010702	ASPSR1	1.51179	5.97E-12	6.29E-10	8.297358	Up	ASPSR1 tether for SLC2A4, UBX domain

							containing
7983969	CCNB2	2.319658	6.46E-12	6.69E-10	8.278639	Up	cyclin B2
8117589	H3C10	1.696874	7.88E-12	8.04E-10	8.231228	Up	H3 clustered histone 10
8179884	EHMT2	1.320889	8.21E-12	8.29E-10	8.221633	Up	euchromatic histone lysine methyltransferase 2
7909568	DTL	2.233746	8.4E-12	8.46E-10	8.216126	Up	denticleless E3 ubiquitin protein ligase homolog
7907092	MPZL1	1.110293	8.5E-12	8.53E-10	8.213284	Up	myelin protein zero like 1
8095139	SRD5A3	1.175968	9.52E-12	9.41E-10	8.186395	Up	steroid 5 alpha-reductase 3
8111524	UGT3A2	2.01295	9.97E-12	9.77E-10	8.175221	Up	UDP glycosyltransferase family 3 member A2
7997962	DPEP1	3.412187	1E-11	9.77E-10	8.17388	Up	dipeptidase 1
8139737	PSPH	1.589526	1.04E-11	1E-09	8.165654	Up	phosphoserine phosphatase
7909689	SMYD2	1.198165	1.13E-11	1.08E-09	8.146548	Up	SET and MYND domain containing 2
8015460	ACLY	1.170475	1.21E-11	1.16E-09	8.128833	Up	ATP citrate lyase
8156923	PLPPR1	2.206895	1.23E-11	1.17E-09	8.124985	Up	phospholipid phosphatase related 1
8117382	H2BC5	1.61958	1.46E-11	1.36E-09	8.084132	Up	H2B clustered histone 5
8138289	ETV1	1.561422	1.48E-11	1.37E-09	8.080755	Up	ETS variant transcription factor 1
7903144	SLC44A3	1.297252	1.59E-11	1.46E-09	8.063483	Up	solute carrier family 44 member 3
8117415	H3C6	1.51443	1.63E-11	1.48E-09	8.058698	Up	H3 clustered histone 6
7920877	ARHGEF2	1.092916	1.65E-11	1.49E-09	8.055614	Up	Rho/Rac guanine nucleotide exchange factor 2
8014706	PCGF2	1.247281	1.89E-11	1.69E-09	8.022518	Up	polycomb group ring finger 2
7955217	SPATS2	1.11028	1.97E-11	1.74E-09	8.013341	Up	spermatogenesis associated serine rich 2
8117408	H2AC8	1.98058	2.08E-11	1.83E-09	7.999654	Up	H2A clustered histone 8
8040843	CAD	1.453107	2.09E-11	1.83E-09	7.999061	Up	carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase
7991234	MFGE8	1.667152	2.13E-11	1.85E-09	7.995034	Up	milk fat globule-EGF factor 8 protein
8131205	SDK1	1.496044	2.21E-11	1.92E-09	7.985481	Up	sidekick cell adhesion molecule 1
8071758	MMP11	1.897841	2.33E-11	2E-09	7.973596	Up	matrix metalloproteinase 11
8173232	AMER1	1.237163	2.38E-11	2.03E-09	7.968581	Up	APC membrane recruitment protein 1
7959786	AACS	1.233763	2.63E-11	2.18E-09	7.94434	Up	acetoacetyl-CoA synthetase
7947744	LRP4	1.133139	2.81E-11	2.31E-09	7.928712	Up	LDL receptor related protein 4
8124388	H3C2	2.616121	2.83E-11	2.31E-09	7.927171	Up	H3 clustered histone 2
8126710	SUPT3H	1.300222	2.85E-11	2.32E-09	7.925237	Up	SPT3 homolog, SAGA and STAGA complex component
7925130	TARBP1	1.332726	2.96E-11	2.38E-09	7.916179	Up	TAR (HIV-1) RNA binding protein 1
8007154	FKBP10	2.292068	3.03E-11	2.41E-09	7.910412	Up	FKBP prolylisomerase 10
8140955	CDK6	1.279018	3.07E-11	2.44E-09	7.907408	Up	cyclin dependent kinase 6
7923426	UBE2T	1.869772	3.11E-11	2.46E-09	7.904575	Up	ubiquitin conjugating enzyme E2 T
8050702	TP53I3	1.552431	3.15E-11	2.47E-09	7.901598	Up	tumor protein p53 inducible protein 3
7964271	PRIM1	1.160505	3.18E-11	2.49E-09	7.899112	Up	DNA primase subunit 1
8173457	ZMYM3	1.168042	3.29E-11	2.56E-09	7.891207	Up	zinc finger MYM-type containing 3
7974404	CDKN3	2.086537	3.33E-11	2.58E-09	7.888052	Up	cyclin dependent kinase inhibitor 3
8102643	CCNA2	1.859122	3.83E-11	2.92E-09	7.854457	Up	cyclin A2
8031913	TRIM28	1.211235	4.04E-11	3.05E-09	7.842322	Up	tripartite motif containing 28
8171725	MAP7D2	1.266487	4.07E-11	3.06E-09	7.840093	Up	MAP7 domain containing 2
8066051	NDRG3	1.081445	4.37E-11	3.22E-09	7.823338	Up	NDRG family member 3
8064502	SNRNPB	1.332234	4.41E-11	3.24E-09	7.821419	Up	small nuclear ribonucleoprotein polypeptides B and B1
7927694	PHYHIPL	2.165208	4.55E-11	3.34E-09	7.813598	Up	phytanoyl-CoA 2-hydroxylase interacting protein like

8021349	ST8SIA3	1.769577	4.59E-11	3.35E-09	7.811812	Up	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3
7953200	CCND2	2.156667	5.04E-11	3.63E-09	7.789308	Up	cyclin D2
8127031	MCM3	1.171845	5.14E-11	3.67E-09	7.784447	Up	minichromosome maintenance complex component 3
7964522	CDK4	1.214576	5.21E-11	3.71E-09	7.781424	Up	cyclin dependent kinase 4
7899870	ZNF362	1.098151	6.55E-11	4.53E-09	7.727025	Up	zinc finger protein 362
7906163	RHBG	2.119375	6.94E-11	4.74E-09	7.713065	Up	Rh family B glycoprotein (gene/pseudogene)
8150529	DKK4	3.254585	7.18E-11	4.87E-09	7.705005	Up	dickkopf WNT signaling pathway inhibitor 4
8115099	PDGFRB	1.426811	7.8E-11	5.22E-09	7.685287	Up	platelet derived growth factor receptor beta
8101945	H2AZ1	1.224085	7.99E-11	5.31E-09	7.679606	Up	H2A.Z variant histone 1
8113504	NREP	1.755236	8.08E-11	5.35E-09	7.676911	Up	neuronal regeneration related protein
8112649	FAM169A	1.639021	8.18E-11	5.41E-09	7.673846	Up	family with sequence similarity 169 member A
8119689	PTK7	1.610193	8.47E-11	5.59E-09	7.665614	Up	protein tyrosine kinase 7 (inactive)
7924055	C1orf74	1.2052	8.85E-11	5.78E-09	7.655279	Up	chromosome 1 open reading frame 74
8155214	MELK	1.740406	1E-10	6.43E-09	7.625947	Up	maternal embryonic leucine zipper kinase
8117402	H4C5	1.499917	1E-10	6.44E-09	7.625166	Up	H4 clustered histone 5
8061471	GINS1	2.259058	1.01E-10	6.45E-09	7.624055	Up	GINS complex subunit 1
8117395	H2BC7	2.308545	1.16E-10	7.21E-09	7.591471	Up	H2B clustered histone 7
8119016	MAPK13	1.277062	1.24E-10	7.68E-09	7.574291	Up	mitogen-activated protein kinase 13
7898677	HS6ST1	1.399556	1.26E-10	7.76E-09	7.570808	Up	heparansulfate 6-O-sulfotransferase 1
7910694	EDARADD	1.312902	1.29E-10	7.91E-09	7.564484	Up	EDAR associated death domain
8143270	ZC3HAV1L	1.298956	1.37E-10	8.26E-09	7.551778	Up	zinc finger CCCH-type containing, antiviral 1 like
7952268	THY1	1.81187	1.51E-10	9.03E-09	7.52734	Up	Thy-1 cell surface antigen
7955078	PFKM	1.365442	1.59E-10	9.39E-09	7.51514	Up	phosphofructokinase, muscle
7969243	CKAP2	1.635932	1.6E-10	9.44E-09	7.513267	Up	cytoskeleton associated protein 2
8014974	TOP2A	2.113914	1.68E-10	9.79E-09	7.502838	Up	DNA topoisomerase II alpha
8007302	TUBG1	1.147034	1.87E-10	1.07E-08	7.477071	Up	tubulin gamma 1
8056323	FIGN	1.830289	1.89E-10	1.08E-08	7.474481	Up	fidgetin, microtubule severing factor
7919340	GJA5	1.379924	2.06E-10	1.17E-08	7.453672	Up	gap junction protein alpha 5
7961142	OLR1	2.837839	2.06E-10	1.17E-08	7.453644	Up	oxidized low density lipoprotein receptor 1
7955317	ASIC1	1.858678	2.37E-10	1.32E-08	7.420063	Up	acid sensing ion channel subunit 1
8077958	HDAC11	1.279624	2.44E-10	1.34E-08	7.412689	Up	histone deacetylase 11
8055426	MCM6	1.336	2.61E-10	1.41E-08	7.396883	Up	minichromosome maintenance complex component 6
7994109	PLK1	2.38288	2.86E-10	1.52E-08	7.374901	Up	polo like kinase 1
7997504	CDH13	1.283624	2.99E-10	1.58E-08	7.364641	Up	cadherin 13
7905754	ATP8B2	1.240409	3.22E-10	1.69E-08	7.346859	Up	ATPase phospholipid transporting 8B2
8150881	PLAG1	1.439715	3.26E-10	1.71E-08	7.343913	Up	PLAG1 zinc finger
8104912	SKP2	1.12123	3.49E-10	1.81E-08	7.327205	Up	S-phase kinase associated protein 2
7909789	TGFB2	2.218334	3.55E-10	1.83E-08	7.323557	Up	transforming growth factor beta 2
8044212	SULT1C2	2.008067	3.6E-10	1.85E-08	7.320077	Up	sulfotransferase family 1C member 2
8031933	RPS5	1.22843	3.69E-10	1.88E-08	7.314199	Up	ribosomal protein S5
8121319	SOBP	1.145583	3.71E-10	1.89E-08	7.312689	Up	sine oculis binding protein homolog
8091757	TRIM59	1.264872	3.84E-10	1.95E-08	7.304419	Up	tripartite motif containing 59
7985829	FANCI	1.424419	4.13E-10	2.05E-08	7.287464	Up	FA complementation group I
7937020	MKI67	1.584887	4.28E-10	2.12E-08	7.278491	Up	marker of proliferation Ki-67

8053341	REG3A	4.489323	4.3E-10	2.12E-08	7.277812	Up	regenerating family member 3 alpha
7927710	CDK1	1.999852	4.68E-10	2.3E-08	7.257226	Up	cyclin dependent kinase 1
8091780	B3GALNT1	1.1245	4.71E-10	2.31E-08	7.255742	Up	beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)
7968563	RFC3	1.084173	4.74E-10	2.32E-08	7.254523	Up	replication factor C subunit 3
7906671	USP21	1.081837	4.84E-10	2.36E-08	7.249046	Up	ubiquitin specific peptidase 21
8041867	MSH2	1.233487	4.92E-10	2.39E-08	7.245238	Up	mutS homolog 2
7989770	IGDCC3	1.939267	5.24E-10	2.52E-08	7.230351	Up	immunoglobulin superfamily DCC subclass member 3
8116532	SNORD95	1.087937	5.48E-10	2.61E-08	7.219705	Up	small nucleolar RNA, C/D box 95
7935230	ALDH18A1	1.187678	5.83E-10	2.75E-08	7.204798	Up	aldehyde dehydrogenase 18 family member A1
8163086	TMEM245	1.116402	5.83E-10	2.75E-08	7.204595	Up	transmembrane protein 245 phosphatidylinositol glycan anchor biosynthesis class U
8065762	PIGU	1.288087	6.29E-10	2.92E-08	7.186581	Up	TOX high mobility group box family member 3
8001394	TOX3	1.276311	6.37E-10	2.95E-08	7.183457	Up	PCNA clamp associated factor
7989647	PCLAF	1.94471	6.98E-10	3.19E-08	7.161489	Up	zinc finger protein 704
8151496	ZNF704	1.156776	7.25E-10	3.3E-08	7.152369	Up	H4 clustered histone 14
8180321	H4C14	2.262123	7.8E-10	3.52E-08	7.135014	Up	microfibril associated protein 2
7912887	MFAP2	1.788574	8.44E-10	3.77E-08	7.115996	Up	brain expressed X-linked 1
8174201	BEX1	2.637884	8.62E-10	3.84E-08	7.111107	Up	H2B clustered histone 14
8117594	H2BC14	2.692001	8.95E-10	3.96E-08	7.101912	Up	forkhead box M1
7960340	FOXN1	1.969922	9.69E-10	4.23E-08	7.082801	Up	H4 clustered histone 9
8117537	H4C9	1.111644	1.04E-09	4.49E-08	7.065205	Up	PLAG1 like zinc finger 2
8065607	PLAGL2	1.104062	1.08E-09	4.62E-08	7.056891	Up	basal cell adhesion molecule (Lutheran blood group)
8029489	BCAM	1.55279	1.09E-09	4.65E-08	7.054641	Up	acyl-CoA synthetase long chain family member 4
8174474	ACSL4	2.16322	1.09E-09	4.65E-08	7.054027	Up	tectonic family member 2
7959638	TCTN2	1.231161	1.11E-09	4.72E-08	7.049572	Up	protein kinase AMP-activated catalytic subunit alpha 2
7901720	PRKAA2	1.824199	1.16E-09	4.9E-08	7.038901	Up	heparansulfate 6-O-sulfotransferase 1
8055130	HS6ST1	1.142804	1.19E-09	5E-08	7.034017	Up	TOPBP1 interacting checkpoint and replication regulator
7985873	TICRR	1.734731	1.22E-09	5.11E-08	7.028088	Up	small nucleolar RNA, C/D box 113-3
7976810	SNORD113-3	2.630163	1.23E-09	5.17E-08	7.024914	Up	cell adhesion associated, oncogene regulated minichromosome maintenance complex component 7
7952526	CDON	1.07604	1.26E-09	5.28E-08	7.018896	Up	PARP1 binding protein
8141395	MCM7	1.289311	1.29E-09	5.39E-08	7.013274	Up	tweety family member 3
7958031	PARPBP	1.561417	1.37E-09	5.69E-08	6.998999	Up	lysozyme
8131179	TTYH3	1.19538	1.38E-09	5.7E-08	6.997808	Up	helicase, lymphoid specific
7957023	LYZ	1.516768	1.49E-09	6.09E-08	6.978759	Up	syntrophin gamma 1
7929438	HELLS	1.619774	1.51E-09	6.15E-08	6.975973	Up	aurora kinase A
8146403	SNTG1	1.714133	1.53E-09	6.21E-08	6.973109	Up	hormonally up-regulated Neu-associated kinase
8067167	AURKA	1.642884	1.55E-09	6.26E-08	6.970758	Up	anillin actin binding protein
8068180	HUNK	1.430039	1.7E-09	6.83E-08	6.947745	Up	solute carrier family 25 member 36
8132318	ANLN	1.871495	1.74E-09	6.94E-08	6.942799	Up	H3 clustered histone 11
8083063	SLC25A36	1.166967	1.82E-09	7.22E-08	6.931608	Up	Aly/REF export factor
8124531	H3C11	2.493895	1.85E-09	7.33E-08	6.927557	Up	minichromosome maintenance complex component 5
8019772	ALYREF	1.248489	1.92E-09	7.57E-08	6.918898	Up	
8072687	MCM5	1.269489	1.95E-09	7.71E-08	6.914242	Up	

8124397	H1-2	1.460665	1.96E-09	7.72E-08	6.913797	Up	H1.2 linker histone, cluster member
8147503	LAPTM4B	1.648679	2.11E-09	8.2E-08	6.896147	Up	lysosomal protein transmembrane 4 beta
8046488	CDCA7	1.829823	2.13E-09	8.26E-08	6.89368	Up	cell division cycle associated 7
8055872	CACNB4	1.408438	2.38E-09	9.07E-08	6.866662	Up	calcium voltage-gated channel auxiliary subunit beta 4
8109639	PTTG1	1.409636	2.43E-09	9.22E-08	6.861809	Up	PTTG1 regulator of sister chromatid separation, securin
8120088	MEP1A	3.099691	2.48E-09	9.37E-08	6.857128	Up	meprin A subunit alpha
8093906	WFS1	1.247632	2.51E-09	9.48E-08	6.853833	Up	wolframin ER transmembrane glycoprotein
8131326	SLC29A4	1.783121	2.63E-09	9.83E-08	6.842322	Up	solute carrier family 29 member 4
7927876	TET1	1.160637	2.66E-09	9.88E-08	6.840356	Up	tetmethylcytosinedioxygenase 1
7945014	CHEK1	1.433501	2.92E-09	1.07E-07	6.817566	Up	checkpoint kinase 1
8015806	ETV4	2.003846	2.99E-09	1.09E-07	6.811933	Up	ETS variant transcription factor 4
8105828	CCNB1	1.605348	3.07E-09	1.12E-07	6.805569	Up	cyclin B1
8048995	ITM2C	1.101134	3.16E-09	1.15E-07	6.798376	Up	integral membrane protein 2C
8149955	PBK	1.695675	3.37E-09	1.21E-07	6.782753	Up	PDZ binding kinase
8075785	FOXRED2	1.137162	3.38E-09	1.21E-07	6.782334	Up	FAD dependent oxidoreductase domain containing 2
8124437	H3C7	1.802897	3.59E-09	1.28E-07	6.767659	Up	H3 clustered histone 7
8163181	C9orf152	1.297831	4E-09	1.39E-07	6.741575	Up	chromosome 9 open reading frame 152
8095043	RASL11B	1.58962	4.45E-09	1.52E-07	6.715665	Up	RAS like family 11 member B
7970513	SKA3	1.861349	4.57E-09	1.56E-07	6.709461	Up	spindle and kinetochore associated complex subunit 3
7989073	PRTG	2.1855	4.57E-09	1.56E-07	6.709058	Up	proteogenin
7991406	PRC1	1.481765	4.6E-09	1.57E-07	6.707793	Up	protein regulator of cytokinesis 1
8035297	PLVAP	1.101067	4.89E-09	1.65E-07	6.693086	Up	plasmalemma vesicle associated protein
7986757	NDN	1.194378	5.03E-09	1.7E-07	6.685849	Up	necdin, MAGE family member
8127094	GSTA4	1.084808	5.2E-09	1.75E-07	6.678028	Up	glutathione S-transferase alpha 4
8124394	H2BC3	2.273395	5.26E-09	1.76E-07	6.67505	Up	H2B clustered histone 3
8048411	TTLL4	1.244147	5.93E-09	1.96E-07	6.646133	Up	tubulin tyrosine ligase like 4
7923086	ASPM	1.819916	6.05E-09	1.99E-07	6.641488	Up	abnormal spindle microtubule assembly
8012257	TP53	1.137668	6.47E-09	2.11E-07	6.624957	Up	tumor protein p53
8060339	NRSN2	1.263849	6.63E-09	2.15E-07	6.619348	Up	neurensin 2
8122071	ENPP3	1.71035	6.94E-09	2.22E-07	6.608135	Up	ectonucleotidepyrophosphatase/phosphodiesterase 3
8117426	H2BC9	2.10049	7.54E-09	2.38E-07	6.588109	Up	H2B clustered histone 9
8100338	ERVMER34-1	2.007219	7.92E-09	2.48E-07	6.576121	Up	endogenous retrovirus group MER34 member 1, envelope
7976795	MEG3	1.828145	8.77E-09	2.71E-07	6.551152	Up	maternally expressed 3
7900699	CDC20	1.7169	9.54E-09	2.91E-07	6.530873	Up	cell division cycle 20
8128329	MMS22L	1.170289	1E-08	3.04E-07	6.518602	Up	MMS22 like, DNA repair protein
8082350	MCM2	1.217066	1.1E-08	3.3E-07	6.495191	Up	minichromosome maintenance complex component 2
7919642	H2AC21	1.956987	1.12E-08	3.33E-07	6.492634	Up	H2A clustered histone 21
8026954	PIK3R2	1.106202	1.15E-08	3.42E-07	6.485456	Up	phosphoinositide-3-kinase regulatory subunit 2
8040223	RRM2	1.476306	1.31E-08	3.79E-07	6.454468	Up	ribonucleotidereductase regulatory subunit M2
8147101	E2F5	1.402752	1.35E-08	3.89E-07	6.447204	Up	E2F transcription factor 5
8124527	H1-5	2.471316	1.38E-08	3.96E-07	6.44064	Up	H1.5 linker histone, cluster member
8117608	H2AC16	1.556151	1.44E-08	4.11E-07	6.429976	Up	H2A clustered histone 16

7983306	WDR76	1.258491	1.56E-08	4.41E-07	6.410536	Up	WD repeat domain 76
8113278	LIX1	2.018797	1.66E-08	4.65E-07	6.395277	Up	limb and CNS expressed 1
7935903	NPM3	1.086385	1.67E-08	4.67E-07	6.393835	Up	nucleophosmin/nucleoplasmin 3
7904907	BCL9	1.106154	1.79E-08	4.94E-07	6.377753	Up	BCL9 transcription coactivator
8095646	AFP	3.83748	1.81E-08	4.99E-07	6.374893	Up	alpha fetoprotein
8057959	PGAP1	1.471941	1.81E-08	4.99E-07	6.374553	Up	post-GPI attachment to proteins inositol deacylase 1
8117535	H2AC11	1.107153	1.87E-08	5.13E-07	6.366871	Up	H2A clustered histone 11
8034122	SPC24	1.423052	1.96E-08	5.36E-07	6.354851	Up	SPC24 component of NDC80 kinetochore complex
7980828	CCDC88C	1.407228	2E-08	5.43E-07	6.350011	Up	coiled-coil domain containing 88C
8179839	LSM2	1.15632	2.01E-08	5.43E-07	6.349736	Up	LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated
8037537	ERCC2	1.099511	2.12E-08	5.68E-07	6.33655	Up	ERCC excision repair 2, TFIIH core complex helicase subunit
8113981	P4HA2	1.085801	2.24E-08	5.98E-07	6.322577	Up	prolyl 4-hydroxylase subunit alpha 2
7947189	CCDC34	1.070471	2.34E-08	6.19E-07	6.312211	Up	coiled-coil domain containing 34
7927915	STOX1	1.471997	2.49E-08	6.51E-07	6.296502	Up	storkhead box 1
7953936	TMEM52B	1.811869	2.52E-08	6.57E-07	6.293851	Up	transmembrane protein 52B
8168794	CENPI	1.3902	2.56E-08	6.65E-07	6.290422	Up	centromere protein I
7924996	C1orf198	1.109491	2.58E-08	6.69E-07	6.287933	Up	chromosome 1 open reading frame 198
8124413	H4C4	1.653762	2.62E-08	6.76E-07	6.283905	Up	H4 clustered histone 4
7973724	NYNRIN	1.663616	2.8E-08	7.15E-07	6.267648	Up	NYN domain and retroviral integrase containing
7978846	POLE2	1.095891	2.88E-08	7.33E-07	6.260822	Up	DNA polymerase epsilon 2, accessory subunit
8112376	CENPK	1.477442	3.28E-08	8.17E-07	6.229044	Up	centromere protein K
8094278	NCAPG	1.432309	3.3E-08	8.2E-07	6.228059	Up	non-SMC condensin I complex subunit G
7919645	SV2A	1.333202	3.37E-08	8.35E-07	6.222416	Up	synaptic vesicle glycoprotein 2A
8168589	ZNF711	1.37908	3.37E-08	8.35E-07	6.222223	Up	zinc finger protein 711
7959408	KNTC1	1.196141	3.63E-08	8.87E-07	6.204236	Up	kinetochore associated 1
8021946	COLEC12	1.380321	3.67E-08	8.96E-07	6.201361	Up	collectin subfamily member 12
8155898	PCSK5	1.129146	3.74E-08	9.09E-07	6.197184	Up	proproteinconvertasubtilisin/kexin type 5
8118322	SNORD52	1.208826	3.9E-08	9.4E-07	6.18694	Up	small nucleolar RNA, C/D box 52
7948511	VWCE	1.095833	3.94E-08	9.49E-07	6.184463	Up	von Willebrand factor C and EGF domains
8050537	MATN3	2.720682	4.04E-08	9.69E-07	6.178101	Up	matrilin 3
8102560	MAD2L1	1.278696	4.07E-08	9.75E-07	6.175993	Up	mitotic arrest deficient 2 like 1
8138566	IGF2BP3	1.579554	4.31E-08	1.02E-06	6.162134	Up	insulin like growth factor 2 mRNA binding protein 3
8144669	FDFT1	1.105711	4.44E-08	1.05E-06	6.15497	Up	farnesyl-diphosphatefarnesyltransferase 1
7929258	KIF11	1.48831	4.75E-08	1.11E-06	6.137906	Up	kinesin family member 11
7915926	STIL	1.173564	4.79E-08	1.11E-06	6.136329	Up	STIL centriolar assembly protein
7941936	GSTP1	1.687065	5E-08	1.16E-06	6.125301	Up	glutathione S-transferase pi 1
8028194	ZNF382	1.15122	5.3E-08	1.21E-06	6.111155	Up	zinc finger protein 382
8008982	TBX4	1.988481	5.58E-08	1.27E-06	6.098463	Up	T-box transcription factor 4
8061579	TPX2	1.602018	5.8E-08	1.31E-06	6.089062	Up	TPX2 microtubule nucleation factor
8141950	RELN	1.465983	5.86E-08	1.32E-06	6.086227	Up	reelin
8008784	PRR11	1.251565	6.02E-08	1.35E-06	6.079752	Up	proline rich 11
8124440	H3C8	1.356755	6.34E-08	1.41E-06	6.066925	Up	H3 clustered histone 8
8056730	LINC01124	1.076875	6.38E-08	1.42E-06	6.065428	Up	long intergenic non-protein coding RNA 1124

8117543	H2AC12	1.453751	6.42E-08	1.43E-06	6.063814	Up	H2A clustered histone 12
8179564	KIFC1	1.166165	6.53E-08	1.45E-06	6.059474	Up	kinesin family member C1
8064904	FERMT1	1.41378	6.62E-08	1.46E-06	6.056228	Up	fermitin family member 1
8056572	SPC25	1.515156	6.93E-08	1.53E-06	6.044851	Up	SPC25 component of NDC80 kinetochore complex
8146357	MCM4	1.193519	7.06E-08	1.55E-06	6.040466	Up	minichromosome maintenance complex component 4
7920971	GLMP	1.189511	7.24E-08	1.58E-06	6.034126	Up	glycosylated lysosomal membrane protein
7981427	CKB	1.244081	7.38E-08	1.61E-06	6.02945	Up	creatine kinase B
8021187	SKA1	1.176912	7.54E-08	1.64E-06	6.023885	Up	spindle and kinetochore associated complex subunit 1
7967107	HNF1A-AS1	2.094372	7.55E-08	1.64E-06	6.023575	Up	HNF1A antisense RNA 1
8116579	FOXQ1	1.161237	7.59E-08	1.65E-06	6.022424	Up	forkhead box Q1
7906930	NUF2	1.617239	7.6E-08	1.65E-06	6.022216	Up	NUF2 component of NDC80 kinetochore complex
8043602	NCAPH	1.305281	7.88E-08	1.7E-06	6.013175	Up	non-SMC condensin I complex subunit H
8044225	SULT1C4	1.359027	8.12E-08	1.75E-06	6.005665	Up	sulfotransferase family 1C member 4
7955702	SOAT2	1.825381	8.15E-08	1.75E-06	6.004777	Up	sterol O-acyltransferase 2
8124510	H2BC13	1.739418	8.39E-08	1.8E-06	5.997706	Up	H2B clustered histone 13
8144036	XRCC2	1.432502	8.47E-08	1.81E-06	5.995224	Up	X-ray repair cross complementing 2
7950906	CTSC	1.144283	8.66E-08	1.84E-06	5.989658	Up	cathepsin C
8112260	DEPDC1B	1.289933	9.06E-08	1.91E-06	5.978501	Up	DEP domain containing 1B
8034772	ASF1B	1.316287	9.44E-08	1.98E-06	5.968251	Up	anti-silencing function 1B histone chaperone
8124540	H2AC17	1.453337	9.58E-08	2.01E-06	5.964593	Up	H2A clustered histone 17
7965048	NAP1L1	1.188292	9.77E-08	2.04E-06	5.959936	Up	nucleosome assembly protein 1 like 1
7909708	CENPF	1.663748	1.01E-07	2.09E-06	5.952622	Up	centromere protein F
8083779	SERPINI1	2.073734	1.07E-07	2.2E-06	5.937839	Up	serpin family I member 1
7989657	PCLAF	1.205918	1.15E-07	2.35E-06	5.919128	Up	PCNA clamp associated factor
8003204	GINS2	1.221379	1.16E-07	2.36E-06	5.917065	Up	GINS complex subunit 2
7963750	CBX5	1.168128	1.16E-07	2.37E-06	5.916593	Up	chromobox 5
8007071	CDC6	1.448856	1.31E-07	2.62E-06	5.886254	Up	cell division cycle 6
7976814	SNORD114-2	2.626252	1.33E-07	2.65E-06	5.882831	Up	small nucleolar RNA, C/D box 114-2
8114425	CDC25C	1.080816	1.4E-07	2.78E-06	5.870115	Up	cell division cycle 25C
8083494	MME	2.403426	1.42E-07	2.8E-06	5.866764	Up	membrane metalloendopeptidase
7982889	NUSAP1	1.084423	1.42E-07	2.8E-06	5.866751	Up	nucleolar and spindle associated protein 1
8156783	COL15A1	1.081673	1.42E-07	2.81E-06	5.866266	Up	collagen type XV alpha 1 chain
8073775	FBLN1	1.444665	1.43E-07	2.81E-06	5.865909	Up	fibulin 1
8127987	SNORD50A	1.30339	1.45E-07	2.84E-06	5.862335	Up	small nucleolar RNA, C/D box 50A
7940147	FAM111B	1.102513	1.51E-07	2.95E-06	5.851532	Up	family with sequence similarity 111 member B
8124391	H2AC4	1.837145	1.52E-07	2.97E-06	5.849662	Up	H2A clustered histone 4
8097857	MND1	1.287054	1.53E-07	2.98E-06	5.848494	Up	meiotic nuclear divisions 1
8124524	H2AC15	1.836025	1.6E-07	3.09E-06	5.837586	Up	H2A clustered histone 15
8001197	NETO2	1.566949	1.62E-07	3.13E-06	5.833735	Up	neuropilin and tolloid like 2
8054580	BUB1	1.453709	1.64E-07	3.16E-06	5.831246	Up	BUB1 mitotic checkpoint serine/threonine kinase
7939665	MDK	1.198721	1.64E-07	3.16E-06	5.831147	Up	midkine
7905909	EFNA4	1.257778	1.69E-07	3.25E-06	5.822645	Up	ephrin A4
8117389	H2BC6	1.201097	1.73E-07	3.29E-06	5.818167	Up	H2B clustered histone 6
8043945	MAP4K4	1.102691	1.77E-07	3.37E-06	5.811659	Up	mitogen-activated protein kinase kinasekinase 4

7979307	DLGAP5	1.537596	1.78E-07	3.38E-06	5.810596	Up	DLG associated protein 5
8148049	CCN3	1.177401	1.96E-07	3.67E-06	5.786281	Up	cellular communication network factor 3
8090823	SLCO2A1	1.249091	2.26E-07	4.14E-06	5.751146	Up	solute carrier organic anion transporter family member 2A1
8019737	KPNA2	1.271643	2.39E-07	4.32E-06	5.736739	Up	karyopherin subunit alpha 2
8007043	RAPGEFL1	1.172339	2.47E-07	4.45E-06	5.728041	Up	Rap guanine nucleotide exchange factor like 1
8007108	TMEM99	1.071856	2.5E-07	4.5E-06	5.724999	Up	transmembrane protein 99 (putative)
8019316	PYCR1	1.428201	2.53E-07	4.55E-06	5.722011	Up	pyrroline-5-carboxylate reductase 1
8124385	H4C2	1.446077	2.64E-07	4.72E-06	5.711608	Up	H4 clustered histone 2
8098423	NEIL3	1.087616	2.65E-07	4.74E-06	5.71063	Up	nei like DNA glycosylase 3
7990151	PKM	1.077351	3.18E-07	5.55E-06	5.664467	Up	pyruvate kinase M1/2
8085754	SGO1	1.324156	3.19E-07	5.56E-06	5.664033	Up	shugoshin 1
7985089	RCN2	1.071374	3.35E-07	5.78E-06	5.651905	Up	reticulocalbin 2
8027297	ZNF738	1.351542	3.52E-07	6.04E-06	5.639132	Up	zinc finger protein 738
8038624	C19orf48	1.204102	3.92E-07	6.63E-06	5.612166	Up	chromosome 19 open reading frame 48
8124196	DCDC2	1.598298	4.25E-07	7.09E-06	5.591397	Up	doublecortin domain containing 2
8124537	H3C12	1.937416	4.42E-07	7.31E-06	5.581513	Up	H3 clustered histone 12
8083941	ECT2	1.20662	4.57E-07	7.53E-06	5.573164	Up	epithelial cell transforming 2
8145418	CDCA2	1.093462	4.79E-07	7.85E-06	5.56127	Up	cell division cycle associated 2
8016387	PRR15L	1.181372	4.89E-07	8E-06	5.555831	Up	proline rich 15 like
7905088	H2AC20	1.156635	5.02E-07	8.18E-06	5.549327	Up	H2A clustered histone 20
7995681	MMP2	1.565987	5.36E-07	8.64E-06	5.532707	Up	matrix metalloproteinase 2
7976818	SNORD114-6	1.739232	5.43E-07	8.72E-06	5.52954	Up	small nucleolar RNA, C/D box 114-6
8124518	H2AC14	1.847687	5.44E-07	8.73E-06	5.529042	Up	H2A clustered histone 14
8077817	SLC6A11	1.437606	5.67E-07	9.04E-06	5.518368	Up	solute carrier family 6 member 11
7947248	KIF18A	1.24503	6.01E-07	9.51E-06	5.503598	Up	kinesin family member 18A
7934936	SLC16A12	1.462218	6.31E-07	9.92E-06	5.491296	Up	solute carrier family 16 member 12
8019857	NDC80	1.074707	6.4E-07	1E-05	5.487786	Up	NDC80 kinetochore complex component
7924619	ENAH	1.118615	6.61E-07	1.03E-05	5.479597	Up	ENAH actin regulator
8036302	LINC00665	1.6579	6.87E-07	1.07E-05	5.469711	Up	long intergenic non-protein coding RNA 665
8109830	SPDL1	1.132734	6.93E-07	1.07E-05	5.467406	Up	spindle apparatus coiled-coil protein 1
8106210	ARHGEF28	1.104557	6.93E-07	1.07E-05	5.467397	Up	Rho guanine nucleotide exchange factor 28
8114964	SPINK1	3.373751	7.06E-07	1.09E-05	5.462577	Up	serine peptidase inhibitor, Kazal type 1
8120838	TTK	1.471652	7.17E-07	1.1E-05	5.458675	Up	TTK protein kinase
8092067	RPL22L1	1.2499	7.53E-07	1.15E-05	5.446096	Up	ribosomal protein L22 like 1
8134384	DYNC1H1	1.512531	7.54E-07	1.15E-05	5.445869	Up	dynein cytoplasmic 1 intermediate chain 1
7962703	COL2A1	1.174349	7.86E-07	1.19E-05	5.435142	Up	collagen type II alpha 1 chain
8097356	PLK4	1.106919	8.31E-07	1.24E-05	5.421205	Up	polo like kinase 4
7953218	RAD51AP1	1.089541	9.29E-07	1.37E-05	5.392483	Up	RAD51 associated protein 1
8059838	HJURP	1.144152	9.36E-07	1.37E-05	5.390682	Up	Holliday junction recognition protein
8047174	SLC39A10	1.183434	9.57E-07	1.4E-05	5.385019	Up	solute carrier family 39 member 10
7993588	TMC7	1.120446	1.04E-06	1.5E-05	5.363637	Up	transmembrane channel like 7
7978407	PRKD1	1.212447	1.05E-06	1.51E-05	5.3618	Up	protein kinase D1
8068651	PCP4	1.775862	1.06E-06	1.52E-05	5.357563	Up	Purkinje cell protein 4
8066260	SNORA71C	1.253776	1.08E-06	1.55E-05	5.353069	Up	small nucleolar RNA, H/ACA box 71C
8013771	TLCD1	1.25362	1.18E-06	1.67E-05	5.33018	Up	TLC domain containing 1

8172670	DGKK	1.370881	1.2E-06	1.69E-05	5.32659	Up	diacylglycerol kinase kappa
7982358	ARHGAP11A	1.312616	1.21E-06	1.7E-05	5.32471	Up	Rho GTPase activating protein 11A potassium inwardly rectifying channel subfamily J member 5
7945146	KCNJ5	1.160467	1.23E-06	1.72E-05	5.319834	Up	small nucleolar RNA, C/D box 30
7948900	SNORD30	1.109137	1.38E-06	1.9E-05	5.291793	Up	ribonuclease A family member 1, pancreatic
7977615	RNASE1	1.104973	1.41E-06	1.93E-05	5.285302	Up	solute carrier family 5 member 9
7901316	SLC5A9	1.285379	1.48E-06	2.02E-05	5.272818	Up	progastricin
8126324	PGC	2.837666	1.62E-06	2.18E-05	5.250163	Up	olfactomedin like 2B
7921882	OLFML2B	1.439349	1.64E-06	2.2E-05	5.247015	Up	ubiquitin like with PHD and ring finger domains 1
8024900	UHRF1	1.134639	1.68E-06	2.25E-05	5.240511	Up	5-hydroxytryptamine receptor 4
8114977	HTR4	1.249641	1.79E-06	2.38E-05	5.223864	Up	cystatin SN
8065412	CST1	2.95569	1.87E-06	2.47E-05	5.212371	Up	H3 clustered histone 3
8117339	H3C3	1.175204	2.1E-06	2.72E-05	5.182459	Up	solute carrier family 1 member 5
8037835	SLC1A5	1.246562	2.12E-06	2.74E-05	5.17932	Up	lin-28 homolog B
8121251	LIN28B	2.073173	2.21E-06	2.84E-05	5.168955	Up	carboxypeptidase A6
8151191	CPA6	1.377275	2.4E-06	3.05E-05	5.147568	Up	lysophosphatidylcholineacyltransferase 2
7995697	LPCAT2	1.093687	2.64E-06	3.31E-05	5.122589	Up	collagen type IV alpha 1 chain
7972750	COL4A1	1.120372	2.68E-06	3.35E-05	5.118795	Up	small nucleolar RNA, H/ACA box 5A
8139482	SNORA5A	1.113557	2.81E-06	3.47E-05	5.106866	Up	NYN domain and retroviral integrase containing
7973727	NYNRIN	1.316514	2.81E-06	3.47E-05	5.106855	Up	dynein axonemal heavy chain 17
8018902	DNAH17	1.079276	3.04E-06	3.73E-05	5.086139	Up	gap junction protein beta 6
7970448	GJB6	1.151659	3.05E-06	3.75E-05	5.084986	Up	solute carrier family 22 member 11
7941062	SLC22A11	1.090335	3.19E-06	3.9E-05	5.072988	Up	small nucleolar RNA, C/D box 44
7922410	SNORD44	1.281937	3.33E-06	4.04E-05	5.062197	Up	endoplasmic reticulum protein 27
7961524	ERP27	1.711109	3.6E-06	4.33E-05	5.04163	Up	solute carrier family 2 member 1
7915472	SLC2A1	1.578424	3.64E-06	4.37E-05	5.038442	Up	TNF superfamily member 4
7922343	TNFSF4	1.329627	3.77E-06	4.48E-05	5.029716	Up	prostate androgen-regulated transcript 1
8105495	PART1	1.952691	3.88E-06	4.6E-05	5.022157	Up	hes related family bHLH transcription factor with YRPW motif 1
8151457	HEY1	1.111906	4.07E-06	4.78E-05	5.009246	Up	small nucleolar RNA, C/D box 81
7922400	SNORD81	1.143675	4.14E-06	4.86E-05	5.004817	Up	steroid receptor associated and regulated protein
7898296	SRARP	1.145389	4.22E-06	4.94E-05	4.99958	Up	H3 clustered histone 1
8117330	H3C1	1.687935	4.57E-06	5.3E-05	4.97862	Up	retinol binding protein 1
8091078	RBP1	1.12892	4.65E-06	5.38E-05	4.973948	Up	metallophosphoesterase domain containing 2
7947274	MPPED2	1.46169	5.39E-06	6.1E-05	4.935059	Up	chromosome 12 open reading frame 75
7958253	C12orf75	1.082506	5.68E-06	6.37E-05	4.92133	Up	MYCN proto-oncogene, bHLH transcription factor
8040419	MYCN	1.747252	5.7E-06	6.39E-05	4.920366	Up	ribosomal protein S27
7900157	RPS27	1.213684	6.23E-06	6.89E-05	4.896722	Up	SPARC related modular calcium binding 2
8123446	SMOC2	1.285284	6.25E-06	6.91E-05	4.895744	Up	MYB proto-oncogene like 2
8062766	MYBL2	1.23121	6.77E-06	7.38E-05	4.874699	Up	cytoskeleton associated protein 2 like
8054702	CKAP2L	1.07398	7.57E-06	8.11E-05	4.844738	Up	glycerol-3-phosphate dehydrogenase 1 like
8078386	GPD1L	1.177626	7.58E-06	8.11E-05	4.844443	Up	EGF like repeats and discoidin domains 3
8112980	EDIL3	1.846642	7.69E-06	8.21E-05	4.840643	Up	solute carrier family 13 member 3
8066757	SLC13A3	1.330843	8.58E-06	9E-05	4.811329	Up	fatty acid desaturase 2
7940565	FADS2	1.592897	8.65E-06	9.06E-05	4.809411	Up	stimulated by retinoic acid 6
7990309	STRA6	1.331824	9.88E-06	0.000102	4.773758	Up	

8180221	LINC01549	1.53009	1.04E-05	0.000106	4.759131	Up	long intergenic non-protein coding RNA 1549
7946661	DKK3	1.130968	1.06E-05	0.000108	4.75429	Up	dickkopf WNT signaling pathway inhibitor 3
8149465	FGF20	1.073473	1.11E-05	0.000112	4.742249	Up	fibroblast growth factor 20
8175539	LDOC1	1.208443	1.21E-05	0.00012	4.719431	Up	LDOC1 regulator of NFkB signaling
8117429	H2BC10	1.38951	1.22E-05	0.000121	4.71683	Up	H2B clustered histone 10
8124534	H4C13	1.307289	1.37E-05	0.000134	4.685836	Up	H4 clustered histone 13
8052399	BCL11A	1.200078	1.41E-05	0.000137	4.677891	Up	BAF chromatin remodeling complex subunit BCL11A
7916898	DEPDC1	1.146694	1.43E-05	0.000139	4.672977	Up	DEP domain containing 1
7910047	DNAH14	1.199719	1.44E-05	0.00014	4.67228	Up	dynein axonemal heavy chain 14
7923034	B3GALT2	1.609957	1.51E-05	0.000145	4.65966	Up	beta-1,3-galactosyltransferase 2
8095456	ODAM	1.939405	1.83E-05	0.000172	4.606453	Up	odontogenic, ameloblast associated
8119915	LINC01512	1.120676	1.86E-05	0.000174	4.601874	Up	long intergenic non-protein coding RNA 1512
8092000	TERC	1.460588	1.94E-05	0.000181	4.591415	Up	telomerase RNA component
7973093	EDDM3A	1.630095	2.01E-05	0.000186	4.581305	Up	epididymal protein 3A
8043725	ZAP70	1.198079	2.01E-05	0.000186	4.581065	Up	zeta chain of T cell receptor associated protein kinase 70
7974689	DACT1	1.084031	2.13E-05	0.000195	4.565431	Up	dishevelled binding antagonist of beta catenin 1
8140534	SEMA3C	1.349176	2.29E-05	0.000208	4.545191	Up	semaphorin 3C
7964722	WIF1	2.203195	2.59E-05	0.000232	4.512239	Up	WNT inhibitory factor 1
8170695	DUSP9	1.568434	2.77E-05	0.000246	4.492719	Up	dual specificity phosphatase 9
8084704	EIF4A2	1.254997	2.96E-05	0.00026	4.475328	Up	eukaryotic translation initiation factor 4A2
8046078	B3GALT1	1.372365	3.08E-05	0.000268	4.464103	Up	beta-1,3-galactosyltransferase 1
8064539	CPXM1	1.143805	3.43E-05	0.000294	4.433923	Up	carboxypeptidase X, M14 family member 1
8056363	SLC38A11	1.23444	4.29E-05	0.000354	4.371576	Up	solute carrier family 38 member 11
8042788	ACTG2	1.634227	4.35E-05	0.000359	4.367776	Up	actin gamma 2, smooth muscle
7922408	SNORD78	1.125285	5.42E-05	0.00043	4.306296	Up	small nucleolar RNA, C/D box 78
8106743	VCAN	1.710818	5.63E-05	0.000445	4.295297	Up	versican
7981974	SNORD116-13	1.536529	5.64E-05	0.000445	4.294904	Up	small nucleolar RNA, C/D box 116-13
8079422	TDGF1	1.276329	6.21E-05	0.000483	4.26769	Up	teratocarcinoma-derived growth factor 1
7939559	TSPAN18	1.474805	6.87E-05	0.000526	4.239236	Up	tetraspanin 18
8055314	LYPD1	1.101297	7.08E-05	0.000539	4.230705	Up	LY6/PLAUR domain containing 1
7976850	MIR154	1.417225	7.21E-05	0.000548	4.225565	Up	microRNA 154
7981945	PWAR6	1.312355	8.34E-05	0.00062	4.184142	Up	PraderWilli/Angelman region RNA 6
7955963	MUCL1	1.288673	9.71E-05	0.000705	4.140575	Up	mucin like 1
7923578	FMOD	1.35917	0.000146	0.000999	4.021923	Up	fibromodulin
7981970	SNORD116-11	1.238358	0.000147	0.001006	4.019603	Up	small nucleolar RNA, C/D box 116-11
8139087	SFRP4	1.32531	0.000172	0.001141	3.975198	Up	secreted frizzled related protein 4
8141140	DLX5	1.103599	0.000175	0.001161	3.969296	Up	distal-less homeobox 5
8062064	MYH7B	1.333397	0.000189	0.001241	3.946157	Up	myosin heavy chain 7B
7904158	OLFML3	1.126637	0.000208	0.001343	3.918088	Up	olfactomedin like 3
7921533	KCNJ10	1.205856	0.000224	0.00143	3.896127	Up	potassium inwardly rectifying channel subfamily J member 10
8016646	COL1A1	1.350822	0.000246	0.001541	3.868442	Up	collagen type I alpha 1 chain
8160168	FREM1	1.4308	0.000249	0.001555	3.865391	Up	FRAS1 related extracellular matrix 1
8015349	KRT19	1.098654	0.00027	0.001665	3.841552	Up	keratin 19

8077366	LRRN1	1.102835	0.000302	0.001834	3.807336	Up	leucine rich repeat neuronal 1
8001800	CDH11	1.339772	0.000319	0.001921	3.790961	Up	cadherin 11
8101659	SPARCL1	1.403522	0.000358	0.002107	3.756636	Up	SPARC like 1
7980152	LTBP2	1.120783	0.000412	0.002381	3.713848	Up	latent transforming growth factor beta binding protein 2
8134263	COL1A2	1.362936	0.000461	0.002622	3.679363	Up	collagen type I alpha 2 chain
8057506	FRZB	1.236166	0.000536	0.002976	3.633053	Up	frizzled related protein
8164215	SNORA65	1.071443	0.000604	0.003295	3.596379	Up	small nucleolar RNA, H/ACA box 65
8102200	DKK2	1.135208	0.000629	0.003412	3.583603	Up	dickkopf WNT signaling pathway inhibitor 2
7976842	MIR382	1.163973	0.000747	0.003943	3.530113	Up	microRNA 382
8142270	NRCAM	1.090841	0.000915	0.004692	3.466516	Up	neuronal cell adhesion molecule
7921099	CRABP2	1.182176	0.00104	0.005236	3.425781	Up	cellular retinoic acid binding protein 2
8060805	CHGB	1.339338	0.001143	0.005656	3.395404	Up	chromogranin B
8044700	DPP10	1.190213	0.001157	0.005711	3.391597	Up	dipeptidyl peptidase like 10
8002303	NQO1	1.457459	0.001157	0.005711	3.391563	Up	NAD(P)H quinone dehydrogenase 1
7906501	ATP1A2	1.179812	0.001184	0.005816	3.384181	Up	ATPase Na ⁺ /K ⁺ transporting subunit alpha 2
7981998	SNORD116-25	1.09447	0.001463	0.00694	3.315816	Up	small nucleolar RNA, C/D box 116-25
7907156	XCL1	1.072172	0.001723	0.007953	3.262539	Up	X-C motif chemokine ligand 1
7968678	FREM2	1.334139	0.001866	0.008504	3.236245	Up	FRAS1 related extracellular matrix 2 multiple C2 and transmembrane domain containing 1
8113130	MCTP1	1.120834	0.002095	0.009349	3.197977	Up	GDNF family receptor alpha 3
8114415	GFRA3	1.369131	0.002286	0.010041	3.169062	Up	secreted phosphoprotein 1
8096301	SPP1	1.325145	0.004041	0.016054	2.975164	Up	complement component 3 precursor pseudogene
8025522	C3P1	-3.30609	8.35E-23	8.99E-19	-14.652	Down	solute carrier family 22 member 1
8123232	SLC22A1	-4.39446	3.36E-22	2.72E-18	-14.2635	Down	retinol dehydrogenase 16
7964292	RDH16	-2.8987	1.17E-21	7.54E-18	-13.9213	Down	hydroxyacid oxidase 2
7904396	HAO2	-4.29552	7.31E-21	3.38E-17	-13.4236	Down	glutaminase 2
7964183	GLS2	-3.29957	8.52E-21	3.44E-17	-13.3824	Down	monoglyceride lipase
8090433	MGLL	-2.12582	5.41E-20	1.34E-16	-12.8905	Down	tetratricopeptide repeat domain 36
7944271	TTC36	-1.42939	1.09E-19	2.35E-16	-12.7059	Down	serine dehydratase
7966621	SDS	-3.73349	2.09E-19	3.75E-16	-12.5359	Down	fetuin B
8084657	FETUB	-3.60928	1.18E-18	1.73E-15	-12.0873	Down	PZP alpha-2-macroglobulin like
7960984	PZP	-2.70226	1.53E-18	1.98E-15	-12.0195	Down	C-type lectin domain family 4 member M
8025303	CLEC4M	-3.38324	1.74E-18	2.17E-15	-11.9864	Down	glucosylceramidase beta 3 (gene/pseudogene)
8094361	GBA3	-2.94063	2.71E-18	3.24E-15	-11.8738	Down	cytochrome P450 family 1 subfamily A member 2
7984862	CYP1A2	-3.62456	5.29E-18	5.7E-15	-11.7029	Down	glycerol-3-phosphate acyltransferase 3
8096116	GPAT3	-2.94539	9.99E-18	9.5E-15	-11.5416	Down	beta-carotene oxygenase 2
7943867	BCO2	-3.65423	1.63E-17	1.46E-14	-11.4187	Down	asparaginase
7977203	ASPG	-1.45501	1.9E-17	1.66E-14	-11.3796	Down	xanthine dehydrogenase
8051322	XDH	-3.34633	1.99E-17	1.66E-14	-11.3676	Down	steroid 5 alpha-reductase 2
8051361	SRD5A2	-3.13906	2.05E-17	1.66E-14	-11.3598	Down	carbonic anhydrase 2
8147132	CA2	-2.38418	2.48E-17	1.91E-14	-11.3125	Down	N-acetyltransferase 2
8144866	NAT2	-2.33039	2.61E-17	1.96E-14	-11.2997	Down	tribblespseudokinase 1
8148304	TRIB1	-2.00232	3.94E-17	2.71E-14	-11.1962	Down	steroid 5 alpha-reductase 1
8104369	SRD5A1	-1.3541	7.83E-17	5.07E-14	-11.0243	Down	dihydroorotate dehydrogenase (quinone)
7997179	DHODH	-1.76163	7.84E-17	5.07E-14	-11.0241	Down	

7964142	APOF	-4.31305	1.11E-16	6.77E-14	-10.9373	Down	apolipoprotein F
7939056	BBOX1	-2.07186	1.2E-16	7.17E-14	-10.9184	Down	gamma-butyrobetaine hydroxylase 1
7929466	CYP2C18	-3.30808	1.61E-16	9.16E-14	-10.8441	Down	cytochrome P450 family 2 subfamily C member 18
7910950	KMO	-3.05616	1.86E-16	1.04E-13	-10.8085	Down	kynurenine 3-monooxygenase
8028955	CYP2B7P	-5.1472	1.9E-16	1.04E-13	-10.8038	Down	cytochrome P450 family 2 subfamily B member 7, pseudogene
7917548	GBP7	-2.46798	2.02E-16	1.09E-13	-10.789	Down	guanylate binding protein 7
7898655	CDA	-1.90793	2.12E-16	1.12E-13	-10.7766	Down	cytidinedeaminase
7957551	SOCS2	-1.87597	4.18E-16	2.05E-13	-10.6083	Down	suppressor of cytokine signaling 2
7913138	AKR7L	-2.04447	5.43E-16	2.58E-13	-10.5438	Down	aldo-ketoreductase family 7 like (gene/pseudogene)
8093792	HGFAC	-1.88966	5.59E-16	2.58E-13	-10.5367	Down	HGF activator
8161174	GNE	-1.58207	7.08E-16	3.22E-13	-10.4788	Down	glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase
7979269	GCH1	-1.83997	9.28E-16	4.11E-13	-10.4121	Down	GTP cyclohydrolase 1
7933537	OGDHL	-2.50293	1.04E-15	4.47E-13	-10.3845	Down	oxoglutarate dehydrogenase like
7964660	AVPR1A	-3.20147	1.25E-15	5.25E-13	-10.3386	Down	arginine vasopressin receptor 1A
8106999	LINC01554	-1.46225	1.3E-15	5.4E-13	-10.3288	Down	long intergenic non-protein coding RNA 1554
8148902	GPT	-1.30617	1.71E-15	6.91E-13	-10.2621	Down	glutamic--pyruvic transaminase
8033433	CLEC4G	-2.18996	2.18E-15	8.49E-13	-10.2025	Down	C-type lectin domain family 4 member G
7994572	SNX29P2	-1.66299	2.43E-15	8.87E-13	-10.176	Down	sorting nexin 29 pseudogene 2
8102249	ETNPPL	-2.18886	2.43E-15	8.87E-13	-10.1757	Down	ethanolamine-phosphate phospho-lyase
8039779	SLC27A5	-2.25185	2.76E-15	9.82E-13	-10.1447	Down	solute carrier family 27 member 5
8130608	LPA	-2.7282	3.55E-15	1.2E-12	-10.0834	Down	lipoprotein(a)
7958931	DTX1	-1.88938	3.87E-15	1.28E-12	-10.0627	Down	deltex E3 ubiquitin ligase 1
8127087	GSTA3	-1.44025	4.33E-15	1.41E-12	-10.0353	Down	glutathione S-transferase alpha 3
8180222	CFHR4	-3.45805	4.4E-15	1.41E-12	-10.0313	Down	complement factor H related 4
8022803	GAREM1	-1.6652	4.4E-15	1.41E-12	-10.0311	Down	GRB2 associated regulator of MAPK1 subtype 1
8159919	SPATA6L	-1.73127	4.45E-15	1.41E-12	-10.0286	Down	spermatogenesis associated 6 like
8098246	ANXA10	-1.50375	5.49E-15	1.69E-12	-9.97756	Down	annexin A10
8129627	VNN3	-2.72847	6.82E-15	2E-12	-9.9245	Down	vanin 3
7949679	SPTBN2	-1.42585	7.22E-15	2.08E-12	-9.91075	Down	spectrin beta, non-erythrocytic 2
8129783	MAP7	-1.76963	7.28E-15	2.08E-12	-9.90855	Down	microtubule associated protein 7
8154135	SLC1A1	-3.71391	1.15E-14	3.21E-12	-9.79728	Down	solute carrier family 1 member 1
7952249	USP2	-1.42685	1.61E-14	4.42E-12	-9.71564	Down	ubiquitin specific peptidase 2
8119620	GNMT	-2.93948	1.64E-14	4.44E-12	-9.71223	Down	glycine N-methyltransferase
8159211	FCN2	-1.78277	1.75E-14	4.67E-12	-9.69629	Down	ficolin 2
7962884	RND1	-2.16105	1.83E-14	4.86E-12	-9.68472	Down	Rho family GTPase 1
8021653	SERPINB8	-2.22196	2.12E-14	5.39E-12	-9.64968	Down	serpin family B member 8
7908481	CFHR3	-4.14346	2.26E-14	5.68E-12	-9.63444	Down	complement factor H related 3
7963826	PPP1R1A	-2.05531	2.27E-14	5.68E-12	-9.63341	Down	protein phosphatase 1 regulatory inhibitor subunit 1A
8145736	NRG1	-1.78632	2.32E-14	5.76E-12	-9.628	Down	neuregulin 1
8133961	RUNDC3B	-2.03249	2.59E-14	6.39E-12	-9.60096	Down	RUN domain containing 3B
7918558	KCND3	-1.91677	2.85E-14	6.93E-12	-9.5777	Down	potassium voltage-gated channel subfamily D member 3
8028963	CYP2B6	-5.07072	2.87E-14	6.93E-12	-9.57607	Down	cytochrome P450 family 2 subfamily B member 6
8091863	SLITRK3	-2.21545	3.76E-14	8.81E-12	-9.51088	Down	SLIT and NTRK like family member 3

8044773	MARCO	-1.53571	5.02E-14	1.16E-11	-9.44114	Down	macrophage receptor with collagenous structure
7902290	CTH	-2.4056	5.36E-14	1.21E-11	-9.42567	Down	cystathionine gamma-lyase
8149885	ADRA1A	-2.76568	5.54E-14	1.23E-11	-9.41775	Down	adrenoceptor alpha 1A
8032834	LRG1	-2.20529	6E-14	1.32E-11	-9.3985	Down	leucine rich alpha-2-glycoprotein 1
8151942	RIDA	-2.71821	6.34E-14	1.38E-11	-9.38509	Down	reactive intermediate imine deaminase A homolog
8124211	GPLD1	-2.0305	7.35E-14	1.57E-11	-9.34937	Down	glycosylphosphatidylinositol specific phospholipase D1
7908492	CFHR4	-3.15853	7.47E-14	1.59E-11	-9.34562	Down	complement factor H related 4
7970905	N4BP2L1	-1.63736	1.08E-13	2.22E-11	-9.25605	Down	NEDD4 binding protein 2 like 1
7942793	THRSF	-2.8613	1.25E-13	2.52E-11	-9.22242	Down	thyroid hormone responsive
8174598	IL13RA2	-1.39909	1.28E-13	2.57E-11	-9.21564	Down	interleukin 13 receptor subunit alpha 2
7943998	NNMT	-3.28874	1.34E-13	2.67E-11	-9.2052	Down	nicotinamide N-methyltransferase
8068593	ETS2	-1.47029	1.68E-13	3.26E-11	-9.15028	Down	ETS proto-oncogene 2, transcription factor
7961102	CLEC1B	-2.34611	2.03E-13	3.84E-11	-9.10496	Down	C-type lectin domain family 1 member B
8070182	RCAN1	-1.31852	2.67E-13	4.93E-11	-9.03976	Down	regulator of calcineurin 1
7940135	GLYATL1	-2.55705	2.98E-13	5.34E-11	-9.01332	Down	glycine-N-acyltransferase like 1
7965606	HAL	-3.8406	3.2E-13	5.69E-11	-8.99606	Down	histidine ammonia-lyase
8136459	AKR1D1	-3.07329	3.35E-13	5.92E-11	-8.98508	Down	aldo-ketoreductase family 1 member D1
8146669	TRIM55	-1.75502	4.27E-13	7.38E-11	-8.92707	Down	tripartite motif containing 55
7995739	GNAO1	-1.94451	4.45E-13	7.64E-11	-8.91753	Down	G protein subunit alpha o1
8127065	GSTA2	-2.98827	4.65E-13	7.91E-11	-8.90668	Down	glutathione S-transferase alpha 2
8023598	RNF152	-2.08533	4.86E-13	8.18E-11	-8.89618	Down	ring finger protein 152
7929478	CYP2C19	-4.12324	5.26E-13	8.73E-11	-8.87708	Down	cytochrome P450 family 2 subfamily C member 19
7929322	CYP26A1	-1.39111	5.37E-13	8.81E-11	-8.87235	Down	cytochrome P450 family 26 subfamily A member 1
8101637	HSD17B13	-4.66433	6.42E-13	1.03E-10	-8.82952	Down	hydroxysteroid 17-beta dehydrogenase 13
8058591	ACADL	-2.57041	6.57E-13	1.05E-10	-8.8243	Down	acyl-CoA dehydrogenase long chain
7933084	NAMPT	-2.48145	6.68E-13	1.06E-10	-8.82006	Down	nicotinamidephosphoribosyltransferase
8000582	SULT1A2	-1.62619	6.69E-13	1.06E-10	-8.81979	Down	sulfotransferase family 1A member 2
7909446	HSD11B1	-3.80584	7.57E-13	1.17E-10	-8.79037	Down	hydroxysteroid 11-beta dehydrogenase 1
8122744	IYD	-1.39701	7.67E-13	1.18E-10	-8.78696	Down	iodotyrosinedeiodinase
8021169	LIPG	-2.02788	8.88E-13	1.35E-10	-8.75207	Down	lipase G, endothelial type
7931840	AKR1C8P	-2.05835	9.43E-13	1.42E-10	-8.7377	Down	aldo-ketoreductase family 1 member C8, pseudogene
8142120	NAMPT	-2.52935	1.01E-12	1.5E-10	-8.72041	Down	nicotinamidephosphoribosyltransferase
8122843	ESR1	-1.44899	1.05E-12	1.55E-10	-8.71108	Down	estrogen receptor 1
8099967	RBM47	-1.37808	1.07E-12	1.55E-10	-8.70838	Down	RNA binding motif protein 47
8137526	INSIG1	-1.93931	1.14E-12	1.64E-10	-8.6925	Down	insulin induced gene 1
8162276	NFIL3	-1.78475	1.14E-12	1.64E-10	-8.69206	Down	nuclear factor, interleukin 3 regulated
7995829	MT1H	-2.49774	1.21E-12	1.72E-10	-8.67912	Down	metallothionein 1H
8159491	C8G	-2.04665	1.31E-12	1.83E-10	-8.65911	Down	complement C8 gamma chain
8111136	RETREG1	-1.95114	1.35E-12	1.86E-10	-8.65192	Down	reticulophagy regulator 1
7930561	HABP2	-3.32781	1.36E-12	1.86E-10	-8.65051	Down	hyaluronan binding protein 2
8071107	SLC25A18	-2.2498	1.54E-12	2.08E-10	-8.62032	Down	solute carrier family 25 member 18
8132250	BMPER	-1.38255	1.65E-12	2.21E-10	-8.60362	Down	BMP binding endothelial regulator
7942603	MOGAT2	-1.85221	1.74E-12	2.3E-10	-8.59133	Down	monoacylglycerol O-acyltransferase 2
8083471	ARHGEF26	-2.64106	1.75E-12	2.3E-10	-8.59068	Down	Rho guanine nucleotide exchange factor 26

8027819	HAMP	-2.65013	1.75E-12	2.3E-10	-8.59054	Down	hepcidin antimicrobial peptide
8100994	CXCL2	-2.40976	1.75E-12	2.3E-10	-8.58988	Down	C-X-C motif chemokine ligand 2
8143961	PRKAG2	-1.34504	1.79E-12	2.33E-10	-8.58517	Down	protein kinase AMP-activated non-catalytic subunit gamma 2
7979878	SLC10A1	-4.00122	1.87E-12	2.42E-10	-8.57446	Down	solute carrier family 10 member 1
7958466	ACACB	-1.73003	1.89E-12	2.43E-10	-8.57187	Down	acetyl-CoA carboxylase beta
8155802	GDA	-3.17581	2.16E-12	2.73E-10	-8.53945	Down	guanine deaminase
7959834	GLT1D1	-2.37102	2.18E-12	2.74E-10	-8.53743	Down	glycosyltransferase 1 domain containing 1
7935169	CYP2C8	-5.51991	2.78E-12	3.34E-10	-8.47972	Down	cytochrome P450 family 2 subfamily C member 8
7970793	SLC46A3	-2.10954	2.79E-12	3.34E-10	-8.47898	Down	solute carrier family 46 member 3
7933665	MBL2	-2.43825	2.82E-12	3.37E-10	-8.47586	Down	mannose binding lectin 2
8103094	NR3C2	-1.26058	3.01E-12	3.57E-10	-8.46055	Down	nuclear receptor subfamily 3 group C member 2
8170215	F9	-4.54581	3.13E-12	3.67E-10	-8.45176	Down	coagulation factor IX
7935627	GOT1	-1.66843	3.21E-12	3.75E-10	-8.44535	Down	glutamic-oxaloacetic transaminase 1
8154153	CDC37L1	-1.83529	3.25E-12	3.75E-10	-8.44245	Down	cell division cycle 37 like 1
8099912	SMIM14	-1.38867	3.26E-12	3.75E-10	-8.44187	Down	small integral membrane protein 14
8024485	GADD45B	-1.63015	3.27E-12	3.75E-10	-8.44101	Down	growth arrest and DNA damage inducible beta
7935270	BLNK	-1.81437	3.28E-12	3.75E-10	-8.44022	Down	B cell linker
7956271	HSD17B6	-4.29901	3.82E-12	4.3E-10	-8.40396	Down	hydroxysteroid 17-beta dehydrogenase 6
8097038	NDST3	-1.44387	4.63E-12	5.12E-10	-8.35822	Down	N-deacetylase and N-sulfotransferase 3 aminocarboxymuconatesemialdehyde decarboxylase
8045368	ACMSD	-2.12824	5.18E-12	5.58E-10	-8.33136	Down	NFKB inhibitor zeta
8081386	NFKBIZ	-1.49828	5.24E-12	5.62E-10	-8.32868	Down	solute carrier family 7 member 2
8144786	SLC7A2	-1.4625	5.59E-12	5.99E-10	-8.31302	Down	complement factor H related 5
7908499	CFHR5	-3.54183	5.7E-12	6.06E-10	-8.30873	Down	solute carrier family 51 alpha subunit
8084929	SLC51A	-2.2238	7.24E-12	7.43E-10	-8.25144	Down	androgen receptor
8167998	AR	-2.82868	8.04E-12	8.17E-10	-8.2267	Down	transmembrane serine protease 2
8070467	TMPRSS2	-1.85089	8.98E-12	8.98E-10	-8.20024	Down	adhesion G protein-coupled receptor A3
8099612	ADGRA3	-1.31537	9.49E-12	9.41E-10	-8.18717	Down	RALBP1 associated Eps domain containing 2
8166243	REPS2	-1.51316	9.65E-12	9.51E-10	-8.18314	Down	actin binding LIM protein family member 3
8109093	ABLIM3	-1.92407	1E-11	9.77E-10	-8.17457	Down	oncoprotein induced transcript 3
7928330	OIT3	-2.61604	1.02E-11	9.9E-10	-8.16991	Down	carosinedipeptidase 1
8021741	CNDP1	-1.70905	1.19E-11	1.13E-09	-8.13411	Down	metallothionein 1J, pseudogene
7995803	MT1JP	-1.72208	1.23E-11	1.17E-09	-8.12454	Down	6-pyruvoyltetrahydropterin synthase
7943882	PTS	-1.47906	1.33E-11	1.25E-09	-8.10612	Down	bone morphogenetic protein 10
8052747	BMP10	-2.32658	1.35E-11	1.26E-09	-8.10346	Down	proteoglycan 3, pro eosinophil major basic protein 2 pseudogene
8103975	SLED1	-1.38012	1.38E-11	1.29E-09	-8.09773	Down	succinate-CoA ligase GDP-forming beta subunit
8088664	SUCLG2	-1.35898	1.48E-11	1.37E-09	-8.08195	Down	RAB27A, member RAS oncogene family
7989023	RAB27A	-1.47546	1.64E-11	1.49E-09	-8.05674	Down	glutathione S-transferase alpha 1
8127072	GSTA1	-3.24627	1.8E-11	1.62E-09	-8.03415	Down	solute carrier family 22 member 10
7940737	SLC22A10	-3.35491	1.89E-11	1.69E-09	-8.02281	Down	LON peptidase N-terminal domain and ring finger 3
8169603	LONRF3	-1.93486	1.96E-11	1.74E-09	-8.01449	Down	complement C9
8111757	C9	-4.7115	2.07E-11	1.82E-09	-8.00103	Down	NEDD4 binding protein 2 like 1
7970892	N4BP2L1	-1.41185	2.24E-11	1.93E-09	-7.98304	Down	peptidoglycan recognition protein 2
8035069	PGLYRP2	-2.41658	2.33E-11	2E-09	-7.97284	Down	aldehyde dehydrogenase 8 family member A1
8129695	ALDH8A1	-2.35724	2.4E-11	2.05E-09	-7.96564	Down	

8101304	RASGEF1B	-1.90736	2.43E-11	2.06E-09	-7.96279	Down	RasGEF domain family member 1B
8126860	MMUT	-1.61234	2.44E-11	2.06E-09	-7.96257	Down	methylmalonyl-CoA mutase
7930413	DUSP5	-1.25841	2.57E-11	2.15E-09	-7.95008	Down	dual specificity phosphatase 5
8097991	TDO2	-4.09773	2.64E-11	2.18E-09	-7.9438	Down	tryptophan 2,3-dioxygenase
8051799	HAAO	-1.37137	2.65E-11	2.19E-09	-7.94249	Down	3-hydroxyanthranilate 3,4-dioxygenase
7932433	NSUN6	-2.29379	2.79E-11	2.3E-09	-7.93016	Down	NOP2/Sun RNA methyltransferase 6
7901287	CYP4Z1	-1.33307	2.85E-11	2.32E-09	-7.92514	Down	cytochrome P450 family 4 subfamily Z member 1
8071907	UPB1	-2.54565	2.86E-11	2.32E-09	-7.92451	Down	beta-ureidopropionase 1
8086330	CSRNP1	-1.43202	2.91E-11	2.35E-09	-7.92001	Down	cysteine and serine rich nuclear protein 1
8095395	UGT2B7	-2.82403	3.61E-11	2.77E-09	-7.86872	Down	UDP glucuronosyltransferase family 2 member B7
8072328	SEC14L2	-1.86709	4.13E-11	3.1E-09	-7.83654	Down	SEC14 like lipid binding 2
8180391	CYP2D6	-2.37754	4.17E-11	3.12E-09	-7.83444	Down	cytochrome P450 family 2 subfamily D member 6
7942674	TSKU	-1.63072	4.28E-11	3.17E-09	-7.8283	Down	tsukushi, small leucine rich proteoglycan
8028652	ZFP36	-1.80429	4.29E-11	3.17E-09	-7.82768	Down	ZFP36 ring finger protein major facilitator superfamily domain containing 2A
7900365	MFSD2A	-2.32595	4.83E-11	3.5E-09	-7.79937	Down	
7948344	GLYAT	-3.82575	5.06E-11	3.63E-09	-7.78854	Down	glycine-N-acyltransferase
8103706	AADAT	-1.56007	5.14E-11	3.67E-09	-7.78466	Down	aminoadipate aminotransferase dehydrogenase E1 and transketolase domain containing 1
7926170	DHTKD1	-1.35823	5.53E-11	3.92E-09	-7.76721	Down	
8130598	LPAL2	-1.65196	5.7E-11	4.02E-09	-7.75994	Down	lipoprotein(a) like 2, pseudogene
8111864	C6	-3.10762	5.74E-11	4.04E-09	-7.75836	Down	complement C6
8022022	LPIN2	-1.42389	7.39E-11	4.98E-09	-7.69828	Down	lipin 2
8042270	UGP2	-1.96632	7.73E-11	5.2E-09	-7.68756	Down	UDP-glucose pyrophosphorylase 2
8047069	INPP1	-1.6834	8.67E-11	5.68E-09	-7.65995	Down	inositol polyphosphate-1-phosphatase HECT and RLD domain containing E3 ubiquitin protein ligase 5
8096361	HERC5	-1.28599	8.68E-11	5.68E-09	-7.65972	Down	
7972461	SLC15A1	-1.83756	9.61E-11	6.19E-09	-7.63551	Down	solute carrier family 15 member 1
8055688	RND3	-1.99088	1.02E-10	6.5E-09	-7.62202	Down	Rho family GTPase 3
8156706	TMOD1	-1.88776	1.05E-10	6.69E-09	-7.61389	Down	tropomodulin 1
8135069	SERPINE1	-2.57236	1.08E-10	6.86E-09	-7.6075	Down	serpin family E member 1
8099633	PPARGC1A	-2.53119	1.09E-10	6.91E-09	-7.60509	Down	PPARG coactivator 1 alpha
7937016	CLRN3	-1.47526	1.12E-10	7E-09	-7.59958	Down	clarin 3
7931810	KLF6	-1.30168	1.21E-10	7.48E-09	-7.58102	Down	Kruppel like factor 6
8145766	NRG1	-1.75348	1.31E-10	7.96E-09	-7.56233	Down	neuregulin 1 cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene)
8076431	CYP2D7	-2.36353	1.32E-10	8.02E-09	-7.55981	Down	
7965573	NTN4	-1.28012	1.33E-10	8.08E-09	-7.55747	Down	netrin 4
8020806	RNF125	-1.78113	1.45E-10	8.75E-09	-7.53672	Down	ring finger protein 125
8044793	STEAP3	-1.30611	1.47E-10	8.82E-09	-7.53354	Down	STEAP3 metalloredutase
8171472	CLTRN	-1.42312	1.54E-10	9.2E-09	-7.52265	Down	collectrin, amino acid transport regulator
7928944	PAPSS2	-1.60888	1.56E-10	9.26E-09	-7.52052	Down	3'-phosphoadenosine 5'-phosphosulfate synthase 2 amyloid beta precursor protein binding family B member 1 interacting protein
7926786	APBB1IP	-1.59777	1.57E-10	9.28E-09	-7.51913	Down	
8066493	SLPI	-2.32059	1.64E-10	9.64E-09	-7.50755	Down	secretory leukocyte peptidase inhibitor
7965964	SLC41A2	-2.64558	1.7E-10	9.92E-09	-7.49899	Down	solute carrier family 41 member 2
8156228	CTSL	-1.38428	1.71E-10	9.93E-09	-7.4983	Down	cathepsin L
7995838	MT1X	-1.97592	1.71E-10	9.93E-09	-7.49746	Down	metallothionein 1X

7916526	C8B	-1.96774	1.75E-10	1.01E-08	-7.49195	Down	complement C8 beta chain
8172333	CFP	-1.36208	2.07E-10	1.18E-08	-7.45237	Down	complement factor properdin
7904717	HJV	-2.2743	2.1E-10	1.19E-08	-7.44885	Down	hemojuvelin BMP co-receptor
7988990	WDR72	-1.86418	2.22E-10	1.25E-08	-7.43592	Down	WD repeat domain 72
8105121	GHR	-2.70155	2.22E-10	1.25E-08	-7.43559	Down	growth hormone receptor
7961673	GYS2	-3.56074	2.35E-10	1.31E-08	-7.42258	Down	glycogen synthase 2
7958056	STAB2	-2.78056	2.35E-10	1.31E-08	-7.42204	Down	stabilin 2
8173120	PFKFB1	-2.42424	2.38E-10	1.32E-08	-7.41854	Down	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1
7917779	GCLM	-1.25786	2.51E-10	1.37E-08	-7.40665	Down	glutamate-cysteine ligase modifier subunit
8066513	SDC4	-1.5745	2.61E-10	1.41E-08	-7.3967	Down	syndecan 4
8103695	MFAP3L	-1.86335	2.69E-10	1.44E-08	-7.3901	Down	microfibril associated protein 3 like
8162502	FBP1	-2.39102	2.82E-10	1.51E-08	-7.37827	Down	fructose-bisphosphatase 1
8130556	SOD2	-1.94629	2.84E-10	1.52E-08	-7.37694	Down	superoxide dismutase 2
8160670	AQP3	-1.59899	3.15E-10	1.66E-08	-7.35231	Down	aquaporin 3 (Gill blood group)
8103951	ACSL1	-2.05877	3.23E-10	1.7E-08	-7.34593	Down	acyl-CoA synthetase long chain family member 1
7973530	PCK2	-1.55202	3.49E-10	1.81E-08	-7.32726	Down	phosphoenolpyruvatecarboxykinase 2, mitochondrial
8146687	ADHFE1	-1.55946	3.61E-10	1.85E-08	-7.3197	Down	alcohol dehydrogenase iron containing 1
7937707	FAM99A	-1.70828	3.65E-10	1.87E-08	-7.31652	Down	family with sequence similarity 99 member A
7993726	ACSM5	-2.25416	3.97E-10	2E-08	-7.29699	Down	acyl-CoA synthetase medium chain family member 5
8105153	NNT	-1.30858	4E-10	2.01E-08	-7.29484	Down	nicotinamide nucleotide transhydrogenase
7901513	SCP2	-1.76413	4.13E-10	2.05E-08	-7.28753	Down	sterol carrier protein 2
8020630	TTC39C	-1.37749	4.24E-10	2.1E-08	-7.28108	Down	tetratricopeptide repeat domain 39C
8149264	PPP1R3B	-2.14794	4.32E-10	2.13E-08	-7.27644	Down	protein phosphatase 1 regulatory subunit 3B
8114612	CD14	-1.6395	4.46E-10	2.19E-08	-7.26884	Down	CD14 molecule
8084668	HRG	-3.56797	4.9E-10	2.38E-08	-7.24657	Down	histidine rich glycoprotein
8163149	PTPN3	-1.68999	5.05E-10	2.44E-08	-7.23913	Down	protein tyrosine phosphatase non-receptor type 3
8141066	PON3	-1.83258	5.12E-10	2.47E-08	-7.23584	Down	paraoxonase 3
8106418	CRHBP	-2.78333	5.25E-10	2.52E-08	-7.22964	Down	corticotropin releasing hormone binding protein
7955348	GPD1	-1.76474	5.54E-10	2.64E-08	-7.21675	Down	glycerol-3-phosphate dehydrogenase 1
8090366	UROCI	-1.93575	5.55E-10	2.64E-08	-7.2164	Down	urocanatehydratase 1
7995813	MT1DP	-1.26488	5.68E-10	2.69E-08	-7.21083	Down	metallothionein 1D, pseudogene
7925452	GREM2	-1.64378	5.88E-10	2.77E-08	-7.20253	Down	gremlin 2, DAN family BMP antagonist
8004534	SHBG	-1.75486	6.34E-10	2.94E-08	-7.18456	Down	sex hormone binding globulin
8040960	GCKR	-2.07768	6.62E-10	3.05E-08	-7.17422	Down	glucokinase regulator
7985809	ABHD2	-1.3522	6.63E-10	3.05E-08	-7.17394	Down	abhydrolase domain containing 2
8088371	DNASE1L3	-2.11688	6.66E-10	3.06E-08	-7.17298	Down	deoxyribonuclease 1 like 3
8013112	RASD1	-1.27291	6.92E-10	3.16E-08	-7.16372	Down	ras related dexamethasone induced 1
8002556	TAT	-3.99579	7.35E-10	3.34E-08	-7.14924	Down	tyrosine aminotransferase
8035083	CYP4F2	-2.51451	8.13E-10	3.65E-08	-7.12513	Down	cytochrome P450 family 4 subfamily F member 2
7995907	CETP	-1.82566	8.36E-10	3.74E-08	-7.11841	Down	cholesteryl ester transfer protein
7960757	C1RL	-1.26603	8.6E-10	3.83E-08	-7.1115	Down	complement C1r subcomponent like
7946986	SAA1	-2.68675	8.69E-10	3.86E-08	-7.10895	Down	serum amyloid A1
8081298	ADGRG7	-1.98044	8.83E-10	3.91E-08	-7.10521	Down	adhesion G protein-coupled receptor G7
8115445	TIMD4	-2.38949	9E-10	3.97E-08	-7.1006	Down	T cell immunoglobulin and mucin domain containing 4

8126770	CYP39A1	-2.56861	9.6E-10	4.19E-08	-7.08526	Down	cytochrome P450 family 39 subfamily A member 1
8165258	AGPAT2	-1.46668	9.83E-10	4.28E-08	-7.07956	Down	1-acylglycerol-3-phosphate O-acyltransferase 2
8079060	VIPR1	-1.37382	9.91E-10	4.31E-08	-7.07758	Down	vasoactive intestinal peptide receptor 1
8056583	ABCB11	-3.73353	1.03E-09	4.44E-08	-7.06933	Down	ATP binding cassette subfamily B member 11
7995787	MT1M	-2.67289	1.04E-09	4.49E-08	-7.0661	Down	metallothionein 1M
8100798	SULT1B1	-1.92576	1.04E-09	4.49E-08	-7.06491	Down	sulfotransferase family 1B member 1
8141052	PON1	-3.52937	1.05E-09	4.5E-08	-7.06421	Down	paraoxonase 1
8140840	STEAP4	-2.80855	1.16E-09	4.89E-08	-7.04016	Down	STEAP4 metalloredutase
7946167	HPX	-2.40952	1.45E-09	5.95E-08	-6.98567	Down	hemopexin
7964834	CPM	-1.51954	1.54E-09	6.23E-08	-6.97213	Down	carboxypeptidase M
8080184	ALAS1	-1.33461	1.58E-09	6.39E-08	-6.96559	Down	5'-aminolevulinate synthase 1
7996361	CES3	-1.87271	1.6E-09	6.45E-08	-6.96254	Down	carboxylesterase 3
7954810	LRRK2	-1.55656	1.65E-09	6.66E-08	-6.95433	Down	leucine rich repeat kinase 2
7914075	FCN3	-3.00647	1.72E-09	6.9E-08	-6.94503	Down	ficolin 3
7921449	CRP	-4.39223	1.72E-09	6.9E-08	-6.94474	Down	C-reactive protein
8123678	PXDC1	-1.29407	1.76E-09	7E-08	-6.93956	Down	PX domain containing 1
8045539	KYNU	-1.7714	1.98E-09	7.79E-08	-6.91071	Down	kynureninase
7960744	C1R	-2.0944	2E-09	7.86E-08	-6.90839	Down	complement C1r
8013243	SHMT1	-1.60648	2.06E-09	8.05E-08	-6.90175	Down	serine hydroxymethyltransferase 1
8129618	VNN1	-3.69454	2.06E-09	8.05E-08	-6.90152	Down	vanin 1
7995793	MT1L	-1.45389	2.09E-09	8.16E-08	-6.89762	Down	metallothionein 1L, pseudogene
7957654	AMDHD1	-1.48367	2.1E-09	8.17E-08	-6.89713	Down	amidohydrolase domain containing 1
7898693	ALPL	-1.99339	2.35E-09	8.97E-08	-6.86999	Down	alkaline phosphatase, biomineralization associated
7922976	PTGS2	-1.74777	2.4E-09	9.12E-08	-6.86494	Down	prostaglandin-endoperoxide synthase 2
8156309	GADD45G	-1.56976	2.53E-09	9.53E-08	-6.85238	Down	growth arrest and DNA damage inducible gamma
8180303	SAA2	-3.97211	2.57E-09	9.65E-08	-6.84816	Down	serum amyloid A2
7934755	MAT1A	-2.42118	2.9E-09	1.07E-07	-6.81906	Down	methionine adenosyltransferase 1A
7968734	SLC25A15	-1.31884	2.91E-09	1.07E-07	-6.81827	Down	solute carrier family 25 member 15
7921840	NR1I3	-2.05147	3.08E-09	1.12E-07	-6.8046	Down	nuclear receptor subfamily 1 group I member 3
7943605	ACAT1	-1.7042	3.1E-09	1.13E-07	-6.80306	Down	acetyl-CoA acetyltransferase 1
8097920	LRAT	-1.25758	3.17E-09	1.15E-07	-6.79778	Down	lecithin retinol acyltransferase
7938758	SAA1	-3.68479	3.23E-09	1.16E-07	-6.79337	Down	serum amyloid A1
8072735	APOL1	-1.70039	3.27E-09	1.17E-07	-6.79033	Down	apolipoprotein L1
7909441	G0S2	-1.50675	3.3E-09	1.18E-07	-6.78833	Down	G0/G1 switch 2
7951545	EXPH5	-1.38387	3.5E-09	1.25E-07	-6.77342	Down	exophilin 5
8113214	GLRX	-1.33472	3.62E-09	1.28E-07	-6.76582	Down	glutaredoxin
8033248	TNFSF14	-1.33632	3.98E-09	1.39E-07	-6.7426	Down	TNF superfamily member 14
7903239	AGL	-1.41891	4.15E-09	1.44E-07	-6.73235	Down	amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase
8158671	ASS1	-1.30123	4.81E-09	1.63E-07	-6.69681	Down	argininosuccinate synthase 1
7972650	FGF14	-1.66652	5E-09	1.69E-07	-6.68762	Down	fibroblast growth factor 14
8018558	ACOX1	-1.31806	5.01E-09	1.69E-07	-6.68701	Down	acyl-CoA oxidase 1
8142554	AASS	-1.34628	5.17E-09	1.74E-07	-6.67964	Down	aminoadipate-semialdehyde synthase
7946983	SAA2	-2.8486	5.37E-09	1.79E-07	-6.67046	Down	serum amyloid A2
7932094	PHYH	-1.31377	6.13E-09	2.02E-07	-6.63824	Down	phytanoyl-CoA 2-hydroxylase
8075390	SEC14L4	-1.33014	6.83E-09	2.2E-07	-6.61194	Down	SEC14 like lipid binding 4

8081219	ST3GAL6	-1.57399	6.84E-09	2.2E-07	-6.61172	Down	ST3 beta-galactoside alpha-2,3-sialyltransferase 6
7958425	DAO	-2.38843	6.92E-09	2.22E-07	-6.60872	Down	D-amino acid oxidase
8112822	DMGDH	-1.6327	7.03E-09	2.25E-07	-6.60489	Down	dimethylglycine dehydrogenase
7936494	GFRA1	-1.86775	7.99E-09	2.5E-07	-6.57387	Down	GDNF family receptor alpha 1
8152264	DPYS	-1.69797	8.22E-09	2.56E-07	-6.56702	Down	dihydropyrimidinase
8121916	RSP03	-1.32827	8.44E-09	2.62E-07	-6.5606	Down	R-spondin 3
7931824	AKR1C6P	-1.45603	8.44E-09	2.62E-07	-6.56051	Down	aldo-ketoreductase family 1 member C6, pseudogene
7946579	LYVE1	-2.02445	8.53E-09	2.64E-07	-6.55808	Down	lymphatic vessel endothelial hyaluronan receptor 1
8025601	ICAM1	-1.33796	8.92E-09	2.74E-07	-6.5472	Down	intercellular adhesion molecule 1
7906777	FCGR2B	-1.92992	9.17E-09	2.81E-07	-6.54046	Down	Fc fragment of IgG receptor IIb
8077441	BHLHE40	-1.4694	9.48E-09	2.9E-07	-6.53235	Down	basic helix-loop-helix family member e40
7905220	ECM1	-1.33693	9.53E-09	2.91E-07	-6.53115	Down	extracellular matrix protein 1
8081758	GRAMD1C	-1.65952	1.19E-08	3.52E-07	-6.47716	Down	GRAM domain containing 1C
7901748	FGGY	-1.52673	1.22E-08	3.59E-07	-6.47015	Down	FGGY carbohydrate kinase domain containing
7976755	SLC25A47	-1.73283	1.27E-08	3.7E-07	-6.4619	Down	solute carrier family 25 member 47
7993126	ABAT	-1.32248	1.29E-08	3.74E-07	-6.45821	Down	4-aminobutyrate aminotransferase
8101893	ADH1C	-2.4717	1.29E-08	3.74E-07	-6.45802	Down	alcohol dehydrogenase 1C (class I), gamma polypeptide
8008454	ABCC3	-1.7914	1.38E-08	3.96E-07	-6.44061	Down	ATP binding cassette subfamily C member 3
8174937	TENM1	-1.46934	1.48E-08	4.21E-07	-6.42333	Down	teneurintransmembrane protein 1
8056491	SCN9A	-1.34545	1.65E-08	4.61E-07	-6.39787	Down	sodium voltage-gated channel alpha subunit 9
8027760	FXYD1	-1.51988	1.73E-08	4.8E-07	-6.38576	Down	FXYD domain containing ion transport regulator 1
8103769	HPGD	-2.16403	1.78E-08	4.92E-07	-6.37879	Down	15-hydroxyprostaglandin dehydrogenase
8176193	F8	-1.54742	1.88E-08	5.15E-07	-6.36607	Down	coagulation factor VIII
8098084	ETFDH	-1.74079	2.02E-08	5.47E-07	-6.34757	Down	electron transfer flavoprotein dehydrogenase
7962559	SLC38A4	-2.66277	2.11E-08	5.67E-07	-6.33716	Down	solute carrier family 38 member 4
7953603	C1S	-2.01706	2.16E-08	5.79E-07	-6.33114	Down	complement C1s
7938366	WEE1	-1.42515	2.33E-08	6.19E-07	-6.31265	Down	WEE1 G2 checkpoint kinase
7917530	GBP2	-1.8953	2.56E-08	6.65E-07	-6.28987	Down	guanylate binding protein 2
7901732	C8A	-1.92378	2.83E-08	7.2E-07	-6.26583	Down	complement C8 alpha chain
8035095	CYP4F11	-2.38933	2.92E-08	7.4E-07	-6.25793	Down	cytochrome P450 family 4 subfamily F member 11
7954729	FGD4	-1.40933	3.14E-08	7.88E-07	-6.23957	Down	FYVE, RhoGEF and PH domain containing 4
8062119	MT1P3	-1.49548	3.31E-08	8.22E-07	-6.22695	Down	metallothionein 1 pseudogene 3
8088020	ITIH4	-1.82356	3.39E-08	8.37E-07	-6.22122	Down	inter-alpha-trypsin inhibitor heavy chain 4
8096875	ENPEP	-1.76169	3.54E-08	8.65E-07	-6.21081	Down	glutamylaminopeptidase
8098637	CYP4V2	-1.44696	3.59E-08	8.78E-07	-6.20709	Down	cytochrome P450 family 4 subfamily V member 2
8001531	MT1G	-1.90291	3.87E-08	9.35E-07	-6.18833	Down	metallothionein 1G
8038577	ASPDH	-1.27155	4.13E-08	9.86E-07	-6.1728	Down	aspartate dehydrogenase domain containing
7943413	BIRC3	-1.63886	4.63E-08	1.09E-06	-6.14463	Down	baculoviral IAP repeat containing 3
8026456	CYP4F3	-1.77709	4.63E-08	1.09E-06	-6.14427	Down	cytochrome P450 family 4 subfamily F member 3
8141317	CYP3A4	-3.28494	4.69E-08	1.1E-06	-6.14125	Down	cytochrome P450 family 3 subfamily A member 4
8024323	REEP6	-1.42033	4.84E-08	1.13E-06	-6.13374	Down	receptor accessory protein 6
7951853	APOA5	-1.72683	5.12E-08	1.18E-06	-6.11968	Down	apolipoprotein A5
8091385	CP	-3.19062	5.18E-08	1.19E-06	-6.11678	Down	ceruloplasmin
8022666	CHST9	-2.52243	5.27E-08	1.21E-06	-6.11256	Down	carbohydrate sulfotransferase 9

8047784	ZDBF2	-1.35095	5.29E-08	1.21E-06	-6.11151	Down	zinc finger DBF-type containing 2
7923929	PIGR	-1.72961	5.57E-08	1.27E-06	-6.09874	Down	polymeric immunoglobulin receptor
8140556	HGF	-2.03352	5.67E-08	1.28E-06	-6.0944	Down	hepatocyte growth factor
8099760	ARAP2	-1.66089	5.84E-08	1.31E-06	-6.08737	Down	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2
7912361	MASP2	-1.58025	6.06E-08	1.36E-06	-6.07825	Down	mannan binding lectin serine peptidase 2
7926451	MRC1	-1.4052	6.39E-08	1.42E-06	-6.06508	Down	mannose receptor C-type 1
8129804	MAP3K5	-1.31322	7.23E-08	1.58E-06	-6.03432	Down	mitogen-activated protein kinase kinasekinase 5
7942135	ANO1	-1.34907	7.45E-08	1.63E-06	-6.02692	Down	anoctamin 1
7995797	MT1E	-1.39677	8.35E-08	1.79E-06	-5.99878	Down	metallothionein 1E
7929487	CYP2C9	-3.50453	9.27E-08	1.95E-06	-5.97288	Down	cytochrome P450 family 2 subfamily C member 9
8148029	COLEC10	-2.54783	9.75E-08	2.04E-06	-5.96021	Down	collectin subfamily member 10
7908312	PRG4	-2.06069	1.04E-07	2.16E-06	-5.94347	Down	proteoglycan 4
8072710	APOL6	-1.38091	1.08E-07	2.22E-06	-5.93553	Down	apolipoprotein L6
8097628	HHIP	-1.96877	1.1E-07	2.26E-06	-5.93013	Down	hedgehog interacting protein
7938951	ANO5	-1.30862	1.12E-07	2.29E-06	-5.9255	Down	anoctamin 5
8141328	CYP3A5	-2.1131	1.12E-07	2.3E-06	-5.92492	Down	cytochrome P450 family 3 subfamily A member 5
7916506	FYB2	-1.56566	1.21E-07	2.45E-06	-5.90667	Down	FYN binding protein 2
8146115	TCIM	-1.31689	1.31E-07	2.62E-06	-5.88708	Down	transcriptional and immune response regulator
8096733	SGMS2	-1.44287	1.31E-07	2.62E-06	-5.88608	Down	sphingomyelin synthase 2
8157446	ORM1	-2.16082	1.39E-07	2.76E-06	-5.87248	Down	orosomucoid 1
7902367	ACADM	-1.32844	1.46E-07	2.86E-06	-5.86008	Down	acyl-CoA dehydrogenase medium chain
7962250	CPNE8	-1.44212	1.78E-07	3.39E-06	-5.80968	Down	copine 8
8157524	TLR4	-1.30042	1.81E-07	3.42E-06	-5.80672	Down	toll like receptor 4
8151890	TP53INP1	-1.32335	1.87E-07	3.54E-06	-5.79778	Down	tumor protein p53 inducible nuclear protein 1
7995729	CES1P1	-1.66875	2.06E-07	3.84E-06	-5.77342	Down	carboxylesterase 1 pseudogene 1
8119782	SLC22A7	-2.11006	2.08E-07	3.87E-06	-5.77123	Down	solute carrier family 22 member 7
8163839	C5	-1.59069	2.17E-07	4E-06	-5.76085	Down	complement C5
8018864	SOCS3	-1.3559	2.28E-07	4.16E-06	-5.7489	Down	suppressor of cytokine signaling 3
8026047	JUNB	-1.3023	2.56E-07	4.59E-06	-5.7196	Down	JunB proto-oncogene, AP-1 transcription factor subunit
7909306	C4BPB	-1.44907	2.6E-07	4.65E-06	-5.71562	Down	complement component 4 binding protein beta
7965873	IGF1	-1.55889	2.62E-07	4.68E-06	-5.71387	Down	insulin like growth factor 1
8044574	IL1RN	-1.41944	2.81E-07	4.99E-06	-5.69566	Down	interleukin 1 receptor antagonist
8095585	SLC4A4	-2.15757	3.16E-07	5.51E-06	-5.66645	Down	solute carrier family 4 member 4
8063590	PCK1	-2.67178	3.23E-07	5.62E-06	-5.66069	Down	phosphoenolpyruvatecarboxykinase 1
8017964	ABCA6	-2.58625	3.54E-07	6.07E-06	-5.63781	Down	ATP binding cassette subfamily A member 6
8145532	EPHX2	-1.25206	3.67E-07	6.26E-06	-5.62845	Down	epoxide hydrolase 2
7980096	ALDH6A1	-1.30877	4.08E-07	6.87E-06	-5.60181	Down	aldehyde dehydrogenase 6 family member A1
7954208	PIK3C2G	-1.75132	4.13E-07	6.93E-06	-5.59899	Down	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma
8086457	CYP8B1	-2.22218	4.13E-07	6.93E-06	-5.59874	Down	cytochrome P450 family 8 subfamily B member 1
8047127	MYO1B	-1.3558	4.26E-07	7.1E-06	-5.59066	Down	myosin IB
7901272	CYP4X1	-1.69863	4.29E-07	7.14E-06	-5.58897	Down	cytochrome P450 family 4 subfamily X member 1
8062461	LBP	-2.43644	4.39E-07	7.27E-06	-5.58351	Down	lipopolysaccharide binding protein
7997192	HPR	-1.79671	4.45E-07	7.35E-06	-5.58016	Down	haptoglobin-related protein
8162884	ALDOB	-2.21083	4.73E-07	7.76E-06	-5.56425	Down	aldolase, fructose-bisphosphate B

8108370	EGR1	-1.58275	5.05E-07	8.22E-06	-5.54771	Down	early growth response 1
8037949	SULT2A1	-2.17964	5.55E-07	8.87E-06	-5.5238	Down	sulfotransferase family 2A member 1
8111474	AGXT2	-1.53967	6.06E-07	9.57E-06	-5.50164	Down	alanine--glyoxylate aminotransferase 2
7972157	EDNRB	-1.31399	6.07E-07	9.59E-06	-5.50118	Down	endothelin receptor type B
7901293	CYP4A22	-2.3035	6.22E-07	9.79E-06	-5.49513	Down	cytochrome P450 family 4 subfamily A member 22
7913216	PLA2G2A	-2.64827	6.3E-07	9.91E-06	-5.49161	Down	phospholipase A2 group IIA
8018006	ABCA10	-1.46642	6.69E-07	1.04E-05	-5.47642	Down	ATP binding cassette subfamily A member 10
7983650	SLC27A2	-1.65365	6.81E-07	1.06E-05	-5.47188	Down	solute carrier family 27 member 2
8092523	EHHADH	-1.51289	6.83E-07	1.06E-05	-5.47095	Down	enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase
7947512	PAMR1	-1.45987	7.05E-07	1.09E-05	-5.46293	Down	peptidase domain containing associated with muscle regeneration 1
8122807	AKAP12	-1.27834	7.28E-07	1.12E-05	-5.45487	Down	A-kinase anchoring protein 12
8064928	HAO1	-2.12616	7.29E-07	1.12E-05	-5.45461	Down	hydroxyacid oxidase 1
8049737	AGXT	-1.51295	7.31E-07	1.12E-05	-5.45388	Down	alanine--glyoxylate and serine--pyruvate aminotransferase
8026424	CYP4F22	-1.30941	7.37E-07	1.13E-05	-5.45176	Down	cytochrome P450 family 4 subfamily F member 22
7956426	INHBE	-1.40106	7.79E-07	1.18E-05	-5.43765	Down	inhibin subunit beta E
8023528	ALPK2	-1.32137	8.53E-07	1.27E-05	-5.4145	Down	alpha kinase 2
7964872	PTPRB	-1.28146	9.04E-07	1.33E-05	-5.39961	Down	protein tyrosine phosphatase receptor type B
8151931	TSPYL5	-1.34811	1.02E-06	1.47E-05	-5.36932	Down	TSPY like 5
7924058	IRF6	-1.28907	1.03E-06	1.48E-05	-5.36692	Down	interferon regulatory factor 6
8017927	ABCA9	-2.02411	1.06E-06	1.52E-05	-5.35938	Down	ATP binding cassette subfamily A member 9
8149927	CLU	-1.4172	1.11E-06	1.58E-05	-5.34696	Down	clusterin
8129637	VNN2	-1.34704	1.13E-06	1.6E-05	-5.34287	Down	vanin 2
8113641	CDO1	-1.26056	1.16E-06	1.64E-05	-5.33513	Down	cysteine dioxygenase type 1
8103494	NPY1R	-1.66142	1.2E-06	1.69E-05	-5.32638	Down	neuropeptide Y receptor Y1
8115831	DUSP1	-1.41784	1.21E-06	1.7E-05	-5.32461	Down	dual specificity phosphatase 1
7907297	FMO4	-1.32575	1.31E-06	1.82E-05	-5.30372	Down	flavin containing dimethylanilinemonooxygenase 4
8122058	ARG1	-1.80372	1.31E-06	1.82E-05	-5.30368	Down	arginase 1
8006005	PIPOX	-1.72596	1.4E-06	1.92E-05	-5.28805	Down	pipecolic acid and sarcosine oxidase
8143127	FAM180A	-1.27569	1.41E-06	1.93E-05	-5.28509	Down	family with sequence similarity 180 member A
8098654	KLKB1	-2.13475	1.47E-06	2.01E-05	-5.27503	Down	kallikrein B1
7981078	SERPINA11	-1.28036	1.56E-06	2.11E-05	-5.25991	Down	serpin family A member 11
7967212	HPD	-2.18315	1.58E-06	2.14E-05	-5.2557	Down	4-hydroxyphenylpyruvate dioxygenase
8140752	ABCB4	-1.53619	1.63E-06	2.2E-05	-5.24717	Down	ATP binding cassette subfamily B member 4
7900336	MACF1	-1.28208	1.7E-06	2.28E-05	-5.23648	Down	microtubule actin crosslinking factor 1
7901883	ANGPTL3	-1.94376	1.94E-06	2.54E-05	-5.20343	Down	angiopoietin like 3
8092661	MASP1	-1.27925	2.03E-06	2.65E-05	-5.19073	Down	mannan binding lectin serine peptidase 1
7961710	ABCC9	-1.78491	2.04E-06	2.66E-05	-5.18957	Down	ATP binding cassette subfamily C member 9
7976496	SERPINA3	-1.51584	2.08E-06	2.7E-05	-5.18422	Down	serpin family A member 3
7993756	ACSM3	-1.46892	2.1E-06	2.72E-05	-5.18286	Down	acyl-CoA synthetase medium chain family member 3
8106504	BHMT	-1.73762	2.24E-06	2.88E-05	-5.16524	Down	betaine--homocysteine S-methyltransferase
7956423	INHBC	-1.55992	2.27E-06	2.91E-05	-5.16175	Down	inhibin subunit beta C
8049532	LRRFIP1	-1.26765	2.32E-06	2.96E-05	-5.15669	Down	LRR binding FLII interacting protein 1
7960794	CD163	-1.31725	2.45E-06	3.09E-05	-5.14266	Down	CD163 molecule

8095390	UGT2B10	-2.31904	2.46E-06	3.11E-05	-5.14111	Down	UDP glucuronosyltransferase family 2 member B10
8102328	CFI	-1.28523	2.55E-06	3.21E-05	-5.13129	Down	complement factor I
8029693	FOSB	-1.85601	2.72E-06	3.39E-05	-5.11456	Down	FosB proto-oncogene, AP-1 transcription factor subunit
7954344	SLCO1B7	-2.11701	2.79E-06	3.47E-05	-5.10783	Down	solute carrier organic anion transporter family member 1B7 (putative)
8141560	TFR2	-1.58955	2.98E-06	3.67E-05	-5.09101	Down	transferrin receptor 2
8085716	SATB1	-1.27231	3.34E-06	4.06E-05	-5.06094	Down	SATB homeobox 1
8024754	CREB3L3	-1.35287	3.46E-06	4.19E-05	-5.05167	Down	cAMP responsive element binding protein 3 like 3
8135734	CPED1	-1.99578	3.51E-06	4.24E-05	-5.04846	Down	cadherin like and PC-esterase domain containing 1
8180234	CES1P1	-1.69778	3.61E-06	4.35E-05	-5.04047	Down	carboxylesterase 1 pseudogene 1
7990391	CYP1A1	-1.81291	3.75E-06	4.47E-05	-5.03104	Down	cytochrome P450 family 1 subfamily A member 1
7901765	HOOK1	-1.2878	3.77E-06	4.49E-05	-5.02937	Down	hook microtubule tethering protein 1
8069676	ADAMTS1	-1.33452	3.85E-06	4.58E-05	-5.02381	Down	ADAM metalloproteinase with thrombospondin type 1 motif 1
8101429	PLAC8	-1.47587	3.85E-06	4.58E-05	-5.02374	Down	placenta associated 8
8047300	AOX1	-1.63392	4.1E-06	4.82E-05	-5.00711	Down	aldehyde oxidase 1
8098671	F11	-1.83668	4.18E-06	4.89E-05	-5.00241	Down	coagulation factor XI
8113073	ARRDC3	-1.52957	4.28E-06	5E-05	-4.99588	Down	arrestin domain containing 3
8180195	CFHR1	-1.82828	5.27E-06	5.98E-05	-4.94131	Down	complement factor H related 1
8091867	BCHE	-1.44446	5.66E-06	6.36E-05	-4.92208	Down	butyrylcholinesterase
8111677	LIFR	-1.94996	5.79E-06	6.48E-05	-4.91621	Down	LIF receptor subunit alpha
7908459	CFH	-1.86945	6.61E-06	7.25E-05	-4.88102	Down	complement factor H
8117304	SLC17A4	-1.73901	6.61E-06	7.26E-05	-4.88087	Down	solute carrier family 17 member 4
7926152	ECHDC3	-1.28824	6.79E-06	7.39E-05	-4.87399	Down	enoyl-CoA hydratase domain containing 3
7938364	WEE1	-1.44305	6.8E-06	7.41E-05	-4.8733	Down	WEE1 G2 checkpoint kinase
8001457	CES1	-1.64592	7.78E-06	8.3E-05	-4.83751	Down	carboxylesterase 1
7931168	ACADSB	-1.2723	8.3E-06	8.77E-05	-4.82033	Down	acyl-CoA dehydrogenase short/branched chain
8134655	CYP3A43	-2.16443	8.73E-06	9.14E-05	-4.80682	Down	cytochrome P450 family 3 subfamily A member 43
8124166	MBOAT1	-1.2583	9.9E-06	0.000102	-4.77302	Down	membrane bound O-acyltransferase domain containing 1
7906458	APCS	-2.84035	1.12E-05	0.000113	-4.73965	Down	amyloid P component, serum
8162870	BAAT	-2.51033	1.2E-05	0.000119	-4.72191	Down	bile acid-CoA:amino acid N-acyltransferase
7925939	AKR1C4	-2.39745	1.22E-05	0.000122	-4.716	Down	aldo-ketoreductase family 1 member C4
7908496	CFHR2	-2.20579	1.23E-05	0.000122	-4.71503	Down	complement factor H related 2
8114249	CXCL14	-1.6038	1.24E-05	0.000123	-4.71174	Down	C-X-C motif chemokine ligand 14
8022045	MYOM1	-1.49905	1.27E-05	0.000126	-4.70532	Down	myomesin 1
8166769	OTC	-1.82077	1.29E-05	0.000127	-4.70175	Down	ornithine carbamoyltransferase
8141374	AZGP1	-1.59014	1.29E-05	0.000127	-4.70117	Down	alpha-2-glycoprotein 1, zinc-binding
7995825	MT1F	-1.58273	1.36E-05	0.000133	-4.68805	Down	metallothionein 1F
7997188	HP	-1.9272	1.38E-05	0.000135	-4.68315	Down	haptoglobin
8096415	MMRN1	-1.37255	1.39E-05	0.000136	-4.68189	Down	multimerin 1
8093278	HGD	-1.31352	1.48E-05	0.000143	-4.66499	Down	homogentisate 1,2-dioxygenase
7915902	CYP4A11	-2.05184	1.56E-05	0.00015	-4.64978	Down	cytochrome P450 family 4 subfamily A member 11
7921332	CD5L	-1.61673	1.58E-05	0.000151	-4.64702	Down	CD5 molecule like
8178115	CFB	-1.30298	1.58E-05	0.000151	-4.64637	Down	complement factor B

8101881	ADH1B	-2.26025	1.66E-05	0.000158	-4.63363	Down	alcohol dehydrogenase 1B (class I), beta polypeptide
7975779	FOS	-1.71493	1.87E-05	0.000174	-4.60171	Down	Fos proto-oncogene, AP-1 transcription factor subunit
8161755	ALDH1A1	-1.4697	1.95E-05	0.000181	-4.58996	Down	aldehyde dehydrogenase 1 family member A1
7922420	SERPINC1	-1.44163	2.1E-05	0.000193	-4.56874	Down	serpin family C member 1
8077833	SLC6A1	-1.57349	2.18E-05	0.0002	-4.55894	Down	solute carrier family 6 member 1
7936734	FGFR2	-1.66795	2.4E-05	0.000217	-4.53254	Down	fibroblast growth factor receptor 2
7907249	FMO3	-2.75355	2.59E-05	0.000232	-4.51151	Down	flavin containing dimethylanilinemonooxygenase 3
7923073	F13B	-1.72855	2.91E-05	0.000256	-4.47984	Down	coagulation factor XIII B chain
8055952	NR4A2	-1.32702	2.96E-05	0.00026	-4.47474	Down	nuclear receptor subfamily 4 group A member 2
7909318	C4BPA	-1.66328	3.22E-05	0.000279	-4.45148	Down	complement component 4 binding protein alpha
8101852	ADH4	-2.06117	4.56E-05	0.000374	-4.35441	Down	alcohol dehydrogenase 4 (class II), pi polypeptide
8083415	AADAC	-2.24518	5.26E-05	0.00042	-4.31472	Down	arylacetamidedeacetylase
8124351	SLC17A3	-1.28272	5.27E-05	0.000421	-4.31389	Down	solute carrier family 17 member 3
7954356	SLCO1B1	-2.10244	6.11E-05	0.000476	-4.27215	Down	solute carrier organic anion transporter family member 1B1
8084679	KNG1	-1.54993	7.26E-05	0.000551	-4.2234	Down	kininogen 1
7907572	PAPPA2	-1.29374	7.36E-05	0.000557	-4.21958	Down	pappalysin 2
7908409	RGS2	-1.34148	7.73E-05	0.000582	-4.20576	Down	regulator of G protein signaling 2
8100784	UGT2B4	-1.64367	7.79E-05	0.000586	-4.20353	Down	UDP glucuronosyltransferase family 2 member B4
7901565	DIO1	-1.43963	8.98E-05	0.000661	-4.16278	Down	iodothyroninedeiodinase 1
7908488	CFHR1	-2.11839	9.82E-05	0.000712	-4.13729	Down	complement factor H related 1
8108006	LEAP2	-1.36857	0.0001	0.000724	-4.13192	Down	liver enriched antimicrobial peptide 2
8095663	AFM	-1.9645	0.0001	0.000724	-4.13185	Down	afamin
7988414	GATM	-1.52108	0.000115	0.000813	-4.09211	Down	glycine amidinotransferase
8103326	FGG	-1.43724	0.000134	0.000928	-4.04642	Down	fibrinogen gamma chain
8017885	ABCA8	-1.46754	0.000155	0.001045	-4.00569	Down	ATP binding cassette subfamily A member 8
8014342	CCL16	-1.70224	0.000174	0.001155	-3.97141	Down	C-C motif chemokine ligand 16
8097910	FGB	-1.34005	0.000194	0.001265	-3.93914	Down	fibrinogen beta chain
7919055	HMGCS2	-1.26433	0.000197	0.001283	-3.93429	Down	3-hydroxy-3-methylglutaryl-CoA synthase 2
7948957	SLC22A25	-1.25362	0.000235	0.001483	-3.88219	Down	solute carrier family 22 member 25
7944035	APOC3	-1.36125	0.000314	0.001894	-3.79577	Down	apolipoprotein C3
8095680	CXCL8	-1.3989	0.000412	0.002381	-3.71382	Down	C-X-C motif chemokine ligand 8
8053025	NAT8	-1.27147	0.00044	0.002521	-3.69351	Down	N-acetyltransferase 8 (putative)
7954330	SLCO1B3	-2.21836	0.000585	0.00321	-3.60636	Down	solute carrier organic anion transporter family member 1B3
7961507	ART4	-1.26353	0.000935	0.004785	-3.45961	Down	ADP-ribosyltransferase 4 (Dombrock blood group)
8160889	CCL21	-1.42737	0.001221	0.005962	-3.37447	Down	C-C motif chemokine ligand 21
7920244	S100A8	-1.26434	0.001884	0.008569	-3.23321	Down	S100 calcium binding protein A8
8105084	C7	-1.71191	0.004783	0.018432	-2.91635	Down	complement C7
7965410	DCN	-1.26964	0.014933	0.046094	-2.49696	Down	decorin

Table 3 The enriched pathway terms of the up regulated differentially expressed genes

BIOCYC

Pathway ID	Pathway Name	P-value	FDR B&H	FDR B&Y	Bonferroni	Gene Count	Gene
547488	proline biosynthesis	8.07E-04	2.10E-02	9.52E-02	4.20E-02	2	PYCR1,ALDH18A1
142287	epoxysqualene biosynthesis	8.07E-04	2.10E-02	9.52E-02	4.20E-02	2	FDFT1,SQLE
703096	4-hydroxy-2-nonenal detoxification	4.53E-03	7.85E-02	3.56E-01	2.36E-01	2	GSTA4,GSTP1
782390	superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis	2.00E-02	1.98E-01	8.98E-01	1.00E+00	3	RRM2,TYMS,CAD
142445	acetyl-CoA biosynthesis from citrate	2.89E-02	1.98E-01	8.98E-01	1.00E+00	1	ACLY
142185	UDP-D-xylose and UDP-D-glucuronate biosynthesis	5.53E-02	1.98E-01	8.98E-01	1.00E+00	1	UXS1
545371	MAP kinase cascade	5.53E-02	1.98E-01	8.98E-01	1.00E+00	1	EPHB2
142427	sulfate activation for sulfonation	5.53E-02	1.98E-01	8.98E-01	1.00E+00	1	PAPSS1
545306	dolichol and dolichyl phosphate biosynthesis	5.53E-02	1.98E-01	8.98E-01	1.00E+00	1	SRD5A3
782396	glycolysis	6.47E-02	1.98E-01	8.98E-01	1.00E+00	2	PFKM,PKM
KEGG							
585563	Alcoholism	5.31E-24	6.51E-22	3.96E-21	1.30E-21	39	HDAC11,H4C9,H2AC15,H2AC14,H2AC16,H2AC6,H2AC4,H2AC17,H2AC20,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,H4C13,H4C14,MACROH2A2,H2AC12,H2AC21,GNG4,H3C7,H2AC11,H2AC8,H2AZ1,H2BC5,H2BC3
83054	Cell cycle	5.66E-16	4.62E-14	2.81E-13	1.39E-13	26	PTTG1,MCM2,MCM3,MCM4,MCM5,MCM6,MC M7,CHEK1,TTK,PLK1,SKP2,BUB1,E2F5,CCNA2,CCNB1,CCND2,TGFB2,C CNB2,CDK1,CDC6,CDC20,CDC25C,TP53,MAD2L1,CDK4,CDK6
523016	Transcriptional misregulation in cancer	1.22E-05	4.99E-04	3.04E-03	3.00E-03	17	ETV1,ETV4,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,ASPSR1,SUPT3H,MYCN,H3C7,C CND2,HMGA2,TP53
83068	ECM-receptor interaction	9.38E-05	2.87E-03	1.75E-02	2.30E-02	10	COL1A1,COL1A2,COL2A1,COL4A1,RELN,SPPI,ITGA6,
83061	Wntsignaling pathway	6.88E-04	1.47E-02	8.92E-02	1.69E-01	12	ITGA2,SV2A,LAMC1AXIN2,BAMBI,SFRP4,N KD1,DKK1,DKK4,DKK2,NOTUM,
83105	Pathways in cancer	1.75E-03	2.97E-02	1.81E-01	4.28E-01	22	CCND2,WIF1,LEF1,TP53PDGFRB,AXIN2,PIK3R2,PLCG1,MMP2,COL4A1,MSH2,SKP2,SLC2A1,ITGA6,ITGA2,BMP4,FGF20,GNA12,GNG4,LAMC1,TGFB2,GSTP1,LEF1,TP53,CDK4,CDK6
692234	PI3K-Akt signaling pathway	3.62E-03	5.22E-02	3.17E-01	8.87E-01	19	PDGFRB,PIK3R2,COL1A1,COL1A2,COL2A1,COL4A1,PRKAA2,RELN,SPP1,ITGA6,ITGA2,FGF20,GNG4,LAMC1,CCND2,EFNA4,TP53,CDK4,CDK6
1474302	Fluid shear stress and atherosclerosis	6.65E-03	7.41E-02	4.51E-01	1.00E+00	10	PIK3R2,MMP2,PRKAA2,MAPK13,BMP4,NQO1,GSTA4,GSTP1,ARHGEF2,TP53

373901	HTLV-I infection	1.33E-02	1.25E-01	7.60E-01	1.00E+00	14	PTTG1,PDGFRB,CHEK1,PIK3R2,POLE2,SLC2A1,MYBL2,CCND2,TGFB2,CCNB2,CDC20,TP53,MA
132956	Metabolic pathways	9.32E-01	9.76E-01	1.00E+00	1.00E+00	28	D2L1,CDK4 ACLY,ENPP3,PFKM,RRM2,CKB,TYMS,ACSL4,F DFT1,PGAP1,PKM,PLCG 1,UXS1,POLE2,PRIM1,B3 GALNT1,B3GALT2,B3G ALT1,IMPDH2,SQLE,PSP H,LPCAT2,PYCR1,ALDH 18A1,P4HA2,CAD,PIGU, PAPSS1,DGKK
REACTOME							
1269741	Cell Cycle	1.59E-38	6.96E-36	5.12E-35	1.39E-35	88	KIF18A,PTTG1,CENPF,H JURP,SPC25,MCM2,MC M3,MCM4,MCM5,MCM6 ,MCM7,CHEK1,MND1,R PS27,RRM2.SGO1,H4C9, TUBG1,TYMS,H2AC14,H 2AC6,H2AC4,H2AC20,H2 BC8,H2BC13,H2BC14,H2 BC7,H2BC6,H2BC9,H2B C10,H3C1,H3C3,H3C6,H3 C11,H3C8,NDC80,H3C12, H3C10,H3C2,H4C4,H4C2, H4C5,H4C13,H4C14,PLK 1,FOXMI,POLE2,SKP2,S PC24,PRIM1,CENPI,TPX 2,GINS2,PLK4,MYBL2,K NTC1,NUF2,CENPK,GIN S1,SPDL1,AURKA,NCAP G,BUB1,NCAPD2,RHNO 1,H3C7,E2F5,RFC3,NCAP H,CCNA2,CCNB1,CCND 2,KIF20A,CCNB2,H2AC8 ,H2AZ1,H2BC5,H2BC3,C DK1,CDC6,CDC20,CDC2 5C,SKA1,TOP2A,TP53,M AD2L1,CDK4,CDK6
1270436	HDACs deacetylate histones	1.46E-30	2.56E-28	1.88E-27	1.28E-27	35	H4C9,H2AC15,H2AC14,H 2AC16,H2AC6,H2AC4,H2 AC17,H2AC20,H2BC8,H2 BC13,H2BC14,H2BC7,H2 BC6,H2BC9,H2BC10,H3C 1,H3C3,H3C6,H3C11,H3C 8,H3C12,H3C10,H3C2,H4 C4,H4C2,H4C5,H4C13,H4 C14,H2AC12,H2AC21,H3 C7,H2AC11,H2AC8,H2B C5,H2BC3
1269810	M Phase	7.36E-29	8.07E-27	5.94E-26	6.46E-26	55	KIF18A,PTTG1,CENPF,S PC25,RPS27.SGO1,H4C9, H2AC14,H2AC6,H2AC4, H2AC20,H2BC8,H2BC13, H2BC14,H2BC7,H2BC6, H2BC9,H2BC10,H3C1,H3 C3,H3C6,H3C11,H3C8,N DC80,H3C12,H3C10,H3C 2,H4C4,H4C2,H4C5,H4C1 3,H4C14,PLK1,SPC24,CE NPI,KNTC1,NUF2,CENP K,SPDL1,NCAPG,BUB1, NCAPD2,H3C7,NCAPH,C CNB1,KIF20A,CCNB2,H2 AC8,H2AZ1,H2BC5,H2B C3,CDK1,CDC20,SKA1, MAD2L1
1269169	Amyloid fiber formation	7.91E-28	5.78E-26	4.25E-25	6.94E-25	34	H4C9,H2AC14,H2AC6,H2 AC4,MFGE8,H2AC20,H2 BC8,H2BC13,H2BC14,H2 BC7,H2BC6,H2BC9,H2B C10,H3C1,H3C3,H3C6,H3 C11,H3C8,H3C12,H3C10,

1269509	RHO GTPase Effectors	1.81E-24	8.34E-23	6.13E-22	1.59E-21	49	H3C2,H4C4,H4C2,H4C5,H4C13,H4C14,ODAM,H3C7,GSN,H2AC8,H2AZ1,H2BC5,H2BC3,LYZ KIF18A,CENPF,SPC25,RPS27,SGO1,H4C9,H2AC14,H2AC6,H2AC4,H2AC20,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,NDC80,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,H4C13,H4C14,PLK1,SPC24,CENPI,KNTC1,NUF2,CENPK,SPDL1,UBI1,H3C7,PRC1,H2AC8,H2AZ1,H2BC5,H2BC3,CD20,CDC25C,SKA1,MA D2L1
1269599	TCF dependent signaling in response to WNT	9.64E-23	3.02E-21	2.22E-20	8.46E-20	43	AMER1,H4C9,AXIN2,H2AC14,DACT1,H2AC6,H2AC4,H2AC20,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,ZNRF3,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,H4C13,H4C14,LGR5,DKK1,DKK4,DKK2,BCL9,RNF43,H3C7,CCDC88C,WIF1,H2AC8,H2AZ1,H2BC5,H2BC3,LEF1
1309095	DNA Double-Strand Break Repair	5.36E-11	7.70E-10	5.66E-09	4.70E-08	24	CHEK1,H4C9,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H4C4,H4C2,H4C5,H4C13,H4C14,POLE2,XRCC2,RAD51,AP1,RHNO1,KPNA2,RFC3,CCNA2,H2BC5,H2BC3,TP53
1270302	Developmental Biology	1.97E-05	1.94E-04	1.42E-03	1.72E-02	54	EPHB2,PDGFRB,TRPC1,H4C9,H2AC14,H2AC6,H2AC4,H2AC20,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,PIK3R2,H4C13,H4C14,PLCG1,MM2,PCOLCE,ENAH,CD24,PCGF2,ITGA2,GFRA3,FGF20,CDON,H3C7,CACNB4,ARHGEF28,NRCAM,KRT19,DUSP9,LAMC1,TDGF1,EFNA4,H2AC8,H2AZ1,H2BC5,H2BC3,ROBO1,CDK4
1268677	Metabolism of proteins	2.55E-04	2.26E-03	1.66E-02	2.24E-01	69	USP11,RPS5,CTSC,RPS27,H4C9,AXIN2,H2AC15,H2AC14,H2AC16,H2AC6,H2AC4,MFGE8,H2AC17,H2AC20,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,H4C13,H4C14,PGAP1,MME,RPL22L1,MP2,H2AC12,WFS1,H2AC21,SKP2,USP21,UBE2T,PCGF2,AURKA,LYPD1,MUCL1,ODAM,GNG4,DYNC1H1,H3C7,H2AC11,SRD5A3,PIGU,ST8SIA3,GSN,CCNA2,RAB34,THY1

1269649	Gene Expression	1.38E-02	8.59E-02	6.32E-01	1.00E+00	67	.EIF4A2,H2AC8,H2AZ1,H2BC5,H2BC3,CDC20,LYZ,TOP2A,TP53 ERCC2,RP55,CHEK1,RP527,H4C9,H2AC14,H2AC6,H2AC4,ZNF610,H2AC20,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,H4C13,H4C14,RPL22L1,TP53I3,MSH2,ZNF711,IGF2BP1,IGF2BP3,IGF2BP2,TET1,PRKAA2,TPX2,UHRF1,LSM2,SNRPB,MYBL2,SMYD2,AURKA,EHMT2,ZNF738,RHNO1,ZNF704,H3C7,E2F5,RFC3,CCNA2,CCNB1,TRIM28,ZNF382,FANCI,EIF4A2,H2AC8,H2AZ1,H2BC5,H2BC3,ALYREF,CDK1,CD25C,TP53
Gen MAPP							
MAP00100	Sterol biosynthesis	3.04E-02	5.22E-01	1.00E+00	5.77E-01	2	FDFT1,SQLE
MAP00220	Urea cycle and metabolism of amino groups	8.08E-02	5.22E-01	1.00E+00	1.00E+00	2	CKB,PYCR1
MAP00240	Pyrimidine metabolism	1.25E-01	5.22E-01	1.00E+00	1.00E+00	3	RRM2,TYMS,CAD
MAP00710	MAP kinase activity	2.04E-01	5.22E-01	1.00E+00	1.00E+00	1	MAPK13
MAP00030_	Carbon fixation	3.66E-01	5.22E-01	1.00E+00	1.00E+00	1	PKM
MAP00020	Pentose phosphate cycle	3.84E-01	5.22E-01	1.00E+00	1.00E+00	1	PFKM
MAP00562	Citrate cycle TCA cycle	4.01E-01	5.22E-01	1.00E+00	1.00E+00	1	ACLY
MAP00230	Inositol phosphate metabolism	4.18E-01	5.22E-01	1.00E+00	1.00E+00	1	PLCG1
MAP00480	Purine metabolism	4.20E-01	5.22E-01	1.00E+00	1.00E+00	3	RRM2,PKM,IMPDH2
MAP00480	Glutathione metabolism	4.65E-01	5.22E-01	1.00E+00	1.00E+00	1	GSTP1
Pathway Interaction Database							
138007	PLK1 signaling events	7.67E-12	8.74E-10	4.65E-09	8.74E-10	14	SGO1,TUBG1,NDC80,PLK1,SPC24,TPX2,AURKA,BUB1,ECT2,CCNB1,KIF20A,CDK1,CDC20,CDC25C
138080	Aurora B signaling	8.12E-08	4.63E-06	2.46E-05	9.26E-06	10	SGO1,NDC80,RACGAP1,AURKA,NCAPG,BUB1,NCAPD2,NCAPH,KIF20A,CBX5
137935	FOXM1 transcription factor network	6.00E-07	2.28E-05	1.21E-04	6.83E-05	9	CENPF,MMP2,PLK1,FOX M1,SKP2,CCNB1,CCNB2,CDK1,CDK4
169351	Validated targets of C-MYC transcriptional activation	2.42E-06	6.90E-05	3.67E-04	2.76E-04	12	PFKM,SERPINI1,SUPT3H,LIN28B,SLC2A1,PEG10,CAD,CCNB1,CCND2,CDA7,TP53,CDK4
137934	E2F transcription factor network	3.40E-05	7.76E-04	4.13E-03	3.88E-03	10	MCM3,RRM2,TYMS,MYBL2,E2F5,CCNA2,TRIM28,CBX5,CDK1,CDC6
138073	C-MYB transcription factor network	3.20E-04	5.02E-03	2.67E-02	3.65E-02	9	MCM4,COL1A2,CCNB1,TRIM28,CD34,H2AZ1,LYZ,LEF1,CDK6
169352	Regulation of Wnt-mediated beta catenin signaling and target gene transcription	3.52E-04	5.02E-03	2.67E-02	4.02E-02	9	AXIN2,MMP2,IGF2BP1,DKK1,VCAN,DKK4,BCL9,CCND2,LEF1
137939	Direct p53 effectors	3.99E-03	5.06E-02	2.69E-01	4.55E-01	10	AFP,MMP2,MAP4K4,TP53I3,MSH2,DKK1,VCAN,SP1,CCNB1,TP53
138019	p75(NTR)-mediated signaling	2.78E-02	1.87E-01	9.92E-01	1.00E+00	5	SORT1,MAGED1,BEX1,NDN,TP53
169347	Notch-mediated HES/HEY network	7.45E-01	8.09E-01	1.00E+00	1.00E+00	1	HEY1

MSigDB C2 BIOCARTA (v6.0)							
M6682	CDK Regulation of DNA Replication	3.12E-07	3.62E-05	1.93E-04	3.62E-05	7	MCM2,MCM3,MCM4,MCM5,MCM6,MCM7,CDC6
M17761	Wnt/beta-catenin Pathway	3.38E-06	1.96E-04	1.05E-03	3.92E-04	8	AXIN2,DACT1,NKD1,DKK1,DKK4,DKK3,DKK2,WIF1
M5884	Ensemble of genes encoding core extracellular matrix including ECM glycoproteins, collagens and proteoglycans	9.91E-06	3.83E-04	2.04E-03	1.15E-03	22	MATN3,MFAP2,MFGE8,FBLN1,SPARCL1,COL1A1,COL1A2,COL2A1,COL4A1,FRAS1,COL15A1,FMOD,VCAN,RELN,SPP1,SMOC2,CCN3,NPNT,LAMC1,VWCE,EDIL3,LTBP2
M5889	Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins	3.02E-04	5.00E-03	2.67E-02	3.50E-02	48	PCSK5,CTSC,MATN3,MDK,TNFSF4,MEP1A,COLEC12,MFAP2,MFGE8,FBLN1,SERPINE2,SERPINI1,SPARCL1,MMP2,MMP11,XCL1,COL1A1,COL1A2,COL2A1,COL4A1,SEMA3C,FRAS1,SFRP4,COL15A1,FMOD,VCAN,FRZB,CST1,RELN,SPP1,SMOC2,FREM1,BMP4,FREM2,GPC3,MUCL1,FGF20,CCN3,NPNT,P4HA2,LAMC1,TGFB2,WIF1,REG3A,LTBP2
M3008	Genes encoding structural ECM glycoproteins	4.16E-04	5.36E-03	2.86E-02	4.82E-02	15	MATN3,MFAP2,MFGE8,FBLN1,SPARCL1,FRAS1,RELN,SPP1,SMOC2,CCN3,NPNT,LAMC1,VWCE,EDIL3,LTBP2
M5885	Ensemble of genes encoding ECM-associated proteins including ECM-affiliated proteins, ECM regulators and secreted factors	1.58E-01	5.78E-01	1.00E+00	1.00E+00	26	PCSK5,CTSC,MDK,TNFSF4,MEP1A,COLEC12,SERPINE2,SERPINI1,MMP2,MMP11,XCL1,SEMA3C,SFRP4,FRZB,CST1,FREM1,BMP4,FREM2,GPC3,MUCL1,FGF20,P4HA2,TGFB2,WIF1,REG3A
M5880	Genes encoding proteins affiliated structurally or functionally to extracellular matrix proteins	2.05E-01	6.60E-01	1.00E+00	1.00E+00	7	COLEC12,SEMA3C,FREM1,FREM2,GPC3,MUCL1,REG3A
M3468	Genes encoding enzymes and their regulators involved in the remodeling of the extracellular matrix	2.25E-01	6.64E-01	1.00E+00	1.00E+00	9	PCSK5,CTSC,MEP1A,SERPINE2,SERPINI1,MMP2,MMP11,CST1,P4HA2
M13863	MAPKinase Signaling Pathway	4.42E-01	6.73E-01	1.00E+00	1.00E+00	3	MAP4K4,MAPK13,TGFB2
M5883	Genes encoding secreted soluble factors	4.99E-01	6.73E-01	1.00E+00	1.00E+00	10	MDK,TNFSF4,XCL1,SFRP4,FRZB,BMP4,FGF20,TGFB2,WIF1
Panther DB							
P00057	Wnt signaling pathway	5.59E-03	3.50E-01	1.00E+00	4.20E-01	17	ACTG2,AXIN2,SFRP4,MYH7B,NKD1,DKK1,FRZB,DKK4,DKK2,MYCN,BCL9,GNG4,LEF1,CDH11,CDH13,TP53,HELLS
P00017	DNA replication	9.32E-03	3.50E-01	1.00E+00	6.99E-01	3	H3C2,PRIM1,TOP2A
P00034	Integrin signalling pathway	1.93E-02	3.50E-01	1.00E+00	1.00E+00	10	PIK3R2,COL1A1,COL1A2,COL2A1,COL4A1,COL15A1,MAPK13,ITGA6,ITGA2,LAMC1
P00059	p53 pathway	2.33E-02	3.50E-01	1.00E+00	1.00E+00	6	RRM2,PIK3R2,CCNB1,CDK1,CDC25C,TP53
P00005	Angiogenesis	6.04E-02	4.53E-01	1.00E+00	1.00E+00	8	EPHB2,PDGFRB,AXIN2,

P04391	Oxytocin receptor mediated signaling pathway	2.00E-01	6.65E-01	1.00E+00	1.00E+00	3	PIK3R2,PLCG1,FRZB,PRKD1,DLK1 PLCG1,GNG4,CACNB4
P00004	Alzheimer disease-presenilin pathway	2.11E-01	6.65E-01	1.00E+00	1.00E+00	5	TRPC1,ACTG2,MMP2,LRP4,LEF1
P00052	TGF-beta signaling pathway	2.52E-01	7.20E-01	1.00E+00	1.00E+00	4	BAMBI,MAPK13,BMP4,TGFB2
P00029	Huntington disease	4.54E-01	7.88E-01	1.00E+00	1.00E+00	4	ACTG2,TP53I3,DYNC1I1,TP53
P00026	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway	6.10E-01	7.88E-01	1.00E+00	1.00E+00	4	HTR1D,HTR4,KCNJ5,GN G4
Pathway Ontology							
PW:0000384	G2/M DNA damage checkpoint	8.56E-05	6.08E-03	2.95E-02	6.08E-03	3	CHEK1,CCNB1,CDK1
PW:0000248	steroid biosynthetic canonical	1.62E-03	2.00E-02	9.69E-02	1.15E-01	3	FDFT1,SQLE,NQO1
PW:0000201	Wntsignaling	1.69E-03	2.00E-02	9.69E-02	1.20E-01	6	AXIN2,DKK1,DKK4,DK K2,WIF1,LEF1
PW:0000087	G1 phase	2.31E-03	2.05E-02	9.93E-02	1.64E-01	2	E2F5,CDK4
PW:0000718	p53 signaling pathway	9.32E-03	6.62E-02	3.21E-01	6.62E-01	16	CHEK1,SMYD2,TP53
PW:0000373	glutathione conjugation	2.48E-02	1.46E-01	7.10E-01	1.00E+00	9	GSTA4,GSTP1
PW:0000343	altered Notch signaling involving promoters	2.89E-02	1.46E-01	7.10E-01	1.00E+00	1	HEY1
PW:0000300	renal disease, renal disorder	2.89E-02	1.46E-01	7.10E-01	1.00E+00	1	SPP1
PW:0000301	renal failure	5.53E-02	1.96E-01	9.52E-01	1.00E+00	1	SOAT2
PW:0000232	phosphatidylinositol 3-kinase-Akt signaling	6.90E-02	2.33E-01	1.00E+00	1.00E+00	3	MDK,PIK3R2,PLCG1
SMPDB							
SMP00197	Lysinuric Protein Intolerance	2.89E-02	3.58E-01	1.00E+00	1.00E+00	1	SLC7A6
SMP00112	Risedronate Pathway	4.30E-02	3.58E-01	1.00E+00	1.00E+00	2	FDFT1,SQLE
SMP00040	Glycolysis	4.99E-02	3.69E-01	1.00E+00	1.00E+00	2	PFKM,PKM
SMP00018	Alpha Linolenic Acid and Linoleic Acid Metabolism	5.53E-02	3.69E-01	1.00E+00	1.00E+00	1	FADS2
SMP00136	2-Hydroxyglutric Aciduria (D And L Form)	6.47E-02	4.04E-01	1.00E+00	1.00E+00	2	AACS,OXCT1
SMP00071	Ketone Body Metabolism	1.33E-01	4.25E-01	1.00E+00	1.00E+00	1	OXCT1
SMP00046	Pyrimidine Metabolism	1.54E-01	4.25E-01	1.00E+00	1.00E+00	2	TYMS,CAD
SMP00010	Nucleotide Sugars Metabolism	1.81E-01	4.25E-01	1.00E+00	1.00E+00	1	UXS1
SMP00029	Selenoamino Acid Metabolism	2.26E-01	4.25E-01	1.00E+00	1.00E+00	1	PAPSS1
SMP00392	Benzocaine Pathway	2.48E-01	4.25E-01	1.00E+00	1.00E+00	1	ATP1A2

Table 4 The enriched pathway terms of the down-regulated differentially expressed genes

BIOCYC							
Pathway ID	Pathway Name	P-value	FDR B&H	FDR B&Y	Bonferroni	Gene Count	Gene
835392	superpathway of tryptophan utilization	4.23E-08	5.12E-06	2.75E-05	5.12E-06	10	ADH1B,CYP4X1,KMO,CYP1A2,CYP2C19,SULT1A2,KYNU,TDO2,HAAO,ACMSD
545316	bile acid biosynthesis, neutral pathway	9.20E-07	5.57E-05	2.99E-04	1.11E-04	6	SCP2,CYP8B1,BAAT,AKR1D1,SLC27A5,SLC27A2
142385	tryptophan degradation	1.88E-06	7.59E-05	4.08E-04	2.28E-04	5	KMO,KYNU,TDO2,HAAO,ACMSD
782404	fatty acid beta-oxidation (peroxisome)	3.77E-05	7.61E-04	4.09E-03	4.57E-03	5	ACOX1,ACSL1,SCP2,SLC27A2,EHHADH
142356	histidine degradation	3.30E-04	3.33E-03	1.79E-02	4.00E-02	3	UROCI,AMDHD1,HAL
1108778	glycine betaine degradation	3.30E-04	3.33E-03	1.79E-02	4.00E-02	3	DMGDH,SHMT1,BHMT
142386	tyrosine degradation	3.30E-04	3.33E-03	1.79E-02	4.00E-02	3	HGD,HPD,TAT
782398	pyrimidine ribonucleosides	6.44E-04	5.20E-03	2.80E-02	7.80E-02	3	UPB1,DPYS,CDA

1108771	degradation allopregnanolone biosynthesis	6.44E-04	5.20E-03	2.80E-02	7.80E-02	3	AKR1C4,SRD5A1,SRD5A2
142151	glycine biosynthesis	1.10E-03	6.68E-03	3.59E-02	1.34E-01	2	AGXT,AGXT2
KEGG							
132956	Metabolic pathways	9.62E-31	2.71E-28	1.69E-27	2.71E-28	124	EPHX2,HGD,NAT2,CDO1,ABAT,SGMS2,ACACB,ACADL,ACADM,ACADS,B,ACAT1,CES1,MAT1A,ACOX1,PIPOX,MGLL,AKR1C4,HMGCS2,HAO1,ADH1B,ADH1C,ADH4,NDS3,ACSL1,ACSM3,FBP1,ST3GAL6,PIK3C2G,HDP,LIPG,AGL,AGXT,UGP2,UGT2B4,UGT2B7,UGT2B10,SCP2,PLA2G2A,AAS1,ALDH1A1,HSD11B1,ALDOB,ALDH6A1,ALPL,DMGDH,AGPAT2,AOX1,PON1,PON3,SHMT1,XDH,CYP4F2,ETNPPL,KMO,ARG1,GBA3,AGXT2,GDA,RDH16,HSD17B6,AAS1,LPIN2,OGDHL,CTH,MMUT,CYP1A1,CYP1A2,CYP2B6,CYP2C19,UPB1,CYP2C8,CYP2C9,CYP2C18,GLS2,MBOAT1,CYP3A4,CYP3A5,CYP4A11,INPP1,CYP8B1,CYP26A1,BAT,AKR1D1,GATM,DAO,CHST9,GCH1,UROCL,SUCLG2,PTGS2,BHMT,GCLM,PTS,DHODH,ACSM5,NNMT,KYNU,SDS,TAT,GOT1,SLC27A5,CNDP1,DPYS,GNE,GPT,GPAT3,AMDHD1,TDO2,PAPSS2,OTC,NAMPT,EHHADH,AASS,GYS2,HAAO,CDA,CYP4F3,HAL,ACMSD,ADAT,NNT,HAO2,PCK1,PCK2
83073	Complement and coagulation cascades	4.15E-22	5.85E-20	3.64E-19	1.17E-19	28	CFH,MBL2,F8,F9,F11,F13B,CLU,FGB,FGG,CFI,SERPINC1,MASP2,MASP1,CFB,C1R,C1S,C4BPA,C4BPB,C5,C6,C7,C8A,C8B,C8G,C9,KLKB1,KNG1,SERPINE1
83020	Retinol metabolism	6.17E-16	5.80E-14	3.61E-13	1.74E-13	21	LRAT,ADH1B,ADH1C,ADH4,UGT2B4,UGT2B7,UGT2B10,ALDH1A1,AOX1,RDH16,HSD17B6,CYP1A1,CYP1A2,CYP2B6,CYP2C8,CYP2C9,CYP2C18,CYP3A4,CYP3A5,CYP4A11,CYP26A1
673221	Chemical carcinogenesis	8.27E-16	5.83E-14	3.63E-13	2.33E-13	23	NAT2,ADH1B,ADH1C,ADH4,UGT2B4,UGT2B7,UGT2B10,HSD11B1,CYP3A43,CYP1A1,CYP1A2,CYP2C19,CYP2C8,CYP2C9,CYP2C18,CYP3A4,CYP3A5,PTGS2,SULT1A2,SULT2A1,GSTA1,GSTA2,GSTA3
83032	Drug metabolism - cytochrome P450	4.41E-14	2.49E-12	1.55E-11	1.24E-11	20	ADH1B,ADH1C,ADH4,UGT2B4,UGT2B7,UGT2B10,FMO3,FMO4,AOX1,CYP1A2,CYP2B6,CYP2C19,CYP2C8,CYP2C9,CYP2D6,CYP3A4,CYP3A5,GSTA1,GSTA2,GSTA3

131226	Peroxisome	6.42E-08	1.47E-06	9.12E-06	1.81E-05	15	EPHX2,ACOX1,PIPOX,H AO1,ACSL1,PHYH,AGX T,SCP2,XDH,SOD2,BAA T,DAO,SLC27A2,EHHAD H,HAO2
83042	PPAR signaling pathway	6.76E-08	1.47E-06	9.12E-06	1.91E-05	14	ACADL,ACADM,ACOX1 ,HMGCS2,ACSL1,SCP2,A POC3,CYP8B1,SLC27A5, SLC27A2,APOA5,EHHA DH,PCK1,PCK2
814926	Carbon metabolism	8.71E-07	1.53E-05	9.54E-05	2.46E-04	16	ACADM,ACAT1,HAO1,F BP1,AGXT,ALDOB,ALD H6A1,SHMT1,OGDHL,M MUT,SUCLG2,SDS,GOT 1,GPT,EHHADH,HAO2
790012	Biosynthesis of amino acids	5.13E-06	7.62E-05	4.74E-04	1.45E-03	12	MAT1A,ALDOB,SHMT1, ARG1,ASS1,CTH,SDS,TA T,GOT1,GPT,OTC,AADA T
634527	NF-kappa B signaling pathway	5.96E-05	6.00E-04	3.73E-03	1.68E-02	12	BLNK,CCCL21,ICAM1,BI RC3,CXCL8,GADD45B,T NFSF14,PTGS2,LBP,CXC L2,CD14,TLR4
Pathway Interaction Database							
138006	ATF-2 transcription factor network	3.85E-04	3.55E-02	1.81E-01	3.55E-02	8	FOS,ARG1,CXCL8,PPAR GC1A,JUNB,DUSP1,DUS P5,SOC3
137932	IL6-mediated signaling events	2.57E-03	1.18E-01	6.04E-01	2.37E-01	6	FGG,FOS,CRP,JUNB,SO CS3,LBP
138014	Glucocorticoid receptor regulatory network	5.26E-03	1.61E-01	8.23E-01	4.84E-01	8	FGG,VIPR1,FOS,ICAM1, CXCL8,NR1H3,EGR1,PCK 2
137911	FOXA2 and FOXA3 transcription factor networks	1.39E-02	2.13E-01	1.00E+00	1.00E+00	5	ACADM,ALAS1,ALDOB, TAT,PCK1
138010	Glypican 1 network	5.17E-02	5.29E-01	1.00E+00	1.00E+00	3	NRG1,PLA2G2A,SERPIN C1
137943	p38 MAPK signaling pathway	6.77E-02	5.94E-01	1.00E+00	1.00E+00	3	MAP3K5,GADD45B,GAD D45G
137945	amb2 Integrin signaling	7.10E-02	5.94E-01	1.00E+00	1.00E+00	4	HP,ICAM1,KNG1,LPA
169347	Notch-mediated HES/HEY network	2.07E-01	8.22E-01	1.00E+00	1.00E+00	3	AR,GHR,RCAN1
137934	E2F transcription factor network	2.16E-01	8.22E-01	1.00E+00	1.00E+00	4	CES1,SULT2A1,SERPINE 1,CES3
137939	Direct p53 effectors	2.63E-01	8.22E-01	1.00E+00	1.00E+00	6	HGF,TP53INP1,DUSP1,D USP5,SERPINE1,STEAP3
REACTOME							
1270189	Biological oxidations	1.19E-25	8.10E-23	5.75E-22	8.10E-23	48	GLYAT,NAT2,AADAC,C ES1,MAT1A,CYP39A1,A DH1B,ADH1C,ADH4,GL YATL1,UGP2,UGT2B4,U GT2B7,UGT2B10,ALDH1 A1,FMO3,CYP3A43,CYP 4F2,AKR7L,CYP4F22,CY P4F11,CYP1A1,CYP1A2, CYP2B6,CYP2C19,CYP2 C8,CYP2C9,CYP2C18,CY P2D6,CYP3A4,CYP3A5,C YP4A11,CYP8B1,CYP26 A1,SULT1A2,SULT1B1,S ULT2A1,GCLM,ACSM5, NNMT,CYP4V2,PAPSS2, CYP4A22,GSTA1,GSTA2 ,GSTA3,CES3,CYP4F3
1269241	Complement cascade	1.57E-20	5.33E-18	3.78E-17	1.07E-17	23	CFH,MBL2,CLU,FCN2,C OLEC10,CFL,FCN3,CRP, MASP2,MASP1,CFB,CFH R3,C1R,C1S,C4BPA,C4B PB,C5,C6,C7,C8A,C8B,C8 G,C9
1270190	Phase 1 - Functionalization of compounds	1.11E-18	2.51E-16	1.78E-15	7.54E-16	29	AADAC,CES1,CYP39A1, ADH1B,ADH1C,ADH4,A LDH1A1,FMO3,CYP3A43 ,CYP4F2,CYP4F22,CYP4 F11,CYP1A1,CYP1A2,CY P2B6,CYP2C19,CYP2C8,

							CYP2C9,CYP2C18,CYP2D6,CYP3A4,CYP3A5,CYP4A11,CYP8B1,CYP26A1,CYP4V2,CYP4A22,CES3,CYP4F3
1270001	Metabolism of lipids and lipoproteins	2.71E-18	4.60E-16	3.26E-15	1.84E-15	78	EPHX2,SGMS2,ACACB,ACADL,ACADM,ACAT1,CETP,ACOX1,MGLL,AKR1C4,HMGCS2,CYP39A1,ABCB4,ACSL1,PHYH,ACSM3,PIK3C2G,LIPG,HPGD,HSD17B13,SCP2,PLA2G2A,ALAS1,HSD11B1,PRKAG2,DMGDH,MOGAT2,G0S2,AGPAT2,APOF,PON1,PON3,CYP4F2,ETNPPL,APOC3,SLCO1B1,GBA3,SLC10A1,LPIN2,ABCB11,CYP4F22,CYP4F11,MMUT,CYP1A1,CYP1A2,ABCC3,CYP2C19,CYP2C8,CYP2C9,MBOAT1,CYP4A11,CYP8B1,INSIG1,BAAT,SRD5A1,SRD5A2,AKR1D1,SLCO1B3,BCHHE,PTGS2,BHMT,PPARGC1A,SULT2A1,ANGPTL3,CREB3L3,SLC27A5,SLC27A2,GPD1,APOA5,GPAT3,CYP4A22,MFSD2A,THRSP,EHHADH,LPA,CES3,CYP4F3,HAO2
1270158	Metabolism of amino acids and derivatives	2.54E-13	2.87E-11	2.04E-10	1.72E-10	43	HGD,CDO1,ACADSB,ACAT1,MAT1A,PIPOX,HAO1,HPD,AGXT,DHTKD1,BBOX1,ALDH6A1,IYD,SHMT1,KMO,ARG1,AGXT2,ASS1,CTH,GLS2,GATM,DAO,UROC1,GNMT,BHMT,GCLM,DIO1,NNMT,KYNU,TAT,GOT1,ASPG,GPT,AMDHD1,TDO2,PAPSS2,OTC,AASS,SLC25A15,HAAO,HAL,ACMSD,AADAT
1309221	Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism	8.45E-11	5.73E-09	4.06E-08	5.73E-08	14	HGD,PIPOX,HPD,KMO,UROC1,KYNU,TAT,AMDHD1,TDO2,AASS,HAAO,HAL,ACMSD,AADAT
1270040	Bile acid and bile salt metabolism	6.04E-10	3.41E-08	2.42E-07	4.09E-07	13	AKR1C4,CYP39A1,SCP2,SLCO1B1,SLC10A1,ABCB11,ABCC3,CYP8B1,BAAT,AKR1D1,SLCO1B3,SLC27A5,SLC27A2
1270207	Phase II conjugation	2.88E-09	1.39E-07	9.88E-07	1.95E-06	19	GLYAT,NAT2,MAT1A,GLYATL1,UGP2,UGT2B4,UGT2B7,UGT2B10,CYP1A2,SULT1A2,SULT1B1,SULT2A1,GCLM,ACSM5,NNMT,PAPSS2,GSTA1,GSTA2,GSTA3
1269242	Initial triggering of complement	3.00E-08	1.11E-06	7.90E-06	2.03E-05	10	MBL2,FCN2,COLEC10,FCN3,CRP,MASP2,MASP1,CFB,C1R,C1S
1269203	Innate Immune System	1.10E-03	1.39E-02	9.83E-02	7.46E-01	63	CFH,HGF,NRG1,SERPINA3,MBL2,CFP,PGLYRP2,LEAP2,LRG1,PLAC8,S100A8,SAA1,PIGR,CLU,HP,FCN2,AGL,FGB,PLA2G2A,FGFR2,FGG,APBB1IP,FOS,AGPAT2,BIRC3,COLEC10,CFI,FCN3,CRP,ARG1,SLPI,CTSL,MASP2,MASP1,SPTBN2,GFRA1,CFB,CFHR3,PTPRB,RNF

							125,VNN1,C1R,C1S,C4BP A,C4BPB,C5,C6,C7,C8A, C8B,C8G,C9,RAB27A,SL C27A2,DUSP1,DUSP5,LB P,ORM1,CD14,TLR4,CD A,HERC5,LRRFIP1
Gen MAPP							
MAP00071	Fatty acid metabolism	7.25E-17	3.48E-15	1.55E-14	3.48E-15	19	ACADL,ACADM,ACAT1 ,ACOX1,ADH1B,ADH1C, ADH4,ALDH1A1,CYP1A 1,CYP1A2,CYP2B6,CYP2 C8,CYP2C9,CYP2C18,CY P2D6,CYP3A4,CYP3A5,C YP4A11,EHHADH
MAP00380	Tryptophan metabolism	2.93E-14	7.04E-13	3.14E-12	1.41E-12	17	ACAT1,ALDH1A1,AOX1 ,CYP1A1,CYP1A2,CYP2 B6,CYP2C8,CYP2C9,CYP 2C18,CYP2D6,CYP3A4,C YP3A5,KYNU,TDO2,EH HADH,HAAO,ACMSD
MAP00640	Propanoate metabolism	1.09E-07	1.30E-06	5.82E-06	5.22E-06	8	ABAT,ACACB,ACADM, ACAT1,ALDH1A1,ALDH 6A1,MMUT,EHHADH
MAP00120	Bile acid biosynthesis	3.88E-07	3.73E-06	1.66E-05	1.86E-05	8	ADH1B,ADH1C,ADH4,A LDH1A1,BAAT,SRD5A1, SRD5A2,AKR1D1
MAP00150	Androgen and estrogen metabolism	1.63E-04	7.11E-04	3.17E-03	7.82E-03	5	UGT2B4,HSD11B1,SRD5 A1,SRD5A2,AKR1D1
MAP00650	Butanoate metabolism	2.90E-04	1.16E-03	5.17E-03	1.39E-02	5	ABAT,ACAT1,HMGCS2, ALDH1A1,EHHADH
MAP00252	Alanine and aspartate metabolism	4.81E-04	1.77E-03	7.91E-03	2.31E-02	5	ABAT,AGXT,ASS1,GOT 1,GPT
MAP00630	Glyoxylate and dicarboxylate metabolism	4.03E-02	5.87E-02	2.62E-01	1.00E+00	2	HAO1,HAO2
MAP00240	Pyrimidine metabolism	1.73E-01	1.98E-01	8.83E-01	1.00E+00	3	DHODH,DPPYS,CDA
MAP00230	Purine metabolism	7.66E-01	7.66E-01	1.00E+00	1.00E+00	2	XDH,GDA
MSigDB C2 BIOCARTA (v6.0)							
M917	Complement Pathway	2.38E-12	3.19E-10	1.75E-09	3.19E-10	11	MBL2,MASP2,MASP1,CF B,C1R,C1S,C5,C6,C7,C8A ,C9
M15997	Intrinsic Prothrombin Activation Pathway	3.88E-07	1.30E-05	7.12E-05	5.20E-05	8	F8,F9,F11,FGB,FGG,SER PINC1,KLKB1,KNIG1
M5885	Ensemble of genes encoding ECM-associated proteins including ECM-affiliated proteins, ECM regulators and secreted factors	2.82E-06	7.56E-05	4.14E-04	3.78E-04	49	HGF,HGFAC,NRG1,SER PINA3,MBL2,CLEC1B,C LEC4M,F9,F13B,S100A8, SERPINB8,FCN2,HPX,H RG,FGF14,CCL16,CCL21, SDC4,PAPPA2,PAMR1,A DAMTS1,CXCL14,COLE C10,FCN3,CRHBP,SERPI NA11,IGF1,CLEC4G,SLP I,SERPINC1,IL1RN,CTSL ,CXCL8,MASP2,MASP1, TNFSF14,INHBC,ITIH4,B MP10,ANGPTL3,PZP,KN G1,INHBE,CXCL2,HHIP, LPA,SERPINE1,ANXA10, HABP2
M5889	Ensemble of genes encoding extracellular matrix and extracellular matrix- associated proteins	6.70E-06	1.50E-04	8.19E-04	8.97E-04	60	HGF,HGFAC,NRG1,SER PINA3,MBL2,CLEC1B,C LEC4M,LRG1,F9,F13B,S1 00A8,SERPINB8,FCN2,H PX,FGB,HRG,FGF14,CCL 16,FGG,CCL21,SDC4,PA PPA2,PAMR1,ADAMTS1 ,CXCL14,COLEC10,FCN 3,CRHBP,TSKU,MMRN1, SERPINA11,IGF1,OIT3,C LEC4G,SLPI,SERPINC1,I L1RN,CTSL,CXCL8,MAS P2,MASP1,TNFSF14,INH BC,DCN,ITIH4,BMP10,A NGPTL3,BMPER,PZP,KN G1,INHBE,ECM1,CXCL2, RSP03,NTN4,HHIP,LPA,

M3468	Genes encoding enzymes and their regulators involved in the remodeling of the extracellular matrix	1.08E-04	1.60E-03	8.77E-03	1.44E-02	20	SERPINE1,ANXA10,HABP2 SERPINA3,F9,F13B,SERP INB8,HRG,PAPPA2,PAM R1,ADAMTS1,SERPINA1 1,SLPI,SERPINC1,CTSL, MASP2,MASP1,ITIH4,PZ P,KNG1,LPA,SERPINE1, HABP2
M5883	Genes encoding secreted soluble factors	1.82E-02	1.63E-01	8.91E-01	1.00E+00	19	HGF,HGFAC,NRG1,S100 A8,FGF14,CCL16,CCL21, CXCL14,CRHBP,IGF1,IL 1RN,CXCL8,TNFSF14,IN HBC,BMP10,ANGPTL3,I NHBE,CXCL2,HHIP
M5880	Genes encoding proteins affiliated structurally or functionally to extracellular matrix proteins	5.42E-02	3.46E-01	1.00E+00	1.00E+00	10	MBL2,CLEC1B,CLEC4M, FCN2,HPX,SDC4,COLEC 10,FCN3,CLEC4G,ANXA 10
M3008	Genes encoding structural ECM glycoproteins	1.10E-01	5.72E-01	1.00E+00	1.00E+00	10	LRG1,FGB,FGG,TSKU,M MRN1,OIT3,BMPER,EC M1,RSPO3,NTN4
M12645	G alpha 13 Pathway	1.19E-01	5.72E-01	1.00E+00	1.00E+00	3	MAP3K5,CFB,LPA
M5884	Ensemble of genes encoding core extracellular matrix including ECM glycoproteins, collagens and proteoglycans	2.89E-01	7.37E-01	1.00E+00	1.00E+00	11	LRG1,FGB,FGG,TSKU,M MRN1,OIT3,DCN,BMPE R,ECM1,RSPO3,NTN4
Panther DB							
P00011	Blood coagulation	4.34E-06	2.65E-04	1.26E-03	2.86E-04	9	F8,F9,F13B,FGB,FGG,SE RPINC1,KLKB1,KNG1,S ERPINE1
P02771	Pyrimidine Metabolism	8.02E-06	2.65E-04	1.26E-03	5.29E-04	5	ABAT,ALDH6A1,UPB1, DPYS,CDA
P00050	Plasminogen activating cascade	1.91E-03	4.20E-02	2.01E-01	1.26E-01	4	FGB,FGG,LPA,SERPINE 1
P05914	Nicotine degradation	1.68E-02	1.89E-01	9.04E-01	1.00E+00	3	UGT2B7,FMO3,AOX1
P00059	p53 pathway	2.58E-01	6.32E-01	1.00E+00	1.00E+00	4	PIK3C2G,GADD45B,GA DD45G,SERPINE1
P00052	TGF-beta signaling pathway	3.47E-01	7.63E-01	1.00E+00	1.00E+00	4	INHBC,JUNB,BMP10,IN HBE
P00021	FGF signaling pathway	6.53E-01	9.22E-01	1.00E+00	1.00E+00	3	MAP3K5,FGF14,FGFR2
P00026	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway	7.28E-01	9.30E-01	1.00E+00	1.00E+00	4	ADRA1A,CREB3L3,RGS 2,GYS2
P00034	Integrin signalling pathway	8.00E-01	9.30E-01	1.00E+00	1.00E+00	4	MAP3K5,RND3,RND1,N TN4
P00031	Inflammation mediated by chemokine and cytokine signaling pathway	9.52E-01	9.86E-01	1.00E+00	1.00E+00	3	CCL21,CXCL8,JUNB
Pathway Ontology							
PW:0000054	tryptophan metabolic	9.77E-10	1.11E-07	5.92E-07	1.11E-07	10	ACAT1,AOX1,KMO,CYP 1A1,CYP1A2,CYP2C19,K YNU,TDO2,HAAO,AAD AT
PW:0000729	statin pharmacokinetics pathway	5.49E-08	3.13E-06	1.66E-05	6.26E-06	7	SLCO1B1,ABCB11,CYP2 C8,CYP2C9,CYP2D6,CY P3A4,SLCO1B3
PW:0000047	glycine, serine and threonine metabolic	2.83E-06	1.07E-04	5.71E-04	3.22E-04	6	AGXT,ALAS1,SHMT1,C TH,GATM,GNMT
PW:0000049	cysteine metabolic	4.12E-06	1.17E-04	6.24E-04	4.70E-04	5	CDO1,CTH,SULT1A2,SD S,GOT1
PW:0000058	fatty acid metabolic	5.90E-06	1.35E-04	7.16E-04	6.73E-04	7	ACADL,ACADM,ACAT1 ,ADH4,CYP1A1,CYP1A2, CYP2C19
PW:0000028	alanine and aspartate metabolic	8.02E-06	1.52E-04	8.10E-04	9.14E-04	5	ABAT,AGXT,ASS1,GOT 1,GPT
PW:0000641	gluconeogenesis pathway	1.07E-05	1.75E-04	9.28E-04	1.22E-03	6	PFKFB1,FBP1,ALDOB,G OT1,PCK1,PCK2
PW:0000375	bioactivation via cytochrome P450	1.60E-05	2.28E-04	1.21E-03	1.83E-03	4	CYP1A1,CYP1A2,CYP2C 19,CYP2D6
PW:0000726	repaglinide pharmacokinetics pathway	3.59E-05	4.09E-04	2.18E-03	4.09E-03	3	SLCO1B1,CYP2C8,CYP3 A4
PW:0000074	lysine biosynthetic	3.13E-03	1.55E-02	8.25E-02	3.57E-01	2	VNN1,AASS

SMPDB							
SMP00272	Enoxaparin Pathway	1.46E-09	6.40E-08	3.68E-07	2.56E-07	9	F8,F9,F11,F13B,FGB,FGG, SERPINC1,KLKB1,KNG1
SMP00004	Glycine, Serine and Threonine Metabolism	5.01E-08	3.99E-07	2.29E-06	8.77E-06	9	AKR1C4,CYP39A1,SCP2, CYP8B1,BAAT,AKR1D1, SLC27A5
SMP00035	Bile Acid Biosynthesis	5.55E-07	4.05E-06	2.33E-05	9.71E-05	7	AOX1,KMO,CYP1A1,TD O2,HAAO,ACMSD,AAD AT
SMP00063	Tryptophan Metabolism	5.55E-07	4.05E-06	2.33E-05	9.71E-05	7	PLA2G2A,CYP1A2,CYP2 B6,CYP2C19,CYP2C9,CY P3A4,CYP3A5
SMP00260	Clopidogrel Pathway	8.83E-07	6.18E-06	3.55E-05	1.55E-04	7	ABAT,ACADM,ACADSB ,ACAT1,HMGCS2,ALDH 6A1,AOX1,MMUT
SMP00032	Valine, Leucine and Isoleucine Degradation	3.79E-06	2.55E-05	1.46E-04	6.63E-04	8	ARG1,ASS1,GLS2,GPT,O TC
SMP00059	Urea Cycle	4.12E-06	2.67E-05	1.53E-04	7.21E-04	5	AKR1C4,CYP39A1,SCP2, CYP8B1,BAAT,AKR1D1, SLC27A5
SMP00007	Beta-Alanine Metabolism	3.64E-05	2.20E-04	1.26E-03	6.37E-03	4	ALDH6A1,UPB1,CNDP1, DPYS
SMP00051	Fatty acid Metabolism	3.77E-05	2.20E-04	1.27E-03	6.60E-03	5	ACADL,ACADM,ACADS B,ACAT1,ACSL1
SMP00186	GlutaricAciduria Type III	1.24E-04	6.60E-04	3.79E-03	2.18E-02	4	ACAT1,PIPOX,AASS,AA DAT

Table 5 The enriched GO terms of the up regulated differentially expressed genes

GO ID	CATEGORY	GO Name	P Value	FDR B&H	FDR B&Y	Bonferroni	Gene Count	Gene
GO:0051276	BP	chromosome organization	1.25E-28	7.36E-25	6.81E-24	7.36E-25	103	NUSAP1,KIF18A,HDA C11,PTTG1,ERCC2,CE NPF,HJURP,MCM2,M CM3,MCM4,MCM5,M CM6,MCM7,CHEK1,S GO1,H4C9,TTK,TUBG 1,NPM3,AXIN2,H2AC 15,H2AC16,H2AC6,H2 AC4,H2AC17,H2AC20, H2BC8,H2BC13,H2BC 14,H2BC7,H2BC6,H2B C9,H2BC10,H3C1,H3C 3,H3C6,H3C11,H3C8,N DC80,H3C12,H3C10,H 3C2,H4C4,H4C2,H4C5, H4C13,H4C14,MKI67, MACROH2A2,PLK1,H 2AC12,SUPT3H,POLE 2,H2AC21,MSH2,USP2 1,ASF1B,PRIM1,TET1, PRKAA2,CENPI,RAC GAP1,UHRF1,GINS2,P RKD1,PCGF2,DLGAP5 ,NAP1L1,NUF2,CENP K,GINS1,SMYD2,SPD L1,AURKA,NCAPG,E HMT2,BUB1,NCAPD2, KIFC1,H3C7,H2AC11, RFC3,PRC1,TERC,NC APH,CCNA2,CCNB1,H MGA2,TRIM28,H1- 2,H1- 5,H2AC8,H2AZ1,H2BC 5,H2BC3,CDK1,CDC6, CDC20,LEF1,TOP2A,T P53,MAD2L1,HELLS
GO:0071103	BP	DNA conformation change	1.70E-27	4.98E-24	4.61E-23	9.96E-24	52	NUSAP1,ERCC2,HJUR P,MCM2,MCM3,MCM 4,MCM5,MCM6,MCM

								7,H4C9,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,H4C13,H4C14,MACROH2A2,ASF1B,CENPI,GINS1,NCAPG,NCAPD2,H3C7,RFC3,NCAPH,CCNB1,HMGA2,H1-2,H1-5,H2BC5,H2BC3,CDK1,TP53,HELLS
GO:0006325	BP	chromatin organization	7.79E-18	3.05E-15	2.82E-14	4.57E-14	66	HDAC11,HJURP,MCM2,CHEK1,H4C9,NPM3,H2AC15,H2AC16,H2AC6,H2AC4,H2AC17,H2AC20,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,H4C13,H4C14,MKI67,MACROH2A2,H2AC12,SUPT3H,H2AC21,USP21,ASF1B,TET1,PRKA2,CENPI,UHRF1,PRKD1,PCGF2,NAP1L1,CENPK,SMYD2,AURKA,EHMT2,H3C7,H2AC11,CCNA2,CCNB1,HMGA2,TRIM28,H1-2,H1-5,H2AC8,H2AZ1,H2BC5,H2BC3,CDK1,LEF1,TP53,HELLS
GO:0000280	BP	nuclear division	1.01E-17	3.70E-15	3.42E-14	5.92E-14	83	NUSAP1,CDKN3,KIF18A,PTTG1,ERCC2,PDGFRB,CENPF,SPC25,MCM2,MCM3,MCM4,MCM5,MCM6,MCM7,CHEK1,MND1,RRM2,SGO1,TTK,TUBG1,TYMS,DACT1,NDC80,ANLN,MKI67,ASPM,PLK1,FOXMI1,TICRR,POLR2A,DTL,MSH2,STIL,XRCC2,SKP2,PRIM1,TPX2,RACGAP1,PLK4,MYBL2,KNTC1,DLGAP5,PBK,NUF2,STOX1,SPOC2,MELK,CENPK,GINS1,SPDL1,AURKA,BMP4,NCAPG,EHMT2,BUB1,NCAPD2,KIF11,KIFC1,CACNB4,E2F5,PRC1,NCAPH,ECT2,CCNA2,CCNB1,CCND2,KIF20A,HMGA2,CCNB2,CDK1,CKAP2,ARHGAP2,SKA3,CDC6,CDC20,CDC25C,SKA1,TP53,OP2A,CDH13,TP53,MAD2L1,CDK4,CDK6
GO:0051301	BP	cell division	2.40E-17	8.29E-15	7.67E-14	1.41E-13	60	NUSAP1,PTTG1,ERCC2,CENPF,SPC25,MDK,SGO1,FBLN1,NDC80,ZNRF3,ANLN,ASPM,PLK1,FERMT1,SPC24,TPX2,CD24,RACGAP1,KNTC1,NUF2,STOX1,RNF43,SPDL1,CDCA2,AURKA,BMP4,NCAP

								G,BUB1,NCAPD2,KIF11,KIFC1,PARD3B,PRC1,FIGN,NCAPH,ECT2,CCNA2,CCNB1,CCND2,KIF20A,TGFB2,HMGA2,CCNB2,CD34,CDK1,CKAP2,ARHGEF2,SKA3,CDC6,CDC20,CDC25C,SKA1,EPCAM,LEF1,TP53,MA2L1,CDK4,CDK6,HELLS
GO:0007049	BP	cell cycle	9.50E-16	2.94E-13	2.72E-12	5.58E-12	105	NUSAP1,CDKN3,KIF18A,PTTG1,ERCC2,PDGFRB,CENPF,HJURP,SPC25,MCM2,MCM3,MCM4,MCM5,MCM6,MCM7,CHEK1,MND1,RRM2,WDR76,SGO1,TTK,TUBG1,AXIN2,TYMS,DACT1,NDC80,ANLN,MKI67,ASPM,PLK1,FOXO1,TICRR,WFS1,POLE2,DTL,MSH2,STIL,XRCC2,SKP2,SPC24,PRIM1,PRKAA2,TPX2,RACGAP1,UHRF1,PRR11,MAPK13,PLK4,MYBL2,KNTC1,PCGF2,PCLAF,BEX1,DLGA5,PBK,NUF2,STOX1,SMOC2,MELK,CENPK,GINS1,SPDL1,CDCA2,AURKA,BMP4,NCAPG,EHMT2,BUB1,NCAPD2,RHNO1,KIF11,KIFC1,CACNB4,PARD3B,E2F5,RFC3,PRC1,FIGN,NCAPH,ECT2,CCNA2,CCNB1,CCND2,KIF20A,TGFB2,HMGA2,CBX5,CCNB2,FANCI,CDK1,CKAP2,ARHGEF2,SKA3,CDC6,CDC20,CDC25C,SKA1,LEF1,TP53,CDH13,TP53,MAD2L1,CDK4,CDK6,HELLS
GO:0006259	BP	DNA metabolic process	3.27E-11	6.00E-09	5.55E-08	1.92E-07	63	PTTG1,ERCC2,PDGFRB,CENPF,MCM2,MCM3,MCM4,MCM5,MCM6,MCM7,CHEK1,MEG3,MND1,RRM2,H4C9,AXIN2,TNFSF4,TYMS,H4C4,H4C2,H4C5,H4C13,H4C14,NYNRIN,FOXO1,TICRR,POLE2,DTL,MSH2,XRCC2,RA2D1,AP1,UBE2T,PRIM1,TET1,UHRF1,GINS2,PCLAF,NAP1L1,STOX1,SMOC2,GINS1,EHMT2,PARBP,RHNO1,KPNA2,MMS22L,RFC3,FIGN,TERC,CCNA2,HMGA2,TRIM28,FANCI,H1-2,H1-5,ALYREF,NEIL3,CDK1,CDC6,LEF1,TP53,HELLS
GO:0051726	BP	regulation of cell cycle	2.99E-09	3.45E-07	3.19E-06	1.76E-05	66	NUSAP1,CDKN3,PTTG1,ERCC2,PDGFRB,CENPF,CHEK1,RRM2,WDR76,TTK,TUBG1,AXIN2,DACT1,NDC80,

									ANLN,MKI67,ASPM,PLK1,FOXM1,TICRR,WFS1,DTL,MSH2,STIL,SKP2,PRKAA2,TPX2,RACGAP1,PRR11,PLK4,MYBL2,KNTC1,PCGF2,PCLAF,DLGAP5,STOX1,SMOC2,SPDL1,AKURKA,BMP4,EHMT2,BUB1,RHNO1,KIF11,CCACNB4,E2F5,PRC1,ECT2,CCNA2,CCNB1,CCND2,KIF20A,TGFB2,HMGA2,CBX5,CCNB2,CDK1,CDC6,CDC20,CDC25C,LEF1,TOP2A,TP53,MAD2L1,CDK4,CDK6
GO:0009790	BP	embryo development	6.70E-09	7.28E-07	6.74E-06	3.93E-05	64	EPHB2,PCSK5,ERCC2,PDGFRB,CHEK1,MEG3,AXIN2,ACSL4,DACT1,MFAP2,SALL2,HS6ST1,PGAP1,PLCG1,MMP2,COL1A1,COL2A1,SEMA3C,FRAS1,TBX4,FLVCR1,MSH2,STIL,XRCC2,CRABP2,NKD1,DKK1,ASF1B,FRZB,TET1,ENAH,RACGAP1,PLK4,MYCN,PCGF2,GJB6,DLK1,ITGA2,PSPH,STOX1,GINS1,PTK7,BMP4,FREM2,GJA5,GPC3,GNA12,DLX5,STRA6,CDON,KRT19,SOBP,TDGF1,CCNB1,TGFB2,HMGA2,HEY1,TTRIM28,CCNB2,LRP4,CDK1,LEF1,TP2A,TP53	
GO:0042127	BP	regulation of cell population proliferation	1.53E-06	7.36E-05	6.81E-04	8.98E-03	78	CDKN3,PTTG1,PDGFRB,ENPP3,ETV4,CHEK1,LDOC1,MDK,TTK,SLC7A11,AXIN2,TNFSF4,H2AC6,H2AC4,FBLN1,SERPINE2,ASPM,PLAG1,BAMBI,PLCG1,MMP2,XCL1,FOXM1,SFRP4,MAGED1,FERMT1,LGR5,SKP2,ZAP70,FRZB,TET1,CD24,UHRF1,PRKD1,MYCN,GJB6,SQLE,NAP1L1,DLK1,NDN,ITGA2,STOX1,SMYD2,BMP4,GSDME,PTPN14,GPC3,FGF20,ODAM,DLX5,CCN3,CDON,CACNB4,LAMC1,TDGF1,SLC39A10,PRC1,CCNA2,CCNB1,CCND2,TGFB2,GSTP1,HMGA2,CDCA7,HEY1,H2AC8,ROBO1,REG3A,CDK1,ARHGEF2,CDK6,CDC20,EPCAM,LEF1,CDH13,TP53,CDK4,CDK6	
GO:0034622	BP	cellular protein-containing complex assembly	6.07E-06	2.48E-04	2.29E-03	3.57E-02	56	ERCC2,CENPF,RPS5,HJURP,MCM2,MCM3,MCM4,MCM5,MCM6,MCM7,RPS27,H4C9,TUBG1,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C	

								8,H3C12,H3C10,H3C2, H4C4,ANLN,H4C2,H4 C5,PIK3R2,H4C13,H4C 14,MACROH2A2,TICR R,FMOD,ASF1B,PRKA A2,CENPI,LSM2,SNRP B,NAP1L1,CENPK,RH OBTB1,SV2A,H3C7,T ERC,GSN,H1-2,H1- 5,H2BC5,H2BC3,TP53, HELLS
GO:0048699	BP	generation of neurons	9.91E-06	3.75E-04	3.47E-03	5.82E-02	70	EPHB2,PCP4,PRTG,ER CC2,ETV1,ETV4,BCL1 1A,MDK,NREP,RNF15 7,ACSL4,DACT1,SERP INE2,NRXN3,SERPINI 1,HS6ST1,ASPM,PLA G1,PLCG1,MME,MMP 2,MAP4K4,SEMA3C,D CDC2,ZSWIM5,XRCC 2,CRABP2,USP21,NK D1,DKK1,TMEM98,EN AH,CD24,RACGAP1,P RKD1,MYCN,RELN,S PP1,NAP1L1,ITGA6,N DN,GFRA3,PTK7,AUR KA,BMP4,GSDME,EH MT2,FGF20,ITM2C,DL X5,SDK1,CDON,ARH GEF28,NRCAM,LAMC 1,ECT2,TGFB2,EFNA4 ,HMGA2,THY1,HEY1, LRP4,ROBO1,CDK1,A RHGEF2,CDC20,LEF1, CDH11,TP53,CDK6
GO:0044815	CC	DNA packaging complex	4.14E-37	2.58E-34	1.81E-33	2.58E-34	41	H4C9,H2AC15,H2AC1 6,H2AC6,H2AC4,H2A C17,H2AC20,H2BC8,H 2BC13,H2BC14,H2BC7 ,H2BC6,H2BC9,H2BC1 0,H3C1,H3C3,H3C6,H3 C11,H3C8,H3C12,H3C 10,H3C2,H4C4,H4C2,H 4C5,H4C13,H4C14,MA CROH2A2,H2AC12,H2 AC21,NCAPG,NCAPD 2,H3C7,H2AC11,NCAP H,H1-2,H1- 5,H2AC8,H2AZ1,H2BC 5,H2BC3
GO:0098687	CC	chromosomal region	5.59E-20	8.70E-18	6.10E-17	3.48E-17	45	KIF18A,CENPF,HJURP ,SPC25,MCM2,MCM3, MCM4,MCM5,MCM6, MCM7,CHEK1,SGO1, H4C9,TTK,NDC80,H4 C4,H4C2,H4C5,H4C13, H4C14,MKI67,MACRO H2A2,PLK1,MSH2,SP C24,CENPI,KNTC1,NU F2,CENPK,SPDL1,AU RKA,NCAPG,BUB1,N CAPD2,DYNC1I1,TER C,CCNB1,CBX5,H2BC 3,ALYREF,CDK1,SKA 3,SKA1,MAD2L1,HEL LS
GO:0005819	CC	spindle	1.29E-10	8.95E-09	6.27E-08	8.05E-08	32	NUSAP1,KIF18A,ERC C2,CENPF,SGO1,TTK, TUBG1,ASPM,PLK1,D CDC2,TPX2,RACGAP1 ,KNTC1,DLGAP5,SPD L1,AURKA,DYNC1I1, KIF11,KIFC1,PRC1,EC T2,CCNB1,KIF20A,CK AP2L,CDK1,CKAP2,A

GO:0062023	CC	collagen-containing extracellular matrix	2.79E-09	1.16E-07	8.13E-07	1.74E-06	35	RHGEF2,SKA3,CDC6, CDC20,SKA1,MAD2L1 CTSC,MATN3,MDK,C OLEC12,MFAP2,MFG E8,FBLN1,SERPINE2, PKM,SPARCL1,MMP2 ,COL1A1,COL1A2.CO L2A1,COL4A1,SEMA3 C,FRAS1,COL15A1,F MOD,VCAN,RELN,IT GA6,SMOC2,FREM1,F REM2,GPC3,CCN3,CD ON,NPNT,LAMC1,EDI L3,TGFB2,LTBP2,BCA M,CDH13
GO:0015630	CC	microtubule cytoskeleton	3.88E-05	8.07E-04	5.66E-03	2.42E-02	56	NUSAP1,KIF18A,ERC C2,CENPF,CTSC,MCM 2,MCM3,CHEK1,PFK M,SGO1,TTK,TUBG1, AXIN2,NDC80,ASPM, PLK1,DCDC2,DTL,STI L,XRCC2,SLC1A4,TTL L4,DNAH17,TPX2,RA CGAP1,PLK4,KNTC1, PCLAF,DLGAP5,NDN, STOX1,DNAH14,SPDL 1,AURKA,MAP7D2,D YNC111,KIF11,KIFC1, PRC1,FIGN,ECT2,CCN B1,KIF20A,CCDC88C, CCNB2,CKAP2L,CDK 1,CKAP2,ARHGEF2,S KA3,CDC6,CDC20,SK A1,TOP2A,MAD2L1,C DK6
GO:0000790	CC	nuclear chromatin	4.61E-03	4.87E-02	3.42E-01	1.00E+00	63	PTTG1,FOXQ1,ETV1, ETV4,BCL11A,H4C9,H 2AC15,H2AC16,H2AC 6,H2AC4,H2AC17,ZNF 610,H2AC20,SALL2,H 3C1,H3C3,H3C6,H3C1 1,H3C8,H3C12,H3C10, H3C2,H4C4,H4C2,H4C 5,H4C13,H4C14,PLAG 1,PLAGL2,MACROH2 A2,H2AC12,FOXMI,T BX4,H2AC21,ZNF711, RAD51AP1,ASF1B,TE T1,UHRF1,PLK4,MYB L2,MYCN,PCGF2,ND N,ZNF362,EHMT2,TO X3,DLX5,H3C7,H2AC 11,E2F5,HMGA2,HEY 1,TRIM28,CBX5,ZNF3 82,H1-2,H1- 5,H2AC8,H2AZ1,LEF1, ZMYM3,TP53
GO:0099081	CC	supramolecular polymer	4.80E-03	4.95E-02	3.47E-01	1.00E+00	52	PCP4,NUSAP1,KIF18A ,CENPF,TRPC1,ACTG 2,PFKM,SLC7A11,TU BG1,MFAP2,FBLN1,A SPM,MME,MMP2,PLK 1,SOAT2,COL1A1,CO L1A2,COL2A1,COL4A 1,DCDC2,MYH7B,SLC 1A4,SLC2A1,IGF2BP1, TTLL4,DNAH17,ENA H,TPX2,CD24,RACGA P1,KNTC1,ITGA6,DN AH14,AURKA,ODAM, KCNJ10,GNA12,DYNC 111,KIF11,KIFC1,NPN T,DPEP1,KRT19,PRC1, FIGN,KIF20A,CDK1,C KAP2,ARHGEF2,SKA3

GO:0005887	CC	integral component of plasma membrane	3.45E-02	2.09E-01	1.00E+00	1.00E+00	52	,SKA1 EPHB2,TSPAN18,TMC7,APCDD1,PDGFRB,ASIC1,TRPC1,TNFSF4,MEP1A,NRXN3,ZNRF3,HS6ST1,FADS2,MME,SEMA3C,HTR1D,DPPI0,HTR4,FLVCR1,IGDCC3,LGR5,SLC1A4,SLC1A5,SLC2A1,SLC6A11,SLC02A1,ATP1A2,SLC22A11,ITGA6,ITGA2,PLPPR1,RNF43,SLC16A12,PTK7,GJA5,GPC3,KCNJ5,KCNJ10,STRA6,CDON,NPNT,NRCAM,RHBG,MPZL1,SLC39A10,SLC7A6,OLR1,TSPAN5,THY1,CD34,ROBO1,BCAM
GO:0099513	CC	polymeric cytoskeletal fiber	5.72E-02	2.72E-01	1.00E+00	1.00E+00	40	PCP4,NUSAP1,KIF18A,CENPF,ACTG2,PFKM,SLC7A11,TUBG1,ASPM,MME,PLK1,SOAT2,DCDC2,SLC1A4,IGF2BP1,TTLL4,DNAH17,ENAH,TPX2,CD24,RACGAP1,KNTC1,ITGA6,DNAH14,AURKA,KCNJ10,GNA12,DYNC111,KIF11,KIFC1,DPEP1,KRT19,PRC1,FIGN,KIF20A,CDK1,CKAP2,ARHGEF2,SKA3,SKA1
GO:1902494	CC	catalytic complex	2.23E-01	5.44E-01	1.00E+00	1.00E+00	41	HDAC11,ERCC2,MCM3,PFKM,RRM2,PIK3R2,PKM,SUPT3H,DCDC2,WFS1,ZSWIM5,POLE2,DTL,SKP2,NKD1,PRI M1,DNAH17,PRKAA2,LSM2,SNRNP,PCGF2,DNAH14,GPD1L,GNA12,GNG4,DYNC111,P4HA2,PIGU,TERC,PAPSS1,CCNA2,CCNB1,CCND2,CBX5,CCNB2,ALYREF,CDK1,CDC20,TP53,CDK4,CDK6
GO:0008301	MF	DNA binding, bending	8.46E-27	8.98E-24	6.78E-23	8.98E-24	44	NUSAP1,HJURP,MCM2,H4C9,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,H4C13,H4C14,MACROH2A2,ASF1B,CENPI,NAP1L1,CENPK,NCAPG,NCAPD2,H3C7,NCAPH,CCNB1,HMGA2,H1-2,H1-5,H2BC5,H2BC3,CDK1,LEF1,TOP2A,TP53,HELLS
GO:0046983	MF	protein dimerization activity	5.56E-09	1.48E-06	1.11E-05	5.90E-06	74	CENPF,BCL11A,PFKM,RRM2,H4C9,TTK,TYMS,H2AC15,H2AC16,H2AC6,H2AC4,H2AC17,H2AC20,H2BC8,H2BC13,H2BC14,H2BC7,H2BC6,H2BC9,H2BC10,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,H4C4,H4C2,H4C5,PIK3R2,H4C13,H4C

								14,MACROH2A2,MME,XCL1,H2AC12,SUPT3H,UXS1,OLFML2B,TP53I3,H2AC21,MSH2,HIF1AN,MYCN,PLVAP,ITGA2,PSPH,GPD1L,AURKA,BMP4,TOX3,CDON,H3C7,H2AC11,E2F5,PAPSS1,ECT2,GSTA4,TGFB2,OXCT1,HEY1,CBX5,H2AC8,LRP4,H2AZ1,H2BC5,H2BC3,TOP2A,CDH11,CDH13,TP53,MAD2L1
GO:0032559	MF	adenyribonucleotide binding	1.89E-05	1.18E-03	8.89E-03	2.00E-02	63	EPHB2,KIF18A,ERCC2,PDGFRB,ACLY,ACTG2,MCM2,MCM3,MCM4,MCM5,MCM6,MCM7,CHEK1,HUNK,PFKM,TTK,CKB,ACSL4,MKI67,PKM,PLK1,MAP4K4,SOAT2,TRIB2,MYH7B,MSH2,XRCC2,ZAP70,UBE2T,TTLL4,DNAH17,PRKAA2,AACS,PRKD1,ATP1A2,MAPK13,PLK4,PBK,MELK,DNAH14,PTK7,AURKA,KCNJ10,BUB1,ALDH18A1,ITM2C,MPPE2,KIF11,KIFC1,CAD,FIGN,PAPSS1,ATP8B2,KIF20A,EIF4A2,DGKK,CDK1,CDC6,TOP2A,TP53,CDK4,CDK6,HELLS
GO:0008144	MF	drug binding	1.06E-04	4.68E-03	3.53E-02	1.12E-01	67	EPHB2,KIF18A,ERCC2,PDGFRB,ACLY,ACTG2,MCM2,MCM3,MCM4,MCM5,MCM6,MCM7,CHEK1,HUNK,PFKM,TTK,CKB,TYMS,ACSL4,MKI67,PKM,PLK1,MAP4K4,FKBP10,TRIB2,MYH7B,MSH2,XRCC2,HIF1AN,ZAP70,UBE2T,TTLL4,DNAH17,PRKAA2,AACS,PRKD1,ATP1A2,MAPK13,PLK4,PBK,MELK,DNAH14,PTK7,AURKA,LYPD1,KCNJ10,BUB1,ALDH18A1,ITM2C,MPPE2,KIF11,KIFC1,CAD,FIGN,PAPSS1,ATP8B2,KIF20A,GSTP1,EIF4A2,DGKK,CDK1,CDK6,TOP2A,TP53,CDK4,CDK6,HELLS
GO:0044877	MF	protein-containing complex binding	1.25E-04	5.32E-03	4.01E-02	1.33E-01	54	EPHB2,PTTG1,AMER1,CENPF,TTK,COLEC12,MFAP2,MFGE8,FBLN1,SALL2,H3C1,H3C3,H3C6,H3C11,H3C8,H3C12,H3C10,H3C2,PKM,SPARCL1,PLCG1,PLK1,WFS1,MYH7B,FERMT1,MSH2,UHRF1,SNRPB,SPP1,ITGA6,NUF2,ITGA2,SPDL1,GNA12,CCN3,NPNT,H3C7,KRT19,TERC,EDIL3,OLR1,GSN,CCNB1,HMG A2,THY1,CBX5,H1-2,H1-

GO:0032555	MF	purine ribonucleotide binding	3.43E-04	1.14E-02	8.58E-02	3.64E-01	69	5,H2AZ1,CDC20,EPCAM,CDH13,TP53,CDK4,EPHB2,KIF18A,ERCC2,PDGFRB,ACLY,ACTG2,MCM2,MCM3,MC4,MCM5,MCM6,MC7,CHEK1,HUNK,PFKM,TTK,TUBG1,CKB,ACSL4,MKI67,PKM,PLK1,MAP4K4,SOAT2,TRIB2,MYH7B,MSH2,XRCC2,ZAP70,UBE2T,TTLL4,DNAH17,PRKA2,AACS,RASL11B,PRKD1,ATP1A2,MAPK13,PLK4,PBK,MELK,DNAH14,PTK7,AURKA,RHOB1,KCNJ10,BUB1,ALDH18A1,GNA12,ITM2C,MPPED2,KIF11,KIFC1,CAD,FIGN,PAPSS1,ATP8B2,KIF20A,TGFB2,RAB34,EIF4A2,DGKK,CDK1,CDC6,TOP2A,TP53,CDK4,CDK6,HELLS
GO:0016772	MF	transferase activity, transferring phosphorus-containing groups	1.49E-03	3.44E-02	2.60E-01	1.00E+00	64	EPHB2,PCP4,CDKN3,ERCC2,PDGFRB,CHEK1,HUNK,PFKM,TTK,AXIN2,CKB,PIK3R2,PKM,PLK1,MAP4K4,TRIB2,MAGED1,POLE2,STIL,ZAP70,DKK1,PRIM1,PRKAA2,TPX2,CD24,PRKD1,MAPK13,PLK4,RELN,PBK,STOX1,MELK,PTK7,AURKA,BMP4,BUB1,ALDH18A1,CAD,DUSP9,TDGF1,RFC3,TERC,PAPSS1,ECT2,CCNA2,CCNB1,CCND2,TGFB2,GSTP1,EFNA4,HMGA2,THY1,TRIM28,CCNB2,EIF4A2,DGKK,ROBO1,CDK1,CDC6,CDC25C,TOX2,TP53,CDK4,CDK6
GO:0042802	MF	identical protein binding	3.30E-03	6.27E-02	4.73E-01	1.00E+00	66	EPHB2,APCDD1,CENPF,CTSC,HJURP,MCM6,PFKM,RRM2,TTK,TUBG1,TYMS,FBLN1,H2BC8,H2BC7,H2BC6,H2BC10,NDC80,PKM,ME,PLK1,XCL1,COL1A1,COL1A2,COL2A1,UXS1,MAGED1,OLFM1,L2B,TP53,MSH2,STIL,SKP2,HIF1AN,SLC2A1,UHRF1,PRKD1,PLK4,PLVAP,PSPH,GPD1L,BMP4,KCNJ10,TOX3,NQO1,PYCR1,ALDH18A1,SDK1,CAD,PRC1,PAPSS1,ST8SIA3,ECT2,OLR1,GSTA4,TGFB2,OXCT1,HEY1,CBX5,LRP4,ROBO1,REG3A,LYZ,TOP2A,CDH11,CDH13,TP53,MAD2L1
GO:0003690	MF	double-stranded DNA binding	1.03E-02	1.35E-01	1.00E+00	1.00E+00	37	FOXQ1,ETV1,ETV4,MCM2,MCM3,MCM4,MCM5,MCM6,MCM7,BCL11A,MND1,SALL2,PLAG1,MACROH2A2,

GO:0017111	MF	nucleoside-triphosphatase activity	4.56E-02	2.64E-01	1.00E+00	1.00E+00	44	FOXM1,TBX4,MSH2,ZNF711,RAD51,API1,UHRF1,MYBL2,MYCN,NDN,STOX1,EHMT2,TOX3,DLX5,ZNF704,HMG2,HEY1,H1-2,H1-5,H2AZ1,NEIL3,CDC6,LEF1,TP53,KIF18A,ERCC2,MCM2,MCM3,MCM4,MCM5,MCM6,MCM7,TUBG1,XCL1,MAP4K4,MYH7B,DEPDC1,MSH2,XRCC2,DNAH17,RACGAP1,UHRF1,GINS2,RASL11B,ATP1A2,DEPDC1B,ITGA6,ARHGAP11A,GINS1,DNAH14,RHOBTB1,ODAM,GNA12,GNG4,DYNC1H1,KIF11,KIFC1,RFC3,FIGN,NCAPH,ECT2,KIF20A,RAB34,THY1,EIF4A2,TP2A,TP53,HELLS
Biological Process(BP), Cellular Component(CC) and Molecular Functions (MF)								

Table 6 The enriched GO terms of the down regulated differentially expressed genes

GO ID	CATEGORY	GO Name	P Value	FDR B&H	FDR B&Y	Bonferroni	Gene Count	Gene
GO:0006082	BP	organic acid metabolic process	6.40E-63	3.69E-59	3.40E-58	3.69E-59	145	EPHX2,RIDA,GLYAT,HGD,HGF,CDO1,ABAT,ACACB,ACADL,ACADM,ACADSB,ACAT1,CES1,MAT1A,ACOX1,VNN3,ETFDH,ALDH8A1,PIPOX,MGLL,AKR1C4,PFB1,HAO1,CYP39A1,ADH1B,ADH1C,NDS,T3,ACSL1,GLYATL1,PHYH,ACSM3,FBP1,ST3GAL6,HPD,LIPG,HPGD,AGXT,UGP2,UGT2B4,UGT2B7,SCP2,PRKAG2,ALDOB,DHTKD1,ALDH6A1,DMGDH,STAB2,IYD,PON1,PON3,SHMT1,CYP4F2,APOC3,KMO,ARG1,AGXT2,SLC7A2,IGF1,ART4,ASS1,LPIN2,ABCB11,OGDHL,CYP4F22,CTH,CYP4F11,MMUT,CYP1A1,CYP1A2,CYP2B6,CYP2C19,UPB1,CYP2C8,CYP2C9,CYP2C18,CYP2D7,GLS2,CYP2D6,SLC17A3,AVPR1A,CYP3A4,CYP3A5,CYP4A11,CYP8B1,INSIG1,CYP26A1,BAA1,AKR1D1,GATM,DAO,CHST9,GCH1,GCKR,UROC1,GNMT,SUCLG2,DCN,PTGS2,ITIH4,BHMT,GHR,PPARGC1A,LYVE1,SULT1A2,ADHFE1,SUL

GO:0044282	BP	small molecule catabolic process	1.86E-38	1.53E-35	1.41E-34	1.07E-34	72	T1B1,SULT2A1,GCLM,VNN2,VNN1,PTS,ANGPTL3,ACSM5,KYNU,SDS,TAT,GOT1,SLC27A5,SLC27A2,GPD1,CYP4V2,DPYS,GNE,APOA5,ASPG,ABHD2,GPT,AMDHD1,TDO2,PAPSS2,CYP4A22,GSTA1,OTC,BCO2,EHHADH,AASS,TLR4,HAAO,CYP4F3,HAL,ACMSD,AADAT,HAO2,PCK1,PCK2,RIDA,HGD,CDO1,ABAT,ACACB,ACADL,ACADM,ACADSB,ACAT1,MAT1A,ACOX1,ETFDH,ALDH8A1,PIPOX,HAO1,CYP39A1,ADH4,PHYH,HPD,AGXT,SCP2,ALDH1A1,ALDOB,ALDH6A1,STAB2,PON1,PON3,SHMT1,CYP4F2,KMO,ARG1,AGXT2,LPIN2,CTH,CYP4F11,MUT,CYP1A1,UPB1,GLS2,CYP4A11,INPP1,CYP26A1,AKR1D1,DAO,UROCI,LYVE1,SULT1A2,ADHFE1,SULT1B1,SULT2A1,KYNU,SDS,TAT,GOT1,SLC27A2,DPYS,ABHD2,GPT,AMDHD1,TDO2,OTC,EHHADH,AASS,HAAO,CDA,CYP4F3,HAL,ACMSD,AADAT,HAO2,PCK1,PCK2
GO:0006629	BP	lipid metabolic process	5.85E-35	3.74E-32	3.45E-31	3.37E-31	120	EPHX2,LRAT,SERPINA3,AADAC,SGMS2,ACACB,ACADL,ACADM,ACADSB,ACAT1,CES1,CETP,ESR1,ACOX1,ETFDH,ALDH8A1,MGLL,AKR1C4,HMGCS2,HAO1,CYP39A1,ABCB4,ADH1B,ADH1C,ADH4,ACSL1,PHYH,ACSM3,ST3GAL6,CLU,PIK3C2G,LIPG,HPGD,HSD17B13,UGT2B7,UGT2B10,SCP2,PLA2G2A,LAS1,ALDH1A1,HSD11B1,PRKAG2,CCL21,SDC4,MOGAT2,CYP3A43,G0S2,AGPAT2,APOF,PON1,PON3,CYP4F2,ETNPPL,APOC3,APOLI,GBA3,IGF1,RDH16,HSD17B6,LPIN2,ABCB11,IL1RN,CYP4F11,MMUT,CYP1A1,CYP1A2,CYP2B6,CYP2C19,CYP2C8,CYP2C9,CYP2C18,CYP2D7,CYP2D6,MBOAT1,AVPR1A,CYP3A4,CYP3A5,CYP4A11,INPP1,CYP8B1,INSIG1,CYP26A1,BAAT,SRD5A1,SRD5A2,AKR1

								D1,PTGS2,SOC2,PP ARGC1A,SULT1A2,S ULT1B1,SULT2A1,A NGPTL3,ACSM5,SLC 27A5,SLC27A2,GPD1 ,CYP4V2,GPLD1,AP OA5,ASPG,ABHD2,S OCS3,GPAT3,AKR1C 8P,MAP7,CYP4A22,G STA1,MFSD2A,THRS P,BCO2,EGR1,EHHA DH,LPA,CES3,CYP4F 3,HAO2,PCK1,PCK2, SEC14L2
GO:0055114	BP	oxidation- reduction process	5.06E-34	2.91E-31	2.69E-30	2.91E-30	108	HGD,CDO1,ACACB, ACADL,ACADM,AC ADSB,ACAT1,ESR1, ACOX1,LRRK2,ETF DH,ALDH8A1,PIPOX ,AKR1C4,PFKFB1,H AO1,CYP39A1,F8,AD H1B,ADH1C,ADH4,P HYH,FBP1,HP,HPD,H PGD,AGL,HSD17B13 ,UGP2,SCP2,CYP4X1, ALDH1A1,HSD11B1, PRKAG2,ALDOB,DH TKD1,BBOX1,ALDH 6A1,ASPDH,DMGDH ,STAB2,FMO3,FMO4, CYP4Z1,CYP3A43,A OX1,IYD,XDH,CP,C YP4F2,KMO,PPP1R1 A,IGF1,RDH16,AKR7 L,HSD17B6,OGDHL, CYP4F22,CYP4F11,S OD2,CYP1A1,CYP1A 2,CYP2B6,CYP2C19, CYP2C8,CYP2C9,CY P2C18,CYP2D7,CYP2 D6,CYP3A4,CYP3A5, CYP4A11,CYP8B1,C YP26A1,SRD5A1,SR D5A2,AKR1D1,DAO, GCH1,GCKR,GNMT, SUCLG2,PTGS2,PPA RGC1A,ADHFE1,GL RX,DHODH,DIO1,SL C27A2,GPD1,CYP4V 2,SLC25A18,PPP1R3 B,STEAP4,AKR1C8P, TDO2,CYP4A22,GST A1,BCO2,EHHADH, AASS,GYS2,STEAP3, HAAO,CYP4F3,NNT, HAO2,PCK2
GO:0006952	BP	defense response	1.80E-18	3.04E-16	2.81E-15	1.03E-14	106	CFH,EPHX2,HGF,CD O1,SERPINA3,ESR1, MBL2,LRRK2,BLNK, CLEC1B,MGLL,CFP, C1RL,PGLYRP2,CLE C4M,LEAP2,F8,CD16 3,PLAC8,MAP3K5,S1 00A8,SAA1,SAA2,FC GR2B,CLU,HP,FCN2, HPR,HPX,SCN9A,FG B,PLA2G2A,HRG,CC L16,FGG,CCL21,MR C1,STAB2,FOS,ICAM 1,APCS,BIRC3,COLE C10,APOL1,CFI,FCN 3,CRHBP,ZFP36,CRP, ARG1,SLC7A2,IGF1, ASS1,SLPI,SERPINC 1,HAMP,IL1RN,CTSL

									CYP4F11,MARCO,C XCL8,MASP2,MASP1 ,GBP7,GBP2,IRF6,GC H1,CFHR5,PTGS2,ITI H4,CFB,RNF125,VN N1,C1R,C1S,C4BPA, C4BPB,C5,C6,CREB3 L3,C7,C8A,C8B,C8G, C9,KLKB1,KYNU,D NASE1L3,RAB27A,K NG1,SOC3,NFKBIZ, ABCC9,LBP,ECM1,C XCL2,EDNRB,TFR2, ORM1,NAMPT,CD5L ,CD14,EGR1,TLR4,SE RPINE1,HERC5
GO:0010038	BP	response to metal ion	1.38E-16	1.85E-14	1.71E-13	7.95E-13	43	CPNE8,ABAT,LRRK2 ,S100A8,FBP1,FGB,H RG,FGG,ALDOB,FOS ,FOSB,ICAM1,XDH,C P,AQP3,CRHBP,CRP, ARG1,SLC6A1,MT1E ,MT1F,MT1G,MT1H, MT1M,MT1X,ASS1,H AMP,CYP1A1,CYP1 A2,GATM,PTGS2,PP ARGC1A,JUNB,MT1 DP,TAT,GOT1,CA2,G PLD1,DUSP1,TFR2,O TC,CD14,HAAO	
GO:0033993	BP	response to lipid	1.57E-16	2.05E-14	1.89E-13	9.02E-13	70	RIDA,LRAT,CDO1,E SR1,PFKFB1,ABCB4, ACSL1,S100A8,CLU, HPGD,AGL,AGXT,N R3C2,FGFR2,CCL21, ALPL,MRC1,FOS,FO SB,ICAM1,PON1,AQ P3,AR,CRHBP,ZFP36, KMO,AKAP12,ARG1, SLC6A1,IGF1,ASS1,S LPI,HAMP,IL1RN,GR AMD1C,CXCL8,CYP 1A1,CYP1A2,AVPR1 A,INSIG1,CYP26A1,S RD5A1,BCHE,GCH1, DCN,PTGS2,GHR,SO CS2,PPARGC1A,JUN B,SULT1A2,GLRX,T AT,NR1I3,GOT1,CA2 ,GPLD1,ABHD2,DUS P1,NR4A2,LBP,MAP7 ,CXCL2,EDNRB,CD1 4,TLR4,SERPINE1,T RIB1,PCK1,PCK2	
GO:0051707	BP	response to other organism	5.27E-16	6.74E-14	6.22E-13	3.03E-12	92	CFH,LRAT,ESR1,MB L2,CFP,C1RL,PGLYR P2,CLEC4M,LEAP2,L RG1,PLAC8,MAP3K5 ,S100A8,SAA1,FCGR 2B,CLU,HP,FCN2,HP GD,HPX,FGB,PLA2G 2A,HRG,FGFR2,CCL 16,FGG,CCL21,ALPL, MRC1,STAB2,FOS,IC AM1,APCS,BIRC3,C OLEC10,APOL1,CFI, FCN3,ZFP36,KMO,A KAP12,CRP,ARG1,A SS1,SLPI,HAMP,IL1R N,CTSL,MARCO,CX CL8,MASP2,CYP1A1, CYP1A2,MASP1,GBP 7,GBP2,IRF6,GCH1,C FHR5,DCN,PTGS2,C FB,PPARGC1A,JUNB	

									,RNF125,VNN1,C1R, C1S,C4BPA,C4BPB,C 5,C6,C7,C8A,C8B,C8 G,C9,KYNU,RAB27A ,SOCS3,ABCC9,LBP, CXCL2,EDNRB,THR SP,CD14,EGR1,TLR4, SERPINE1,TRIB1,PC K1,HERC5
GO:0019637	BP	organophosphate metabolic process	5.20E-13	4.05E-11	3.74E-10	2.99E-09	71	GLYAT,LRAT,SGMS 2,ACACB,ACADSB, ACAT1,CETP,LRRK2 ,PIPOX,HMGCS2,PF KFB1,ACSL1,ACSM3 ,FBP1,PIK3C2G,LIPG ,UGP2,SCP2,PLA2G2 A,ALDH1A1,HSD11B 1,PRKAG2,CCL21,AL DOB,DHTKD1,ASPD H,AGPAT2,PON1,SH MT1,XDH,ETNPPL,A POC3,KMO,GDA,IGF 1,LPIN2,OGDHL,MB OAT1,INPP1,BAAT,G CH1,GCKR,SUCLG2, PTGS2,SOCS2,PPAR GC1A,SULT1A2,SUL T1B1,SULT2A1,DHO DH,ANGPTL3,ACSM 5,NNMT,KYNU,GPD 1,GPLD1,APOA5,ASP G,SOCS3,GPAT3,TD O2,PAPSS2,MFSD2A, NAMPT,EHHADH,A ASS,HAAO,CDA,AC MSD,AADAT,PCK1 CFH,CFHR1,CFHR2, ESR1,MBL2,LRRK2, CFP,C1RL,PGLYRP2, S100A8,FCGR2B,CL U,FCN2,HPX,FGB,H RG,FGG,CCL21,FYB 2,FOS,ICAM1,APCS, BIRC3,CXCL14,COL EC10,CFL,FCN3,AQP 3,CRP,ARG1,IGF1,H AMP,CTSL,MARCO, CXCL8,MASP2,IL13 RA2,MASP1,TNFSF1 4,CFHR5,CFB,CFHR4 ,RNF125,VNN1,C1R, C1S,C4BPA,C4BPB,C 5,C6,C7,C8A,C8B,C8 G,C9,RAB27A,CA2,G PLD1,NFKBIZ,LBP,C D5L,CD14,TLR4,SER PINE1,TRIB1	
GO:0002684	BP	positive regulation of immune system process	2.08E-09	9.96E-08	9.20E-07	1.20E-05	65	ABAT,ACACB,CETP, CLTRN,ANO5,AKR1 C4,ABCA10,ABCA9, ABCA8,ABCB4,ACS L1,SLC41A2,ADRA1 A,AGXT,HPX,SCN9A ,SCP2,PLA2G2A,HR G,FGF14,PRKAG2,C CL21,SLC51A,FXYD 1,ICAM1,CP,MYO1B, CYP4F2,APOC3,APO L1,SLCO1B1,SLC1A1 ,CRHBP,KMO,ARG1, SLC6A1,SLC7A2,IGF 1,SLC10A1,SLC15A1, SLC22A1,ABCB11,H AMP,SLC4A4,IL1RN, ABCC3,SLC22A25,G	
GO:0006811	BP	ion transport	6.45E-08	2.26E-06	2.09E-05	3.71E-04	83		

GO:0072562	CC	blood microparticle	2.90E-22	1.37E-19	9.22E-19	1.37E-19	32	LS2,SLC17A3,AVPR1 A,CYP4A11,SLCO1B 3,PTGS2,SLC22A7,PP ARGC1A,PTPN3,KC ND3,GLRX,SLC22A1 0,GNAO1,SLC27A5,C A2,SLC27A2,GPLD1, SLC25A18,APOA5,SL C38A4,SLC17A4,AN O1,STEAP4,ABCC9,R GS2,TFR2,SLCO1B7, USP2,MFSD2A,THRS P,ABCA6,SLC25A15, SERPINE1,STEAP3,S LC25A47,NNT CFH,CFHR1,SERPIN A3,CLU,HP,FCN2,AF M,HPR,HPX,FGB,HR G,FGG,PON1,APCS,C P,APO1,FCN3,SERP INC1,BCHE,ITIH4,CF B,CFHR3,C1R,C1S,C 4BPA,C8A,C8G,C9,P ZP,KNG1,ORM1,CD5 L
GO:0005789	CC	endoplasmic reticulum membrane	1.86E-11	2.19E-09	1.48E-08	8.76E-09	63	LRAT,AADAC,SGMS 2,MGLL,ANO5,CYP3 9A1,MAP3K5,ACSL1, SMIM14,HPD,RETRE G1,UGT2B4,UGT2B7, UGT2B10,CYP4X1,P LA2G2A,NR3C2,HSD 11B1,SLC51A,ALDO B,FMO3,FMO4,CYP4 Z1,MOGAT2,CYP3A4 3,AGPAT2,CYP4F2,R DH16,LPIN2,CYP4F2 2,GRAMD1C,CYP4F1 1,CYP1A1,CYP1A2,C YP2B6,CYP2C19,CY P2C8,CYP2C9,CYP2C 18,CYP2D6,MBOAT1 ,SLC17A3,CYP3A4,C YP3A5,CYP4A11,CY P8B1,INSIG1,CYP26 A1,SRD5A1,SRD5A2, PTGS2,RNF125,REEP 6,DIO1,CREB3L3,SL C27A5,SLC27A2,CYP 4V2,GPAT3,NAT8,C YP4A22,MFSD2A,CY P4F3
GO:0031012	CC	extracellular matrix	5.17E-07	1.52E-05	1.03E-04	2.44E-04	35	SERPINA3,MBL2,CF P,F9,S100A8,SERPIN B8,CLU,HPX,FGB,H RG,FGFR2,FGG,ALP L,ADAMTS1,ICAM1, APCS,APOC3,TSKU, MMRN1,IGF1,SLPI,S ERPINC1,CTSL,AZG P1,DCN,ITIH4,BMPE R,PZP,KNG1,GPLD1, INHBE,ECM1,ORM1, NTN4,SERPINE1
GO:0005739	CC	mitochondrion	7.05E-07	1.85E-05	1.25E-04	3.33E-04	76	RIDA,GLYAT,ABAT, ACACB,ACADL,AC ADM,ACADSB,ACA T1,ESR1,ACOX1,LR RK2,ETFDH,HMGCS 2,ABCA9,ACSL1,GL YATL1,PHYH,ACSM 3,CLU,AGXT,SCP2,A LAS1,DHTKD1,BBO X1,ALDH6A1,DMGD H,G0S2,SHMT1,ETN

GO:0031226	CC	intrinsic component of plasma membrane	1.69E-04	3.20E-03	2.15E-02	8.00E-02	65	PPL,KMO,ARG1,AGXT2,ASS1,OGDHL,MUT,SOD2,CYP1A1,CYP2D7,GLS2,CYP2D6,GATM,DAO,GCKR,SUCLG2,DCN,GHR,PPARGC1A,ADHFE1,GCLM,PTS,GLRX,DHODH,ACSM5,KYNU,SDS,TAT,GOT1,SLC27A2,GPD1,SLC25A18,ABCC9,RGS2,ECHDC3,OTC,BCO2,EHHADH,AASS,SLC25A15,ANXA10,HAAO,SLC25A47,AADAT,NNT,HAO2,PCK1,PCK2NRG1,SGMS2,CLEC1B,CLEC4M,CD163,ABCB4,ADRA1A,PIGR,FCGR2B,SCN9A,FGFR2,FXYP1,SDC4,HJV,MRC1,VIPR1,STAB2,ICAM1,IYD,CP,SLITRK3,SLCO1B1,AQP3,SLC1A1,SLC6A1,SLC7A2,SLC10A1,SLC15A1,SLC22A1,ABCB11,SLC4A4,MARCO,ABCC3,SLC17A3,AVPR1A,SLCO1B3,SLC22A7,GHR,LYVE1,PTPRB,KCND3,C5,C6,C7,C8A,C8B,C8G,C9,NPY1R,SLC38A4,SLC17A4,ANO1,ABCC9,EDNRB,TFR2,SLCO1B7,ADGRG7,LIFR,MFSD2A,HHIP,CD14,TLR4,TENM1,TMPRSS2,ENPEP
GO:0099503	CC	secretory vesicle	6.07E-03	7.52E-02	5.06E-01	1.00E+00	38	HGF,SERPINA3,LRRK2,CFP,LRG1,F8,PLAC8,S100A8,PIGR,CLU,HP,AGL,FGB,PLA2G2A,HRG,FGG,AGPAT2,CDC37L1,CRHBP,ARG1,MMRN1,IGF1,SLPI,SPTBN2,ITIH4,PTPRB,VNN1,RAB27A,KNG1,SLC27A2,NPY1R,ABHD2,ABCC9,ECM1,ORM1,CD14,SERPINE1,CDA
GO:0009986	CC	cell surface	2.52E-02	1.69E-01	1.00E+00	1.00E+00	34	NRG1,MBL2,CD163,MAP3K5,FCGR2B,CLU,LIPG,FGB,HRG,FGFR2,FGG,SDC4,HJV,MRC1,STAB2,ICAM1,CPM,SLC6A1,IL13RA2,AZGP1,GFRA1,GHR,BMP10,ANGPTL3,ADGRA3,ANO1,LBP,TFR2,LIFR,HHIP,CD5L,CD14,TLR4,ENPEP
GO:0031967	CC	organelle envelope	3.43E-01	8.47E-01	1.00E+00	1.00E+00	32	ACACB,ACADL,ACADM,ACAT1,LRRK2,ETFDH,HMGCS2,ACSL1,ADRA1A,CLU,PIK3C2G,SCP2,HSD11B1,KMO,ARG1,OIT3,ASS1,SOD2,CYP1A1,GATM,DAO,BCHE,GCH1,GLRX,DHODH,

GO:0098805	CC	whole membrane	3.70E-01	8.73E-01	1.00E+00	1.00E+00	43	SLC25A18,EDNRB,OTC,SLC25A15,HAAO,SLC25A47,NNT,ACACB,ACOX1,LRRK2,CD163,ABCB4,ACSL1,ADRA1A,PIGR,SCP2,HRG,FXSD1,SDC4,FYB2,MRC1,STAB2,RNF152,ICAM1,AGPAT2,BIRC3,CP,MYO1B,SLC1A1,KMO,ARG1,HSD17B6,ASS1,MARCO,ABCC3,DAO,PTGS2,PTPRB,KCND3,REEP6,VNN1,RAB27A,SLC27A2,GPLD1,STEAP4,EDNRB,CD14,TLR4,STEAP3,ENPEP
GO:0005794	CC	Golgi apparatus	7.16E-01	1.00E+00	1.00E+00	1.00E+00	35	SGMS2,ESR1,LRRK2,F8,F9,NDST3,ST3GAL6,CLU,PIK3C2G,HP,HPD,LIPG,RETREG1,FGFR2,SDC4,CXCL14,MYO1B,COLEC10,CRHBP,RND3,ABCB11,INSIG1,SPTBN2,GBP2,CHST9,DCN,RNF125,FGD4,ANGPTL3,CREB3L3,RAB27A,STEAP4,CD14,TENM1,MACF1
GO:0043005	CC	neuron projection	8.03E-01	1.00E+00	1.00E+00	1.00E+00	33	NRG1,ABAT,ACADM,ESR1,LRRK2,MGLL,FCGR2B,CLU,SCN9A,FOS,AR,CRHBP,CRP,ARG1,SLC6A1,ASS1,SRD5A1,SRD5A2,GCH1,PTGS2,GFRA1,PPARGC1A,KCND3,REEP6,GLRX,GNAO1,RAB27A,GOT1,CA2,NPY1R,MAP7,RGS2,TENM1
GO:0048037	MF	cofactor binding	8.00E-36	1.05E-32	8.15E-32	1.05E-32	76	ABAT,ACACB,ACADL,ACADM,ACADS,ACAT1,ACOX1,ETFDH,HAO1,CYP39A1,ADH4,PHYH,HPGD,AGXT,HPX,SCP2,CYP4X1,HRG,ALAS1,ALDH1A1,HSD11B1,DHDKD1,ALDH6A1,ASPDH,DMGDH,FMO3,FMO4,CYP4Z1,CYP3A43,AOX1,IYD,SHMT1,XDH,CYP4F2,ETNPPL,KMO,AGXT2,OGDHL,CYP4F22,CTH,CYP4F11,MMUT,CYP1A1,CYP1A2,CYP2B6,CYP2C19,CYP2C8,CYP2C9,CYP2C18,CYP2D7,CYP2D6,CYP3A4,CYP3A5,CYP4A11,CYP8B1,CYP26A1,SRD5A1,DAO,GCH1,GNMT,PTGS2,DHODH,KYNU,SDS,TAT,GOT1,GPD1,CYP4V2,GPT,STEAP4,TD02,CYP4A22,CYP4F3,AADAT,NNT,HAO2,HGD,CD01,ACADL,ACADM,ACADSB,ES
GO:0016491	MF	oxidoreductase activity	2.50E-32	1.64E-29	1.27E-28	3.28E-29	96	

									R1,ACOX1,LRRK2,ETFDH,ALDH8A1,PIPOX,AKR1C4,PFKFB1,HAO1,CYP39A1,F8,ADH1B,ADH1C,ADH4,PHYH,FBP1,HP,HPD,HPGD,HSD17B13,CYP4X1,ALDH1A1,HSD11B1,PRKAG2,ALDOB,DHTKD1,BBOX1,ALDH6A1,ASPDH,DMGDH,STAB2,FMO3,FMO4,CYP4Z1,CYP3A43,AOX1,IYD,XDH,CP,CYP4F2,KMO,IGF1,RDH16,AKR7L,HSD17B6,OGDHL,CYP4F22,CYP4F11,SOD2,CYP1A1,CYP1A2,CYP2B6,CYP2C19,CYP2C8,CYP2C9,CYP2C18,CYP2D7,CYP2D6,CYP3A4,CYP3A5,CYP4A11,CYP8B1,CYP26A1,SRD5A1,SRD5A2,AKR1D1,DAO,GCH1,GCKR,SUCLG2,PTGS2,PPARGC1A,ADHFE1,GLRX,DHODH,DIO1,GPD1,CYP4V2,STEAP4,AKR1C8P,TDO2,CYP4A22,GSTA1,BCO2,EHHADH,AASS,STEAP3,HAAO,CYP4F3,NNT,HAO2
GO:0050662	MF	coenzyme binding	1.40E-23	6.11E-21	4.74E-20	1.83E-20	47	ABAT,ACACB,ACADL,ACADM,ACADSB,ACAT1,ACOX1,ETFDH,HAO1,ADH4,PHYH,HPGD,AGXT,SCP2,ALAS1,ALDH1A1,HSD11B1,DHTKD1,ALDH6A1,ASPDH,DMGDH,FMO3,FMO4,AOX1,IYD,SHMT1,XDH,ETNPPL,KMO,AGXT2,OGDHL,CTH,SRD5A1,DAO,GCH1,GNMT,DHODH,KYNU,SDS,TAT,GOT1,GPD1,GPT,STEAP4,AADAT,NNT,HAO2	
GO:0046914	MF	transition metal ion binding	1.61E-15	2.35E-13	1.82E-12	2.11E-12	75	RIDA,CDO1,ESR1,PGLYRP2,CYP39A1,F8,ADH1B,ADH1C,ADH4,S100A8,PHYH,CYP4X1,HRG,NR3C2,BBOX1,PAPPA2,CYP4Z1,ADAMTS1,CYP3A43,AOX1,SHMT1,XDH,CP,CYP4F2,ZDBF2,CYP4F11,SOD2,CYP1A1,CYP1A2,CYP2B6,CYP2C19,UPB1,CYP2C8,CYP2C9,CYP2C18,CYP2D7,CYP2D6,CYP3A4,CYP3A5,CYP4A11,CYP8B1,CYP26A1,GCH1,BHMT,RNF125,TRIM55,NR1I3,KN	

								G1,CA2,CYP4V2,DP YS,DTX1,NR4A2,CY P4A22,HHIP,EGR1,H AAO,CDA,CYP4F3,A CMSD,ENPEP,PCK1, PCK2
GO:0042802	MF	identical protein binding	5.95E-08	2.00E-06	1.55E-05	7.81E-05	87	EPHX2,CFHR1,RIDA, CFHR2,HGD,HGF,NR G1,ABAT,ACACB,A CADM,ACAT1,MAT1 A,CLTRN,ESR1,ACO X1,LRRK2,MGLL,PF KFB1,F11,MAP3K5,F BP1,HOKK1,HP,HPG D,AGXT,UGP2,SCP2, NR3C2,ALAS1,FGFR 2,FGG,SLC51A,ALD OB,BBOX1,SDC4,AO X1,PON1,APCS,PON 3,SHMT1,XDH,BHLH E40,CRP,RDH16,SLC 22A1,ASS1,SERPINC 1,CTH,SLC4A4,MMU T,SOD2,MASP1,UPB 1,MYOM1,TNFSF14, GBP2,BCHE,GCH1,C FHR5,GNMT,PTGS2, GHR,SULT1A2,GAD D45G,PTS,TRIM55,C 1S,CREB3L3,KYNU, SDS,GPD1,RCAN1,N R4A2,ANO1,ABCC9, TDO2,GREM2,USP2, NAMPT,THRSP,GYS 2,TLR4,TENM1,STE AP3,CDA,AADAT,LR RFIP1
GO:0008289	MF	lipid binding	2.24E-07	6.53E-06	5.06E-05	2.94E-04	45	RIDA,LRAT,CPNE8, CETP,ESR1,ACOX1, MBL2,ADH4,S100A8, PIK3C2G,UGT2B4,U GT2B7,SCP2,PLA2G2 A,NR3C2,HSD11B1,A LDOB,SEC14L4,ARA P2,SHBG,APOF,PON 1,MYO1B,APOC3,AP OL1,AR,CRP,IGF1,G RAMD1C,CYP4F11,C YP3A4,PXDC1,SPTB N2,CYP26A1,AKR1D 1,VNN1,C8G,APOA5, LBP,OTC,CD14,TLR4 ,ANXA10,APOL6,SE C14L2
GO:0016829	MF	lyase activity	2.74E-06	6.42E-05	4.98E-04	3.59E-03	34	PFKFB1,ADRA1A,FB P1,ALDH1A1,ARRD C3,PRKAG2,ALDOB, DHTKD1,SHMT1,ET NPPL,AKAP12,IGF1, OGDHL,CTH,MARC O,CYP1A1,GCKR,UR OC1,PPARGC1A,PTS ,GNAO1,SDS,GOT1,C A2,GPD1,NPY1R,RG S2,EDNRB,ADGRG7, EHHADH,HAL,ACM SD,PCK1,PCK2
GO:0004175	MF	endopeptidase activity	7.51E-06	1.70E-04	1.32E-03	9.87E-03	43	HGF,HGFAC,SERPIN A3,C1RL,F9,F11,MAP 3K5,S100A8,SERPIN B8,HP,HPR,HRG,PAP PA2,PAMR1,ADAMT S1,XDH,BIRC3,CFL,F ETUB,SERPINA11,C3 P1,IGF1,SLPI,SERPIN

								C1,LPAL2,CTSL,MA SP2,MASP1,TNFSF14 ,PTGS2,ITIH4,CFB,C 1R,C1S,C5,PZP,KLK B1,KNG1,USP2,LPA, SERPINE1,TMPRSS2, HABP2
GO:0046983	MF	protein dimerization activity	2.79E-05	5.38E-04	4.18E-03	3.66E-02	64	EPHX2,CFHR1,RIDA, CFHR2,HGF,NRG1,A BAT,ACAT1,MAT1A, CLTRN,ACOX1,LRR K2,MGLL,ANO5,MA P3K5,ADRA1A,HP,H PGD,AGXT,SCP2,NR 3C2,FGFR2,FGG,SLC 51A,FOS,AOX1,PON 1,PON3,SHMT1,XDH, BHLHE40,AR,CRP,R DH16,SLC22A1,MM UT,MASP1,UPB1,MY OM1,DAO,GBP2,GC H1,CFHR5,SUCLG2,P TGS2,GHR,SULT1A2 ,GCLM,PTS,CREB3L 3,KYNU,SDS,GPD1,N R4A2,ANO1,GREM2, NAMPT,THRSP,GYS 2,TLR4,TENM1,CDA, AADAT,LRRFIP1
GO:0008270	MF	zinc ion binding	2.35E-04	3.47E-03	2.69E-02	3.08E-01	38	ESR1,PGLYRP2,ADH 1B,ADH1C,ADH4,S1 00A8,HRG,NR3C2,B BOX1,PAPPA2,ADA MTS1,SHMT1,ZDBF2 ,CPM,AR,MT1E,MT1 F,GDA,MT1G,MT1H, MT1M,MT1X,UPB1, GCH1,BHMT,RNF125 ,TRIM55,NR1I3,KNG 1,CA2,DPYS,DTX1,N R4A2,HHIP,EGR1,CD A,ACMSD,ENPEP

Biological Process(BP), Cellular Component(CC) and Molecular Functions (MF)

Table 7 Topology table for up and down regulated genes

Regulation	Node	Degree	Betweenness	Stress	Closeness	Clustering Coefficient
Up	TP53	528	0.287608	69156720	0.377953	0.001861
Up	TCTN2	209	0.087158	17425224	0.283914	4.60E-05
Up	PLK1	171	0.075638	11941560	0.346513	0.007044
Up	AURKA	141	0.056164	6895708	0.337941	0.0049
Up	CDK1	138	0.058532	10959680	0.345207	0.01732
Up	ANLN	137	0.048016	14980992	0.289589	0.001073
Up	CBX5	131	0.041726	6411634	0.306394	0.004603
Up	SORT1	128	0.050901	6390878	0.305958	4.92E-04
Up	HDAC11	127	0.040953	9836954	0.307423	1.25E-04
Up	PLCG1	111	0.038331	8225866	0.290547	0.00344
Up	USP11	105	0.039087	4707940	0.317424	0.004378
Up	FOXQ1	104	0.032233	3881566	0.309702	0.00224
Up	CDK6	102	0.028674	5160016	0.306024	0.010707
Up	TRIM28	99	0.031277	5255050	0.324363	0.009235
Up	MCM7	96	0.027867	7236722	0.311631	0.025852
Up	CDK4	95	0.028636	6233742	0.307269	0.013214
Up	KIF11	94	0.032768	5548692	0.301309	0.001194
Up	TUBG1	83	0.022938	9086132	0.297107	0
Up	MAGED1	83	0.029887	4261058	0.304875	0.003395
Up	EHMT2	80	0.022876	5320996	0.290273	0.006329
Up	CDC20	78	0.020321	3395252	0.314892	0.028772
Up	CCNB1	76	0.016518	4768666	0.314524	0.022807
Up	STIL	75	0.023122	5438820	0.291038	0.001802
Up	CCNA2	74	0.014526	3212664	0.303713	0.027027
Up	SKP2	73	0.015565	3487514	0.30188	0.020121
Up	PRKAA2	71	0.019643	7480336	0.281961	0

Up	MCM2	70	0.016722	2962672	0.309368	0.058385
Up	MME	68	0.023192	3877286	0.278385	0
Up	KPNA2	68	0.022268	5439794	0.306547	0.001865
Up	LDOC1	64	0.019593	4907268	0.271534	0
Up	RPS5	61	0.014909	9342932	0.260646	0
Up	RACGAP1	60	0.020049	2522402	0.301162	0.00605
Up	SNRPB	59	0.01543	4402074	0.26682	0
Up	NDC80	56	0.013808	3254894	0.290488	0.032844
Up	PIK3R2	55	0.015636	3088392	0.283334	0.005387
Up	PKM	55	0.015741	4453604	0.283764	7.26E-04
Up	PRR11	55	0.015896	4023928	0.260851	0
Up	FOXMI	53	0.015703	2462790	0.300049	0.018142
Up	NAP1L1	53	0.014305	3256110	0.289842	0.002353
Up	PDGFRB	50	0.015539	2294394	0.284929	0.015071
Up	MAD2L1	47	0.012738	1624310	0.28885	0.010101
Up	MCM6	47	0.008747	1626358	0.303007	0.09596
Up	TOP2A	46	0.008299	1885166	0.318812	0.030918
Up	HIF1AN	46	0.01434	5371702	0.257788	0
Up	ALYREF	44	0.009885	3750706	0.274181	0
Up	CHEK1	43	0.010041	1532280	0.310955	0.031008
Up	MCM3	43	0.007583	1452902	0.30468	0.094131
Up	KRT19	42	0.008917	2818958	0.270919	0
Up	MCM5	42	0.007315	1817608	0.300091	0.088269
Up	SGO1	42	0.007067	1569360	0.271466	0.009292
Up	DLK1	40	0.013366	3561522	0.241037	0
Up	BUB1	39	0.011834	2045032	0.300279	0.066066
Up	SKA1	39	0.010598	1481646	0.270884	0.017544
Up	PTP4A3	39	0.009211	1234758	0.281721	0.004049
Up	TSPAN5	39	0.014887	1810750	0.215765	0
Up	EIF4A2	39	0.0118	3675518	0.26368	0
Up	FANCI	38	0.01309	2268286	0.297251	0.003175
Up	TTK	38	0.008964	1445912	0.303199	0.015873
Up	GSN	38	0.009753	3083576	0.279761	0
Up	MCM4	38	0.003613	955734	0.303949	0.152381
Up	MSH2	37	0.007683	1252274	0.309324	0.023529
Up	PCGF2	36	0.008136	1726876	0.273623	0.008913
Up	NUF2	34	0.008187	1318856	0.285629	0.069519
Up	CDC6	34	0.018039	2783104	0.302453	0.092692
Up	LSM2	34	0.00666	1852228	0.255994	0
Up	ASF1B	33	0.006615	885750	0.273363	0.051136
Up	NDN	32	0.008861	1267136	0.299694	0.02069
Up	MYBL2	32	0.005504	1009282	0.276631	0.013793
Up	ZAP70	32	0.006898	1145650	0.269139	0.027586
Up	IMPDH2	31	0.011486	1577314	0.292462	0.007389
Up	RPS27	31	0.005015	2667206	0.267883	0
Up	KIF20A	29	0.007456	1398776	0.266407	0
Up	PTTG1	29	0.005157	589460	0.302092	0.031339
Up	UHRF1	29	0.005259	718940	0.301753	0.054131
Up	CAD	29	0.006816	1259828	0.288734	0.002849
Up	SKA3	29	0.007885	1032030	0.260535	0.019704
Up	CDC25C	28	0.004534	733590	0.309502	0.068783
Up	SPC24	28	0.004283	783166	0.272152	0.100529
Up	ASPM	28	0.007391	793284	0.278187	0.002646
Up	IGF2BP1	27	0.005589	862628	0.303777	0.048433
Up	MKI67	27	0.005123	1811602	0.276063	0
Up	NCAPH	27	0.005462	1810694	0.26209	0.042735
Up	ARHGEF2	27	0.004835	1806136	0.277936	0
Up	CHGB	25	0.009303	3086112	0.249551	0
Up	GSTP1	25	0.005588	1318884	0.258858	0
Up	PTPN14	25	0.005648	1010004	0.275322	0.006667
Up	SPC25	24	0.002981	454108	0.26588	0.115942
Up	PRKD1	24	0.006094	1195410	0.265634	0
Up	BCL11A	23	0.007557	826802	0.272083	0.007905
Up	ENAH	23	0.005446	1405796	0.258905	0
Up	HELLS	23	0.006398	1979584	0.286447	0
Up	SLC1A5	22	0.005961	845672	0.250948	0
Up	MAP4K4	22	0.005098	1055904	0.251785	0
Up	MAGED2	22	0.006949	864750	0.306002	0.017316
Up	CKB	22	0.00433	1320042	0.261184	0
Up	KIF18A	22	0.004953	979638	0.263148	0
Up	CKAP2	22	0.002002	820372	0.26588	0
Up	USP21	22	0.004655	1264612	0.249363	0
Up	ECT2	21	0.006747	746722	0.282832	0.02381
Up	DTL	21	0.003192	400558	0.289277	0.057143
Up	TPX2	21	0.008379	1105552	0.295191	0.019048

Up	RRM2	21	0.010534	1434776	0.302156	0.038095
Up	PBK	21	0.007725	885496	0.296554	0.015789
Up	LEF1	21	0.00414	1231474	0.254059	0
Up	PLK4	20	0.003849	921766	0.256482	0
Up	ACSL4	20	0.006802	897134	0.264963	0
Up	CCNB2	20	0.003758	481048	0.291511	0.078947
Up	ERCC2	20	0.004405	504734	0.283465	0.03268
Up	MMP2	20	0.007281	1225236	0.238248	0
Up	FBLN1	20	0.00745	1280400	0.263842	0
Up	RFC3	20	0.004242	1731726	0.269831	0
Up	ZMYM3	20	0.004768	704720	0.283185	0.005263
Up	CENPF	20	0.002317	623860	0.263745	0
Up	ASPSCR1	20	0.004978	1417058	0.255189	0
Up	SUPT3H	19	0.0041	1404600	0.252449	0
Up	B3GALNT1	19	0.01109	1445772	0.234126	0
Up	TDGF1	19	0.006333	635088	0.239641	0
Up	UBE2T	19	0.004524	1151644	0.242546	0
Up	PTK7	19	0.005354	1427068	0.248484	0
Up	RCN2	19	0.006145	871978	0.275763	0
Up	COL1A2	18	0.004321	719206	0.224993	0
Up	NCAPD2	18	0.00186	791970	0.25989	0.098039
Up	NETO2	18	0.004464	807100	0.241118	0
Up	SLC2A1	17	0.003279	661710	0.260551	0
Up	POLE2	17	0.004219	443958	0.254962	0
Up	ITGA6	17	0.003751	1207838	0.223382	0
Up	ACLY	17	0.002171	567752	0.253103	0
Up	HJURP	17	0.003582	372538	0.26302	0
Up	IGF2BP2	17	0.001386	429984	0.27286	0.036765
Up	MYCN	16	0.001753	285684	0.278692	0.016667
Up	MPZL1	16	0.003685	711976	0.222377	0
Up	PFKM	16	0.003767	626168	0.262314	0.021978
Up	NEIL3	16	0.004567	505440	0.246802	0
Up	VCAN	16	0.007886	998064	0.217598	0
Up	PYCR1	16	0.002228	798838	0.245689	0
Up	PCSK5	16	0.003734	932690	0.219306	0
Up	MYH7B	15	0.003221	814324	0.242888	0
Up	DYNC1I1	15	0.003495	861976	0.22807	0
Up	PRC1	15	0.002451	278580	0.276649	0.012821
Up	COL1A1	15	0.005289	966562	0.245815	0
Up	ITGA2	15	0.00438	515656	0.222746	0
Up	LAPTM4B	15	0.005051	939754	0.244711	0
Up	SPDL1	15	0.002573	711922	0.238182	0
Up	LRRC1	15	0.002879	1013596	0.257387	0
Up	MAPK13	14	0.004211	425542	0.256009	0.010989
Up	P4HA2	14	0.003876	638982	0.230848	0
Up	PEG10	14	0.003542	271700	0.233465	0
Up	LAMC1	14	0.003325	798112	0.247769	0
Up	CCND2	14	0.00127	213052	0.272549	0.164835
Up	ETV1	14	0.002882	1218408	0.246435	0
Up	RNF43	14	0.003234	893136	0.234304	0
Up	SALL2	14	0.003952	1136004	0.224115	0
Up	IGF2BP3	13	0.001409	248702	0.279979	0.076923
Up	NCAPG	13	0.001084	252222	0.261851	0.179487
Up	SPP1	13	0.003875	713040	0.23604	0
Up	FDFT1	13	0.003312	636316	0.232809	0
Up	HMGA2	13	0.001665	685268	0.253043	0
Up	AXIN2	13	0.00229	429246	0.259592	0
Up	ARHGAP11A	13	3.56E-04	99262	0.258299	0.128205
Up	EDARADD	13	0.002742	818844	0.234995	0
Up	HEY1	13	0.002518	584936	0.230514	0
Up	BEX1	13	0.002062	646290	0.244225	0
Up	DUSP9	12	0.002101	350460	0.256742	0
Up	GNB4	12	0.003718	639784	0.233225	0
Up	COLEC12	12	0.003004	404870	0.210787	0
Up	SLC39A10	12	0.005085	975630	0.255979	0
Up	XRCC2	11	0.003654	334884	0.251476	0
Up	DKK1	11	0.007155	1257912	0.234088	0
Up	AFP	11	0.003854	540400	0.212893	0
Up	SMYD2	11	0.00134	157162	0.287096	0.127273
Up	EPHB2	11	0.001153	272886	0.227419	0
Up	PRIM1	11	0.001689	268382	0.235214	0
Up	ALDH18A1	11	0.003535	782850	0.24814	0
Up	TARBP1	11	0.001857	334520	0.247669	0
Up	GREB1	11	0.001327	324158	0.237577	0
Up	ARL6IP6	11	0.003702	346104	0.202694	0

Up	PIGU	11	0.003891	386118	0.238803	0.018182
Up	RAD51AP1	11	0.00271	550000	0.245717	0
Up	NUSAP1	11	0.00336	680684	0.24583	0
Up	AMER1	10	0.001431	205210	0.26946	0.044444
Up	CDH13	10	0.002065	256868	0.265847	0.022222
Up	COL2A1	10	0.002568	462452	0.236858	0
Up	BMP4	10	1	56	1	0
Up	TRPC1	10	0.002437	988630	0.209107	0
Up	KNTC1	10	0.001471	454736	0.23456	0
Up	SPATS2	10	0.001382	219242	0.262202	0.022222
Up	CTSC	10	0.001094	188744	0.241078	0
Up	GNA12	10	0.002149	464270	0.239468	0
Up	CENPK	10	0.002447	416858	0.23497	0
Up	SULT1C2	9	0.00194	654556	0.208106	0
Up	DLX5	9	0.001033	299260	0.229751	0
Up	KCNJ10	9	0.002387	336046	0.226796	0
Up	MELK	9	0.001529	325500	0.239069	0
Up	CDCA2	9	5.74E-04	210918	0.24492	0
Up	WDR76	9	3.44E-04	59928	0.261358	0
Up	CACNB4	8	0.00243	243528	0.208025	0
Up	LRP4	8	0.001522	292854	0.213856	0
Up	CRABP2	8	0.001867	274362	0.214517	0
Up	LYZ	8	0.001026	99724	0.215333	0
Up	DLGAP5	8	6.45E-04	171954	0.2537	0
Up	TMEM52B	8	0.002631	308936	0.217334	0
Up	MAP7D2	8	8.33E-04	207316	0.237394	0
Up	FLVCR1	8	0.002268	285718	0.213814	0
Up	DKK3	7	7.06E-04	72378	0.261612	0
Up	WIF1	7	0.002169	191832	0.255144	0
Up	PAPSS1	7	0.001544	124196	0.243603	0
Up	EDIL3	7	0.001513	253928	0.19215	0
Up	NPM3	7	5.34E-04	138652	0.242491	0
Up	CST1	7	0.002256	262616	0.194424	0
Up	TP53I3	7	0.002715	337624	0.277059	0
Up	NQO1	7	6.68E-04	73162	0.276952	0.2
Up	TYMS	7	1.26E-04	21636	0.242874	0
Up	CDKN3	7	9.31E-04	105560	0.263406	0.2
Up	GINS2	7	6.47E-04	88946	0.250174	0.238095
Up	MMS22L	7	4.22E-05	9536	0.245032	0.333333
Up	E2F5	7	9.40E-04	364070	0.23479	0
Up	SFRP4	7	0.001891	317742	0.233668	0
Up	RPL22L1	7	0.001431	405904	0.219664	0
Up	PLPPR1	7	1	42	1	0
Up	ZNRF3	7	0.001731	424096	0.232005	0
Up	ROBO1	7	0.001435	414538	0.244669	0
Up	B3GALT2	6	0.002323	406490	0.159607	0
Up	PSPH	6	5.18E-04	57344	0.220237	0
Up	MPPED2	6	9.90E-04	190630	0.197105	0
Up	FRAS1	6	0.001245	137570	0.206706	0
Up	DEPDC1B	6	0.001624	160424	0.235678	0
Up	TTYH3	6	0.00166	630234	0.189176	0
Up	C1orf198	6	8.32E-04	260248	0.230329	0
Up	ITM2C	6	0.001059	208564	0.201839	0
Up	DACT1	6	9.02E-05	25780	0.244503	0
Up	GSTA4	5	4.72E-04	138274	0.169938	0
Up	MATN3	5	9.66E-04	186690	0.22201	0
Up	WFS1	5	7.99E-04	107898	0.22008	0
Up	ETV4	5	4.45E-05	16058	0.227035	0
Up	GPC3	5	0.001859	666124	0.167016	0
Up	SQLE	5	0.001859	184220	0.207594	0
Up	HSDL1	5	0.00158	160992	0.209514	0
Up	FAM111B	5	6.47E-04	124304	0.23405	0
Up	FOXRED2	5	1	20	1	0
Up	TRIB2	5	6.28E-04	156636	0.230972	0
Up	KIFC1	5	5.19E-05	12126	0.230798	0
Up	PLVAP	5	0.001505	198580	0.165398	0
Up	OLFML3	5	0.001493	196160	0.214581	0
Up	BCL9	4	0.001394	220608	0.221325	0
Up	GSDME	4	8.47E-04	184994	0.245605	0
Up	COL4A1	4	5.26E-04	88308	0.231955	0
Up	SERPINE2	4	1	12	1	0
Up	RNASE1	4	1.07E-05	2770	0.224243	0
Up	RBP1	4	6.21E-04	100188	0.220057	0
Up	DPEP1	4	2.90E-05	4032	0.205257	0
Up	GJA5	4	9.50E-04	105410	0.194214	0

Up	PCP4	4	4.01E-05	8288	0.209708	0
Up	ATP1A2	4	0.001394	129822	0.196709	0
Up	EFNA4	4	1	12	1	0
Up	OLR1	4	2.30E-07	150	0.226712	0
Up	ATP8B2	4	9.67E-04	180506	0.169757	0
Up	HTR4	4	1	2	1	0
Up	GINS1	4	3.50E-07	20	0.205374	0.333333
Up	LIN28B	4	9.36E-04	175832	0.190685	0
Up	PGAP1	4	7.77E-04	140244	0.197195	0
Up	TRIM59	4	1	12	1	0
Up	DPP10	4	1	2	1	0
Up	GLMP	4	8.52E-04	140094	0.201933	0
Up	CENPI	4	1.07E-04	29502	0.2122	0
Up	ERP27	4	1.98E-04	31920	0.207814	0
Up	ZC3HAV1L	4	5.14E-04	126094	0.250073	0
Up	GPX7	4	5.27E-04	61242	0.195689	0
Up	RHNO1	4	1.40E-04	39418	0.237237	0
Up	NRSN2	4	0.001394	205464	0.177487	0
Up	DCDC2	4	9.93E-04	201082	0.236871	0
Up	GPD1L	4	9.46E-04	123600	0.19814	0
Up	NKD1	4	8.31E-05	17768	0.236507	0
Up	HS6ST1	3	6.39E-04	59796	0.192072	0
Up	FADS2	3	2.79E-04	36586	0.231419	0
Up	MDK	3	1.80E-04	25912	0.218194	0
Up	SLC1A4	3	8.27E-05	15618	0.193142	0
Up	XCL1	3	0	0	1	0
Up	KCNJ5	3	9.29E-04	372754	0.182315	0
Up	BCAM	3	6.05E-04	112764	0.228385	0
Up	PLAG1	3	2.18E-04	20484	0.24984	0
Up	OXCT1	3	4.85E-04	46990	0.204934	0
Up	HUNK	3	4.94E-04	69796	0.225619	0
Up	TGFB2	3	6.45E-04	101128	0.227071	0
Up	ASIC1	3	5.44E-04	71454	0.200915	0
Up	DNAH14	3	6.58E-04	64682	0.207754	0
Up	REG3A	3	0	0	0.203039	0
Up	DEPDC1	3	9.29E-04	122506	0.23086	0
Up	SPARCL1	3	3.11E-04	65266	0.230279	0
Up	NREP	3	6.91E-04	105760	0.216427	0
Up	SV2A	3	8.37E-05	12654	0.203818	0
Up	CKAP2L	3	8.72E-06	5920	0.237184	0
Up	UXS1	3	6.18E-05	9870	0.187405	0
Up	FKBP10	3	1.02E-04	23742	0.230477	0
Up	MUCL1	3	7.20E-04	130080	0.189877	0
Up	MND1	3	2.35E-05	7456	0.230058	0
Up	NYNRIN	3	4.71E-04	71716	0.216068	0
Up	ACTG2	3	1.30E-04	38408	0.222194	0
Up	SDK1	3	8.77E-04	158706	0.246336	0
Up	PHYHIP1L	3	9.29E-04	135794	0.226152	0
Up	CDCA7	3	3.06E-05	17280	0.238989	0
Up	TMEM245	3	4.91E-04	58934	0.214817	0
Up	NT5DC2	3	4.74E-04	51730	0.197639	0
Up	SLC7A11	3	6.57E-04	88918	0.223893	0
Up	TOX3	2	4.65E-04	48740	0.206033	0
Up	ST8SIA3	2	0	0	0	0
Up	RHOB1	2	4.46E-06	1098	0.208418	0
Up	TICRR	2	8.03E-06	986	0.236481	0
Up	CCDC88C	2	4.65E-04	116662	0.23763	0
Up	RELN	2	4.65E-04	42474	0.194231	0
Up	MFG8	2	3.74E-05	4528	0.184742	0
Up	TTL4	2	1.87E-05	2688	0.223788	0
Up	PCLAF	2	8.10E-07	202	0.236897	0
Up	UGT3A2	2	3.14E-05	9378	0.196943	0
Up	ZNF704	2	9.23E-06	3184	0.22801	0
Up	STOX1	2	1	2	1	0
Up	LIX1	2	4.65E-04	52180	0.186213	0
Up	TLCD1	2	2.15E-04	32522	0.229261	0
Up	SRD5A3	2	1	2	1	0
Up	CD24	2	4.74E-06	10026	0.240337	0
Up	BAMBI	2	1	2	1	0
Up	LTBP2	2	5.94E-06	2852	0.223579	0
Up	MEP1A	2	4.65E-04	58726	0.151658	0
Up	CDON	2	4.65E-04	66788	0.219418	0
Up	FREM2	2	1	2	1	0
Up	APCDD1	2	4.65E-04	81302	0.159559	0
Up	NRCAM	2	4.65E-04	57154	0.177795	0

Up	SLC25A36	2	1.22E-04	14216	0.182594	0
Up	RASL11B	2	2.42E-04	45546	0.227083	0
Up	FERMT1	2	1.59E-06	4156	0.244253	0
Up	SLC22A11	2	4.65E-04	53916	0.210282	0
Up	PARBP	2	6.11E-06	3044	0.229665	0
Up	PLAGL2	2	1	2	1	0
Up	ZNF711	2	1.58E-06	464	0.200112	0
Up	GXYLT2	1	0	0	0.171359	0
Up	ODAM	1	0	0	0.207164	0
Up	SOBP	1	0	0	1	0
Up	SULT1C4	1	0	0	0.172265	0
Up	GFRA3	1	0	0	1	0
Up	TNFSF4	1	0	0	1	0
Up	CD34	1	0	0	0.182446	0
Up	TBX4	1	0	0	1	0
Up	FMOD	1	0	0	1	0
Up	ZNF382	1	0	0	0.244934	0
Up	AACS	1	0	0	0.165864	0
Up	CPA6	1	0	0	1	0
Up	CCDC34	1	0	0	1	0
Up	RHBG	1	0	0	1	0
Up	EPCAM	1	0	0	0.177766	0
Up	MFAP2	1	0	0	1	0
Up	CDH11	1	0	0	0.2267	0
Up	FIGN	1	0	0	1	0
Up	NPNT	1	0	0	1	0
Up	LPCAT2	1	0	0	0.193715	0
Up	ABHD12B	1	0	0	1	0
Up	ZBED8	1	0	0	0.192012	0
Up	SLC44A3	1	0	0	0.169503	0
Up	TET1	1	0	0	1	0
Up	PARD3B	1	0	0	0.224115	0
Up	RNF157	1	0	0	1	0
Up	SERPINI1	1	0	0	1	0
Up	SNTG1	1	0	0	0.17574	0
Up	DKK2	1	0	0	0.185099	0
Up	DNAH17	1	0	0	0.207364	0
Up	NDRG3	1	0	0	0.166705	0
Up	FAM169A	1	0	0	0.172735	0
Down	ESR1	896	0.309979	299570632	0.386231	8.97E-04
Down	LRRK2	483	0.133172	158516094	0.342501	2.08E-04
Down	AR	415	0.106663	62216644	0.360041	0.002891
Down	FOS	264	0.065906	28932854	0.34933	0.004036
Down	ICAM1	178	0.033095	51537552	0.303149	1.30E-04
Down	CLU	148	0.044563	25001298	0.325958	9.45E-04
Down	FGB	115	0.028557	20661818	0.298618	0.002593
Down	IL13RA2	108	0.027484	20955756	0.279672	0
Down	MAP3K5	106	0.021135	15381740	0.313573	0.002427
Down	USP2	106	0.030969	21121988	0.307701	7.19E-04
Down	FGFR2	99	0.025154	27949726	0.291426	0
Down	BIRC3	95	0.017212	20907718	0.292562	0
Down	TRIM55	93	0.017057	24643106	0.278829	9.77E-04
Down	ASS1	88	0.020199	11346616	0.308247	0.004925
Down	SOCS3	84	0.020952	9302066	0.322588	0.013196
Down	MACF1	83	0.015233	8958998	0.304395	6.17E-04
Down	ACAT1	81	0.013409	13609238	0.291319	0
Down	JUNB	80	0.013345	3520692	0.31819	0.024309
Down	BHLHE40	79	0.015913	11753664	0.294501	0
Down	RGS2	78	0.022665	6500040	0.306783	0.004101
Down	PCK1	77	0.013103	12847238	0.302028	0.001367
Down	SOD2	77	0.015795	11261720	0.295913	7.40E-04
Down	S100A8	75	0.016715	7355576	0.329693	0.006088
Down	MYO1B	72	0.015859	6136180	0.333153	0.010172
Down	PPARGC1A	72	0.010329	4302602	0.321226	0.021127
Down	SHBG	71	0.015597	9905376	0.282661	0
Down	CYP11A1	71	0.014919	20866070	0.270491	0
Down	NRG1	68	0.017635	11230792	0.276759	0
Down	ZFP36	65	0.011562	13837378	0.291029	0
Down	TLR4	64	0.015406	8208520	0.291533	0.002644
Down	SLC15A1	64	0.012571	8309474	0.260238	0
Down	GNAO1	62	0.017069	10123798	0.282963	0
Down	GOT1	62	0.012129	9981328	0.275155	0
Down	CRP	61	0.013437	6180018	0.275237	0.00526
Down	GADD45G	60	0.014125	3241436	0.319912	0.011864
Down	AGL	60	0.011612	9273372	0.287638	0

Down	ALAS1	59	0.012151	5367252	0.278955	0.00188
Down	WEE1	59	0.008825	11362378	0.285626	0
Down	ACADM	57	0.010367	7668586	0.286067	0.006734
Down	UGP2	57	0.011493	8172720	0.283208	0
Down	GHR	55	0.008712	4614994	0.29849	0.011611
Down	SATB1	55	0.008792	15527466	0.26675	0
Down	EGR1	54	0.007556	3144224	0.297276	0.018868
Down	KNG1	53	0.01237	5851206	0.28103	0.004706
Down	PTPN3	53	0.009152	7438096	0.290755	0
Down	CTH	51	0.013176	4082662	0.283773	0
Down	TMOD1	51	0.005474	5091854	0.284136	0.003922
Down	FBP1	50	0.009048	11285584	0.26684	0
Down	DUSP1	50	0.008891	10378298	0.275278	0
Down	SHMT1	50	0.01026	13844154	0.265716	0
Down	HERC5	50	0.007274	9914444	0.28025	0
Down	CTSL	48	0.010586	4444460	0.280463	0.004831
Down	SPTBN2	47	0.00602	7556250	0.282187	0
Down	SUCLG2	47	0.008951	3779538	0.279911	0.009251
Down	NNT	47	0.010291	8100184	0.272068	0
Down	CD14	46	0.009258	3323924	0.27135	9.66E-04
Down	GBP2	46	0.008203	3779530	0.288445	0.005797
Down	SCP2	46	0.010354	4074630	0.279531	0.003865
Down	KYNU	45	0.006811	2586768	0.285128	0.019192
Down	SERPINA3	44	0.007664	4502382	0.284368	0
Down	ACOX1	44	0.009868	3506656	0.284412	0.003171
Down	PTPRB	44	0.00811	3926218	0.288835	0
Down	DCN	43	0.011811	4945324	0.29563	0.003322
Down	SLC27A2	43	0.010272	7446722	0.271629	0
Down	MAP7	42	0.007337	6511888	0.28103	0
Down	ETS2	41	0.005105	2519244	0.29106	0.017544
Down	PCK2	41	0.011497	3698052	0.299197	0.007317
Down	LRRFIP1	41	0.006765	1884314	0.309467	0.02834
Down	NR1I3	41	0.003727	2540248	0.27827	0.015647
Down	F9	40	0.008221	6098910	0.260629	0.00569
Down	BLNK	40	0.006153	2200960	0.294517	0.011538
Down	VNN2	39	0.009277	9185422	0.242649	0
Down	NAMPT	39	0.009728	2391300	0.289271	0.006006
Down	ARG1	39	0.006317	1733142	0.312409	0.010796
Down	NR3C2	39	0.002614	1794230	0.294267	0.033033
Down	CDA	39	0.007883	6112372	0.261648	0
Down	PTGS2	39	0.009909	4682156	0.316251	0.003003
Down	PIGR	38	0.00659	2067682	0.270254	0.003175
Down	GDA	38	0.007239	3477776	0.274529	0.018492
Down	CXCL8	37	0.006908	3072842	0.281772	0.020168
Down	FGG	37	0.006246	1777802	0.278522	0.040336
Down	HAL	37	0.005876	5246022	0.268621	0
Down	ARRDC3	37	0.006225	4213558	0.253226	0
Down	ABAT	36	0.006759	1741224	0.277547	0.008913
Down	SLC1A1	35	0.007842	4681630	0.280137	0
Down	EHHADH	34	0.00772	2095766	0.284645	0.008913
Down	HOOK1	34	0.00767	1579368	0.26606	0.002016
Down	ECM1	34	0.005761	3075272	0.275797	0
Down	VIPR1	34	0.011034	4956966	0.26818	0.001783
Down	REEP6	34	0.00749	2931720	0.26275	0
Down	RCAN1	34	0.00554	4877812	0.283555	0
Down	AKAP12	34	0.005471	6668604	0.273637	0
Down	KCND3	34	0.004592	8695142	0.258976	0
Down	PLA2G2A	33	0.005893	1257034	0.27795	0.004301
Down	HP	33	0.006005	3565910	0.291441	0
Down	SDC4	33	0.00587	4262690	0.286422	0
Down	ADRA1A	32	0.006268	1133850	0.247946	0.004598
Down	NR4A2	32	0.004645	2855890	0.280081	0.008065
Down	RAB27A	32	0.007238	4038790	0.27566	0
Down	GNE	32	0.007084	2548154	0.271908	0
Down	ALDOB	31	0.004619	3948276	0.276745	0
Down	EDNRB	31	0.006582	4990088	0.254584	0
Down	GCH1	31	0.004367	3991740	0.266353	0
Down	MBOAT1	31	0.005692	7498044	0.251631	0
Down	MASP1	30	0.002511	1968902	0.271629	0.026455
Down	GADD45B	30	0.004944	1236040	0.300981	0.03908
Down	BCHE	30	0.006531	7736328	0.232035	0
Down	CDC37LI	30	0.003709	6777390	0.268452	0
Down	AZGP1	29	0.00598	1838220	0.298682	0.005698
Down	REPS2	29	0.005285	1424822	0.289966	0.009852
Down	STEAP3	29	0.005471	2977070	0.244228	0

Down	RIDA	28	0.004379	1662822	0.263898	0.003077
Down	RNF125	27	0.004007	1731534	0.284908	0.01
Down	PRKAG2	27	0.004832	2830662	0.261599	0
Down	NFIL3	26	0.002765	1041744	0.264024	0.021739
Down	SERPINE1	26	0.002443	1190408	0.26564	0
Down	KLF6	26	0.004385	3318478	0.283194	0.009231
Down	SERPINB8	26	0.004412	2379938	0.26643	0
Down	DTX1	26	0.003329	3065438	0.267934	0
Down	SOC2	25	0.002013	625286	0.26879	0.066667
Down	TRIB1	25	0.004127	1004106	0.285891	0.033333
Down	FCGR2B	25	0.002985	1979616	0.268478	0.016667
Down	CFH	25	0.005117	2951108	0.272215	0.006667
Down	HGF	25	0.004124	2192050	0.256987	0.009524
Down	GCCLM	25	0.004237	3106626	0.277922	0
Down	THRSP	25	0.002173	2856688	0.260519	0
Down	HAO2	25	0.004285	4808910	0.25823	0
Down	SERPINC1	24	0.003345	1730408	0.262266	0.008658
Down	BAAT	24	0.002957	2800382	0.260214	0
Down	CREB3L3	24	0.003062	1200446	0.270914	0.030303
Down	F8	23	0.003884	1039040	0.25923	0.009524
Down	INSIG1	23	0.004133	2976792	0.251905	0
Down	CLEC4G	23	0.002899	1111948	0.2615	0
Down	CPM	23	0.002059	1765838	0.266878	0
Down	GLRX	23	0.00358	1168444	0.282302	0.003953
Down	GNMT	23	0.003769	3638242	0.252432	0
Down	LIPG	23	0.004362	2949902	0.250124	0
Down	NAT2	22	0.003077	2962386	0.269193	0
Down	SLC7A2	22	0.004698	908164	0.229182	0.004329
Down	APCS	21	0.003129	1035782	0.271165	0.052632
Down	ADAMTS1	21	0.004304	1275184	0.233862	0
Down	ACACB	20	0.001914	1684424	0.274665	0
Down	CA2	20	0.003389	4309148	0.261685	0
Down	CYP2C8	20	0.002339	888270	0.253168	0.006536
Down	LIFR	20	0.004051	3817640	0.266111	0
Down	ALDH6A1	20	0.002834	1248912	0.258867	0
Down	PTS	20	0.003577	2360228	0.230744	0
Down	BBOX1	19	0.003707	1741390	0.242311	0
Down	HRG	19	0.001592	860580	0.250496	0.017544
Down	LBP	19	0.003321	1193680	0.267122	0.017544
Down	DUSP5	19	0.002019	1791148	0.259569	0
Down	RETREG1	19	0.00224	1353492	0.273866	0
Down	FXYP1	18	0.003686	3320202	0.2525	0
Down	MBL2	18	0.001551	406976	0.261808	0.05
Down	PHYH	18	0.003994	1532650	0.270531	0
Down	ORM1	18	0.002	981922	0.254852	0
Down	CNDP1	18	0.004334	850302	0.306107	0.008333
Down	HSD11B1	18	0.004216	2091866	0.247792	0
Down	TD02	18	0.002662	1453194	0.251494	0
Down	FOSB	17	3.45E-04	164544	0.279124	0.191176
Down	IGF1	17	0.002724	2487460	0.241185	0
Down	GSTA1	17	0.003814	996750	0.272562	0.038095
Down	CYP3A4	17	0.003177	2367788	0.257058	0.009524
Down	CXCL2	17	0.001553	607104	0.267328	0.07619
Down	ACADSB	17	0.002838	1569448	0.258362	0
Down	INHBE	17	0.003291	1602250	0.278243	0
Down	MMRN1	17	0.002547	1037546	0.259085	0
Down	APBB1IP	17	0.003406	3834888	0.230122	0
Down	CCL21	16	0.003278	577492	0.275756	0.008333
Down	CP	16	0.001592	1151616	0.249517	0
Down	CFB	16	0.001261	589046	0.250394	0.021978
Down	C4BPA	16	0.004043	2098058	0.266226	0.025
Down	RND3	16	0.003163	3146786	0.249562	0
Down	CPNE8	16	0.003116	1842528	0.265932	0
Down	RND1	16	0.003113	1403764	0.217182	0
Down	TMPSR2	15	2.34E-04	104730	0.283035	0.141026
Down	PAPSS2	15	0.001973	773082	0.276387	0
Down	C4BPB	15	0.002637	1071148	0.236753	0
Down	SLC25A15	15	0.003605	775762	0.251551	0
Down	ACSM5	15	0.004056	1939834	0.241185	0
Down	CIR	14	0.001705	531074	0.276856	0.060606
Down	C1S	14	6.72E-04	373556	0.247075	0.045455
Down	CYP2C9	14	0.002265	643044	0.246943	0.043956
Down	COLEC10	14	0.001778	346938	0.241394	0
Down	MAT1A	14	0.001982	1350222	0.250598	0
Down	HSD17B6	13	0.002013	1442426	0.21725	0

Down	AGPAT2	13	0.003173	2509068	0.235899	0
Down	C5	13	0.001127	343098	0.24917	0
Down	C6	13	0.00131	736740	0.261119	0
Down	F11	13	0.001844	603870	0.260067	0.054545
Down	HPX	13	0.001729	667494	0.245894	0
Down	CRHBP	13	0.001677	1143382	0.244025	0
Down	INPP1	13	0.002652	1613930	0.236643	0
Down	DHODH	13	0.001463	1507496	0.23258	0
Down	TP53INP1	13	0.001799	1097030	0.25963	0
Down	ARHGEF26	13	0.002416	1567538	0.208907	0
Down	ZDBF2	13	0.001241	982542	0.252122	0
Down	MASP2	12	2.76E-04	165182	0.248201	0.222222
Down	ABCB11	12	4.93E-04	277198	0.256583	0.030303
Down	OTC	12	0.001998	1062950	0.236592	0
Down	CFP	12	0.001809	650212	0.252008	0.030303
Down	KLKB1	12	6.60E-04	224280	0.249148	0.045455
Down	SLPI	12	9.16E-04	313580	0.245459	0.015152
Down	DHTKD1	12	0.003151	1337228	0.255756	0
Down	PFKFB1	12	0.001203	1071564	0.273286	0
Down	IL1RN	12	9.76E-04	779266	0.243575	0
Down	PPP1R3B	12	0.001315	1293766	0.247769	0.015152
Down	ALDH8A1	12	0.00275	447514	0.289981	0
Down	BHMT	12	0.001503	724178	0.199189	0
Down	CLEC4M	12	8.45E-04	393846	0.24248	0
Down	RASD1	12	0.001272	1360920	0.238789	0
Down	TFR2	11	0.00145	263296	0.265996	0
Down	TNFSF14	11	0.001222	821328	0.260825	0
Down	SULT2A1	11	9.72E-04	274484	0.250904	0.027778
Down	HGFAC	11	0.001531	809870	0.239489	0.054545
Down	PPP1R1A	11	0.002515	5390332	0.215941	0
Down	GAREM1	11	0.001023	798762	0.270636	0
Down	GLS2	11	8.23E-04	415740	0.232103	0
Down	ASPDH	10	0.00149	823920	0.246998	0
Down	ABLM3	10	0.001624	1312524	0.255662	0
Down	CXCL14	10	9.45E-04	480018	0.26321	0
Down	ADH1B	10	9.96E-04	402610	0.260507	0
Down	ALPL	10	0.001041	822584	0.247086	0
Down	ACSL1	10	9.32E-04	483436	0.268089	0
Down	PON1	10	0.001622	391370	0.256465	0.066667
Down	CYP2C18	10	0.001389	249172	0.226675	0.022222
Down	GPD1	10	0.001592	635348	0.220222	0
Down	EXPH5	10	0.00185	462530	0.267109	0
Down	MYOM1	10	0.001147	924916	0.23037	0
Down	CDO1	10	0.001584	1653692	0.241783	0
Down	GPAT3	10	0.00178	962402	0.251825	0
Down	MGLL	10	0.001476	851578	0.24009	0
Down	NTN4	10	0.003294	5110696	0.247009	0
Down	ABCC3	9	2.47E-04	214754	0.246155	0
Down	ALDH1A1	9	7.63E-04	886116	0.234981	0
Down	SAA1	9	8.40E-04	502730	0.223366	0
Down	GY52	9	7.84E-04	402462	0.251939	0.027778
Down	GPLD1	9	0.001569	996420	0.245992	0
Down	ITIH4	9	8.06E-04	596242	0.25611	0
Down	LONRF3	9	8.77E-04	645580	0.240558	0
Down	GRAMD1C	9	0.002584	846258	0.245622	0
Down	PIPOX	9	0.00221	1758694	0.233558	0
Down	ANGPTL3	9	0.001937	2527356	0.224758	0
Down	SLCO1B1	9	0.001603	706740	0.236119	0
Down	FCN2	8	2.81E-04	87106	0.241857	0.321429
Down	CYP1A2	8	5.10E-04	317700	0.196206	0
Down	MT1X	8	0.00108	273304	0.277035	0.071429
Down	AASS	8	8.75E-04	236390	0.255591	0
Down	CETP	8	9.82E-04	702086	0.246046	0
Down	DAO	8	0.001228	718678	0.251164	0
Down	TAT	8	6.11E-04	503476	0.243436	0
Down	CYP3A5	8	0.001166	602974	0.238175	0
Down	SULT1A2	8	0.001478	1675470	0.184432	0
Down	AKR1D1	8	0.001232	929478	0.232006	0
Down	AOX1	8	8.17E-05	56800	0.223142	0
Down	SEC14L4	8	0.002122	1129680	0.234485	0
Down	OGDHL	8	2.07E-04	143330	0.248179	0
Down	RBM47	7	9.50E-04	669862	0.25449	0
Down	IRF6	7	0.001805	1065964	0.220126	0
Down	HABP2	7	2.07E-04	33070	0.224949	0
Down	C9	7	0.00122	268198	0.254479	0.047619

Down	LRG1	7	7.84E-04	521906	0.235969	0
Down	CFI	7	0.001231	465800	0.232989	0.047619
Down	C8G	7	5.10E-04	545184	0.217378	0
Down	PZP	7	0.001109	655294	0.199928	0
Down	AGXT	7	5.03E-04	111720	0.252604	0
Down	EPHX2	7	5.80E-04	385960	0.232628	0
Down	NNMT	7	7.28E-04	310450	0.253399	0
Down	CYP4F2	7	2.97E-04	205740	0.251939	0
Down	FYB2	7	0.001808	2714948	0.180559	0
Down	APOA5	7	5.21E-04	306366	0.240308	0
Down	HHIP	7	0.00144	476860	0.165307	0
Down	CSRNPI	7	0.001143	806270	0.251472	0
Down	APOL6	7	5.21E-04	457030	0.212976	0
Down	STAB2	7	1.38E-04	132094	0.243629	0
Down	GFRA1	6	0.001197	219610	0.253967	0
Down	CCL16	6	7.39E-04	807116	0.191663	0
Down	ABCC9	6	8.72E-04	466056	0.230027	0
Down	APOC3	6	2.39E-04	126474	0.238574	0
Down	LPA	6	7.65E-04	133348	0.244411	0.066667
Down	GSTA2	6	7.59E-04	223462	0.217642	0.133333
Down	GSTA3	6	3.29E-04	148180	0.254421	0.5
Down	HPD	6	1.23E-04	52066	0.243554	0.066667
Down	HMGCS2	6	2.63E-04	241608	0.270887	0
Down	INHBC	6	0.00144	1022782	0.133638	0
Down	ENPEP	6	0.00108	520350	0.180003	0
Down	GLYAT	6	7.51E-04	209042	0.20607	0
Down	CES3	6	0.001828	826294	0.249708	0
Down	SLC51A	6	0.0018	499710	0.208101	0
Down	TTC39C	6	4.23E-04	338812	0.241447	0
Down	SGMS2	6	4.22E-04	279040	0.226002	0
Down	HGD	6	7.24E-04	309038	0.215647	0
Down	RUNDC3B	6	4.91E-04	365238	0.252661	0
Down	NFKBIZ	6	4.89E-04	873384	0.244207	0
Down	CYP8B1	6	8.30E-04	535726	0.242131	0
Down	ST3GAL6	6	0.003309	1133634	0.246735	0
Down	LRAT	5	7.20E-04	427634	0.189926	0
Down	CFHR4	5	2.52E-05	6314	0.233126	0
Down	CFHR1	5	9.73E-05	23610	0.235469	0.2
Down	SAA2	5	4.42E-05	22766	0.208202	0
Down	CYP2D6	5	2.55E-05	5470	0.208609	0.333333
Down	SRD5A1	5	1.62E-04	202222	0.264024	0
Down	CES1	5	4.52E-04	156516	0.196477	0
Down	GPT	5	8.71E-04	531304	0.225681	0
Down	NPY1R	5	1	20	1	0
Down	ADGRA3	5	0.00128	374516	0.240537	0
Down	AFM	5	7.25E-04	359728	0.230571	0
Down	HAAO	5	4.21E-04	207404	0.235979	0
Down	DPYS	5	4.46E-04	453896	0.208171	0
Down	GCKR	5	9.21E-05	106176	0.253723	0
Down	CYP4V2	5	8.43E-04	570518	0.232346	0
Down	RNF152	5	4.72E-04	435980	0.201964	0
Down	CLEC1B	5	3.86E-04	222916	0.24035	0
Down	TENM1	5	7.20E-04	286198	0.183192	0
Down	SLC4A4	5	7.20E-04	236454	0.195495	0
Down	CD163	5	1.22E-04	66542	0.242713	0
Down	FGD4	5	3.96E-04	204152	0.230332	0
Down	PAPPA2	5	8.00E-05	92852	0.23106	0
Down	CYP39A1	5	4.83E-04	312774	0.220082	0
Down	APOL1	4	7.24E-04	278170	0.217463	0
Down	SULT1B1	4	4.20E-04	82266	0.218593	0
Down	FCN3	4	7.70E-06	3684	0.215849	0
Down	BMP10	4	0.002878	1661946	0.182254	0
Down	ADH1C	4	3.60E-04	158820	0.206691	0
Down	C7	4	4.44E-04	82582	0.260543	0
Down	CFHR3	4	6.28E-05	17502	0.233009	0.166667
Down	AKR1C4	4	5.10E-04	183362	0.221231	0
Down	CYP2B6	4	2.46E-04	195256	0.208007	0
Down	ACADL	4	7.39E-04	257702	0.250496	0
Down	SLC6A1	4	7.24E-04	442960	0.185833	0
Down	GATM	4	2.80E-06	542	0.208413	0
Down	CYP4A11	4	4.53E-04	329054	0.230868	0
Down	ETFDH	4	4.59E-05	36792	0.211492	0
Down	PXDC1	4	7.05E-04	491142	0.223654	0
Down	ADGRG7	4	4.13E-04	192036	0.226963	0
Down	RSPO3	4	7.39E-04	142942	0.206969	0

Down	HAO1	4	0.00108	620136	0.204514	0
Down	AVPR1A	4	7.33E-04	355980	0.204884	0
Down	CHST9	4	3.92E-04	409662	0.214872	0
Down	AQP3	4	4.73E-04	260220	0.254199	0
Down	CFHR5	4	1.04E-04	48504	0.230677	0
Down	PLAC8	4	1.05E-04	89312	0.24454	0
Down	MARCO	4	0.00108	354306	0.245286	0
Down	LYVE1	4	4.04E-04	175194	0.203742	0
Down	MT1DP	3	1.25E-05	6290	0.185535	0
Down	C1RL	3	3.73E-04	76172	0.228165	0
Down	HPR	3	2.56E-05	13292	0.214299	0
Down	C8A	3	1.68E-05	4780	0.20737	0.333333
Down	ADH4	3	6.09E-05	43038	0.254246	0
Down	ABCB4	3	7.20E-04	447626	0.224567	0
Down	MRC1	3	3.38E-05	6054	0.227418	0
Down	XDH	3	7.20E-04	247046	0.23621	0
Down	MT1H	3	2.03E-04	49574	0.220274	0
Down	HAMP	3	4.90E-05	11464	0.199698	0
Down	APOF	3	7.20E-04	342410	0.205483	0
Down	IYD	3	3.79E-04	282996	0.232327	0
Down	HSD17B13	3	3.66E-04	151596	0.180196	0
Down	SPATA6L	3	3.64E-04	112340	0.212952	0
Down	ETNPPL	3	3.82E-04	152152	0.246549	0
Down	NSUN6	3	5.53E-05	20424	0.226214	0
Down	TSKU	3	7.20E-04	388086	0.220082	0
Down	LPIN2	3	3.65E-04	171480	0.24009	0
Down	AMDH1	3	4.16E-04	154054	0.216818	0
Down	SMIM14	3	7.20E-04	447678	0.222793	0
Down	SLC25A18	3	5.08E-05	17890	0.216084	0
Down	RASGEF1B	3	1.44E-04	58950	0.248446	0
Down	ABCA9	3	1.01E-04	101642	0.244476	0
Down	BMPER	3	2.40E-04	870218	0.124359	0
Down	ACMSD	3	7.20E-04	193526	0.210858	0
Down	SLC41A2	3	4.01E-04	159456	0.227502	0
Down	GLT1D1	3	6.09E-04	190956	0.208288	0
Down	NAT8	3	4.20E-05	29670	0.244025	0
Down	KMO	2	3.60E-04	289722	0.190473	0
Down	SLC22A1	2	1	2	1	0
Down	CYP26A1	2	3.10E-07	358	0.227055	0
Down	CD5L	2	2.42E-05	17014	0.216809	0
Down	SEC14L2	2	3.60E-04	184378	0.159662	0
Down	SLITRK3	2	8.03E-06	2444	0.246647	0
Down	C8B	2	3.91E-05	26264	0.246976	0
Down	F13B	2	0	0	0.217864	1
Down	MT1G	2	1.74E-04	25586	0.220484	0
Down	MT1F	2	4.88E-06	264	0.237665	0
Down	AGXT2	2	7.08E-06	768	0.226214	0
Down	UGT2B7	2	3.60E-04	275732	0.204514	0
Down	CYP2C19	2	0	0	0.201861	1
Down	PON3	2	0	0	0.204131	1
Down	G0S2	2	3.60E-04	462290	0.207665	0
Down	GBP7	2	3.60E-04	131252	0.223897	0
Down	CFHR2	2	7.55E-05	16542	0.246855	0
Down	DIO1	2	0	0	0	0
Down	ACSM3	2	6.30E-07	460	0.224958	0
Down	SLC25A47	2	6.89E-06	3908	0.199849	0
Down	ABCA10	2	7.91E-06	4862	0.231446	0
Down	FGF14	2	1.63E-05	9246	0.209237	0
Down	ART4	2	3.90E-05	32642	0.245242	0
Down	FGGY	2	1	2	1	0
Down	MOGAT2	2	1.23E-05	4986	0.194441	0
Down	ANO1	2	1.96E-05	14720	0.224377	0
Down	STEAP4	2	3.60E-04	124230	0.230332	0
Down	ANO5	2	2.17E-04	89640	0.247958	0
Down	ADHFE1	2	3.60E-04	109268	0.202634	0
Down	MT1M	2	8.44E-06	5014	0.209237	0
Down	CLRN3	2	4.80E-05	17224	0.200245	0
Down	PRG4	2	9.38E-06	17410	0.249495	0
Down	GBA3	2	4.32E-05	23632	0.225626	0
Down	GREM2	2	1.20E-04	435106	0.124353	0
Down	FETUB	2	1.46E-05	14364	0.232921	0
Down	ANXA10	2	1.19E-05	10254	0.221178	0
Down	SLC27A5	2	3.60E-04	101338	0.224286	0
Down	CPED1	1	0	0	0.245221	0
Down	TTC36	1	0	0	0.221319	0

Down	MT1E	1	0	0	0.230208	0
Down	UGT2B4	1	0	0	0.222062	0
Down	FMO4	1	0	0	0.199304	0
Down	UGT2B10	1	0	0	0.223843	0
Down	CYP4A22	1	0	0	0.187572	0
Down	SLC10A1	1	0	0	1	0
Down	TSPYL5	1	0	0	0.217565	0
Down	CYP4F11	1	0	0	0.207308	0
Down	HPGD	1	0	0	0.245221	0
Down	FMO3	1	0	0	0.193183	0
Down	DNASE1L3	1	0	0	0.192961	0
Down	SCN9A	1	0	0	0.235799	0
Down	LPAL2	1	0	0	0.186884	0
Down	SLC46A3	1	0	0	0.186752	0
Down	ASPG	1	0	0	0.198166	0
Down	CYP4X1	1	0	0	1	0
Down	ABCA6	1	0	0	0.205453	0
Down	AADAT	1	0	0	1	0
Down	MFSD2A	1	0	0	0.201319	0
Down	AKR7L	1	0	0	1	0
Down	OIT3	1	0	0	0.17799	0
Down	ARAP2	1	0	0	1	0
Down	TCIM	1	0	0	0.222757	0
Down	UPB1	1	0	0	0.193055	0
Down	DMGDH	1	0	0	1	0
Down	SLC17A4	1	0	0	0.232989	0
Down	SLC22A7	1	0	0	1	0

Table 8 miRNA - target gene interaction table

Regulation	Target Genes	Degree	MicroRNA	Regulation	Target Genes	Degree	MicroRNA
Up	PLAGL2	189	hsa-mir-4710	Down	SOD2	257	hsa-mir-4803
Up	CDK6	188	hsa-mir-4657	Down	WEE1	182	hsa-mir-4647
Up	CCND2	179	hsa-mir-5192	Down	SULT1B1	131	hsa-mir-3163
Up	SLC1A5	174	hsa-mir-4284	Down	APOL6	127	hsa-mir-4455
Up	PKM	160	hsa-mir-4525	Down	DHODH	119	hsa-mir-1200
Up	CBX5	140	hsa-mir-7973	Down	ABHD2	116	hsa-mir-4284
Up	PEG10	138	hsa-mir-8072	Down	ACOX1	113	hsa-mir-3165
Up	TP53	130	hsa-mir-2110	Down	CPM	111	hsa-mir-7977
Up	HMGA2	126	hsa-mir-4418	Down	TSKU	107	hsa-mir-4505
Up	TMEM245	126	hsa-mir-3674	Down	HHIP	107	hsa-mir-4510
Up	GXYLT2	123	hsa-mir-3929	Down	IGF1	98	hsa-mir-3929
Up	PTPN14	116	hsa-mir-4484	Down	AR	97	hsa-mir-5193
Up	RACGAP1	112	hsa-mir-2278	Down	SHMT1	97	hsa-mir-3174
Up	ZC3HAV1L	111	hsa-mir-5684	Down	TP53INP1	94	hsa-mir-6069
Up	PRIM1	111	hsa-mir-6745	Down	RNF125	92	hsa-mir-4770
Up	ITGA2	107	hsa-mir-5680	Down	LIPG	89	hsa-mir-6085
Up	CDK4	102	hsa-mir-7641	Down	INSIG1	85	hsa-mir-8073
Up	RRM2	101	hsa-mir-4510	Down	LONRF3	82	hsa-mir-6130
Up	SLC7A11	101	hsa-mir-5193	Down	TRIB1	81	hsa-mir-4426
Up	RNF157	100	hsa-mir-6133	Down	ESR1	72	hsa-mir-4290
Up	COL1A1	97	hsa-mir-2392	Down	ANGPTL3	70	hsa-mir-8054
Up	IGF2BP1	93	hsa-mir-8485	Down	DHTKD1	69	hsa-mir-7150
Up	ENAH	92	hsa-mir-4452	Down	CLU	69	hsa-mir-8085
Up	FLVCR1	88	hsa-mir-6131	Down	NNT	68	hsa-mir-4672
Up	AMER1	87	hsa-mir-6081	Down	PIGR	66	hsa-mir-4486
Up	ZNF704	86	hsa-mir-4527	Down	CCL16	63	hsa-mir-4533
Up	CCNB1	84	hsa-mir-4477a	Down	KLF6	62	hsa-mir-4422
Up	MKI67	84	hsa-mir-4430	Down	UGT2B4	62	hsa-mir-3170
Up	PLAG1	83	hsa-mir-3919	Down	SEC14L4	61	hsa-mir-3652
Up	KPNA2	83	hsa-mir-4302	Down	SRD5A1	60	hsa-mir-4478
Up	OLR1	81	hsa-mir-2054	Down	RNF152	59	hsa-mir-4499
Up	HIF1AN	78	hsa-mir-3911	Down	FOS	58	hsa-mir-8081
Up	FOXRED2	76	hsa-mir-7702	Down	AGXT2	58	hsa-mir-1827
Up	BAMBI	76	hsa-mir-3122	Down	C1RL	57	hsa-mir-4451
Up	LAMC1	75	hsa-mir-4791	Down	MAP7	56	hsa-mir-3666
Up	MELK	74	hsa-mir-4330	Down	LIFR	55	hsa-mir-6126
Up	AURKA	73	hsa-mir-4476	Down	GNE	55	hsa-mir-7641

Up	ZNF711	71	hsa-mir-5701	Down	ALDH6A1	54	hsa-mir-5095
Up	SLC25A36	69	hsa-mir-8066	Down	ZFP36	53	hsa-mir-5700
Up	ACSL4	68	hsa-mir-3666	Down	IYD	51	hsa-mir-4435
Up	NPM3	68	hsa-mir-4429	Down	KCND3	50	hsa-mir-8082
Up	ITM2C	67	hsa-mir-4533	Down	AQP3	50	hsa-mir-8485
Up	BUB1	67	hsa-mir-4302	Down	GATM	49	hsa-mir-8069
Up	FIGN	65	hsa-mir-3149	Down	CNDP1	49	hsa-mir-3135b
Up	TRIM28	65	hsa-mir-4481	Down	TTC39C	49	hsa-mir-4464
Up	XRCC2	65	hsa-mir-1470	Down	SPTBN2	48	hsa-mir-8059
Up	NKD1	65	hsa-mir-5095	Down	MFSD2A	48	hsa-mir-1913
Up	MMS22L	64	hsa-mir-3665	Down	RCAN1	47	hsa-mir-5190
Up	CAD	64	hsa-mir-4426	Down	PPP1R3B	47	hsa-mir-3201
Up	MDK	63	hsa-mir-4489	Down	MBL2	47	hsa-mir-4311
Up	SPC25	63	hsa-mir-548i	Down	LRAT	47	hsa-mir-6088
Up	SGO1	63	hsa-mir-4532	Down	ARAP2	46	hsa-mir-6071
Up	LIN28B	62	hsa-mir-4718	Down	LEAP2	46	hsa-mir-4279
Up	PCLAF	62	hsa-mir-4705	Down	TNFSF14	46	hsa-mir-4292
Up	NRXN3	61	hsa-mir-5707	Down	SLC7A2	45	hsa-mir-4666b
Up	ERVMER34-1	61	hsa-mir-2052	Down	PTPRB	44	hsa-mir-548z
Up	ZNRF3	60	hsa-mir-6134	Down	SMIM14	44	hsa-mir-6078
Up	PRR11	56	hsa-mir-3926	Down	CYP2B6	43	hsa-mir-4651
Up	PLCG1	56	hsa-mir-4635	Down	MAT1A	43	hsa-mir-6131
Up	TTYH3	56	hsa-mir-4468	Down	SATB1	42	hsa-mir-8066
Up	IGF2BP3	52	hsa-mir-5191	Down	ACADL	42	hsa-mir-6134
Up	CDK1	52	hsa-mir-5688	Down	RAB27A	40	hsa-mir-1281
Up	CHEK1	52	hsa-mir-466	Down	EPHX2	40	hsa-mir-1470
Up	NAP1L1	51	hsa-mir-4803	Down	APOC3	40	hsa-mir-548s
Up	MCM7	51	hsa-mir-4283	Down	AVPR1A	40	hsa-mir-1276
Up	DNAH17	51	hsa-mir-4673	Down	CYP4A11	39	hsa-mir-4683
Up	SLC2A1	50	hsa-mir-4434	Down	COLEC10	39	hsa-mir-3713
Up	MCM4	48	hsa-mir-8055	Down	CYP4F11	38	hsa-mir-4439
Up	DEPDC1	48	hsa-mir-4698	Down	CYP4A22	37	hsa-mir-4483
Up	CKAP2L	47	hsa-mir-4729	Down	CXCL8	36	hsa-mir-4426
Up	ZNF610	46	hsa-mir-4459	Down	SDC4	36	hsa-mir-4739
Up	GNG4	46	hsa-mir-1273e	Down	ARHGEF26	36	hsa-mir-1260a
Up	MYBL2	45	hsa-mir-8089	Down	SLC41A2	35	hsa-mir-6134
Up	NETO2	44	hsa-mir-4495	Down	BHLHE40	34	hsa-mir-3941
Up	EIF4A2	43	hsa-mir-300	Down	ICAM1	34	hsa-mir-3975
Up	NCAPD2	43	hsa-mir-8070	Down	CYP2C19	34	hsa-mir-5186
Up	MYCN	43	hsa-mir-6071	Down	FGD4	34	hsa-mir-302f
Up	ROBO1	43	hsa-mir-548aa	Down	RBM47	34	hsa-mir-298
Up	MPZL1	43	hsa-mir-548ab	Down	GFRA1	34	hsa-mir-6129
Up	SRARP	43	hsa-mir-4641	Down	STEAP3	33	hsa-mir-1275
Up	SPC24	43	hsa-mir-5690	Down	PCK1	33	hsa-mir-548aa
Up	COL4A1	42	hsa-mir-892a	Down	SLC1A1	33	hsa-mir-2113
Up	FOXQ1	42	hsa-mir-3973	Down	SOCS3	32	hsa-mir-8062
Up	HS6ST1	42	hsa-mir-4419a	Down	SERPINC1	32	hsa-mir-4794
Up	GINS2	41	hsa-mir-4499	Down	RUNDC3B	31	hsa-mir-4660
Up	SLC29A4	41	hsa-mir-1321	Down	ETS2	31	hsa-mir-3662
Up	PLK1	40	hsa-mir-4779	Down	SLC25A15	31	hsa-mir-3176
Up	PRKAA2	40	hsa-mir-4771	Down	ETFDH	31	hsa-mir-4441
Up	MATN3	40	hsa-mir-3689c	Down	DUSP1	30	hsa-mir-4500
Up	COLEC12	38	hsa-mir-4500	Down	PPARGC1A	30	hsa-mir-6083
Up	PYCR1	38	hsa-mir-920	Down	ACADSB	30	hsa-mir-5100
Up	LYZ	38	hsa-mir-4252	Down	PLAC8	30	hsa-mir-4481
Up	SRD5A3	38	hsa-mir-4306	Down	HAAO	30	hsa-mir-4770
Up	DKK3	38	hsa-mir-4775	Down	CDC37L1	29	hsa-mir-548z
Up	CCNA2	37	hsa-mir-548aw	Down	CYP8B1	29	hsa-mir-422a
Up	ARHGAP11A	37	hsa-mir-548ag	Down	C8A	29	hsa-mir-1299
Up	TRIM59	37	hsa-mir-4511	Down	FMO4	28	hsa-mir-3118
Up	TCTN2	37	hsa-mir-5186	Down	ABCA6	28	hsa-mir-3135b
Up	TGFB2	35	hsa-mir-378f	Down	SGMS2	28	hsa-mir-3609
Up	EPHB2	35	hsa-mir-6077	Down	JUNB	28	hsa-mir-3202
Up	RAB34	34	hsa-mir-4295	Down	FXYP1	28	hsa-mir-3180
Up	GREB1	34	hsa-mir-548s	Down	CES3	27	hsa-mir-3689c
Up	KCNJ10	34	hsa-mir-3655	Down	GOT1	27	hsa-mir-549a
Up	IGDCC3	34	hsa-mir-378d	Down	PTPN3	26	hsa-mir-4801
Up	ZNF738	33	hsa-mir-147a	Down	ECHDC3	26	hsa-mir-562
Up	CCDC88C	33	hsa-mir-636	Down	SLPI	26	hsa-mir-4419b
Up	NDRG3	33	hsa-mir-4478	Down	PON1	26	hsa-mir-7703
Up	LTBP2	33	hsa-mir-8071	Down	LRRFIP1	25	hsa-mir-4267
Up	LRRC1	32	hsa-mir-1193	Down	MGLL	25	hsa-mir-938
Up	TMC7	32	hsa-mir-4719	Down	CYP1A1	25	hsa-mir-4294
Up	PTK7	32	hsa-mir-2110	Down	SLCO1B3	25	hsa-mir-1470
Up	ARHGEF2	32	hsa-mir-5194	Down	TLR4	24	hsa-mir-630

Up	DUSP9	32	hsa-mir-5703	Down	GLRX	24	hsa-mir-608
Up	THY1	32	hsa-mir-4706	Down	PXDC1	24	hsa-mir-4323
Up	SDK1	32	hsa-mir-128-1-5p	Down	ART4	24	hsa-mir-4417
Up	MMP2	31	hsa-mir-451a	Down	SAA1	24	hsa-mir-4792
Up	SOBP	31	hsa-mir-599	Down	ADH1B	24	hsa-mir-568
Up	NCAPH	31	hsa-mir-6129	Down	EXPH5	23	hsa-mir-548p
Up	GSN	31	hsa-mir-8080	Down	ARRDC3	23	hsa-mir-4753-3p
Up	ARL6IP6	30	hsa-mir-4301	Down	WDR72	23	hsa-mir-4719
Up	LAPTM4B	30	hsa-mir-548aj-5p	Down	SERPINE1	22	hsa-mir-3977
Up	ATP8B2	30	hsa-mir-3689d	Down	SERPINA3	22	hsa-mir-5096
Up	COL1A2	30	hsa-mir-6090	Down	TAT	22	hsa-mir-3689d
Up	FDFT1	30	hsa-mir-4742-5p	Down	MT1E	21	hsa-mir-107
Up	ST8SIA3	30	hsa-mir-507	Down	DUSP5	21	hsa-mir-16-1-3p
Up	SLC1A4	29	hsa-mir-603	Down	FGG	21	hsa-mir-623
Up	DEPDC1B	29	hsa-mir-548z	Down	AKAP12	21	hsa-mir-8057
Up	CDC6	28	hsa-mir-4421	Down	F9	21	hsa-mir-326
Up	ATP1A2	28	hsa-mir-588	Down	NDST3	21	hsa-mir-665
Up	SPATS2	27	hsa-mir-4680-3p	Down	DAO	21	hsa-mir-1587
Up	SLC39A10	27	hsa-mir-591	Down	PTGS2	20	hsa-mir-137
Up	MAPK13	27	hsa-mir-8082	Down	MAP3K5	20	hsa-mir-5191
Up	WDR76	27	hsa-mir-4755-3p	Down	CYP4V2	20	hsa-mir-378a-5p
Up	TBX4	27	hsa-mir-6083	Down	HOOK1	20	hsa-mir-548n
Up	KNTC1	27	hsa-mir-633	Down	AKR1D1	20	hsa-mir-660-3p
Up	E2F5	26	hsa-mir-6501-3p	Down	CFHR5	20	hsa-mir-6777-3p
Up	AXIN2	26	hsa-mir-3617-5p	Down	STEAP4	19	hsa-mir-548ac
Up	FREM2	26	hsa-mir-297	Down	PPP1R1A	19	hsa-mir-378g
Up	PIK3R2	25	hsa-mir-3135b	Down	SLC15A1	19	hsa-mir-3929
Up	PGAP1	25	hsa-mir-4684-5p	Down	SLC4A4	19	hsa-mir-6727-3p
Up	RPS27	24	hsa-mir-4461	Down	GCLM	18	hsa-mir-3155a
Up	MCM5	24	hsa-mir-4692	Down	RGS2	18	hsa-mir-4328
Up	GNA12	24	hsa-mir-1266-5p	Down	PAPSS2	18	hsa-mir-5011-5p
Up	VCAN	24	hsa-mir-643	Down	CTH	18	hsa-mir-3190-5p
Up	CENPI	24	hsa-mir-1200	Down	FBG	18	hsa-mir-6855-5p
Up	HJURP	24	hsa-mir-1827	Down	C6	18	hsa-mir-6511a-3p
Up	MFAP2	24	hsa-mir-4454	Down	DTX1	18	hsa-mir-6888-3p
Up	SALL2	23	hsa-mir-613	Down	GLYAT	18	hsa-mir-3193
Up	SMOC2	23	hsa-mir-8055	Down	TENM1	18	hsa-mir-7154-5p
Up	CDCA7	22	hsa-mir-550a-3-5p	Down	CYP4F3	18	hsa-mir-4793-3p
Up	NPNT	22	hsa-mir-526b-3p	Down	ABCB11	17	hsa-mir-4700-3p
Up	B3GALNT1	22	hsa-mir-890	Down	AKR7L	17	hsa-mir-891a-3p
Up	CDON	22	hsa-mir-4455	Down	CYP3A5	17	hsa-mir-599
Up	RHNO1	22	hsa-mir-661	Down	APOL1	17	hsa-mir-1304-3p
Up	DLGAP5	21	hsa-mir-520b	Down	HSD17B13	17	hsa-mir-6500-5p
Up	LSM2	21	hsa-mir-6127	Down	NAMPT	16	hsa-mir-4662a-5p
Up	KIFC1	20	hsa-mir-4530	Down	NR4A2	16	hsa-mir-217
Up	NCAPG	20	hsa-mir-421	Down	SLC46A3	16	hsa-mir-6796-3p
Up	PCGF2	20	hsa-mir-3685	Down	SUCLG2	16	hsa-mir-2355-5p
Up	EDIL3	20	hsa-mir-548ac	Down	LYVE1	16	hsa-mir-4691-3p
Up	TMEM98	20	hsa-mir-641	Down	ADH4	16	hsa-mir-3944-5p
Up	EDARADD	20	hsa-mir-4674	Down	SLC38A4	16	hsa-mir-3150b-3p
Up	APCDD1	20	hsa-mir-7150	Down	CYP1A2	15	hsa-mir-1273g-3p
Up	TRIB2	19	hsa-mir-548z	Down	GCH1	15	hsa-mir-4802-3p
Up	TET1	19	hsa-mir-3686	Down	GREM2	15	hsa-mir-6072
Up	TUBG1	19	hsa-mir-4477a	Down	VNN3	15	hsa-mir-3916
Up	SNRPB	19	hsa-mir-4457	Down	KYNU	15	hsa-mir-4494
Up	LDOC1	19	hsa-mir-4519	Down	RASD1	15	hsa-mir-6883-5p
Up				Down			hsa-mir-550b-2-5p
Up	CDKN3	18	hsa-mir-4772-3p		EHHADH	15	hsa-mir-544a
Up	CENPK	18	hsa-mir-507	Down	ACACB	15	hsa-mir-5011-3p
Up	HUNK	18	hsa-mir-3157-5p	Down	LRG1	15	hsa-mir-622
Up	PFKM	17	hsa-mir-1199-5p	Down	SCP2	14	hsa-mir-4703-3p
Up	CKAP2	17	hsa-mir-3609	Down	MYO1B	14	hsa-mir-610
Up	PSPH	17	hsa-mir-4444	Down	ZDBF2	14	hsa-mir-296-3p
Up	TOP2A	17	hsa-mir-520d-5p	Down	MACF1	13	hsa-mir-606
Up	MAD2L1	17	hsa-mir-3977	Down	ASS1	13	hsa-mir-5196-3p
Up	BCL11A	17	hsa-mir-6810-5p	Down	ADAMTS1	13	hsa-mir-5088-3p
Up	PRC1	17	hsa-mir-4473	Down	GPD1	13	hsa-mir-620
Up	PARD3B	17	hsa-mir-4267	Down	HAL	13	hsa-mir-6088
Up	STIL	16	hsa-mir-4266	Down	ABAT	13	hsa-mir-6877-3p
Up	DKK1	16	hsa-mir-3177-5p	Down	DNASE1L3	13	hsa-mir-5004-5p
Up	BCAM	16	hsa-mir-634	Down	VNN1	13	hsa-mir-1260b
Up	ALYREF	16	hsa-mir-4666a-5p	Down	REPS2	12	hsa-mir-7113-3p
Up	DCDC2	16	hsa-mir-5692a	Down	VIPR1	12	hsa-mir-2110
Up	ACLY	15	hsa-mir-1229-3p	Down	SLC27A2	11	
Up	KCNJ5	15	hsa-mir-6514-3p	Down	USP2	11	

Up	MCTP1	15	hsa-mir-4755-5p	Down	NNMT	11	hsa-mir-6500-3p
Up	UHRF1	14	hsa-mir-146a-5p	Down	APOA5	11	hsa-mir-4780
Up	RPS5	14	hsa-mir-455-3p	Down	ACSL1	10	hsa-mir-142-3p
Up	SMYD2	14	hsa-mir-4516	Down	MBOAT1	10	hsa-mir-6499-5p
Up	FOXM1	14	hsa-mir-630	Down	C1S	10	hsa-mir-4701-5p
Up	MCM3	14	hsa-mir-147b	Down	ABCC9	10	hsa-mir-890
Up	NREP	14	hsa-mir-571	Down	BMP10	10	hsa-mir-4789-3p
Up	ZNF362	14	hsa-mir-7106-3p	Down	AADAC	10	hsa-mir-1179
Up	ZSWIM5	14	hsa-mir-4325	Down	HGFAC	10	hsa-mir-3607-3p
Up	FREM1	14	hsa-mir-934	Down	HPR	10	hsa-mir-4311
Up	TYMS	13	hsa-mir-433-3p	Down	SLC6A1	10	hsa-mir-7845-5p
Up	ECT2	13	hsa-mir-3591-5p	Down	C7	10	hsa-mir-7162-3p
Up	GJA5	13	hsa-mir-4701-3p	Down	AGL	9	hsa-mir-191-5p
Up	RCN2	13	hsa-mir-1910-3p	Down	FGF14	9	hsa-mir-6867-5p
Up	KIF11	13	hsa-mir-6507-5p	Down	SLITRK3	9	hsa-mir-3130-3p
Up	IMPDH2	12	hsa-mir-378a-5p	Down	DMGDH	9	hsa-mir-518e-3p
Up	DLK1	12	hsa-mir-4299	Down	UGT2B10	9	hsa-mir-6804-3p
Up	CDC20	12	hsa-mir-188-5p	Down	BAAT	9	hsa-mir-5590-3p
Up	CENPF	12	hsa-mir-1226-3p	Down	SCN9A	9	hsa-mir-5480-3p
Up	ARHGEF28	12	hsa-mir-6771-3p	Down	GRAMD1C	9	hsa-mir-548az-3p
Up	SNTG1	12	hsa-mir-513c-3p	Down	GYS2	8	hsa-mir-4659a-3p
Up	SKA1	12	hsa-mir-519e-5p	Down	RND3	8	hsa-mir-106a-5p
Up	CRABP2	12	hsa-mir-449a	Down	NR3C2	8	hsa-mir-548i
Up	GLMP	12	hsa-mir-7162-3p	Down	FCN2	8	hsa-mir-501-3p
Up	MFGE8	12	hsa-mir-4442	Down	EGR1	8	hsa-mir-377-3p
Up	CKB	11	hsa-mir-551a	Down	CFHR3	8	hsa-mir-5007-3p
Up	GPX7	11	hsa-mir-1255a	Down	KMO	8	hsa-mir-302c-5p
Up	HELLS	11	hsa-mir-138-2-3p	Down	C1R	8	hsa-mir-518c-5p
Up	PRKD1	11	hsa-mir-6740-3p	Down	HPGD	7	hsa-mir-4742-3p
Up	ALDH18A1	11	hsa-mir-4709-3p	Down	ST3GAL6	7	hsa-mir-526b-5p
Up	REG3A	11	hsa-mir-2277-3p	Down	ADGRG7	7	hsa-mir-4465
Up	RPL22L1	11	hsa-mir-3614-5p	Down	RASGEF1B	7	hsa-mir-1287-3p
Up	RAPGEFL1	10	hsa-mir-5692c	Down	CRP	7	hsa-mir-4418
Up	RAD51AP1	10	hsa-mir-346	Down	AGXT	7	hsa-mir-3606-5p
Up	SKP2	10	hsa-mir-3613-3p	Down	SLC22A1	7	hsa-mir-466
Up	PDGFRB	10	hsa-mir-224-5p	Down	UGP2	6	hsa-mir-32-5p
Up	ITGA6	10	hsa-mir-140-3p	Down	GBP2	6	hsa-mir-433-3p
Up	BCL9	10	hsa-mir-30c-2-3p	Down	HGF	5	hsa-mir-199a-3p
Up	SULT1C4	10	hsa-mir-6832-3p	Down	CPNE8	5	hsa-mir-4719
Up	MCM2	10	hsa-mir-501-3p	Down	CXCL2	5	hsa-mir-223-3p
Up	SORT1	10	hsa-mir-1185-5p	Down	NFKBIZ	5	hsa-mir-215-5p
Up	CDH13	10	hsa-mir-4307	Down	CXCL14	5	hsa-mir-2276-3p
Up	AACS	10	hsa-mir-4466	Down	SOCS2	4	hsa-mir-16-5p
Up	VWCE	10	hsa-mir-5088-3p	Down	NTN4	4	hsa-mir-20a-5p
Up	FAM169A	10	hsa-mir-3133	Down	ACAT1	4	hsa-mir-23b-3p
Up	IGF2BP2	9	hsa-mir-129-5p	Down	CA2	4	hsa-mir-99b-3p
Up	NT5DC2	9	hsa-mir-760	Down	CYP2C8	4	hsa-mir-107
Up	DTL	9	hsa-mir-138-1-3p	Down	ABCC3	4	hsa-mir-197-3p
Up	ASF1B	9	hsa-mir-3677-5p	Down	LRRK2	4	hsa-mir-582-3p
Up	HSDL1	9	hsa-mir-340-5p	Down	FGFR2	4	hsa-mir-19b-1-5p
Up				Down			hsa-mir-1185-1-3p
Up	TNFSF4	9	hsa-mir-4303		TMOD1	4	hsa-mir-616-3p
Up	MAP4K4	8	hsa-mir-5583-3p	Down	BBOX1	4	hsa-mir-6859-3p
Up	PTTG1	8	hsa-mir-17-5p	Down	MFAP3L	4	hsa-mir-15a-5p
Up	FADS2	8	hsa-mir-423-3p	Down	RIDA	3	hsa-mir-22-3p
Up	MSH2	8	hsa-mir-101-3p	Down	LBP	3	hsa-mir-125b-5p
Up	MEG3	8	hsa-mir-770-5p	Down	S100A8	3	hsa-mir-128-3p
Up	SPDL1	8	hsa-mir-944	Down	ACADM	3	hsa-mir-124-3p
Up	UXS1	7	hsa-mir-519d-3p	Down	F13B	3	hsa-mir-181a-5p
Up	TTK	7	hsa-mir-376a-3p	Down	CFI	3	hsa-mir-124-3p
Up	PRR15L	7	hsa-mir-590-3p	Down	VNN2	3	hsa-mir-511-5p
Up	RASL11B	7	hsa-mir-4652-3p	Down	SLCO1B1	3	hsa-mir-4448
Up	SKA3	6	hsa-mir-6719-3p	Down	MRC1	3	hsa-mir-7-5p
Up	ASPM	6	hsa-mir-218-5p	Down	ARG1	3	hsa-mir-92a-3p
Up	FANCI	6	hsa-mir-505-3p	Down	PTS	3	hsa-mir-375
Up	GINS1	6	hsa-mir-19a-3p	Down	BIRC3	3	hsa-mir-210-5p
Up	DKK2	6	hsa-mir-27a-3p	Down	CFB	3	hsa-mir-183-5p
Up	MCM6	6	hsa-mir-1180-3p	Down	NFIL3	3	hsa-mir-219a-5p
Up	LEF1	6	hsa-mir-34c-3p	Down	MT1F	3	hsa-mir-5087
Up	SPP1	6	hsa-mir-193b-3p	Down	OIT3	3	hsa-mir-212-3p
Up	DLX5	6	hsa-mir-203a-3p	Down	BMPER	3	hsa-mir-383-5p
Up	LGR5	6	hsa-mir-6793-3p	Down	DIO1	3	hsa-mir-381-3p
Up	CDCA2	6	hsa-mir-5586-5p	Down	ANO1	3	hsa-mir-130b-3p
Up	FRRS1L	6	hsa-mir-501-5p	Down	CYP2C9	3	hsa-mir-10a-5p
Up	ZNF382	6	hsa-mir-5095	Down	CPED1	2	

Up	CCNB2	5	hsa-let-7f-5p	Down	PCK2	2	hsa-mir-24-3p
Up	FKBP10	5	hsa-let-7c-5p	Down	GLS2	2	hsa-mir-16-5p
Up	EHMT2	5	hsa-mir-17-5p	Down	AADAT	2	hsa-mir-103a-3p
Up	KIF20A	5	hsa-mir-23a-3p	Down	MT1M	2	hsa-mir-24-3p
Up	CD34	5	hsa-mir-106b-5p	Down	SULT2A1	2	hsa-mir-335-5p
Up	GSTP1	5	hsa-mir-133a-3p	Down	AGPAT2	2	hsa-mir-744-5p
Up	SLC7A6	5	hsa-mir-30a-3p	Down	APOF	2	hsa-mir-324-5p
Up	USP21	5	hsa-mir-331-3p	Down	BCHE	2	hsa-mir-26b-5p
Up	CTSC	5	hsa-mir-199a-5p	Down	HGD	2	hsa-mir-335-5p
Up	TRPC1	5	hsa-mir-192-5p	Down	HSD11B1	2	hsa-mir-26b-5p
Up	ANLN	5	hsa-mir-497-5p	Down	IL13RA2	2	hsa-mir-148b-3p
Up	C1orf198	5	hsa-mir-31-3p	Down	CHST9	2	hsa-mir-92a-3p
Up	PBK	5	hsa-mir-4699-3p	Down	INHBE	2	hsa-mir-98-5p
Up	ZMYM3	4	hsa-mir-330-3p	Down	MT1X	2	hsa-mir-1225-3p
Up	NRSN2	4	hsa-let-7e-5p	Down	ABCA8	2	hsa-mir-192-5p
Up	GPD1L	4	hsa-mir-210-3p	Down	RND1	2	hsa-mir-199a-5p
Up	COL15A1	4	hsa-mir-29c-3p	Down	C5	2	hsa-mir-10a-5p
Up	OXCT1	4	hsa-mir-100-5p	Down	ALDH1A1	2	hsa-mir-140-5p
Up	SFRP4	4	hsa-mir-203a-5p	Down	FOSB	2	hsa-mir-663a
Up	FERMT1	4	hsa-mir-9-5p	Down	HERC5	2	hsa-mir-3529-3p
Up	MMP11	4	hsa-mir-135a-5p	Down	AMDHD1	2	hsa-mir-1-3p
Up	CDC25C	4	hsa-mir-141-3p	Down	ALDOB	2	hsa-mir-378a-3p
Up	ZAP70	4	hsa-mir-631	Down	C4BPB	2	hsa-mir-142-3p
Up	WIF1	4	hsa-mir-374a-5p	Down	NRG1	2	hsa-mir-125a-3p
Up	ERP27	4	hsa-mir-210-3p	Down	GDA	2	hsa-mir-492
Up	CDH11	4	hsa-mir-200c-3p	Down	RETREG1	2	hsa-mir-1260b
Up	FRZB	4	hsa-mir-125b-1-3p	Down	ENPEP	2	hsa-mir-320a
Up	HEY1	4	hsa-mir-410-3p	Down	CYP26A1	2	hsa-mir-132-3p
Up	LPCAT2	4	hsa-mir-449c-5p	Down	CYP39A1	2	hsa-mir-9-5p
Up	MAGED1	4	hsa-let-7g-3p	Down	GAREM1	2	hsa-mir-29a-5p
Up	SQLE	3	hsa-mir-205-5p	Down	SLC25A18	2	hsa-mir-148b-3p
Up	SERPINE2	3	hsa-mir-30e-3p	Down	FYB2	2	hsa-mir-335-5p
Up	ERCC2	3	hsa-mir-770-5p	Down	LPIN2	2	hsa-mir-769-5p
Up	ETV1	3	hsa-mir-20a-5p	Down	OGDHL	2	hsa-mir-130b-5p
Up	RFC3	3	hsa-mir-93-5p	Down	ALAS1	2	hsa-mir-423-3p
Up	BEX1	3	hsa-mir-15b-5p	Down	AASS	2	hsa-mir-591
Up	RHOBTB1	3	hsa-mir-31-5p	Down	ABCA10	2	hsa-mir-1281
Up	LRP4	3	hsa-mir-148b-3p	Down	UROC1	1	hsa-let-7e-5p
Up	LRRN1	3	hsa-mir-30a-5p	Down	CRHBP	1	hsa-mir-16-5p
Up	TSPAN18	3	hsa-mir-597-5p	Down	FCGR2B	1	hsa-mir-18a-5p
Up	SEMA3C	3	hsa-mir-374b-5p	Down	PHYH	1	hsa-mir-20a-5p
Up	PTP4A3	3	hsa-mir-551a	Down	HRG	1	hsa-mir-23a-3p
Up	NUF2	3	hsa-mir-215-5p	Down	AOX1	1	hsa-mir-26b-5p
Up	TICRR	3	hsa-mir-192-5p	Down	CYP2D7	1	hsa-mir-26b-5p
Up	RELN	3	hsa-mir-138-5p	Down	CYP2D6	1	hsa-mir-26b-5p
Up	GPC3	3	hsa-mir-520c-3p	Down	FMO3	1	hsa-mir-26b-5p
Up	SOAT2	3	hsa-mir-377-5p	Down	GSTA1	1	hsa-mir-26b-5p
Up	LIX1	3	hsa-mir-561-3p	Down	OTC	1	hsa-mir-26b-5p
Up	PAPSS1	2	hsa-mir-100-5p	Down	XDH	1	hsa-mir-26b-5p
Up	TOX3	2	hsa-let-7b-5p	Down	BLNK	1	hsa-mir-26b-5p
Up	PRTG	2	hsa-mir-9-5p	Down	FGGY	1	hsa-mir-26b-5p
Up	RNASE1	2	hsa-mir-26b-5p	Down	MT1P3	1	hsa-mir-26b-5p
Up	FMOD	2	hsa-mir-21-5p	Down	SLC22A7	1	hsa-mir-29a-3p
Up	WFS1	2	hsa-mir-7-5p	Down	CTSL	1	hsa-mir-30a-5p
Up	DKK4	2	hsa-mir-25-3p	Down	CES1	1	hsa-mir-197-3p
Up	MME	2	hsa-mir-1-3p	Down	PIPOX	1	hsa-mir-197-3p
Up	SUPT3H	2	hsa-mir-15b-5p	Down	RDH16	1	hsa-mir-7-5p
Up	TP53I3	2	hsa-mir-504-5p	Down	CLEC4G	1	hsa-mir-7-5p
Up	P4HA2	2	hsa-mir-9-5p	Down	SHBG	1	hsa-mir-10a-5p
Up	SV2A	2	hsa-mir-222-3p	Down	GADD45G	1	hsa-mir-181a-5p
Up	TTLL4	2	hsa-mir-877-3p	Down	ALPL	1	hsa-mir-204-5p
Up	COL2A1	2	hsa-mir-29b-3p	Down	ABLM3	1	hsa-mir-214-3p
Up	PLK4	2	hsa-mir-215-5p	Down	ALPK2	1	hsa-mir-214-3p
Up	NEIL3	2	hsa-mir-192-5p	Down	CYP3A4	1	hsa-mir-27b-3p
Up	KIF18A	2	hsa-mir-215-5p	Down	CDO1	1	hsa-mir-124-3p
Up	SULT1C2	2	hsa-mir-7-5p	Down	HSD17B6	1	hsa-mir-124-3p
Up	CD24	2	hsa-mir-373-3p	Down	ETNPPL	1	hsa-mir-124-3p
Up	TARBP1	2	hsa-mir-29c-3p	Down	AZGP1	1	hsa-mir-128-3p
Up	DACT1	2	hsa-mir-124-3p	Down	KNG1	1	hsa-mir-128-3p
Up	MPPED2	2	hsa-mir-448	Down	SLC17A4	1	hsa-mir-128-3p
Up	HTR1D	2	hsa-mir-196b-5p	Down	CYP4Z1	1	hsa-mir-9-5p
Up	KRT19	2	hsa-mir-193b-3p	Down	AKR1C8P	1	hsa-mir-9-5p
Up	MAGED2	2	hsa-mir-877-3p	Down	IL1RN	1	hsa-mir-125a-5p
Up	RNF43	2	hsa-mir-550a-5p	Down	MASP1	1	hsa-mir-125a-5p
Up	NRCAM	2	hsa-mir-708-5p	Down	CFH	1	hsa-mir-146a-5p

Up	ASIC1	1	hsa-let-7b-5p	Down	ITIH4	1	hsa-mir-375
Up	NUSAP1	1	hsa-let-7b-5p	Down	MYOM1	1	hsa-mir-148b-3p
Up	ASPSCR1	1	hsa-let-7b-5p	Down	FETUB	1	hsa-mir-148b-3p
Up	PIGU	1	hsa-let-7b-5p	Down	C8G	1	hsa-mir-335-5p
Up	C19orf48	1	hsa-let-7e-5p	Down	CD5L	1	hsa-mir-335-5p
Up	SERPINI1	1	hsa-mir-21-5p	Down	CD14	1	hsa-mir-335-5p
Up	CCDC34	1	hsa-mir-21-5p	Down	CDA	1	hsa-mir-335-5p
Up	NOTUM	1	hsa-mir-24-3p	Down	CFHR2	1	hsa-mir-335-5p
Up	CACNB4	1	hsa-mir-26b-5p	Down	IRF6	1	hsa-mir-335-5p
Up	EFNA4	1	hsa-mir-26b-5p	Down	NPY1R	1	hsa-mir-335-5p
Up	ETV4	1	hsa-mir-26b-5p	Down	CFP	1	hsa-mir-335-5p
Up	MEP1A	1	hsa-mir-26b-5p	Down	PON3	1	hsa-mir-335-5p
Up	B3GALT1	1	hsa-mir-26b-5p	Down	SLC17A3	1	hsa-mir-335-5p
Up	ODAM	1	hsa-mir-26b-5p	Down	MMRN1	1	hsa-mir-335-5p
Up	FBLN1	1	hsa-mir-30a-3p	Down	GNMT	1	hsa-mir-335-5p
Up	SPARCL1	1	hsa-mir-98-5p	Down	SPATA6L	1	hsa-mir-335-5p
Up	PCSK5	1	hsa-mir-107	Down	ALDH8A1	1	hsa-mir-335-5p
Up	FAM111B	1	hsa-mir-192-5p	Down	LPAL2	1	hsa-mir-335-5p
Up	USP11	1	hsa-mir-10a-5p	Down	RSPO3	1	hsa-mir-335-5p
Up	GFRA3	1	hsa-mir-34a-5p	Down	CYP4F22	1	hsa-mir-335-5p
Up	SLCO2A1	1	hsa-mir-181a-5p	Down	ASPG	1	hsa-mir-335-5p
Up	BMP4	1	hsa-let-7i-5p	Down	FAM99A	1	hsa-mir-335-5p
Up	SPINK1	1	hsa-mir-1-3p	Down	ADRA1A	1	hsa-mir-484
Up	C1orf74	1	hsa-mir-27b-3p	Down	TTC36	1	hsa-mir-484
Up	OLFML2B	1	hsa-mir-30b-5p	Down	ANO5	1	hsa-mir-432-5p
Up	CPA6	1	hsa-mir-124-3p	Down	GPLD1	1	hsa-mir-505-3p
Up	MYH7B	1	hsa-mir-124-3p	Down	PAMR1	1	hsa-mir-93-3p
Up	FRAS1	1	hsa-mir-124-3p	Down	ECM1	1	hsa-mir-486-3p
Up	HDAC11	1	hsa-mir-145-5p	Down	UGT2B7	1	hsa-mir-216b-5p
Up	GSTA4	1	hsa-mir-185-5p	Down	TIMD4	1	hsa-mir-4282
Up	AFP	1	hsa-mir-106b-5p				
Up	CHGB	1	hsa-mir-375				
Up	NDN	1	hsa-mir-148b-3p				
Up	CST1	1	hsa-mir-335-5p				
Up	DYNC1H1	1	hsa-mir-335-5p				
Up	RBP1	1	hsa-mir-335-5p				
Up	TSPAN5	1	hsa-mir-335-5p				
Up	GJB6	1	hsa-mir-335-5p				
Up	FAM3B	1	hsa-mir-335-5p				
Up	OLFML3	1	hsa-mir-335-5p				
Up	ABHD12B	1	hsa-mir-335-5p				
Up	STOX1	1	hsa-mir-335-5p				
Up	LYPD1	1	hsa-mir-423-3p				
Up	FGF20	1	hsa-mir-433-3p				
Up	NYNRIN	1	hsa-mir-484				
Up	POLE2	1	hsa-mir-193b-3p				
Up	NDC80	1	hsa-mir-193b-3p				
Up	TPX2	1	hsa-mir-193b-3p				
Up	MND1	1	hsa-mir-193b-3p				
Up	TMEM99	1	hsa-mir-769-3p				
Up	MAP7D2	1	hsa-mir-505-5p				

Degree – No of miRNA interact with target gene. We taken any one miRNA in table.

Table 9 TF - target gene interaction table

Regulation	TF	Degree	Target Gene	Regulation	TF	Degree	Target Gene
Up	KLF9	121	DCDC2	Down	ATF3	115	MASP2
Up	TFDP1	120	WFS1	Down	YY1	82	OTC
Up	ZNF580	117	ERCC2	Down	MYBL2	76	ACMSD
Up	MXD3	107	DLX5	Down	MBD4	76	AGXT
Up	SMAD5	105	CCNB1	Down	HNF4G	76	SLC15A1
Up	POLR2A	103	HIST1H3G	Down	TFDP1	62	G0S2
Up	ELF1	102	VCAN	Down	KLF16	61	ASPDH
Up	ZNF24	100	RRM2	Down	NR2F1	56	SOD2
Up	ATF1	96	ABHD12B	Down	ATF1	55	SCN9A
Up	MAZ	96	TMC7	Down	ZBTB33	54	SHMT1
Up	GTF2E2	95	MCM5	Down	KLF9	52	ABCC3
Up	IRF1	94	EDARADD	Down	MLX	51	PLA2G2A
Up	DMAP1	94	SLC13A3	Down	SOX13	51	TSKU
Up	CREB3L1	93	ARL6IP6	Down	NR2F6	49	ALAS1
Up	SSRP1	93	VWCE	Down	ZNF580	49	CYP4F11
Up	NR2F6	93	GNG4	Down	SSRP1	48	CREB3L3

Up	KLF16	92	CCNA2	Down	EZH2	47	CDA
Up	PHF8	91	HIST1H2BF	Down	MXD3	46	JUNB
Up	KDM5B	91	MATN3	Down	MAZ	44	CD14
Up	SAP30	91	NRSN2	Down	GATA4	44	HP
Up	SIN3A	90	PAPSS1	Down	GATAD1	44	INHBC
Up	ZBTB26	88	CDCA7	Down	MXD4	42	IL1RN
Up	CHD1	86	KPNA2	Down	FOSL1	41	C1orf168
Up	ELK1	86	RAD51AP1	Down	KDM1A	41	KMO
Up	KLF11	85	AURKA	Down	ZBTB26	41	MAT1A
Up	ZNF76	85	SNORD44	Down	THRB	41	SDC4
Up	TAZF	84	STIL	Down	RAD21	40	ACADSB
Up	ZFP2	83	CD34	Down	RCOR2	40	C1RL
Up	HBP1	82	AACS	Down	ZNF197	40	PCK1
Up	MBD1	82	FBLN1	Down	CREB1	40	RBM47
Up	ARID4B	81	SLC6A11	Down	RERE	40	WEE1
Up	NFRKB	80	ETV1	Down	HMG20A	39	GPR128
Up	BCL6	79	ANLN	Down	BCL6	38	LEAP2
Up	ZEB1	78	FLVCR1	Down	IRF1	38	RASD1
Up	NCOR1	78	SNORD81	Down	DMAP1	38	CP
Up	ZFX	78	TET1	Down	ZNF24	38	TNFSF14
Up	SOX13	74	FAM3B	Down	KDM5B	37	CFB
Up	ZNF324	74	SPC24	Down	SAP30	37	ECHDC3
Up	ZBTB11	73	NRCAM	Down	KLF11	37	F11
Up	ZBTB7A	72	CDKN3	Down	STAT3	37	HSD11B1
Up	ZNF501	72	COL2A1	Down	PHF8	37	INPP1
Up	TFE3	72	HIST2H2AC	Down	HMG20B	37	LBP
Up	DDX20	72	RAB34	Down	MBD1	37	PHYH
Up	MLX	72	SNORA65	Down	NR2F2	36	APCS
Up	WT1	71	BCL9	Down	THAP1	36	CYP2B6
Up	ZNF394	71	CKAP2	Down	ZNF644	36	CYP3A5
Up	GATA4	71	SKA1	Down	TFE3	36	DUSP1
Up	NRF1	71	SNORA71C	Down	NFIA	36	HMGCS2
Up	HMG20B	70	PRR15L	Down	HBP1	36	NR1I3
Up	GTF2F1	69	HIST1H2BD	Down	SIN3A	36	SRD5A1
Up	MYNN	69	KIF18A	Down	ARID4B	35	SHBG
Up	ZNF71	69	PIK3R2	Down	ZBTB11	34	CSRNP1
Up	TGIF2	69	SLC5A9	Down	ZFP2	34	HOOK1
Up	ZFP37	68	MKI67	Down	SMAD5	34	LONRF3
Up	ETS1	68	MMP2	Down	ELF1	34	MUT
Up	ZFP64	68	MYH7B	Down	RXR8	34	SUCLG2
Up	NR2F1	67	CDK1	Down	ZNF639	33	C1S
Up	MXD4	67	ZNF704	Down	TFAP4	33	CYP1A1
Up	ZNF644	66	RNASE1	Down	FOXA3	33	MT1L
Up	ZNF101	65	ECT2	Down	ELF3	33	MT1M
Up	KLF1	65	OXCT1	Down	GATAD2A	33	TAT
Up	KDM5A	64	DLGAP5	Down	TGIF2	32	PPARGC1A
Up	FOSL1	64	ENPP3	Down	NFRKB	31	AGL
Up	E2F4	64	SGOL1	Down	ELK1	31	C8G
Up	FOXJ2	64	SPP1	Down	ZFP64	31	LRRFIP1
Up	RERE	63	B3GALT1	Down	CEBPG	31	WDR72
Up	KLF7	63	CKB	Down	ETV4	30	C8orf4
Up	ZNF197	63	DUSP9	Down	NRF1	30	DUSP5
Up	RCOR2	63	MEG3	Down	DRAP1	29	MT1E
Up	L3MBTL2	63	MELK	Down	RARA	29	SEC14L2
Up	SMARCA5	63	RELN	Down	ZFX	29	TP53INP1
Up	NR2C2	63	TP53I3	Down	IRF4	28	ACSL1
Up	CBFB	62	PRIM1	Down	ZNF175	28	BMP10
Up	CREM	62	PTP4A3	Down	WRNIP1	28	CFP
Up	MLLT1	61	HIST1H2BB	Down	FOXMI	28	CYP4V2
Up	THRB	61	LGR5	Down	NR2C2	28	FGGY
Up	PPARG	61	SQLE	Down	SMAD4	28	MT1JP
Up	GATAD1	60	H2AFZ	Down	SP1	27	EGR1
Up	ELF3	60	NREP	Down	ZBTB7A	27	FOSB
Up	ZNF2	59	ALDH18A1	Down	TEAD3	27	GPD1
Up	NR4A1	59	FKBP10	Down	ZFP37	27	GREM2
Up	KDM1A	59	HTR1D	Down	ZNF589	27	HPD
Up	BCOR	59	IGF2BP1	Down	BCL11B	27	TTC39C
Up	RARA	59	KNTC1	Down	SUZ12	26	GFRA1
Up	ZNF589	59	PARPBP	Down	MLLT1	26	GLS2
Up	ARNT	59	SLC2A1	Down	CHD1	26	GPT
Up	ESRRA	59	SPATS2	Down	ZNF76	26	HHIP
Up	ZHX2	59	TBX4	Down	NR4A1	26	INSIG1
Up	HDGF	59	UBE2T	Down	ZEB1	26	MFSD2A
Up	BCL11B	58	BCAM	Down	ZNF501	26	RND3
Up	GATAD2A	58	FDFT1	Down	CREB3L1	25	ABCA9

Up	NFYC	58	FRAS1	Down	CTCF	25	BMPER
Up	MBD2	58	SV2A	Down	ZNF71	25	CPNE8
Up	SMAD4	57	DPEP1	Down	FOXJ2	25	FOS
Up	ID3	57	HIST1H2BH	Down	MEF2D	25	GLYAT
Up	PML	57	RPS5	Down	ZNF394	25	LIFR
Up	RFXANK	56	BMP4	Down	ZHX2	25	TRIB1
Up	REST	56	FAM169A	Down	POLR2A	24	APOL1
Up	KLF13	56	HDAC11	Down	ZNF263	24	CDO1
Up	ARID1B	56	NCAPH	Down	RFXANK	24	CETP
Up	INSM2	56	PLK4	Down	MYNN	24	MAP7
Up	ZBTB33	56	RHBG	Down	BCL11A	24	REEP6
Up	RXR8	56	SOAT2	Down	SOX5	24	SLC27A2
Up	KLF8	56	TP53	Down	DPF2	24	TMOD1
Up	ZNF639	54	DEPDC1	Down	GTF2E2	23	CXCL2
Up	CCNT2	54	HIST1H4E	Down	ZNF423	23	SOCS3
Up	NFIL3	54	ODAM	Down	ID3	22	ABHD2
Up	SP3	54	ZSWIM5	Down	ESRRA	22	ACAT1
Up	ADNP	53	HEY1	Down	NFYC	22	ACSM3
Up	THRAP3	53	HIST1H4L	Down	L3MBTL2	22	ADAMTS1
Up	MEF2D	53	MPZL1	Down	TEAD1	22	BAAT
Up	WRNIP1	53	PRC1	Down	KLF1	22	ETS2
Up	ZNF384	53	RAPGEFL1	Down	ZNF2	22	GADD45B
Up	GABPA	53	TDGF1	Down	SP2	22	GLRX
Up	POLR2H	53	TRIM59	Down	RNF2	21	AKAP12
Up	SMARCA4	52	ARHGEF2	Down	CEBPA	21	CYP4F3
Up	SIRT6	52	E2F5	Down	ATF4	21	FETUB
Up	HMBOX1	52	HIST1H3J	Down	GLIS2	21	FXDY1
Up	NCOA1	52	PCGF2	Down	SMARCA5	21	LRG1
Up	SP1	52	RGN2	Down	HDGF	21	MMRN1
Up	SP7	52	ST8SIA3	Down	CTBP2	21	MT1DP
Up	CREB1	51	PRKAA2	Down	GATA2	21	PIPOX
Up	SOX5	51	SULT1C2	Down	CREM	21	PRG4
Up	FOXA3	51	TNFSF4	Down	E2F5	21	SPTBN2
Up	TRIM22	50	ASPSR1	Down	GABPA	20	CFH
Up	ZNF83	50	HIST1H2AL	Down	HMG3	20	CYP26A1
Up	GTF2A2	50	HIST1H3E	Down	KLF8	20	CYP4X1
Up	ZKSCAN1	50	KIAA0101	Down	PBX2	20	FGF
Up	ATF3	50	SLC1A4	Down	FOSL2	20	KCND3
Up	ZNF423	50	SUPT3H	Down	BACH1	20	LPIN2
Up	GATA2	49	TNFRSF19	Down	MIXL1	20	SULT2A1
Up	NFIA	48	GSTA4	Down	PPARG	20	TSPYL5
Up	SUPT5H	48	HIST1H1C	Down	ZNF384	20	UGT2B7
Up	KLF6	48	MAP4K4	Down	GTF2F1	20	ZFP36
Up	TEAD3	48	NKD1	Down	MTA2	19	APBB1IP
Up	DRAP1	48	TTYH3	Down	ZBTB40	19	BHLHE40
Up	SMARCE1	47	KRT19	Down	EED	19	CLEC4G
Up	HMG20A	47	SRD5A3	Down	ADNP	19	CYP3A43
Up	SIN3B	46	FOXQ1	Down	REST	19	DHODH
Up	IKZF1	46	MCM7	Down	SIRT6	19	IRF6
Up	TBP	46	SNORD52	Down	SMARCA4	19	LYVE1
Up	HMG3	45	CDK4	Down	ETS1	19	NPY1R
Up	DNMT1	45	SLC1A5	Down	USF2	19	TRIM55
Up	TSHZ1	45	TLCD1	Down	ZNF584	18	ABLIM3
Up	GTF2B	45	WDR76	Down	DDX20	18	APOF
Up	EGR1	44	ASIC1	Down	EBF1	18	DNASE1L3
Up	BCL11A	44	CRABP2	Down	HIC1	18	NFIL3
Up	TEAD1	44	GREB1	Down	ARID1B	18	PPP1R3B
Up	CREB3	44	HIST1H2BI	Down	GLIS1	18	RCAN1
Up	TFAP4	44	IGDCC3	Down	KLF4	18	VNN3
Up	JUNB	44	PTTG1	Down	INSM2	17	CDC37L1
Up	GLI4	44	SKP2	Down	ZNF324	17	CTH
Up	IRF4	44	TRIM28	Down	HHX	17	HAL
Up	ZBTB40	43	HIST1H2AE	Down	KLF13	17	HAMP
Up	MIXL1	43	HIST1H2AH	Down	NCOR1	17	ICAM1
Up	BACH1	43	SORT1	Down	NFE2	17	MACF1
Up	SP2	42	CCDC88C	Down	ZNF341	17	MT1F
Up	CEBPG	42	LYZ	Down	LEF1	17	SLC27A5
Up	GMEB2	42	MCM3	Down	NFIC	16	CD5L
Up	DPF2	42	NQO1	Down	BCOR	16	CES3
Up	ZNF207	42	RPL22L1	Down	HDAC1	16	EPHX2
Up	ZNF18	41	BAMBI	Down	KLF7	16	FCN3
Up	ZNF335	41	DTL	Down	ZKSCAN1	16	GCKR
Up	ZNF121	41	GPD1L	Down	TRIM24	16	HFE2
Up	STAT1	41	HIST1H2AB	Down	TRIM22	16	HPX
Up	POU2F2	41	HIST1H2AM	Down	POLR2H	16	UGP2

Up	ZNF175	41	HIST1H4D	Down	JUND	15	ABCB11
Up	CTCF	41	HUNK	Down	TAL1	15	AQP3
Up	HIC1	41	USP11	Down	PRDM10	15	ASS1
Up	ZNF584	40	CDC25C	Down	TAF7	15	ETFDH
Up	HES1	40	HIST1H2BG	Down	ZNF101	15	HRSP12
Up	TRIM24	39	HIST1H3A	Down	ZNF335	15	NTN4
Up	TBX21	39	MAD2L1	Down	SP3	15	RUNDC3B
Up	CDC5L	38	CDC20	Down	HMBX1	14	ADHFE1
Up	GLIS2	38	COL15A1	Down	GTF2A2	14	DIO1
Up	IRF2	38	HIST1H2BM	Down	FOXK2	14	FGG
Up	EZH2	38	LYPD1	Down	SUPT5H	14	GLT1D1
Up	NFYB	37	HIST1H1B	Down	SMARCE1	14	IGF1
Up	NFATC1	37	HIST1H3H	Down	SMC3	14	KLF6
Up	KAT2A	37	HIST1H3I	Down	TRIM28	14	MYOM1
Up	MTA3	37	TERC	Down	CBFB	14	PCK2
Up	TCF7	36	CTSC	Down	SP7	14	RND1
Up	RELA	36	GSN	Down	ZNF382	14	SERPINB8
Up	HDAC1	36	HIST2H2AB	Down	IKZF1	14	THRSP
Up	ZNF366	36	PYCR1	Down	CCNT2	13	ACOX1
Up	ZNF341	35	FREM2	Down	HES1	13	AGPAT9
Up	HCFC1	35	RFC3	Down	HDAC6	13	ALDH6A1
Up	EED	35	TYMS	Down	RFX3	13	APOC3
Up	CUX1	34	HIST1H3C	Down	MTA1	13	CA2
Up	ZNF623	34	ITM2C	Down	EGR2	13	FAM180A
Up	TAL1	33	KIFC1	Down	CUX1	13	KYNU
Up	ZNF263	33	NAP1L1	Down	ZNF18	13	NNT
Up	ATF4	33	SNRPB	Down	NCOA1	13	NSUN6
Up	PRDM1	33	STRA6	Down	ZNF366	13	PAPSS2
Up	USF2	32	RACGAP1	Down	HDAC2	13	SLC22A7
Up	ZNF512	31	ACTG2	Down	ZNF83	12	ARRDC3
Up	RNF2	31	BUB1	Down	ZNF7	12	HPR
Up	ZNF407	31	DNAH14	Down	PKNX1	12	S100A8
Up	GFI1B	31	NCAPD2	Down	TBX21	12	ST3GAL6
Up	CEBPA	31	TOX3	Down	GATA1	12	ART4
Up	RFX3	30	AFP	Down	FOXA2	11	MBL2
Up	GLIS1	30	HS6ST1	Down	CEBPD	11	BMP10
Up	PBX2	30	TUBG1	Down	TEAD4	11	IGF1
Up	JUND	29	EPCAM	Down	RELA	11	BHLHE40
Up	ZNF558	29	LRRC1	Down	ZNF512	11	PGLYRP2
Up	NFE2	29	ZC3HAV1L	Down	ETV1	11	OIT3
Up	BHLHE40	28	AXIN2	Down	TSHZ1	11	AGPAT2
Up	CTBP2	28	MYCN	Down	GFI1B	11	SLC7A2
Up	RAD21	28	TGFB2	Down	ZNF610	11	MFAP3L
Up	IRF3	27	HIST1H2AJ	Down	HCFC1	11	C3P1
Up	CHD7	27	HIST1H3F	Down	CREB3	11	INHBE
Up	TARDBP	26	CAD	Down	GLI4	11	DTX1
Up	GATA3	26	MAGED2	Down	MAX	11	ASS1
Up	ZNF7	26	MYBL2	Down	PRDM2	11	C1R
Up	FOXK2	24	PRR11	Down	TBX3	10	SERPINA11
Up	FOSL2	23	EHMT2	Down	TCF7	10	BIRC3
Up	SREBF2	23	FADS2	Down	PRDM1	10	GCH1
Up	PRDM10	23	RBP1	Down	ZNF623	10	AGL
Up	HDAC6	22	CDC6	Down	MXI1	10	AGXT
Up	ZNF143	22	HJURP	Down	RXRA	10	SERPINA3
Up	HDAC2	22	HNFI1A-AS1	Down	GMEB2	10	PTS
Up	YY1	22	MSH2	Down	ZBTB17	10	GLRX
Up	NFIC	22	PGC	Down	MITF	10	REEP6
Up	GATA1	21	ASF1B	Down	MBD2	9	SPTBN2
Up	TEAD4	21	ATP8B2	Down	CDC5L	9	EGR1
Up	CEBPD	21	CPXM1	Down	CEBPB	9	THRSP
Up	FOXA2	21	SNORD95	Down	IRF2	9	APOL1
Up	EGR2	20	CCND2	Down	WT1	9	ENPEP
Up	SUZ12	20	CDH13	Down	GATA3	8	MYO1B
Up	KLF4	20	GIN5	Down	SREBF2	8	ETS2
Up	RUNX1	20	HIST1H2BL	Down	RCOR1	8	TRIB1
Up	RFX1	20	KIF20A	Down	THRAP3	8	KLF6
Up	MAX	20	MCM2	Down	HNFA4	8	CCL16
Up	MITF	20	PLCG1	Down	SIN3B	8	TAT
Up	PKNX1	20	SEMA3C	Down	RAD51	8	TP53INP1
Up	ZNF202	19	LIN28B	Down	ZNF207	8	CETP
Up	NFE2L2	19	SNORD30	Down	DIDO1	8	UGP2
Up	MTA1	18	ALYREF	Down	JUN	8	ZFP36
Up	MNT	18	CST1	Down	POU5F1	7	AASS
Up	PRDM2	18	FOXMI	Down	ZNF143	7	USP2
Up	EP300	18	HIST1H2BE	Down	SCRT2	7	GCH1

Up	PYGO2	18	HIST1H3B	Down	ZNF202	7	PRKAG2
Up	ZNF146	18	PEG10	Down	ZNF217	7	FOS
Up	ZNF641	18	SNORD50A	Down	TARDBP	7	ETFDH
Up	MXI1	17	MCM4	Down	TBP	7	JUNB
Up	MTA2	17	SLC39A10	Down	MAFK	6	HFE2
Up	ZBTB1	17	UHRF1	Down	EP300	6	CYP3A43
Up	NR2F2	16	ACLY	Down	ZNF558	6	SGMS2
Up	ZHX1	16	ASPM	Down	CBX8	6	GNAO1
Up	MAFF	16	CCDC34	Down	RFX1	6	TMPRSS2
Up	THAP1	16	COL1A1	Down	STAT1	6	FOSB
Up	RAD51	16	GSTP1	Down	USF1	5	PPARGC1A
Up	ZBTB17	16	NUSAP1	Down	ZNF547	5	SRD5A1
Up	RCOR1	16	RNF43	Down	RUNX1	5	TMOD1
Up	NFYA	15	HIST1H2AG	Down	NFE2L2	5	C4BPB
Up	SCRT1	15	NT5DC2	Down	ARNT	5	ECM1
Up	ZNF217	15	TSPAN5	Down	ZNF146	5	FXYD1
Up	MAFK	14	GNA12	Down	POU2F2	5	RBM47
Up	DEK	14	HIF1AN	Down	E2F6	5	DUSP1
Up	MYB	14	HIST1H4B	Down	ATF2	5	CFP
Up	HHEX	14	NYNRIN	Down	ZNF16	5	CYP4F22
Up	MYC	14	RPS27	Down	SCRT1	5	DUSP5
Up	E2F6	13	CHEK1	Down	ZNF121	5	DHTKD1
Up	CEBPB	13	XRCC2	Down	ZBTB1	5	SOC2
Up	TAF1	12	USP21	Down	ZNF8	5	LRRK2
Up	SMC3	11	CDON	Down	HLF	5	SERPINE1
Up	TBX3	11	ETV4	Down	KDM5A	4	CXCL2
Up	CTBP1	11	GXYLT2	Down	DNMT1	4	NAMPT
Up	ATF2	11	LAMC1	Down	GTF2B	4	ARRDC3
Up	EBF1	11	SPATS2	Down	SREBF1	4	INSIG1
Up	DIDO1	10	NPM3	Down	DEK	4	TRIB1
Up	SCRT2	10	PCP4	Down	ZFP41	3	GADD45B
Up	ZNF547	10	ZNF382	Down	ZNF407	3	ADHFE1
Up	MBD4	9	C1orf74	Down	HDAC8	3	AGL
Up	HNF4G	9	FIGN	Down	AEBP2	3	AMDHD1
Up	HLF	9	KCNJ5	Down	PYGO2	3	GLYAT
Up	CBX8	9	MPPED2	Down	ZNF641	3	ZFP36
Up	GATAD2B	9	OLFML3	Down	MAFG	3	HFE2
Up	POU5F1	9	SLC44A3	Down	ZHX1	3	SLC27A5
Up	HDAC8	9	TMEM98	Down	CTBP1	3	CPNE8
Up	MAFG	8	HIST1H4I	Down	BCL3	3	C8orf4
Up	TCF3	8	IMPDH2	Down	NFATC1	3	KCND3
Up	STAT5A	8	LAPTM4B	Down	MTA3	3	EGR1
Up	BCLAF1	7	HIST1H2AB	Down	ZNF585B	3	F13B
Up	ETV6	7	HIST1H2AM	Down	ZNF488	3	HAMP
Up	NFE2L1	7	HIST1H4I	Down	ZNF239	3	FXYD1
Up	SREBF1	7	LSM2	Down	ZNF707	3	INHBE
Up	JUN	6	HIST1H2AK	Down	MYB	3	TTC39C
Up	POLR3A	6	HIST1H2BI	Down	RUNX3	2	APBB1IP
Up	ZNF264	6	SOBP	Down	SPI1	2	DUSP5
Up	TCF7L2	6	TP53	Down	SETDB1	2	HSD17B6
Up	RBBP5	5	CTSC	Down	KAT2A	2	JUNB
Up	NONO	5	SNORD30	Down	TBL1XR1	2	SOC2
Up	PTRF	5	SNORD78	Down	ETV6	2	BHLHE40
Up	ZNF585B	5	SV2A	Down	MNT	2	GNMT
Up	GTF3C2	5	TERC	Down	MAFF	2	IGF1
Up	SIX4	4	AXIN2	Down	ZNF264	2	DUSP1
Up	SETDB1	4	CDCA7	Down	SRF	2	EGR1
Up	CHD2	4	EIF4A2	Down	GATAD2B	2	JUNB
Up	BDP1	4	HIST1H2AH	Down	ELK4	2	EGR1
Up	USF1	4	PCGF2	Down	NONO	2	GCH1
Up	FOS	4	SNORD114-26	Down	CHD7	2	GRAMD1C
Up	ZNF274	4	SNORD116-13	Down	MYC	2	SPTBN2
Up	BRF1	4	SNORD95	Down	PML	2	ZFP36
Up	SPI1	3	ARHGEF2	Down	NFE2L1	2	MYOM1
Up	CEBPZ	3	ASF1B	Down	YBX1	2	SNX29P2
Up	RUNX3	3	HIST1H4E	Down	EHMT2	2	UGT2B7
Up	STAT3	3	LSM2	Down	TCF7L2	1	ASPDH
Up	PPARGC1A	3	PLCG1	Down	PTTG1	1	BHLHE40
Up	ZNF140	3	PRKD1	Down	PTRF	1	BHLHE40
Up	HSF1	3	SNORD52	Down	TEAD2	1	BHLHE40
Up	ZNF8	3	ZNF382	Down	NANOG	1	CSRNP1
Up	ZNF16	2	ERCC2	Down	CHD4	1	GADD45B
Up	ESR1	2	FREM2	Down	ZNF140	1	HAMP
Up	ZC3H11A	2	GSTA4	Down	ZNF354C	1	HAMP
Up	ZNF239	2	IMPDH2	Down	NFYA	1	INSIG1

Up	CHD4	2	KIF11	Down	HSF1	1	KCND3
Up	RXRA	2	LGR5	Down	TAF1	1	KLF6
Up	ETS2	2	LSM2	Down	NR3C1	1	MFSD2A
Up	UBTF	2	MPZL1	Down	E2F4	1	NSUN6
Up	YBX1	2	NYNRIN	Down	SIX4	1	SPTBN2
Up	AEBP2	2	PEG10	Down	RFX5	1	TP53INP1
Up	ZNF292	2	PTK7	Down	KAT2B	1	ZFP36
Up	PRDM12	2	TMC7	Down	ZNF138	1	ZFP36
Up	TEAD2	2	TRIM59				
Up	ZFP41	1	C19orf48				
Up	RFX5	1	CDK4				
Up	NANOG	1	FKBP10				
Up	TSC22D4	1	HIST1H2BD				
Up	ZNF354C	1	HIST1H3E				
Up	ZNF138	1	HIST1H3E				
Up	ZNF488	1	NRCAM				
Up	MEF2A	1	PTP4A3				
Up	MEF2C	1	PTP4A3				
Up	HNF4A	1	SOAT2				

Degree – No of TF interact with target gene. We taken any one TF in table

Figures

Fig. 1. Box plots of the gene expression data before normalization (A) and after normalization (B). Horizontal axis represents the sample symbol and the vertical axis represents the gene expression values. The black line in the box plot represents the median value of gene expression. (A1 – A53 = hepatoblastoma tissues samples; B1 – B14 = noncancerous liver tissue samples)

Fig. 2. Heat map of up regulated differentially expressed genes. Legend on the top left indicate log fold change of genes. (A1 – A53 = hepatoblastoma tissues samples; B1 – B14 = noncancerous liver tissue samples)

Fig. 3. Heat map of down regulated differentially expressed genes. Legend on the top left indicate log fold change of genes. (A1 – A53 = hepatoblastoma tissues samples; B1 – B14 = noncancerous liver tissue samples)

Fig. 5. Protein–protein interaction network of up regulated genes. Green nodes denotes up regulated genes.

Fig. 6. Scatter plot for up regulated genes. (A- Node degree; B- Betweenness centrality; C- Stress centrality ; D-Closeness centrality; E- Clustering coefficient)

Fig. 7. Protein–protein interaction network of down regulated genes. Red nodes denotes down regulated genes.

Fig. 8. Scatter plot for down regulated genes. (A- Node degree; B- Betweenness centrality; C- Stress centrality ; D-Closeness centrality; E- Clustering coefficient)

Fig. 9. Modules in PPI network. The green nodes denote the up regulated genes

Fig. 10. Modules in PPI network. The red nodes denote the down regulated genes

Fig. 11. The network of up regulated genes and their related miRNAs. The green circles nodes are the up regulated genes, and blue diamond nodes are the miRNAs

Fig. 14. The network of down regulated genes and their related TFs. The green circles nodes are the down regulated genes, and yellow triangle nodes are the TFs.

Fig. 15. Overall survival analysis of up regulated hub genes. Overall survival analyses were performed using the UALCAN online platform. Red line denotes - high expression; Blue line denotes – low expression. A) TP53 B) PLK1 C) AURKA D) CDK1 E) ANLN

Fig. 16. Overall survival analysis of down regulated hub genes. Overall survival analyses were performed using the UALCAN online platform. Red line denotes - high expression; Blue line denotes – low expression. A) ESR1 B) FGB C) ACAT1 D) GOT1 E) ALAS1

Fig. 17. Box plots (expression analysis) hub genes (up and down regulated) were produced using the UALCAN platform. A) TP53 B) PLK1 C) AURKA D) CDK1 E) ANLN F) ESR1 G) FGB H) ACAT1 I) GOT1 G) ALAS1

Fig. 18. Box plots (stage analysis) of hub genes (up and down regulated) were produced using the UALCAN platform A) TP53 B) PLK1 C) AURKA D) CDK1 E) ANLN F) ESR1 G) FGB H) ACAT1 I) GOT1 G) ALAS1

Fig. 19. Mutation analyses of hub genes were produced using the CbioPortal online platform

Fig. 20. Immunohisto chemical(IHC) analyses of hub genes were produced using the human protein atlas (HPA) online platform A) TP53 B) PLK1 C) AURKA D) CDK1 E) ANLN F) ESR1 G) FGB H) ACAT1 I) GOT1 G) ALAS1

Fig. 21. ROC curve validated the sensitivity, specificity of hub genes as a predictive biomarker for hepatoblastoma prognosis A) TP53 B) PLK1 C) AURKA D) CDK1 E) ANLN F) ESR1 G) FGB H) ACAT1 I) GOT1 J) ALAS1

Fig. 22. Validation of hub genes (up and down regulated) by RT-PCR. A) TP53 B) PLK1 C) AURKA D) CDK1 E) ANLN F) ESR1 G) FGB H) ACAT1 I) GOT1 J) ALAS1

Fig. 23. Scatter plot for immune infiltration for hub genes (up and down regulated). A) TP53 B) PLK1 C) AURKA D) CDK1 E) ANLN F) ESR1 G) FGB H) ACAT1 I) GOT1 G) ALAS1